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ABSTRACT 
Endogenous sodium transport inhibitor (ESTI) and renal dopamine (DA) are thought 
to be important in maintaining sodium balance and in the pathogenesis of 
hypertension. In order to study the roles of these factors, methods for the 
measurement of ESTI were developed, based on the inhibition of Na, K-ATPase and 
digoxin-like immunoreactivity. Methods for the extraction of ESTI were studied and 
improved. An HPLC method for the measurement of DA was established and studies 
were done to find an appropriate preservative for urine DA. 
The roles and interrelationship of ESTI and DA were studied in 4 cross-sectional and 
4 longitudinal studies in humans. To define the roles of ESTI further, an animal study 
was done where DA production was inhibited by carbidopa in the rat. 
In cross-sectional studies of healthy subjects there was no correlation between sodium 
excretion and ESTI but there was a significant correlation between sodium and DA 
excretion. However, in normotensive subjects with a family history of hypertension 
and in hypertensive patients, the sodium and DA correlation did not hold. 
In 164 NIDDM patients grouped according to urine albumin excretion, DA excretion 
was lower and atrial natriuretic peptide (ANP) concentration was higher with 
increasing albuminuria. Dissociation between renin and aldosterone levels was also 
observed. ESTI was significantly higher in the hypertensive group. 
In acute volume expansion induced by headout immersion and saline infusion in 
healthy subjects, no significant changes in ESTI and DA were found. The 
dopamine/noradrenaline ratio correlated with sodium excretion. In oral salt loading 
for 5 days in healthy subjects on a controlled diet, there was no significant increase in 
DA excretion despite of 9-fold increase in sodium excretion. Circadian variation of 
DA excretion was affected by dietary salt intake. When sodium excretion reached a 
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new steady state after 3 days of sodium supplementation, plasma ANP peaked and 
followed by an increase in plasma Na, K-ATPase inhibitor. 
During salt loading in the rat, both ESTI and DA increased, but the increase in DA 
lagged behind by 1 day. When rats were treated with carbidopa, there was a 70% 
decrease in DA. ESTI increased in carbidopa-treated rats even on low salt. On day 
5, there was a surge of ESTI in control high salt rats but this surge in the treated rats 
was seen on day 4. 
In summary, both ESTI and renal DA have been found to be associated with changes 
in sodium excretion under different conditions. Changes in these two natriuretic 
factors by experimental manipulation did not affect sodium excretion. Under acute 
expansion of ECF volume, ESTI did not play a significant role. DA excretion 
correlated with sodium excretion under physiological conditions. 
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LIST OF ABBREVIATIONS 
%I Percentage of inhibition 
P Standardized coefficient of regression 
° C Degree Centigrade 
(il Microliter 
|jM Micromole per liter 
A Adrenaline 
ADP Adenosine diphosphate 
AMP Adenosine monophosphate 
ANOVA Analysis of variance 
ANP Atrial natriuretic peptide 
ATP Adenosine triphosphate 
AVP Arginine vasopressin 
BNP Brain natriuretic peptide 
cAMP Cyclic adenosine monophosphate 
CATS Catecholamines 
cGMP Cyclic guanosine monophosphate 
CNP C-type natriuretic peptide 
Cr Creatinine 
CV Coefficient of variation 
d day 
DA Dopamine 
DBP Diastolic blood pressure 
DHBA Dihydroxybenzylamine 
DLI Digoxin-like immunoreactivity 
DNA Deoxyribose nucleic acid 
EA Enzyme acceptor 
ECD Electrochemical detector 
ECF Extracellular fluid 
ED Enzyme donor 
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EDRF Endothelium-derived relaxing factor 
EDTA Ethylenediaminetetraacetic acid 
E G T A Ethylene glycol Bis (p-aminoethylether) N,N,N',N' 
tetraacetic acid 
ESTI Endogenous sodium transport inhibitor 
g gram 
G6PD Glucose-6-phophate dehydrogenase 
GFR Glomerular filtration rate 
GMP Guanosine monophosphate 
GTP Guanosine triphosphate 
h hour 
HbAi Hemoglobin Ai 
HC1 Hydrochloric acid 
HEIA Homogenous enzyme immunoassay 
HPLC High performance liquid chromatography 
IC50 Ouabain concentration required to cause 50% inhibition 
IDDM Insulin dependent diabetes mellitus 
KC1 Potassium chloride 
LD Lactate dehydrogenase 
M Mole per liter 
MAP Mean arterial pressure 
MgS�4 Magnesium sulphate 
min Minute 
ml Milliliter 
mM Millimole per liter 
mmol millimoles 
m V Millivolt 
NA Noradrenaline 
Na，K-ATPase Sodium, potassium activated adenosine triphosphatase 
NaCl Sodium chloride 
NADH Reduced nicotinamide adenine dinucleotide 
NIDDM Non-insulin dependent diabetes mellitus 
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nM Nanomole per liter 
nm Nanometer 
NO Nitric oxide 
OE Ouabain equivalent 
OLI Ouabain-like immunoreactivity 
PEP Phosphoenolpymvate 
PGS Prostaglandins 
PK Pyruvate kinase 
PNPP Para-nitrophenylphosphate 
r Coefficient of correlation 
RCM Radial compression module 
RIA Radioimmunoassay 
RNA Ribose nucleic acid 
SBP Systolic blood pressure 
SD Standard deviation 
sec Second 
SEM Standard error of the mean 
SSBP Supine systolic blood pressure 
TCA Trichloroacetic acid 
TFA Trifluoroacetic acid 
UAE Urinary albumin excretion 
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INTRODUCTION 
Approximately one-third of the total body water is contained within the extracellular 
fluid (ECF) compartment. This space provides the cells with essential nutrients and 
contains the intravascular volume which continually renews the supply of cellular 
nutrients. Maintenance of an appropriate ECF volume is essential for the homeostasis 
of body functions. Sodium is the principal cation in the ECF. The regulation of ECF 
volume is through regulation of renal excretion of sodium. The mechanism of this 
regulation is complicated and accomplished by a combination of factors, including 
systemic and local hormones. 
Essential hypertension, a primary increase in blood pressure (BP), is a common 
disorder affecting 10-15% of the adult population. It affects almost every organ 
system in the body, resulting in high morbidity and mortality. In a proportion of 
hypertensives, BP is ECF volume dependent. It is therefore important to understand 
the pathogenesis of this group of patients so that proper treatment and even 
preventive measures might be implemented. 
Dietary salt intake is one of the many factors which has been suggested to predispose 
the development of high BP. Intervention studies have shown that decrease in sodium 
intake will cause a reduction of BP in hypertensive patients (Morgan et al 1987). 
Epidemiological studies add further support to the role of salt in hypertension. 
Review of data from 27 human populations shows a strong correlation between the 
average salt intake and BP (Glieberman 1973). The prevalence of hypertension 
increases when salt intake is more than 2 grams per day (Berglund 1983). An 
international cooperative study of electrolyte excretion and BP, the INTERS ALT 
study, confirmed that sodium intake is related to BP in individuals and to the rise of 
BP with age (Rose et al 1989). Populations with a very low sodium intake are 
associated with minimal rise of BP with age and near absence of hypertension. 
There is strong evidence to indicate that the kidney plays an important role in the 
‘pathogenesis of salt-induced hypertension. In animals, excessive dietary sodium can 
1-13 
raise BP especially when renal function is impaired (Haddy 1980). A proportion of 
normotensive animals (e.g. rats) become hypertensive on a high salt diet. 
Furthermore, these animals can be made more sensitive to salt if their renal mass is 
reduced. Dahl was able to raise inbred strains of rats that develop hypertension 
without reduction in renal function on a normal or high salt diet. When kidneys of 
these salt sensitive rats were transplanted into normal rats, the BP increased in the 
recipients (Dahl & Heine 1975). In man, reduction in renal mass is associated with a 
reduction in the capacity for natriuresis and is often associated with hypertension 
(Haddy 1980). A low salt diet is often effective in reducing hypertension in end stage 
renal failure, thus supporting a role for salt in the genesis of hypertension in renal 
failure. Diuretics promoting natriuresis can lower BP in many hypertensive patients, 
especially in those with low plasma renin activity. Finally, as in the salt sensitive rats, 
hypertension in humans can be corrected by transplantation of a kidney from a 
normotensive donor (Curtis etal 1983). 
Dahl ^ al suggested that a circulating substance might be involved in the genesis of 
hypertension in salt sensitive rats (Dahl et al 1969). This hypothesis was later 
extended to include the rise of BP in experimental hypertension (Haddy & Overbeck 
1976). Blaustein put forward a hypothesis to explain the mechanism by which a rise 
in circulating sodium transport inhibitor may cause a rise in BP by inhibiting sodium-
calcium exchange (Blaustein 1977). De Wardener and MacGregor later proposed a 
model which also included a role for the kidney in the pathogenesis of induced 
hypertension (de Wardener & MacGregor 1980). According to this hypothesis 
hypertensive patients are predisposed with a renal defect, and when sodium intake 
exceeds the renal excretion capacity, the rise in intrathoracic blood volume 
accompanying the increased ECF volume and plasma volume triggers the release of an 
endogenous sodium transport inhibitor (ESTI). This inhibitor facilitates natriuresis by 
inhibiting tubular sodium reabsorption. The high circulating levels of ESTI not only 
inhibit renal sodium reabsorption, but also sodium transport in other tissues including 
the blood vessels. Such an inhibition will lead to increase in intracellular calcium in 
the blood vessels, as suggested by Blaustein, resulting in a rise in peripheral 
resistance, and thus hypertension. Although there is a large volume of literature 
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supporting the presence ofESTI, its identity has not been elucidated even after many 
years of intense research efforts (Woolfson et al 1994). Furthermore, there are 
conflicting reports that do not support the presence of ESTI during ECF volume 
expansion. 
In this hypothesis of pathogenesis of hypertension, a genetic or acquired deficiency in 
natriuresis plays a critical role in the development of hypertension. However, the 
nature of the renal defect is unknown. Lee suggested that the fault might lie in a 
failure to mobilize dopamine (DA) in the kidney in the presence of increased dietary 
salt (Lee 1987). DA is formed in renal tubular cells from circulating L-dopa (Lee 
1982). Formation of renal DA results in vasodilatation of renal blood vessels, by 
action on vascular receptors. Furthermore, natriuresis is enhanced by an effect on 
vascular sodium transport mechanisms. There is evidence to show that renal DA 
production increases in response to oral sodium load in both man and animals. A 
failure of DA production in response to sodium challenge in some hypertensives has 
been shown. Ethnic groups that have a high prevalence of hypertension fail to 
increase DA. However, later studies showed that the amount of DA production was 
not in parallel with the increase in ECF volume (Cuche et al 1983，Jeffery et al 1989). 
In this thesis, literature on the different factors affecting natriuresis, de Wardener's 
hypothesis and the DA theory are reviewed. This is followed by a description of the 
development of a sensitive semi-automated method for measuring ESTI and a high 
pressure liquid chromatographic method with sensitive electrochemical detection to 
measure DA. The inter-relationships between the sodium excretion, ESTI and DA 
were investigated in cross-sectional studies of healthy individuals, hypertensive 
patients, and non-insulin dependent diabetic (NIDDM) patients. The NIDDM 
patients with proteinuria represented a population with reduced renal tubular fiinction, 
and thus reduced capacity for renal DA production. The roles of ESTI and DA in 
healthy subjects undergoing ECF volume expansion were studied. Volume expansion 
was induced by different methods: water immersion, saline infusion and oral salt 
loading. Major emphasis was on the oral salt loading method since dietary sodium 
intake is the common route for expanding the ECF volume. Ethnic differences in DA 
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response to sodium challenge have been reported (Critchley et al 1989). The present 
studies were conducted in Chinese, about whom there have been no previous reports. 
Finally，the role of ESTI was also examined in rats when the DA production was 
inhibited by carbidopa. 
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RENAL EXCRETION OF SODIUM 
AND ITS REGULATION 
I. SODIUM EXCRETION 
The renal excretion of sodium is the major regulatory mechanism in the maintenance 
of the extracellular fluid (ECF) volume. Following ultrafiltration of the plasma 
through the glomerulus, the epithelial cells that form the individual nephrons 
selectively absorb the important components back to the circulation, for example: 
glucose, sodium, amino acids etc. (Briggs et al 1990, Kirchner & Stein 1994). 
Unabsorbed metabolites pass through the lumen and are excreted in the form of urine. 
Approximately 180 liters of fluid is filtered daily and approximately 178 liters are 
reabsorbed. For sodium, about 22,500 mmol are filtered daily and about 22,300 
mmol are reabsorbed. The sodium left in the lumen is excreted in the urine. There 
are many mechanisms for sensing the status of the ECF volume. These sensors are 
responsible for triggering integrated neural and hormonal factors to influence the rate 
of reabsorption of sodium in order to maintain a constant amount of body sodium and 
an effective ECF volume. 
In healthy people, sodium excretion can vary from less than 1 mmol per day to more 
than 500 mmol per day, according to dietary intake (Briggs et al 1990). Among the 
52 populations examined in the INTERS ALT study, the median for daily renal sodium 
excretion ranged from 0.2 mmol to 242 mmol (Elliott et al 1989). However, with the 
administration of intravenous saline, an excretion of up to 200 mmol/h can be 
achieved depending on the amount of saline infused. The mechanisms controlling 
natriuresis are able to cope with this large variation in sodium intake. 
It has been recognized that the sodium regulatory system operates with a remarkable 
degree of sluggishness and appears to require the existence of rather large error 
signals (Briggs et al 1990). When an acute load of water is given to a healthy 
individual, 80% to 90% of this water load can be excreted through the kidney in a few 
hours. However, when an equal load of isotonic saline is given, it takes many more 
1-1 
hours to eliminate this load. For example, it was reported that only 15% of infused 
sodium was excreted during the first 3 hours and the excretion of all the sodium load 
took 48 hours (Drummer et al 1992). 
An increase in daily sodium intake is associated with a transient period of positive 
sodium balance and the total body sodium rises. With time, sodium balance is re-
established at a new steady-state level of increased total body sodium. Sodium 
excretion is adjusted to balance the amount of sodium intake. The time required to 
achieve balance varies from 1 to 9 days, depending on the amount of change in 
sodium intake (Briggs 1990). When sodium intake was restricted from 133 mmol/day 
to 10 mmol/day, sodium excretion was reduced and it took 4 days to reach a new 
steady state (Sagnella et al 1990). However, when sodium intake was increased to 
350 mmol/day, the new steady state was achieved in only 3 days. 
Sodium excretion is affected by numerous mechanisms with a substantial degree of 
redundancy and overlap (Briggs et al 1990，Rabkins & Dahl 1993). In general, failure 
of a single factor does not cause marked long-term deviations of salt balance. This 
has presented a fundamental problem in studying the effect of individual mechanisms. 
It is very difficult to dissect out only one factor and study its effect on sodium 
excretion. 
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II. CELLULAR MECHANISM OF SODIUM REABSORPTION 
Reabsorption of the filtered sodium is accomplished by the transport of sodium from 
the apical membrane to the basolateral membrane of the epithelial cells lining the 
lumen. The apical membrane faces the lumen and the basolateral membrane is in 
contact with the interstitial fluid. On the basolateral membrane, the sodium-potassium 
active pump (the sodium-potassium adenosine triphosphatase) is the major system 
transporting sodium out of the cells into the circulation (Jorgensen 1986). The 
sodium pump utilizes energy derived from the hydrolysis of adenosine triphosphate 
(ATP). Sodium is transported out and potassium is transported into the cell with a 
stochiometry of 3:2 and an electrochemical gradient for sodium ions across the cell 
membrane is created. This gradient is the driving force for the sodium entry to the 
interior of the cell through specific channels located on the apical side of the cell 
membrane. On the apical membrane, there are transport proteins in the forms of 
channels, carriers, exchangers, or cotransporters. These transport proteins utilize the 
potential energy of existing electrical or chemical gradients to move sodium from the 
lumen into the cells. Examples of these transport mechanisms are: sodium-glucose 
cotransport and sodium-potassium-chloride cotransport on the loop of Henle; sodium 
channels located on the distal nephron and the collecting duct; and sodium-hydrogen 
exchange on the proximal tubules. 
Regulation of the cellular transport of sodium in the nephrons can be brought about 
by a combination of several methods: kinetic factors, process of endocytosis / 
exocytosis, action of second messengers and long-term adaptation (Stokes 1994). 
Kinetic factors 
Kinetic factors involve any process increasing or decreasing the transport rate by 
changing the sodium concentration available to the apical membrane. For example, 
increasing the glomerular filtration rate (GFR) will expose the proximal tubule with 
increasing amount of sodium. This can increase the entry of sodium into the cell on 
the apical membrane and will increase the rate of sodium extrusion by the sodium-
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potassium pump on the basolateral membrane. This mechanism is one reason why 
proximal tubular absorption of sodium exhibits flow dependency. 
Endocytosis and exocytosis 
This type of regulation requires the integrated action of the cytoskeleton. When the 
rate of reabsorption is low, some transporters in the apical membrane are sequestered 
in vesicles just below the surface. Upon appropriate stimulation, the subapical 
vesicles are inserted into the apical membrane，where they fuse to expose the 
transport proteins to the lumen. The increase in the number of available transporters 
increases the rate at which sodium can be transported into the epithelial cells. The 
stimulus activates both exocytosis and endocytosis so that the cycling of vesicles 
increases. Withdrawal of the stimulus reduces the exocytosis so that the vesicles 
reside in a quiescent state beneath the apical membrane ready for the next stimulus. 
Second messengers 
The largest and most diverse category of transport regulation involves the action of 
second messengers. The binding of hormones to specific receptors on the surface of 
the membrane can elicit the activation of second messengers. Examples of second 
messengers are cytosolic calcium, cyclic AMP, cyclic GMP, and membrane 
phospholipid-derived messengers. These messengers can directly affect ion channel 
activity, activate protein kinases that modify transporters, and alter cell pH to render 
transporters more or less sensitive to regulation by other agents. An important 
feature of regulation by second messengers is that many phenomena involve the 
concordant regulation of both apical and basolateral transporters. 
Long-term adaptation 
Most steroid hormones, for example aldosterone, exert their effects by long-term 
adaptation. Through activation of the specific receptor proteins complexing the 
nucleus, specific proteins, messenger RNA etc can be synthesized in the target cells. 
The permeability of the apical membrane to the entry of sodium can be altered to 
affect the transport rate. The rate of protein synthesis can be changed to regulate the 
number of functioning sodium channels or cotransporters on the apical membrane and 
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the number of sodium pumps on the basolateral membrane. Finally, the metabolic 
capacity of the epithelial cells can also be affected. These processes together serve to 
produce a sustained effect for the transport of sodium. 
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III. SENSORS MONITORING ECF VOLUME 
The ECF space consists of the interstitial compartment and the intravascular 
compartment. There are sensors in both compartments to monitor the ECF volume. 
These sensors detect "effective" ECF volume rather than the absolute volume 
(Kirchner & Stein 1994). Effective ECF volume can be defined as the ratio of the 
ECF volume to the holding capacity. Thermoneutral, head-out water immersion 
procedure illustrates this (Epstein 1992). This experimental procedure involves a 
subject sitting in a tank of water filled up to the neck and it results in a sustained and 
marked increase in natriuresis without any change in the absolute ECF volume. It is 
associated with increases in cardiac preload, thoracic blood volume, cardiac output, 
and left atrial pressure. 
Different receptors have been identified as the sensors for monitoring ECF volume 
(Briggs et al 1990; Kirchner & Stein 1994). They are the : 
1. intrathoracic low-pressure receptors, 
2. arterial baroreceptors, 
3. carotid sinus receptors, 
4. intracranial (or cerebrospinal) volume receptors, 
5. intrarenal baroreceptors, 
6. intrahepatic volume receptors, and 
7. tissue receptors. 
Some of these receptors trigger specific responses to control sodium excretion. For 
example, the intrathoracic low-pressure receptors are associated with the sensing of 
atrial stretch and are involved with the release of atrial natriuretic factor. The 
intrarenal baroreceptors are also involved in the release of renin and aldosterone in 
regulation of natriuresis. However, the significance of these receptors in regulating 
ECF volume under normal physiological conditions is controversial. Studies have 
given conflicting results because variations in the experimental designs where subjects 
have been subjected to extremes of volume status. In some studies where the subjects 
were suffering from different disease conditions that might affect the interpretation of 
the results. Furthermore, these receptors are probably acting together to achieve the 
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important task of monitoring ECF volume. It is almost impossible to dissect out any 
one of them and study its effects alone. 
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IV. FACTORS AFFECTING NATRIURESIS 
Maintenance of the ECF volume is under the control of many complicated systems 
consisting of many factors. These factors include flow and pressure, the nervous 
systems, and the endocrine and parenteral systems (Briggs et al 1990; Kirchner & 
Stein 1994). They can also be classified into renal and extrarenal factors. 
Renal factors 
Glomerular filtration rate (GFR) 
Glomerular filtration rate has been listed as one of the factors regulating natriuresis. 
Acute saline infusion and oral salt loading have been reported to increase GFR, 
leading to increase in sodium excretion (Briggs et al 1990). However,the classical 
experiment by de Wardener and colleagues demonstrated that the natriuresis of acute 
ECF volume expansion is partly independent of the GFR (de Wardener et al 1961). 
Even when the GFR of dogs was reduced by inflation of a balloon catheter located in 
the aorta proximal to the renal arteries, marked increase in natriuresis was still 
observed during intravenous saline infusion. Recent evidence suggests that GFR does 
not appear to be necessary for the fine tuning of salt balance. Changes in GFR are 
buffered by the glomerular-tubular balance and feedback mechanisms which are 
immediate and relatively precise adaptations of sodium absorption throughout the 
nephron (Briggs et al 1990; Kirchner & Stein 1994). These mechanisms are activated 
by changes in the postglomerular hemodynamics and peritubular capillary Starling 
forces. However, the presence of these mechanisms does not exclude a role for 
alterations in GFR in the control of natriuresis. In chronic volume expansion, the 
regulatory efficiency of their buffering capacity is suppressed (Briggs et al 1990). 
Renal physical forces 
Other than the GFR, renal physical forces such as the renal perfusion pressure, renal 
interstitial hydrostatic pressure, peritubular capillary hydrostatic pressure and 
peritubular oncotic pressure have been shown to play a significant role in controlling 
sodium excretion. These physical forces also influence one another to maintain 
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sodium homeostasis, thus regulating the ECF volume. For example, renal perfusion 
pressure can influence renal interstitial hydrostatic pressure as well as the peritubular 
capillary hydrostatic pressure (Kirchner & Stein 1994). 
By changing the plasma protein concentration, peritubular oncotic pressure can be 
altered. There is sufficient data to support a correlation between large changes in 
peritubular oncotic pressure and proximal tubular sodium absorption during 
experimental maneuvers. However, its role is less important in physiological 
regulation of salt balance (Briggs et al 1990). 
A technique of increasing the renal interstitial hydrostatic pressure without affecting 
renal blood flow or GFR has been reported (Haas et al 1988). Chronic implantation 
of iso-oncotic saline-albumin solution in a polyethylene matrix in the renal interstitium 
increases the renal interstitial hydrostatic pressure and induces marked natriuresis. On 
the other hand, reduction in the renal interstitial hydrostatic pressure by renal 
decapsulation significantly attenuated the natriuretic response to saline infusion 
(Garcia-Estan et al 1989). Thus changes in this physical force appear to be important 
in natriuresis. 
Alterations in renal perfusion pressure markedly alter sodium excretion through 
mechanisms that are independent of changes in renal blood flow or GFR (Kirchner & 
Stein 1994). Its action is through the inhibition of sodium absorption. Despite 
substantial efforts, neither the site nor the mechanism of pressure-induced changes in 
reabsorption has been identified (Briggs ^ al 1990). Increase in systemic blood 
pressure can increase the renal perfusion pressure and facilitate sodium excretion. In 
normotensive offspring of essential hypertensive parents, higher blood pressure was 
speculated to have compensatory effects to restore normal natriuresis when compared 
with offspring of normotensive parents (Turner & Reilly 1993). Increased renal 
perfusion pressure was reported to be responsible for the 'escape phenomenon' of 
mineralocorticoid administration (Hall et al 1984). When an electronic device was 
used to maintain a constant baseline renal perfusion pressure in experimental dogs 
undergoing aldosterone administration, there was positive sodium balance and the 
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escape phenomenon was not observed. When the electronic device was turned off， 
the renal perfusion pressure increased and sodium balance was restored as a result of 
increase in sodium excretion. It would be difficult to demonstrate the effect of this 
physical force in normal physiological conditions since it interacts with many other 
systems. 
Finally, sodium excretion can be affected without changes in the measurable renal 
forces. During vasodilation or vasoconstriction of the renal vasculature, the same 
renal perfusion pressure will reach the postglomerular peritubular capillary, where it 
can affect the sodium reabsorption process and thus influence sodium excretion 
(Kirchner & Stein 1994). Vasodilation will decrease sodium reabsorption; while 
vasoconstriction tends to increase sodium reabsorption. 
Sympathetic nervous system 
The kidney receives a rich supply of sympathetic nerves and they are found along all 
parts of the arterial tree concentrated in afferent arterioles close to the glomerulus 
(Briggs et al 1990). In addition, both proximal and distal tubular cells are directly 
innervated with adrenergic nerve terminals. Micropuncture techniques have showed 
that the proximal convoluted tubule is the primary site affected by changes in renal 
sympathetic nerve activity. Expansion of the ECF volume, induced by either oral salt 
loading or intravenous saline infusion, is associated with a decrease in the renal 
sympathetic nervous activity and an increase in sodium excretion. 
Biological actions of the sympathetic nervous system are mediated through the release 
of endogenous catecholamines, the neurotransmitters at the adrenergic nerve 
terminals. The major catecholamines acting on the kidney are noradrenaline, 
adrenaline and dopamine. There are 4 types of adrenoreceptors to mediate the 
biological effects of catecholamines: ai, a2, S>i and (Jeffries & Pettinger 1989， 
Rabkins & Dahl 1993). Noradrenaline induces vasoconstriction through arreceptors 
which are postsynaptic. Presynaptic a2-receptors inhibit noradrenaline release from 
sympathetic nerve terminals; while postsynaptic a2-receptors can mediate 
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vasoconstriction, a广receptors are coupled to phospholipase C and their activation 
increase free intracellular calcium as the second messenger for biological actions. On 
the other hand, a2-receptors are coupled to adenylate cyclase by inhibitory G proteins 
and activation of this class of receptors reduces cAMP which is the second 
messenger. Both J3i and Ii2 receptors mediate the inotropic and chronotropic effects 
of catecholamines. B2-receptors also mediate smooth muscle relaxation. Stimulation 
of presynaptic 152-receptors enhances noradrenaline release from the sympathetic 
nerve terminals. Both J3i and receptors are coupled via stimulatory G proteins to 
adenylate cylase. Thus activation of IS receptors elevates cellular cAMP levels. The 
major adrenergic receptor mediating vasoconstriction within the kidney is the ai-
receptor. Stimulation of this class of receptor on the proximal tubular cells increases 
water and sodium reabsorption leading to a decrease in sodium excretion. Activation 
of o(2-receptors reduces cellular cAMP concentration to counteract biological actions 
initiated by other hormones on the nephron. Stimulation of i^i-receptors on the 
juxtaglomerular apparatus enhances renin release. 
The interactions between the renal nervous system and the different ECF volume 
sensors are very complex. During an intravenous sodium load with isotonic and iso-
oncotic dextran in saline, the decrease in renal nerve activity was completely abolished 
by denervation of sinoaortic baroreceptor and vagotomy (Morita & Vatner 1985). 
However, when hypertonic sodium solution was infused, the decrease in renal nerve 
activity was completely abolished with combined hepatic denervation and sinoaortic 
baroreceptor plus vagotomy (Morita et al 1991). Furthermore, an oral sodium load 
resulted in a decrease in renal nerve activity, which was completely abolished by 
hepatic denervation alone (Morita et al 1993). 
Direct stimulation of the renal sympathetic nervous system demonstrates the different 
mechanisms affecting sodium excretion (Kopp & DiBona 1984). The lowest level of 
renal nerve activity only affects the renin response to other simultaneously occurring 
nonneuronal stimuli. Increasing the frequency of stimulation selectively increases 
renin secretion and then reduces urinary sodium excretion. At high frequencies of 
renal nerve stimulation, both GFR and renal blood flow are lowered to reduce sodium 
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excretion. This approach of studying the renal sympathetic nervous system can 
provide information under normal physiological conditions (Kirchner & Stein 1994). 
Renal dopamine 
Dopamine (DA)-containing nerves have been identified within the kidney. However, 
their functional importance has yet to be determined (Rabkins & Dahl 1993). On the 
other hand, DA is also produced by proximal tubular cells by the action of aromatic-
L-amino-acid decarboxylase (EC 4.1.1.28 or commonly known as dopa 
decarboxylase) on dihydroxyphenylalanine (L-dopa) delivered to the kidney by the 
systemic circulation (Brown & Allison 1981’ Wolfovitz et al 1993). Inhibition of the 
dopa decarboxylase by carbidopa leads to a significant decrease in urinary DA 
excretion (Ball & Lee 1977). Damage to the renal tubules in chronic renal diseases 
also results in a decrease in DA excretion (Casson et al 1983). 
Biological actions of DA are mediated by specific receptors: DAi and DA2 ((Felder et 
al 1989，Lee 1993). DAi receptors cause direct vasodilation through activation of 
adenylate cyclase. Activation of DAi receptors causes an increase in natriuresis 
without alterations in renal blood flow or GFR. DA2 receptors cause indirect 
vasodilation by inhibition of noradrenaline release and also inhibit aldosterone 
production. When DA2 receptors are activated, adenylate cyclase is inhibited. Both 
DAi and DA2 receptors are found on the apical and basolateral membranes of the 
proximal tubule. Activation of the 2 receptors can inhibit the sodium pump activity 
on the proximal tubule. Inhibition of the sodium pump involves GTP dependent 
regulatory protein and the intracellular messenger cAMP (Bertorello and Aperia 
1990). Thus, intrarenal DA can influence sodium excretion through both 
hemodynamic and tubular mechanisms (Kirchner & Stein 1994). 
Dietary sodium appears to be a major regulatory factor in the control of renal DA 
synthesis (Alexander et al 1974, Ball et al 1978, Carey et al 1981，Lee 1993). 
There is a close relationship between sodium intake and DA excretion. Increased 
sodium intake increases DA excretion; while sodium depletion leads to a decrease in 
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DA excretion. Even under constant sodium intake, the use of DA receptor 
antagonists or dopa decarboxylase inhibitor reduces sodium excretion (Bass & 
Murphy 1990). It has also been suggested that the chloride ion is important in 
increasing DA excretion (Ball et al 1978). A recent study suggested that dietary salt 
loading increases L-dopa uptake across the basolateral membrane of renal tubular 
cells, thereby increasing the synthesis of DA in the cells (Wolfovitz et al 1993). It 
was also suggested that the proximal tubular reabsorptive capacity regulates the 
synthesis of DA (Eadington et al 1991). Other proposals on the regulation of DA 
synthesis include the tubular transport of sodium dependent aromatic amino acids, 
intratubular effect of sodium, or modulation by other factors affecting natriuresis such 
as atrial natriuretic factors (Lee 1993). 
ECF volume expansion by intravenous saline infusion induces natriuresis and an 
increase in DA production in both man and animals (Bass & Murphy 1990，Lee 1993， 
Kirchner & Stein 1994). Furthermore, natriuresis was attenuated by both selective or 
nonselective DA receptor antagonists, or dopa decarboxylase inhibitors such as 
carbidopa or benserazide. Increase in dietary proteins leads to an increase in DA 
production and in turn affects sodium excretion (William al 1986, Young 1990). 
Provision of the the essential amino acid tyrosine is crucial for the synthesis of L-dopa 
which determines the tubular formation of DA. Protein depleted rats displayed 
increased sympathetic nervous activity and diminished DA excretion. 
Supplementation of a low protein diet with tyrosine restored DA excretion to normal 
but without affecting the sympathetic nervous activity. On the other hand, protein 
enriched rats showed augmentation of DA excretion. Recently, increased dietary 
phosphate intake in rats was also reported to increase DA excretion when the salt 
intake was kept constant (Berndt et al 1993). It is of interest to note that the increase 
in DA excretion was not accompanied by increase in sodium excretion. Increased DA 
excretion was due to an increase in tubular synthesis of DA. The detailed mechanism 
responsible has not been identified. 
There have been reports that endogenous DA does not contribute to the regulation of 
natriuresis under all conditions of sodium loading (Bass & Murphy 1990, Kirchner & 
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Stein 1994). There have also been reports that sodium excretion in animals put on 
normal or high salt diets was not affected by the presence of a DA receptor antagonist 
or dopa decarboxylase inhibitor. When anesthetized dogs were infused with 
hypoosmotic saline, they displayed an increase in sodium excretion independent of DA 
excretion. Similarly, in the presence of DA receptor antagonists, ECF volume 
expansion in dogs with infusion of isoosmotic saline failed to reduce sodium 
excretion. Furthermore, intravenous saline infusion in man treated with earbidopa 
failed to demonstrate a decrease in sodium excretion (Jeffery et al 1989). DA 
excretion increased only in the female laboratory rats in response to sodium challenge 
(Young 1990). Male rats in the same laboratory on high sodium diet had a paradoxial 
fall in DA production. An alternative hypothesis was proposed to explain these 
conflicting results from different research groups on the role of DA in the regulation 
of sodium excretion (Eadington et al 1991). Under some conditions, proximal tubular 
reabsorptive capacity regulates the synthesis of DA instead of the generally accepted 
view that sodium chloride regulates DA synthesis. More studies are necessary to 
clarify the role of renal DA in the regulation of sodium excretion. 
The question whether renal DA interacts with other factors in the homeostasis of 
effective ECF volume remains controversial (Lee 1993). Activation of the DAi 
receptors by agonists can increase plasma renin activity depending on the dose of the 
agonists. On other hand, infusion of angiotensin II in physiological doses resulted in 
the reduction of renal DA and a decrease in sodium excretion. There were also 
conflicting reports on the interaction between DA and vasopressin in blocking the 
hydroosmotic effect of vasopressin on the cortical collecting duct in animals. The 
interaction between DA and atrial natriuretic factor in regulating sodium excretion has 
not been elucidated. More studies are necessary to understand the complicated 
interaction between DA and other factors. 
Renin-angiotensin system 
The renin-angiotensin system has been recognized as an important physiological 
regulating system in controlling sodium excretion (Briggs et al 1990’ Rabkin & Dahl 
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1993，Kirchner & Stein 1994). Renin is released from the granulated cells near the 
juxtaglomerular apparatus； It acts on the glycoprotein angiotensinogen to produce a 
decapeptide angiotensin I. Angiotensin I is biologically inactive, but it is rapidly 
converted to active angiotensin II by the angiotensin converting enzyme in vascular 
endothelium especially in the lung. This octapeptide is further cleaved to form active 
angiotensin III and other smaller inactive fragments. 
The release of renin is regulated by factors affecting sodium excretion. The important 
modulators are blood pressure, tubular sodium concentration, the sympathetic 
nervous system and angiotensin II (Kurtz et al 1990, Hackenthal 射 a/ 1990). Renin 
release responds inversely to changes in renal perfusion pressure, and a fall in pressure 
is associated with an increase in renin secretion. Increase in the sodium load delivered 
to the macula densa reduces renin release. Thus, a high salt diet and volume 
expansion are associated with low plasma renin activity. On the other hand, a low salt 
diet and volume depletion are accompanied by low sodium levels in distal tubular 
fluid, resulting in increase of renin activity. Low frequency stimulation of the renal 
sympathetic nervous system enhances the rate of renin secretion directly without any 
change in GFR and renal blood flow. Angiotensin II inhibits renin secretion in a 
negative feedback loop. This is a direct effect，not dependent on changes in renal 
hemodynamics or tubular transport. Other inhibitory agents are: vasopressin, 
somatostatin, endothelin, endothelium-derived relaxing factor, and adenosine Ai 
receptor agonists. On the other hand, prostaglandins, PTH, glucagon, vasoactive 
intestinal peptide, adenosine A2-agonists, and histamine can stimulate renin release. 
Substances that influence renin secretion directly control the secretion via a limited 
number of intracellular second messengers, for example, cAMP, cGMP or 
phospholipase C The second messengers modulate intracelullar calcium levels. An 
increase in intracellular calcium is associated with decreased renin release, and 
reduced intracellular calcium enhances renin secretion. 
Although some ambiguity still exists about the biological role of the heptapeptide 
angiotensin III，the bulk of evidence suggests that angiotensin II is the major if not the 
sole biological active compound (Humphreys & Lin 1988). Receptors for this peptide 
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hormone have been localized to glomeruli, renal cortex, and the outer strip of inner 
medulla overlying the vasa recta. It has the capacity to influence sodium excretion 
through different mechanisms (Kirchner & Stein 1994). It can directly stimulate the 
synthesis and release of the salt-retaining steroid hormone, aldosterone. It has a 
profound effect on systemic vascular resistance and thereby modulate effective ECF 
volume. Angiotensin II can cause constriction of the efferent arteriolar of the 
glomerulus and contraction of glomerular mesangial cells, thus affecting GFR. Finally 
it affects the proximal tubular reabsorption of sodium directly. Infusion of 
physiological doses of angiotensin II directly into canine renal artery showed that 
angiotensin II can stimulate sodium transport in the proximal tubule. The 
physiological significance of angiotensin II in controlling sodium excretion is well 
defined. When an angiotensin-converting enzyme inhibitor was infused into the renal 
artery of a sodium-depleted dog, a significant increase in sodium excretion was 
observed (McCaa et al 1978). This inappropriate loss of sodium occurred despite a 
fall in both GFR and blood pressure. 
Aldosterone 
The mineralocorticoid aldosterone plays an important role in the control of sodium 
excretion under conditions of alterations in dietary sodium (Briggs et al 1990, Rabkin 
& Dahl 1993, Kirchner & Stein 1994). It is synthesised by the zona glomerulosa cells 
of the adrenal cortex. Its action is to reduce sodium excretion by promoting sodium 
reabsorption at the late tubular segments, such as the cortical and medullary collection 
ducts. Aldosterone secretion is directly stimulated by angiotensin II，plasma 
potassium concentration, adrenocorticotropic hormone, and serotonin and its 
secretion is inhibited by atrial natriuretic peptides and dopamine. Increased dietary 
sodium intake leads to reduced aldosterone activity and sodium excretion is enhanced; 
while sodium restriction leads to increased aldosterone activity and sodium excretion 
decreases. 
The cellular actions of aldosterone in promoting sodium reabsorption are mediated by 
the synthesis of a unique protein. The hormone first binds to cytoplasmic receptor 
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and this hormone-receptor complex is translocated into the cell nucleus, where it 
binds to specific nuclear receptor and initiates transcription of RNA to produce this 
protein. This protein enhances the sodium permeability on the apical side. Increase in 
the intracellular sodium concentration leads to a secondary increase in sodium pump 
activity on the basolateral membrane. 
Renal Prostaglandins 
Prostaglandins (PGS) are a group of cyclic fatty acids produced throughout the body 
and possess a wide range of biological actions (Rabkins & Dahl 1993). They are 
paracrine hormones produced at or near their site of action. Like other hormones, 
PGS act through hormone-specific receptors. However, the cellular mode of action 
varies according to cell type and is not fully understood. 
The kidney is a major site of PGS production, metabolism and action. Intrarenally 
formed PGS have long been considered to affect renal excretion of sodium and water 
(Briggs et at 1990). However, the evidence that PGS play a regulatory role in 
sodium excretion is conflicting (Kirchner & Stein 1994). Infusion of PGS into the 
renal artery of animals results in vasodilation and increase in sodium excretion. It is 
uncertain whether the administration of PGS via the renal artery mimics either the 
physiological concentration or anatomical location of endogenpusly produced PGS. 
Therefore, the interpretation of these findings is difficult. 
Different approaches have been used to overcome this problem (Kirchner & Stein 
1994). The production of renal PGS is correlated with sodium excretion. 
Nonsteroidal anti-inflammatory drugs, potent inhibitors of PGS synthesis have been 
used to study the effect on sodium excretion. The effects of PGS on sodium-
transporting epithelia are studied in vitro. Despite all these efforts, the role of PGS in 
controlling sodium excretion remains highly controversial. For example, urinary 
excretion of PGS is increased in both saline infusion and salt deprivation. Inhibition 
of PGS synthesis can increase, decrease or has no effect on sodium excretion. PGS 
may have a role in the maintenance of renal homeostasis by interaction with other 
hormones (Rabkins & Dahl 1993), 
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Renal Kallikrein-kinin system 
Ihe kallikreins are a series of glycoprotein enzymes (Rabkins & Dahl 1993, Kirchner 
& Stein 1994). There are two major forms of kallikreins: the plasma and the 
glandular (or tissue) forms. A complete kallikrein system in the glandular form is 
found in the kidney and has been proposed to increase sodium excretion in response 
to expansion of the ECF volume. Activation of this system leads to release of the 
protease kallikrein which acts on the substrate kininogen to release kallidin, the renal 
kinin. Kallidin is subsequently converted to bradykinin by aminopeptidases. Kinins 
are degraded into inactive peptides by kininases I and II. The latter is also the 
converting enzyme responsible for the activation of angiotensin I. Kininase II is 
located in the proximal tubule in high concentrations, thus preventing delivery of 
circulating kinins to the distal nephron, the primary site of endogenous kinin activity. 
The kallikrein-kinin system appears to increase sodium excretion and to have 
vasodilatory action (Briggs 1990, Rabkins & Dahl 1993，Kirchner & Stein 1994). 
Acute infusion of exogenous kinins into the renal circulation produces significant 
increase in renal blood flow, sodium and water excretion without affecting GFR. 
Urinary excretion of kallikrein correlates with sodium excretion during saline infusion 
or after mineralocorticoid adminsitration. However, like the problems associated with 
the study of prostaglandins described previously, these results do not necessarily 
prove that the kinins have a regulatory role in sodium excretion. Furthermore, 
inhibition of the kalikrein-kinin system by protease inhibitor or the kinin-receptor 
antagonist do not alter sodium excretion in normal or expanded ECF volume states. 
Available evidence is against a role for kinins in sodium excretion. More studies are 
required to show the direct action of kinins on sodium excretion. 
On the other hand, there is evidence that the kallikrein-kinin system has an indirect 
role in modulating sodium excretion through interaction with other systems (Rabkin 
& Dahl 1993). There are complicated interrelationships between kinins and the renin-
angiotensin-aldosterone system, vasopressin and the prostaglandins. The mechanisms 
of interaction are not M y understood. For example, kininase II inactivates kinins but 
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converts inactive angiotensin I to the active angiotensin II. Aldosterone has been 
shown to increase kallikrein excretion. 
Extra-renal factors 
Natriuretic peptides 
In man, 4 different types of natriuretic peptides have been identified that play a 
significant role in the maintenance of ECF volume through sodium excretion (Jamison 
et al 1992). The atrial natriuretic peptide (ANP), a 28 amino acid peptide, is the 
major circulating type synthesized and released from the cardiac atria. The brain 
natriuretic peptide (BNP), containing 32 amino acids, is synthesized in the brain and 
the heart. Its plasma concentration is about six times lower than that of ANP. 
However, the clearance of BNP is ten times slower than that of ANP. The C-type 
natriuretic peptide (CNP) has 2 variants: a 22 amino acid peptide and a 53 amino acid 
peptide. The larger peptide is mainly found in the brain, while the smaller peptide can 
be found in the kidney. But CNP cannot be found in the circulation. Lastly, 
urodilatin, a 32-amino acid peptide identical to the C-terminal sequence of proANP, 
has been found only in urine. 
Biological activities and regulation of these natriuretic peptides are mediated through 
3 types of receptors: receptors A, B and C (Jamison et at 1992). Binding of the 
natriuretic peptides to receptors A and B stimulates membrane-bound guanylate 
cyclase, which catalyzes the formation of cyclic guanosine monophosphate (cGMP) 
from guanosine triphosphate (GTP). cGMP is the second messenger for the 
biological activities of the peptide. Receptor C functions as a clearance receptor to 
remove natriuretic peptides from the circulation. The peptide-receptor C complex 
undergoes rapid internalization. Receptor C is recycled back to the surface while the 
ligand is hydrolyzed in lysosomes. 
The most important stimulus for the release of ANP is atrial stretch (Brenner et at 
1990，Cogan 1990). This can result from conditions that increase the effective ECF 
volume, for example: salt loading, head-down tilt, head-out water immersion, primary 
aldosteronism, the syndrome of inappropriate antidiuretic hormone, renal failure, or 
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congestive heart failure. ANP regulates the ECF volume by promoting sodium 
excretion through both direct and indirect mechanisms (Briggs et al 1990, Rabkin & 
Dahl 1993, Kirchner & Stein 1994). ANP increases the GFR by increasing the 
glomerular capillary hydrostatic pressure, through afferent arteriolar vasodilation and 
efferent arteriolar constriction. It also reduces the rate of apical sodium entry through 
the luminal amiloride-sensitive sodium channels at the inner medullary collecting 
ducts. These two actions involve the binding of ANP to receptor A located on the 
glomerulus and the collecting ducts, and mediated through cGMP. Therefore, they 
can be regarded as direct actions of ANP to promote sodium excretion by reducing 
sodium reabsorption. On the other hand, there are other actions of ANP on parts of 
the renal structure that do not have ANP receptors and the biological responses are 
not associated with production of cGMP. For example, ANP inhibits angiotensin II-
induced sodium reabsorption at the proximal tubule; it inhibits renin and aldosterone 
secretion; and increases the hydrostatic pressure in deep nephrons resulting in 
unfavorable pressure gradients for sodium reabsorption. 
BNP binds to similar receptors to ANP and has similar biological actions to ANP. 
However, the affinity of BNP to the receptor is lower. In human heart failure, the 
ventricle becomes more important than the atrium in the synthesis and release of BNP 
(Mukoyama et at 1991). The significance of this natriuretic peptide in the 
maintenance of effective ECF volume remains to be elucidated. 
CNP binds to receptor B and has similar cardiovascular actions to ANP but lacks the 
renal actions (Clavell et at 1993). Since CNP is abundant in the brain and cannot be 
found in the circulation, it is suggested that CNP is a neuropeptide. Furthermore，its 
receptor is unique and different from that of ANP and it is suggested that CNP could 
represent another distinct regulatory system (Jamieson et at 1992). Further research 
is required to understand its significance in the homeostasis of ECF volume. 
Urodilatin is a unique intrarenal natriuretic peptide (Goetz 1991). It binds to ANP 
receptors with the same affinity as ANP, activates guanylate cyclase and induces 
natriuresis and diuresis. Unlike ANP, urodilatin does not inhibit renin or aldosterone 
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secretion. Urinary urodilatin correlates with diurnal changes in sodium excretion and 
also correlates better with sodium excretion than plasma ANP (Goetz et at 1990， 
Drummer et at 1991). Thus, it has been considered the most important natriuretic 
peptide regulating natriuresis. However, more work is necessary before this can be 
accepted (Humphreys 1991). 
Natriuretic hormone - the endogenous sodium transport inhibitor (ESTI) 
More than 30 years ago, de Wardener postulated the presence of an endogenous 
natriuretic hormone (de Wardener et al 1961). This hormone increases sodium 
excretion during ECF volume expansion by direct inhibition of sodium reabsorption in 
the nephrons. Infusion of plasma from volume expanded animals can maintain 
profound and long-lasting natriuresis. Since then many studies have shown evidence 
for the existence of this putative natriuretic hormone (de Wardener & Clarkson 1985). 
de Wardener also hypothesized that this natriuretic hormone is related to the 
pathogenesis of essential hypertension in subjects with a renal defect. However, the 
identity and the biosynthetic pathway of this hormone are still poorly understood. 
The scientific community has been confused by the use of a non-specific biological 
action, sodium pump inhibition, to study this hormone (Wechter & Benaksas 1990’ 
Goto et al 1992, Schoner 1992, Woolfson et al 1994). Furthermore, the use of a 
large variety of measurement methods and purification strategies has produced more 
confusion. 
Different names have been used for this putative natriuretic hormone: the third factor, 
sodium pump inhibitor, endogeneous digitalis-like immunoreactivity, endogenous 
digitalis-like factor, ouabain-like factor etc. The ESTI should be distinguished from 
non-specific inhibitors of the sodium pump by its direct binding to the cardiac 
glycoside receptor, the sodium pump (Goto et al 1992). Although it has an inhibitory 
action on the sodium pump, DA should not be considered as the natriuretic hormone 
as it works through the activation of DAi and DA2 receptors via second messenger 
cAMP. 
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More than 20 substances have been proposed as the natriuretic hormone. They 
include lipids, steroids, ouabain, digoxin, bufodienolides, ascorbic acid, lignans, 
urodienolone, hemin, quaternary ammonium or immonium compounds, peptides and 
unknown small molecular weight substances. A detailed listing can be found in recent 
reviews (Wechter & Benaksas 1990, Goto et al 1992, Schoner 1992，Woolfson et al 
1994) ‘ Among all these compounds, only ouabain has been purified to homogeneity 
for structural analysis (Ludens et al 1991, Mathews et al 1991). However, ouabain 
does not show any significant natriuretic activity in vivo except at toxic supra 
physiologic doses (de Wardener & Glarkson 1985). Without the identification of the 
chemical structure of this hormone, it is only possible to understand this hormone by 
its putative physiological mechanism. 
The tissue of origin of this hormone is not known with certainty. Steroid hormones 
are usually synthesized in the adrenals while peptide hormones are products of higher 
centers in the brain and of other endocrine tissues. Based on experiments on focal 
lesions and stimulation of the hypothalamus, intracerebro-ventricular infusions, and 
the use of tissue extracts, it has been proposed that the hypothalamus is involved in 
the production of ESTI (Woolfson et al 1994). 
It has been suggested that the natriuretic hormone is not necessarily restricted to one 
molecule (Wechter & Benaksas 1990). The research focus has also shifted to 
emphasis on the complete purification and characterization of compounds which will 
inhibit the sodium pump in different measurement methods rather than a natriuretic 
compound (Woolfson et al 1994). It is of importance to understand the ESTI 
thoroughly as it may be related to the pathogenesis of essential hypertension, a disease 
affecting 10-15% of the world' s population. 
Vasopressin 
Arginine vasopressin (AVP) is a 9 amino acid peptide secreted from the posterior 
pituitary gland in response to increased osomolarity or hypovolemia (Rabkin & Dahl 
1993)，Its major biological action is to increase water permeability throughout the 
collecting duct, thereby allowing concentration of the urine. Furthermore, this 
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peptide has effects on sodium excretion by affecting GFR and tubular sodium 
reabsorption. 
AVP can specifically bind to two different types of receptors, Vj and V2 ( Humphreys 
& Lin 1988). receptors are found in glomerular mesangium, renal vasculature, and 
medullary interestitial cells. Binding to these receptors leads to an increase in 
intracellular calcium, which mediates vasoconstriction and prostaglandin synthesis. 
V2 receptors are located along the renal tubule, especially the thick ascending limb of 
Henle's loop and the cortical and medullary collecting duct. Binding of AVP to these 
receptors is linked to the activation of adenylate cyclase and the generation of cAMP. 
This is responsible for hydroosmotic effects of the hormone. Increase in circulating 
AVP concentration enhances sodium excretion through binding to Vi receptors. AVP 
induces contraction of the glomerulus to increase GFR, hence increase in sodium 
excretion. Furthermore, activation of these receptors stimulates prostaglandin 
synthesis, which then act locally to decrease tubular sodium reabsorption. 
Endothelins 
The endothelins are a family of three peptides all containing 21 amino acids 
(Simonson & Dunn 1993). They are vasoconstrictors involved in the control of 
cardiovascular and renal function and act as neuromodulators. Although expression 
of mRNA has been reported in other tissues, endothelin-1 is produced mainly by 
endothelial cells, for example renal endothelial cells, glomerulus, and also renal 
tubular cells (Rabkin & Dahl 1993). It is the only form detected in the human 
circulation. It is secreted on the basal side of the endothelial cells (Remuzzi & 
Benigni 1993). Endothelin-2 is only identified in monkey kidney tissue culture and 
endothelin-3 is found in brain homogenates. Studies on the physiological actions of 
endothelins in controlling sodium excretion have been conducted mainly using 
endothelin-1. 
A high affinity specific endothelin receptor has been identified (Rabkin & Dahl 1993, 
Remuzzi & Benigni 1993). Biological actions after the binding to the receptor are 
mediated by the activation of inositol-specific phospholipase C and the subsequent 
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increase in cytosolic calcium concentration. Furthermore, the receptor complex can 
also activate the release of arachidonic acid, depolarize the membrane, enhance 
alkalinisation of the cell interior, and inhibit the active sodium pump. This receptor 
has been found in a large variety of tissues. In the kidney, endothelin-1 binds to 
glomeruli, vasa recta bundles, papillae and the proximal tubules. 
Endothelin-1 is a potent renal vasoconstrictor, 30 times more potent than angiotensin 
n (Rabkin & Dahl 1993). Excretion of endothelin is enhanced by a number of factors, 
for example: increased hemodynamic shear stress, transforming growth factor, 
interleukin-1, angiotensin II，vasopressin, and epinephrine. Its action in affecting 
sodium excretion is through the effect on GFR and tubular reabsorption of sodium. 
Although endothelin can be detected in the circulation, it operates as a local paracrine 
hormone more than through the systemic circulation (Remuzzi & Benigni 1993). 
Micropuncture techniques have shown that in vivo administration of endothelin can 
induce an increase in systemic blood pressure associated with renal vasoconstriction 
(Vercellotti & Tolins 1993). Glomerular capillary plasma flow is reduced, with 
increase in both afferent and efferent arteriolar resistances. The net effect is to cause 
30% - 50% decrease in single-nephron GFR. This will reduce sodium excretion. On 
the other hand, endothelin-1 at picomolar concentration can act as a natriuretic 
hormone by inhibiting the ouabain-sensitive sodium pump in inner medullary 
collecting duct cells by a prostaglandin-dependent mechanism (Zeidel et al 1989). 
The systemic vasoconstrictor effect of endothelin, as reflected in the pressor response 
after in vivo administration, is preceded by a transient vasodilation that is most likely 
mediated by release of vasodilators (Vercellotti & Tolins 1993). Thus, the potent 
vasoconstriction action of endothelin is often guarded by opposing vasodilatory action 
of other factors, such as endothelium-derived relaxing factor, ANP and plasma renin 
activity. 
With its potent vasoconstriction effect, endothelin may play a significant role in a 
number of renal diseases, for example: glomerular inflammation, cyclosporin-induced 
kidney disease and post-ischemic renal failure (Rabkin & Dahl 1993). However, its 
significance in the maintainence of ECF volume through controlling sodium excretion 
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under normal physiological conditions remains to be elucidated (Kirchner & Stein 
1994). 
Endothelium-derived relaxing factor or Nitric oxide 
Endothelium-derived relaxing factor (EDRF) is a short-lived diffusible substance 
released by endothelial cells that mediates the effect of a number of vasorelaxants 
(Rabkin & Dahl 1993). The chemical nature of EDRF is controversial. Some believe 
that nitric oxide (NO) is the EDRF while others would consider it to be part of the 
EDRF molecule. The biosynthetic pathway and the mechanism of biological action of 
NO have been described (King & Brenner 1991, Vercellotti & Tolins 1993). It is 
derived from the terminal guanidino nitrogen atom of L-arginine by the action of a 
soluble enzyme NO synthase. NO produced by the endothelial cells diffuses to the 
nearby target cells, such as smooth muscle cells and glomerular mesangial cells. It 
stimulates the guanylate cyclase to increase the cellular cGMP concentration. cGMP 
activates protein kinase to dephosphorylate the myosin chains causing vasorelaxation. 
Release of NO is stimulated by a number of factors, such as: acetylcholine, 
arachidonic acid, endothelin, shear stress, and hypoxia (Rabkin & Dahl 1993). 
NO is a potent vasodilator. Its role in modulating sodium excretion is studied by the 
use of NO synthase inhibitors in vivo, such as L-N-monomethylarginine or L-N-
nitroarginine-methylester (Vercellotti & Tolins 1993). Inhibition of the NO system 
results in decreased GFR and renal vasoconstriction. Thus, the stimulation of NO 
production induces sodium excretion and inhibition of NO activity decreases renal 
sodium handling. In animal studies, the inhibition of NO synthase significantly 
elevates systemic blood pressure (Baylis et al 1990). This indicates that NO may 
play a significant role in counterbalancing other vasoconstrictors in the control of 
systemic blood pressure, for example, endothelin. 
Other hormones 
A number of other hormones with other primary functions in the gastrointestinal tract, 
the endocrine tissues or brain have also been reported to influence sodium excretion 
(Humphreys & Lin 1988, Kirchner & Stein 1994). Vasoactive intestinal peptide, 
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substance P, secretin, neuro-peptide Y, cholecystokinin octapeptide and parathyroid 
hormone have all been reported to increase sodium excretion; while calcitonin gene 
related peptide, insulin, neurotensin, somatostatin and melanocyte stimulating 
hormone have been reported to reduce renal sodium excretion. Their influence on 
sodium excretion is often observed under supra physiologic doses. Sometimes, these 
hormones may modulate natriuretic activity of other established factors, for example 
parathyroid hormone has recently been reported to modulate the action of ANP 
during acute volume expansion (Geiger et at 1992). The physiological role of these 
hormones in regard to sodium excretion remains to be elucidated. 
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V. CONCLUSION 
The maintenance of a constant effective ECF volume requires very complicated 
mechanisms. The kidney regulates urinary sodium excretion so that the total body 
sodium remains constant. Under normal physiological conditions, sodium excretion is 
adjusted to the amount of dietary sodium intake. Ingestion of additional sodium will 
provoke retention of water by the release of vasopressin to preserve isotonicity. This 
will lead to an increase in ECF volume. These changes are constantly monitored by 
different sensory mechanisms, which in turn trigger a multitude of physical or 
hormonal factors to increase sodium excretion and restore effective ECF volume. 
Different factors can affect sodium excretion through a large variety of pathways. We 
can therefore infer that the body has set a high priority to ensure the homeostasis of 
the ECF volume. Such a system design presents fundamental difficulties in 
understanding the functioning of indiviudual factors. It is extremely challenging, if 
not impossible, to dissect out an individual factor and study its contribution to sodium 
excretion. The use of inhibitors or antagonists for a factor may stimulate the action of 
another factor to maintain the efficiency of sodium excretion especially under normal 
physiologic situations. On the other hand, when acute or relatively large changes in 
ECF volume are used to study different factors, it is difficult to extrapolate the results 
to physiological situations. 
This review shows that many areas concerning sodium excretion remain to be 




MEASUREMENT OF ENDOGENOUS 
SODIUM TRANSPORT INHIBITORS 
I. LITERATURE REVIEW 
A large number of methods for the measurement of endogenous sodium transport 
inhibitors (ESTI) can be found in the literature. These methods were developed to 
assess the changes in ESTI in different physiological / pathophysiological conditions 
and to monitor the progress of the purification procedures. However, all these 
methods suffer from a common problem that the identity of ESTI is still unknown. 
No standard preparation can be used to assess the accuracy of the various methods. 
In most methods reported in the literature, samples were purified before the 
measurement of ESTI. The principle of measurement was based on the ability of the 
samples to inhibit the sodium pump. These methods can be classified into the 
following types: 
A. inhibition of purified Na,K-ATPase activity 
B. inhibition of the sodium pumps in intact cells or tissues 
C. biological effects of sodium pump inhibition on tissues, organs or animals, and 
D. immunoreactivity with anti-digoxin or anti-ouabain antibodies, 
PRETREATMENT AND PURIFICATION PROCEDURES 
PRIOR TO ESTI MEASUREMENT 
Complexity of the pretreatment and purification procedures reported in the literature 
varied significantly depending on the purpose of the study. Research groups reporting 
the presence of ESTI in diseases have usually taken a simpler approach; while groups 
intending to purify the ESTI to homogeneity have developed more complicated 
procedures. 
Simple pretreatment procedures have usually been carried out before the measurement 
o r fijrther purification steps. Some workers have incubated plasma samples at room 
temperature for 30 min to increase the measurable ESTI because it has been 
suggested that there are precursors (Gruber & Buckalew 1978，Pamnani & Haddy 
1988). others have boiled the samples for 5 - 20 min to deproteinise and increase the 
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yield of ESTI (Pamnani & Haddy 1988, Mattiasson & dhlin 1987，Kelly ^ a/ 1985). 
Before boiling, the samples were diluted with water (Lau & Valdes 1988)，acidified to 
pH 5.5 with hydrochloric acid (Hamlyn et al 1982，Balzan et al 1984)，or both diluted 
and acidified (Boschi et al 1985, Bisordi & Holt 1989). Ultrafiltration has been 
another simple pretreatment procedure before or after deproteinization (Ng et al 
1985，Gonick et al 1987，Weiler et al 1990). Solid phase extraction with reverse 
phase resins (e.g. C18, C8) to remove electrolytes and proteins has been one of the 
popular pretreatment methods. ESTI is adsorbed on the resin and then it was eluted 
with methanol (Devynck et al 1983, Vasdev 过 al 1985, Naomi et a/ 1991), different 
concentrations of ethanol (Boschi et al 1985, Buckalew et al 1987, Masugi et al 
1987) or varying amount of acetonitrile in 0.1% trifluoroacetic acid (Morise et al 
1986，Gonick et al 1987，Weber et al 1989, Weiler et al 1990). This popular 
technique also facilitates concentration of samples. Organic solvents are evaporated 
and the residues are reeonstitued with a smaller volume of solvents than the starting 
sample volume. Lyophilization has also been commonly used to concentrate 
pretreated samples before purification (Balzan et al 1984，Boschi et al 1985, Bisordi 
& Holt 1989). 
These methods of pretreatment could significantly affect the results, Moreth et al 
developed a quantitative receptor assay for the measurement of ESTI that did not 
require any pretreatment of the plasma samples (Moreth et al 1987). They were able 
to demonstrate that boiling of acidified plasma or ultrafiltration decreased the amount 
of ESTI in the samples. A significantly higher plasma ESTI concentration in the 
hypertensive patients could not be demonstrated after the samples were pretreated 
with these 2 methods. Boiling of acidified plasma for 10 min was reported to 
decrease ESTI by 25% and by 50% when boiling was prolonged to 20 min (Balzan et 
al 1984). 
Procedures to purify biological samples for measuring or identifying ESTI have been 
mainly by chromatographic techniques (Kelly et al 1985, Goto et al 1989’ Hamlyn et 
a/ 1989’ Ludens et al 1991). Preparative column chromatography was initially used 
to handle the bulky samples. Further refinement would mainly depend on a 
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combination of high performance liquid chromatography (HPLC) methods such as 
ion-exchange chromatography, gel filtration and reverse-phase chromatography. 
Chromatographic eluants were collected to test for the presence of ESTI activity by 
different methods to be described in following sections. Separation by thin-layer 
chromatography has also been reported (Spustova et al 1985). Extraction methods 
using purified Na,K-ATPase preparations (Ludens et al 1991)，anti-digoxin 
antibodies, affinity chromatography using anti-digoxin antibodies (Gruber ^ a/ 1983) 
and anti-ouabain antibodies (Kelly 1986) were used in an attempt to improve the 
specificity of the purified product. There is a common assumption that ESTI is a 
cardiac-glycoside like entity and the purification procedures should be optimized to 
recover substances of that nature (Hamlyn 1988，Schoner 1992，Goto 射 al 1992). 
However, this assumption had not been proven 
METHODS OF MEASURING ESTI 
Inhibition of purified Na,K-ATPase activity 
Purified Na,K-ATPase has been prepared from different sources. Common examples 
are dog kidney (Hamlyn et al 1982, Masugi et al 1987), hog cerebral cortex (Boschi 
et al 1985，Gonick et al 1987) and pig kidney (Moreth et al 1987). An exotic 
example was reported by Kelly et al who purified Na,K-ATPase from the supraorbital 
salt glands of ducks on high salt diet (Kelly et al 1985). 
There has been a large variety of methods reported in the literature to measure the 
inhibition of Na,K-ATPase activity. The increase in the reaction product, phosphate, 
during the reaction was measured by standard chemical reactions (Roulston et al 
1986, Masugi et al 1987). When radioactive adenosine triphosphate (ATP) was used 
as the substrate, the 32P released was separated and counted on a gamma counter 
(Lau & Valdes 1988). The decrease in the substrate ATP was measured by a 
sensitive bioluminescence method and this facilitated the use of very low Na,K-
ATPase activity to improve the sensitivity of the method (Weissberg et al 1984). An 
HPLC method has also been published to measure both ATP and ADP concentrations 
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simultaneously in the reaction mixture. The ratio of the two was used to calculate the 
Na,K-ATPase activity (Shimada et al 1985). The Na,K-ATPase reaction is coupled 
to pyruvate kinase and lactate dehydrogenase. The pyruvate kinase converts the 
product ADP back to ATP in the presence of phospho(enol)pyruvate producing 
pyruvate. Lactate dehydrogenase reduces pyruvate to lactate in the presence of 
reduced nicotinamide adenine dinucleotide (NADH). The rate of decrease in NADH 
concentration is monitored spectrophotometrically at 340 nm. Using this method, it 
was reported that ESTI in hypertensive patients was raised (Hamlyn et al 1982). A 
synthetic substrate, para-nitrophenylphosphate (PNPP), was successfully used to 
measure the inhibition of potassium-activated Na,K-ATPase activity in plasma from 
normotensive subjects with family history of hypertension (Weiler et al 1990). On the 
basis of competitive binding between radioactive [3H]-ouabain and ESTI on the 
binding site of Na,K-ATPase, sensitive radioreceptor assays were developed (Moreth 
et al 1987, Hamlyn et al 1989). The percentage of tracer bound to Na,K-ATPase was 
inversely proportional to the concentration of the competing ESTI. The 
concentration of ESTI was usually expressed in ouabain-equivalent concentration. 
The advantage of using this group of methods is mainly the ease of use. Purified 
Na,K-ATPase is available commercially and this obviates the necessity to purify the 
enzyme. Radioreceptor methods are sensitive and can measure ouabain in the 
nanomolar range. Furthermore, these methods can also be easily modified to 
distinguish ouabain-iike and non-ouabain-like inhibition by varying potassium 
concentration (Masugi et al 1987). On the other hand, this group of methods suffers 
from many non-specific and specific interferences. Both intracellular and extracellular 
binding sites are available on the purified enzymes for inhibitor binding. However, 
only the extracellular binding sites are assessable in vivo. Several substances, 
including unsaturated fatty acids (Tamura et al 1985, Kelly et al 1986), 
lysophosphatidylcholine (Kelly et al 1986), ascorbic acid (Ng et al 1985, Kuske et al 
1987), dehydroepiandrosterone sulfate (Vasdev et al 1985), and mammalian lignans 
(Braquet et al 1986), inhibit purified Na,K-ATPase, but are not able to inhibit sodium 
pumps on intact cells or tissues (Hamlyn 1988，Goto et al 1992). These substances 
do not demonstrate cardiac-glycoside activities. Nevertheless, lysophospholipids 
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were found to be natriuretic in rats (Rauch & Buckalew 1988). Therefore, the 
requirement that ESTI must inhibit the sodium pump similar to cardiac-glycosides has 
not yet been proven. 
Anner et al reported the use of a novel two-sided liposome test system containing 
purified rabbit kidney Na,K-ATPase (Anner et al 1990). The active enzyme 
molecules are accessible on the exterior surface and the time required for inhibitors to 
reach the internal receptors can also be measured. This novel technique provides a 
system to overcome some of the disadvantages inherent to this group of methods. 
However, the preparation of such liposomes is very complicated and technically 
demanding. 
Inhibition of the sodium pump on intact cells or tissues 
A large variety of intact cells and tissues has been used to measure ESTI activities in 
biological fluids. Preparation of washed human red blood cells is a popular choice 
because it is easy to prepare and available in large quantity (Aronson et al 1977, 
Devynck et al 1983, Chimori et al 1986, Ludens et al 1991). Ghost red cell 
membranes after hypotonic shock have also been used (Kelly 1986, Buckalew et al 
1987). Lymphocytes (Moreth et al 1986，Poston et al 1989) and platelets (Linder et 
al 1987, Mattiasson & Ohlin 1987) are the other common cells of human origin that 
have been used. They are also easily accessible but more tedious to work with. 
Although the use of human sigmoidal colon has been reported (Allgayer et al 1986), 
the difficulties in collecting enough human tissues limits its use. 
As it has been suggested that ESTI could have in vivo effects on the renal tubules and 
blood vessels, intact cells and tissues were mostly chosen from these target organs (de 
Wardener & Clarkson 1985). The use of microtome sections of guinea pig kidney 
(Fenton et al 1982) and cultured renal tubular epithelial cell lines from canine and 
porcine (Goto et al 1988b) have been reported. On the blood vessel side, rat tail 
arteries (Pamnani ^ al 1988), rat thoracic aorta rings (Vasdev et al 1989), pig aorta 
(Stokes etal 1990), saphenous vein of dog's hind limb (Jandhyala & Ansari 1986), as 
well as tissue culture of rat aortic smooth muscle cells (Goto et al 1988a, 1989) have 
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been used. Other examples found in the literature include epithelia isolated from the 
frog (Cox & Woods 1987)，fibroblast cell culture (Lichtstein et al 1985) and cortical 
slices of guinea pig brain (Ng et al 1985). 
The principle of measurement in this group of methods is based on the functional 
aspects of the active sodium pump. The effects of ESTI on the ouabain-sensitive 
influx and efflux of sodium (Chimori et al 1986, Moreth et a/ 1986, Cox & Wood 
1987, Poston ct al 1989) and uptake of rubidium, an analogue of potassium 
(Aronson et al 1977，Ng ^ al 1985, Goto et al 1988b, Vasdev et a/ 1989, Stokes et 
al 1990，Ludens et al 1991) in different cells and tissues have been reported. 
Furthermore, inhibition of the sodium pump leads to an increase in intracellular 
calcium concentration. Therefore the movement of radioactive calcium into cultured 
cells has been used to assess the presence of ESTI in urine samples (Goto et al 
1988a). Intracellular free calcium concentration in cells was also studied using 
fluorescent dye binding (Linder et al 1987, Goto et al 1989). The specific [3H]— 
ouabain binding technique on intact cells has been another popular method used in this 
area of research (Devynck et al 1983, Allgayer et al 1986, Kelly 1986, Mattiasson & 
Ohlin 1987, Goto et al 1988b). The radioactive tracer was measured conveniently by 
standard counters. Using Scatchard analysis, the dissociation constant (Kq) and the 
amount of ESTI bound to each cell can be calculated. 
de Wardener's group used a unique cytochemical technique to measure the inhibition 
af Na,K-ATPase activity in the proximal convoluted tubules of guinea pig kidney 
sections (Fenton et al 1982). Inhibition of Na,K-ATPase activity was shown to be 
correlated with the activation of glucose-6-phosphate dehydrogenase (G6PD) activity 
which had improved sensitivity over the inhibition of Na,K-ATPase activity. The 
Na,K-ATPase activity was measured by a hidden metal-capture principle (Chayen et 
al 1981). The G6PD activity was measured by the reduction of neotetrazolium salt to 
produce formazan deposits. The chromogens produced in these methods were 
quantitated by a scanning and integrating microdensitometer over a defined area of 
the tissue sections. It was necessary to dilute plasma samples 100 to 10000 fold. 
This is in contrast to other methods that require concentration of samples. 
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This group of methods was considered to offer the greatest sensitivity and utility in 
excluding most of the false positives, i.e. non-cardiac-glycoside-like inhibitors, 
detected by other methods (Hamlyn 1988). The choice of animals and tissues would 
be an important consideration because species-specific sensitivity of the tissues 
towards ouabain had been reported for partially purified ESTI from volume expanded 
plasma (Hamlyn et al 1988). The presence of 3 isoenzymes of Na,K-ATPase further 
complicate the issue as tissue-specific expression of enzyme activity has been reported 
(Goto et al 1992). Furthermore, the use of cells and tissues requires fresh sample 
preparation which is technically demanding. Biological variation among the animals is 
another obstacle. The use of specific tissue culture cell lines appeared to be a 
practical solution (Goto et al 1988a, 1988b, 1989). Finally, this group of 
measurement methods is still providing results based on in vitro conditions. The 
extrapolation of results to in vivo situations has still to be proven. Oral rubidium 
loading in humans has been used as an in vivo model to study cation transport in 
essential hypertension (Boon et al 1984). However, the results of this study do not 
support the presence of reduced Na,K-ATPase activity in untreated hypertensives. 
Biological effects of sodium pump inhibition on tissues, organs or animals 
Studies on volume-related humoral natriuretic factor have used methods which were 
based on the natriuretic effects of putative ESTI on animals or positive inotropic 
effects on tissues and organs. Examples of tissues and organs used were frog 
epithelia (Cox & Woods 1987), toad hemi-bladders (Granges et al 1986), rat tail 
arteries (Pamnani & Haddy 1988), guinea pig aorta and left atria (Bova et al 1991), 
rabbit femoral arteries and atria (Weber et al 1989) and human mesenteric and uterine 
arteries (Cappuccio et al 1986). The variety of animals used in this group of methods 
was relatively limited Whole animals under anaesthesia such as dogs (Ahmad et al 
1987) and rats (Buckalew et al 1987, Ebara et al 1988) have commonly been used. 
Restrained conscious rats have also been studied for detecting biological activity of 
partially purified urinary ESTI (Clarkson et al 1979). 
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The principle of measurement is based on the ability of ESTI to cause natriuresis and 
positive inotropic effects as a result of sodium pump inhibition. To monitor the effect 
on natriuresis, partially purified ESTI from different biological sources was infused 
into the whole animal via the tail vein (Clarkson et al 1979) or renal arteries (Ahmad 
射 al 1987, Ebara et al 1988). Urine samples were collected over specified time 
periods. The urinary sodium concentration was measured by a standard laboratory 
method to calculate the output or fractional excretion. To monitor the positive 
inotropic effect, tissues were bathed in solutions containing varying amounts of 
extracted ESTI and a combination of electrodes was used to measure the short-circuit 
current, potential difference and direct-current resistance (Granges et al 1986, Cox & 
Woods 1987, Pamnani & Haddy 1988). Contraction response of tissues or organs as 
a result of positive inotropic effects was studied in the presence of the ESTI ( Weber 
et al 1989, Bova ^ al 1991) or ESTI plus other vasoactive compounds such as 
norepinephrine and angiotensin II，that further sensitise the vasculature to the pressor 
effects (Cappuccio etal 1986, Weber ^ a/1989). 
The biological effects on isolated organs and whole animals had been considered to be 
the classic method for the detection of ESTI. However, crude preparation of 
biological samples could contain interfering substances that also elicit the same 
biological response. For example, plasma atrial natriuretic peptide also causes 
natriuresis but not through binding to the sodium pumps (Ackermann 1986). 
Variations in the response of the tested animals could be due to the preparation of the 
animals. For example intrarenal infusion of ESTI preparation in denervated kidneys 
showed a higher natriuretic response than with intact kidneys (Bucklew & Gruber 
1984). Acute stress, and even the use of different anaesthetics have been reported to 
cause abnormal ANF responses in rats (Horky et al 1985, Blizard & Morris 1987). A 
similar scenario for ESTI could lead to misleading conclusions. 
Immunoreactivity with anti-digoxin and anti-ouabain antibodies 
As ESTI is thought to mediate its biological action in a manner similar to cardiac 
glycosides, such as digoxin and ouabain, antibodies against cardiac glycosides are 
expected to crossreact with ESTI The presence of digoxin-like immunoreactivity 
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(DLI) was described in humans, who were not on digoxin treatment, in a large variety 
of physiological and pathological conditions (Howarth et al 1990a and Goto et al 
1991a). Thus, measurement of DLI has been used as a method to measure ESTI. On 
the other hand, studies on the use of ouabain-like immunoreactivity (OLI) to measure 
ESTI are comparatively scarce in the literature (Masugi etal 1986, 1987，Harris 过 a/ 
1991). OLI was measured by polyclonal antibodies using an ELISA method (Harris 
et al 1991). Measurement of DLI was mainly performed with commercially available 
reagent kits using techniques like solid phase radioimmunoassay (Balzan et al 1984), 
double antibody radioimmunoassay (Gruber et al 1983), and automated fluorescence 
polarisation immunoassay (Howarth et al 1990b). In one study, 7 different 
commercial digoxin kits were employed to develop the "immunochemical fingerprint" 
for serum samples collected from different clinical conditions as well as several 
proposed ESTI (Naomi et al 1991). This approach clearly demonstrated the 
differences between the cross reactivity patterns for different preparations of anti-
digoxin antibodies. Most research groups attempted to modify the manufacturers' 
recommended protocol for measurement. Attempts to lower the detection limit and 
to add lower standards were common practice to cover the ESTI concentration that 
was usually on the lower side of the digoxin standard curve. The detection limit was 
decreased, for example, by increasing the sample to tracer volume ratio (Wydicks et 
al 1987). 
The use of immunoreactivity to measure ESTI is convenient and this method is 
available in many clinical laboratories, mainly using commercial digoxin kits. The 
affinities of these antibodies vary for ESTI. Other interfering substances, for example, 
unsaturated fatty acids (Young et al 1986) and bile salts (Vasdev et al 1986) can 
cause interference. Cross-reactivity studies with steroids show that some steroids 
cause measurable DLI only at supra-physiological concentrations (Wong etal 1992). 
It was suggested that ESTI might share the same ligand recognised by the anti-
digoxin antibodies (Gruber et al 1980). Goto et al argued against the use of DLI to 
measure ESTI because the recognition sites of anti-digoxin antibodies are different 
from that of the cardiac glycoside receptor (Goto et al 1992). However, it has been 
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reported that affinity purification using highly specific anti-digoxin antibody reduced 
the binding of partially purified urinary ESTI to cardiac glycoside receptors (Goto et 
a/ 1991b). This result showed that anti-digoxin antibodies competed with the cardiac 
glycoside binding sites for ESTI. In another in vivo study, infusion of high affinity 
digoxin-binding Fab fragments into rats removed ESTI from erythrocytes and kidney 
cortex (Wagener et al 1989). On the other hand, there have been studies showing 
that DLI did not correlate with other methods of measuring ESTI ( Hamlyn et al 
1982, Clarkson & de Wardener 1985，Yamada et al 1988, 1990, Wong et al 1992). 
The recent identification of ouabain as one of the plasma ESTI (Ludens et al 1991) 
provides a strong case for the use of OLI measurement. However, there is only 
limited information available in the literature on the performance of this method. 
Non-specific interference from lipids or steroids would be similar to that reported for 
anti-digoxin antibodies. 
Concluding remarks 
There has been a large variety of methods for the measurement of ESTI reported in 
the literature. However, as the nature of ESTI has not been clarified, it is difficult to 
decide which method of measuring ESTI is superior to others. Although there have 
been strong views that ESTI functions like cardiae-glycosides, there are others with 
conflicting views. The choice of method for the measurement of ESTI would affect 
the outcome of the study. More than one method should be used to characterise the 
ESTI activity in any study. It is generally agreed that it is possible to have more than 
one compound that can promote natriuresis under different physiological and 
pathophysiological conditions. 
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II. METHOD OF MEASUREMENT OF ESTI 
IN THIS STUDY 
PRINCIPLES OF METHODS 
Two methods were developed for the measurement of ESTI in this project, without 
assuming the nature of ESTI. The first method was a sensitive and convenient 
technique to measure the inhibition of purified Na,K-ATPase activity. A pretreatment 
step was required to remove interferences and maximise the inhibitory activity in 
plasma and urine samples. The second method was to measure DLI using 
radioimmunoassay (RIA). During the later part of the project, the production of the 
RIA reagent kit was discontinued by the manufacturer and an automated homogenous 
enzyme immunoassay (HEIA) was used for the same purpose. 
Inhibition of purified dog kidney Na,K-ATPase activity 
ESTI is extracted by Sep Pak C18 resin. Proteins and electrolytes are removed 
during this pretreatment step to eliminate their interference on the subsequent 
reactions In the presence of sodium and ATP, extracted ESTI is allowed to bind 
onto and inhibit a purified dog kidney Na,K-ATPase preparation in a potassium free 
medium. The residual ATPase activity is measured on an automated analyser by an 
enzyme-coupled reaction as illustrated by the following reactions: 
ATP Na,K-ATPase , A D p 
ADP + PEP PK PYRUVATE + ATP 
PYRUVATE + NADH L D H , LACTATE + NAD 
The activity is determined by the rate of change of NADH concentration monitored at 
340 nm. The percentage of inhibition (%I) of the extract is compared with the %I of 
1-11 
a series of aqueous ouabain standards and the concentration of ESTI is expressed as 
%I or as nmol of ouabain equivalent (OE). 
In this method, the hydrolysis of ATP is linked to a regenerating system in which 
pyruvate kinase (PK) catalyses the conversion of phosphoenolpyruvate (PEP) to 
pyruvate with the consequent reconversion of the ADP to ATP. This maintains the 
concentration of ATP constant and prevents the accumulation of ADP, which is an 
ATPase inhibitor. The incorporation of a 2-h incubation of the extracted ESTI with 
the enzyme preparation improved the sensitivity of the method. Another advantage of 
this method is the possibility of automation using routine clinical chemistry analysers. 
The use of a centrifugal analyser in this project facilitated the measurement of 28 
samples in less than 20 minutes. 
Measurement of DLI by radioimmunoassay 
The RIANEN radioimmunoassay has been a popular method for the measurement of 
DLI (Vasdev ^ a/ 1985, Lau & Valdes 1988，Bisordi & Holt 1989, Naomi ^ a/ 
1991)‘ Standards or samples and a fixed amount of the [125I]-labelled digoxin are 
allowed to react with a constant and limiting amount of anti-digoxin antibody. The 
amount of the labelled antigen bound to the antibody is inversely proportional to the 
amount of unlabelled antigen. In this particular kit, separation of the bound from free 
antigen is achieved by a pre-reacted first and second antibody complex. With such a 
system, the pipetting and reaction times are reduced compared to the standard 
sequential double antibody assay. After a single 30 min incubation followed by 
centrifugation, the supernatant is discarded and the pellet is counted to quantitate the 
bound tracer. The normalised percent bound (%B/ B0) data are used to construct a 
standard curve from which the values of the unknowns are obtained by interpolation. 
The manufacturer supplied the typical cross-reactivities of the antibody. The reported 
percentages indicate cross reactivity at 50% displacement compared to digoxin. 
Cross-reactivities of the different compounds tested were: digitoxin 5.3%; 
acetyldigitoxin 1.1%; progesterone 0.056%; ouabain, prednisolone and Cortisol 
<0.02%; testosterone, corticosterone, spironolactone, desoxycortisol and cortisone 
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<0.010/o; 17a-estradiol, 17(3-estradiol, pregnenolone, prednisone and cholesterol 
<0.0002%. 
Measurement of DLI by HEIA 
The CEDIA Digoxin kit supplied by Microgenic was chosen to replace the RIA. This 
HEIA method has the advantages that it can be easily automated on a large variety of 
clinical chemistry analysers and requires no sample pretreatment. The method 
employs 2 inactive polypeptide fragments of P-galactosidase (EC 3.2.1.23) produced 
by recombinant DNA technology (Henderson et al 1986). One fragment, called the 
enzyme-acceptor (EA), is a polypeptide with a small sequence missing in the encoded 
primary structure. The other fragment, called the enzyme-donor (ED), contains the 
missing sequence of the EA polypeptide. EA and ED can reassociate spontaneously 
in solution to form a tetrameric enzymatic entity as active as the native P-
galactosidase. In this kit, digoxin is conjugated to the ED that competes with digoxin 
in the sample for binding sites on a digoxin-specific antibody. Due to steric hindrance, 
the digoxin-ED conjugate bound to the digoxin antibody is prevented from 
reassociation with EA to form an active enzymatic entity. After the competitive 
binding, hydrolysis of the substrate o-nitrophenyl-p-galactopyranoside, monitored at 
420 nm, is used to measure the residual enzyme activity that is directly proportional to 
the concentration of digoxin in the sample. 
According to the manufacturer, the drugs that show clinically significant interference 
with this method include digitoxigenin, digitoxin, digoxigenin and deslanoside. Cross-
reactivities of the different compounds tested were:: ouabain 2.9%, gitalin 29.0%, and 
less than 0.1% for furosemide, prednisolone, prednisone, quinidine, spironolactone, 
testosterone, and theophylline. 
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MATERIALS AND METHODS 
Materials 
Sodium chloride (NaCl); potassium chloride (KC1); magnesium sulphate(MgS04>; 
TES and TRIS buffers; ouabain; phosphoenolphosphate (PEP); nicotinamide adenine 
dinucleotide reduced form (NADH); adenosine triphosphate disodium salt, grade I 
(ATP); ethylenediaminetetraacetic acid (EDTA); ethylene glycol Bis (B-
aminoethylether) N^N^-tetraacetic acid (EGTA); sodium potassium activated, 
ouabain sensitive, adenosine triphosphatase from dog kidney, grade IV (Na,K-
ATPase); pyruvate kinase (PK) and lactate dehydrogenase (LD) from rabbit muscle; 
were purchased from Sigma Chemical Company (St. Louis, MO, USA). Water was 
subjected to reversed osmosis and deionization by the Milli-Q water purification 
system (Millipore, Milford, MA, USA). Methanol and concentrated hydrochloric acid 
(HC1 AR grade) were obtained from Merck (Darmstadt, Germany). C18 Sep Pak 
cartridges were from Waters Company (Millipore, Milford, MA, USA). 
The RIA digoxin kit, RIANEN™, was from New England Nuclear (North Billerica, 
MA, USA). The HEIA digoxin kit was from Microgenic (Concord, CA, USA). 
Theree levels of TDX digoxin quality control samples were from Abbott Laboratories 
(North Chicago, IL, USA). 
Equipment 
The SpeedVac™, a centrifuge connected to a vacuum pump for rapid evaporation of 
volatile solvent, was from Savant Instruments (Farmingdale, NY, USA). The Cobas 
Bio™ and Cobas Fara™, centrifugal chemistry analysers, were from Hoffinan La 
Roche (Basle, Switzerland). The gamma counter was from Packard Instruments 
(Downers, IL, USA). 
Reagent preparation 
Enzyme suspension solution 
This is a 10 mmol/l TES/TRIS buffer solution containing 0.5 mmol/1 ofEDTA (free 
acid), pH 7.4 at 37 °C and is stable at 4°C for at least 6 months. EDTA (0.01462 g), 
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TRIS (0.1211 g) and TES (0.2292 g) were dissolved in 80 ml of deionized distilled 
water. The pH was adjusted to 7.4 at 37 °C with 1 M HC1. The solution was made 
up to volume in a 100-ml volumetric flask. 
StockNa’K-ATPase solution 
A 5-Unit bottle of lyophilized Na,K-ATPase was reconstituted with 1 ml of enzyme 
suspension solution and incubated at room temperature for 3 hours. The solution was 
then aliquoted into small Eppendorf centrifuge tubes (50 in each tube) and kept 
frozen at -70 °C. This stock solution is stable for at least 6 months. 
Buffer A 
This is a 50 mmol/1 of TRIS buffer solution containing 100 mmol/1 of NaCl, 4 mmol/1 
of MgS04 and 0.5 mmol/1 of EDTA (free acid), pH 7 4 at 37 °G It is stable for at 
least 6 months when stored at 4 � C . TRIS (6.055 g), NaCl (5.844 g), MgS04 
(0.4816 g) and EDTA (0.1462 g) were dissolved in 800 ml of deionized distilled 
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water. The pH was adjusted to 7.4 at 37 °C with diluted HC1 solution. The buffer 
was made up to volume in a 1-litre volumetric flask. 
Na,K-ATPase working solution (Reagent D) 
The working solution was prepared by a 1 in 20 dilution of the stock enzyme solution 
with the Buffer A immediately before use. This solution is stable for 12 hours at 4 °C. 
The resulting Na,K-ATPase activity would be in the range of200 - 250 U/l depending 
on the lot of the stock enzyme. 
Ouabain standard solutions 
Working ouabain standard solutions of 5’ 10，20, 30, and 50 nM were prepared by 
appropriate dilution of an aqueous 1 ^M ouabain stock solution with the Buffer A in 
volumetric flasks. 
ATP solution for incubation (Reagent F) 
This is a 5mmol ATP in 5 ml of Buffer A solution and is stable for at least 12 hours 
when kept at 4 � C . ATP (0.0152 g) was dissolved in 5 ml Buffer A fresh prior to use. 
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Buffer B 
This is a 112 mmol/1 ofTES/TRIS buffer solution containing 200 mmol/l ofNaCl, 56 
mmol/1 ofKCl, 13.6 mmol/1 of MgS�4，and 14 mmol/1 of EGTA, pH 7.4 at 37 °C. 
This solution is stable for at least 6 months when kept at 4 °C. TRIS (13.56 g), TES 
(25.67 g), NaCl (11.69 g), MgS04 (4.173 g) and EGTA (5.318 g) were dissolved in 
800 ml of deionized distilled water. The pH was adjusted to 7.4 at 37 °C with 1 M 
HC1. The buffer was made up to volume in a 1-litre volumetric flask. 
A TPase assay reagent (Reagent H) 
This reagent solution contains 7.4 mmol/1 of ATP, 3.4 mmol/1 of PEP, 15 mmol/1 of 
NADH, 3400 U/l of PK, and 4800 U/l of LD in Buffer B. This reagent is stable for at 
least 12 hours when kept at 4 °C . ATP (0.0449 g), PEP (0.0170 g), NADH (0.0112 
g) and 55 \x\ of PK/LD solution were dissolved in 10 ml of Buffer B, prepared fresh 
prior to use. 
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Methods 
Extraction of plasma ESTI using Sep Pak cartridges 
A. A Sep Pak C18 cartridge was primed with 2 ml of methanol and washed with 
10 ml of deionized distilled water. 
B. 300 卩 1 lithium heparin plasma sample was carefully applied into the Sep Pak 
cartridge. After the plasma was all inside the compartment holding the resin, 
it was allowed to stay inside the compartment for 5 min. 
C. The Sep Pak cartridge was washed with 20 ml of deionized distilled water to 
remove protein and electrolytes under vacuum. Water trapped inside the Sep 
Pak was removed as much as possible. 
D. ESTI was eluted slowly from the C18 resin with 2 volumes of 1-ml methanol. 
E. The methanol extract was separated into 3 equal portions and each portion 
was kept in an Eppendorf microcentrifuge tube. 
F. The methanol was evaporated to dryness (either by blow-drying under 
nitrogen or in the Speed-Vac). The methanol extract could be stored 
overnight at -70 °C before the evaporation and the dry residue could be stored 
at -70 °C for at least a month before analysis. 
G. Each plasma sample was extracted twice and the mean of the duplicates is 
presented. 
Extraction of urine ESTI using Sep Pak cartridges 
The extraction of urine ESTI by Sep Pak cartridges was similar to the procedure 
described for the plasma samples. Due to the large variation of urinary concentration 
of ESTI, it was necessary to concentrate the urine sample, usually up to 3 times the 
original concentration. 
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A. 300 of urine was carefully applied to the Sep Pak cartridge and the sample 
was allowed to stay inside the resin compartment for 2 min. The cartridge 
was washed with 20 ml of deionized distilled water under vaccum. 
B. The above procedure was repeated twice with further 300 jul of the urine 
sample. 
C. Then, urine ESTI from the 900 |nl of urine sample was eluted with two 
volumes of 1-ml methanol. 
D. The subsequent procedure was as described for the extraction of plasma 
samples. 
E. For each urine sample, extraction was done with 300 \x\, 600 \x\, and 900 |il of 
sample and this produced 1 fold, 2 fold and 3 fold concentrated extract. 
Incubation with Na’K-A TPase 
A. One portion of the dry residue was reconstituted in the Eppendorf tube with 
100 |il of Buffer A To ensure complete redissolution of the extracted ESTI 
into the buffer solution, the solution was vortexed regularly for at least 1 hour. 
B. 100 卩 1 of each ouabain standard solution was pipetted into different 
Eppendorf tubes and Buffer A was used as the zero standard in duplicates. 
C. All tubes were kept in an ice bath while Reagent D and Reagent F were 
prepared. 
D. 50 fil of reagent D and 50 jil of reagent F were added to each Eppendorf tube. 
The tubes were capped and vortex-mixed. The capped tubes were still kept in 
an ice bath until all the tubes were prepared. 
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E All the tubes were incubated in a 37 °C water bath for 2 hours. They were 
then transferred to an ice bath to stop the binding of ESTI to the Na，K-
ATPase. 
F. The tubes were kept in the ice bath until the residual activity was measured on 
the Cobas Bio. 
Measurement ofATPase activity using a centrifugal analyser 
A. Reagent H was prepared and placed in the main reagent compartment of the 
reagent container. 
B. The content of each Eppendorf tube was transferred to a Cobas Bio sample 
tube that was also kept in ice bath and then transferred to the sample ring. 
C. A new cuvette rotor was always used for the measurement. 
D. The Cobas Bio analyser was programmed as shown on Table 2-1. 
E. After the reaction was completed, the residual Na,K-ATPase activity was 
calculated, and the %I for each sample was calculated by comparing with the 
mean enzyme activity of the duplicate zero tubes. 
F. A standard curve was plotted and %I of each sample was compared with the 
standard curve to determine the plasma ESTI concentration manually, in 
ouabain equivalent unit (OE) either manually or using a non-linear curve 
fitting program on a personal computer. 
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Table 2-1: Cobas Bio Programming for the measurement of Na，K-
ATPase activity 
"a 一 ~ 13 (-) 
1. Units IM 
2. Calculation factor 4013 
3. Standard 1 Cone 0 
4 Standard 2 Cone 0 
5. Standard 3 Cone 0 
6. Limit 0 
7. Temperature (°C) 37.0 
8. Type of analysis 2 
Wavelength (nm) 340 
10. Sample volume (卩1) 40 
11. Diluent volume (\d) 50 
12. Reagent volume (卩 1) 50 
13 . Incubation time (sec) 0 
14. Start reagent volume (卩 1) 0 
15. Time of first reading (sec) “ 300.0 
16. Time interval (sec) 30 
17. Number of readings 21 
18. Blanking mode 0 
19. Printout mode 1 
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Measurement of DU by radioimmunoassay 
The preparation of reagents and the procedure for the measurement of DLI were 
according to the manufacturer's instruction except that the amount of sample and 
reagent volumes were reduced proportionally 2.5 times. 
A. Samples were extracted using Sep Pak cartridges as described in the previous 
section Residues in the Eppendorf tubes were reconstituted with 100 of 
zero standard solution supplied by the manufacturer and left to stand for at 
least 1 hat room temperature with intermittent vortexing. 40 |nl of standards, 
quality control samples and sample extracts were pipetted into plastic tubes in 
duplicates. 
B. 200 |il of the blue tracer solution was added to each tube. 
C. Then, 200 |jl of the digoxin antiserum complex was added to each tube. 
D. Each tube was vortexed for 5 - 10 sec and the tubes were incubated at room 
temperature for 30 min, 
E. All the tubes were centrifuged at 1000 g for 10 min in a 4°C refrigerated 
centrifuge, 
F. The superaatants were aspirated and the antibody complex in each tube was 
counted on a gamma counter for 1 min. 
G. Digoxin concentration were calculated by automatically using the program in 
the counter. 
Measurement of DLI by HEIA 
The preparation of reagent was according to the manufacturer's recommendation. 
However, the reagent and sample volumes were reduced proportionally by about 50% 
to increase the number of tests per kit. 
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A. Samples were extracted using Sep Pak cartridges as described in the previous 
section. Residues in the Eppendorf tubes were reconstituted with 100 \i\ of 
zero standard solution supplied by the manufacturer andl left to stand for at 
least 1 h at room temperature with intermittent mixing. The reconstituted 
samples were then transferred to the Roche sample tubes and placed on the 
sample ring. Three levels of digoxin quality control samples were also 
included in each batch of analysis. 
B. On the reagent container, the 3 standards were placed in the standard 
positions, the enzyme donor/antibody reagent was placed in the main reagent 
compartment, and the enzyme acceptor / substrate was placed in the start 
reagent compartment. 
C. The Cobas Fara was programmed as shown on Table 2-2. 
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Table 2-2: Cobas Fara programming for the measurement of DLI using 
the CEDIA reagent kit. 
GENERAL 
MEASUREMENT MODE t ABSORB 
REACTION MODE: CEDIA 
CALIBRATION MODE: STDNONLIN 
REAGENT BLANK: NO BLANK 
WAVELENGTH: 420 ran 
TEMPERATURE: 37 .0�C 
DECIMAL POSITION: 2 
UNIT: Hg/1 
ANALYSIS 
P SAMPLE: 15^1 DILUENT r' 6叫 
REAGENT: 75^1 
T TEMP. DELAY: 0 s 
10 INCUBATION: 120 s 
SRI START Rl : 45^1 DILUENT; 12»il 
10 INCUBATION: 700S 
AO READINS: 0.5 s NUMBER: 21 
INTERVAL: 10 s 
CALCULATION 
CONVERS. FACTOR: 1.0000 OFF: 0.0000 
REAC DIRECTION ; INCREASE CHECK: ON 
SAMPLE LIMIT: NO 
TEST RANGE: NO HI : NO 
NORM RANGE: NO HI : NO 
CALC STEPS: 1 
CALC STEPS A: KINETIC 
READINGS FIRST: 2 LAST: 21 
REAC. LIMIT: NO 
CALIBRATION 
CALIB. INTERVAL: EACH RUN 
STANDARD NONLINEAR: 
1: 0.00 2: 2.00 
3: 4.00 
DEVIATION: NO 
CALC MODEL: LINREGRESS 
REPLICATE: SINGLE 
CORRECTION STD: OFF 
REACTION MODE ； 
NAME CEDIA 
1 p PARALLEL PIPETTING 
i T INCUBATION SPEC 
3: 10 INCUBATION 
4: SRI START REAGENT 1 
5. 10 INCUBATION 
6 : AO MEASUREMENT CYCLE 
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RESULTS 
Optimization of reagent composition for the measurement of Na,K-ATPase 
activity 
Optimization of the reagent composition for the measurement of Na,K-ATPase 
activity was performed on the Cobas Bio. The programming of the centrifugal 
analyser was similar to that described on Table 2-1. 
Optimization of sodium concentration 
A series of NaCl solutions was prepared by appropriate dilution of a stock NaCl 
solution in TES/TRIS buffer. Six different Reagent H solutions were prepared from 
these NaCl solutions so that the final reaction mixture contained the following sodium 
concentrations; 50, 75, 100’ 125, 150 and 175 mmol/1. These solutions were added to 
the main reagent compartments of six different reagent trays. The Reagent F (Na,K-
ATPase working solution) was modified to contain an activity of about 100 U/l and it 
was placed into 3 different sample tubes on the sample ring. When the analyser 
completed the pipetting sequence for the first Reagent H solution, the system was 
interrupted and the second Reagent H solution was introduced to replace the first one. 
The interruption continued until all the different Reagent H solutions were pipetted 
into the cuvette rotor. After the reaction was completed, mean value of the measured 
Na,K-ATPase activity were plotted against the final sodium concentrations. 
Changes in Na,K-ATPase activity with increasing sodium concentration is shown in 
Figure 2-1 (A). There was a significant increase in enzyme activity between 0 and 50 
mmol/1 of sodium. The enzyme activity peaked at 100 mmol/1 of sodium and further 
increases of sodium concentration led to a gradual decrease in activity. Therefore, an 
optimal concentration of 100 mmol/1 sodium was selected. 
Optimization of potassium concentration 
The procedure was similar to that described for the optimization of sodium. KC1 
solutions were used to provide a final K concentration of 0, 5，10，15，20，25 and 30 
mmol/1. As shown in Figure 2-1 (B), Na,K-ATPase activity increased by more than 
60% when the potassium concentration increased from 0 to 10 mmol/1. However, the 
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enzyme activity was relatively unchanged with higher potassium concentrations. A 
final concentration of 20 mmol/1 potassium was selected. 
Optimization of ATP concentration 
The procedure was similar to that described for the optimization of sodium. ATP 
solutions were used to provide a final concentration of 0，1, 2，3, 4 and 5 mmol/1. The 
results are shown in Figure 2-1 (C). As expected, there was no measurable Na,K-
ATPase activity in the absence of ATP. The activity increased sharply and reached 
the highest activity at 3 mmol/1. Further increase of the ATP concentration, however, 
gradually decreased the activity. A final concentration of 3 mmol/1 ATP was selected. 
Optimization of magnesium concentration 
The procedure was similar to that described for the optimization of sodium. MgSC>4 
solutions were used to provide a final concentration of 0, 2, 4, 6，8 and 10 mmol/1. 
The results are shown in Figure 2-1 (D). Na,K-ATPase activity was not measurable 
in the absence of magnesium. The activity sharply rose with increasing magneisum 
concentrations with an optimal concentration at 6 mmol/1. Further increase of the 
magnesium concentration had no significant effect on the Na,K-ATPase activity. A 
final concentration of 6 mmol/1 magnesium was selected. 
Optimization of EGTA concentration 
The procedure was similar to that described for the optimization of sodium. EGTA 
solutions were used to provide a final concentration of 0，2, 4, 6，8 and 10 mmol/1. 
The results are shown in Figure 2-1. Optimal Na,K-ATPase activity was obtained at 
2 mmol/1 concentration and further increase of EGTA concentrations inhibited the 
enzyme in a dose response manner. A final concentration of 2 mmol/1 EGTA was 
selected. 
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Figure 2-1: Effects of different concentrations of sodium (A), potassium (B), 
ATP (C)，magnesium (D) and EGTA (E) on Na,K-ATPase 
activity. The optimal concentrations are marked with an arrow. 
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EfTect of sample pretreatment on the recovery of solid phase extraction 
In order to improve the efficiency of extracting ESTI, numerous methods of sample 
pretreatment before Sep Pak extraction were evaluated. 
Sample dilution, acidification, and treatment with organic solvents 
A pool of cord plasma was collected from the samples sent to the routine laboratory 
for neonatal hypothyroid screening. Another pool of lithium heparin plasma was 
collected from healthy adult volunteers. Both pools of plasma samples were subjected 
to the following pretreatment methods in triplicates: 
A. No treatment 
B1. Dilution with one volume of deionized distilled water 
B2. Dilution with 2 volumes of deionized distilled water 
B3. Dilution with 4 volumes of deionized distilled water 
CI. Same as Bl, pH adjusted to 5.5 with 1 MHC1 
C2. Same as B2, pH adjusted to 5.5 with 1 M HC1 
C3. Same as B3，pH adjusted to 5.5 with 1 M HC1 
D. Dilution with 9 volumes of methanol/acetone (1: l,v/v) 
E. Dilution with same volume of 30% Trifluoroacetic acid 
(TFA) 
F. Dilution with 9 volumes of 3% of Trichloroacetic acid (TCA) 
After the pretreatment, the sample tubes were centrifuged at 1600 g for 10 min to 
remove protein precipitates. The supernantants were extracted using Sep Pak 
cartridges as described in the METHOD section except that no equilibration time was 
introduced. The supernatants were allowed to pass through the cartridges slowly 
under controlled vaccum. The ESTI was eluted with methanol, dried, reconstituted, 
and analysed as described in the METHOD section. Incubation with Na,K-ATPase 
was done on the Cobas Bio for 5 min before the measurement of residual activity. 
The mean %I for each method was calculated. The result for method A was taken as 
100% and all other results were expressed in relation to this. 
The results for both pools of plasma samples are tabulated on Table 2-3. The 
different pretreatment methods did not significantly improve the recovery of ESTI 
from cord plasma or healthy adult plama. Dilution of the sample with deionized 
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distilled water increased the recovery slightly for healthy adult plasma but had no 
effect on cord plasma. The acidification of both types of samples to pH 5.5 gave 
lower %I compared to no pretreatment. The use of organic solvents or strong acids 
for pretreatment gave even lower recovery. 
Boiling as sample pretreatment method before Sep Pak extraction 
To study the effect of boiling on the recovery of ESTI, a cord plasma pool was used. 
Five ml of cord plasma was added to a 10-ml glass test tube and placed into a boiling 
water bath for 1 min in duplicates. The cord plasma proteins coagulated into 
gelatinous form. A glass rod was used to disrupt the gel thoroughly before the tubes 
were centrifuged at 50000 g for 10 min. Two ml of the supernatant was passed 
through the Sep Pak for extraction of ESTI. The other procedures were similar to 
those described in previous section. The procedure was then repeated for boiling 
times of 2, 4, 5, 10 and 20 min. 
The results are shown in Table 2-4a. A short boiling time of 1 min gave similar %I 
results as the unboiled sample. However, longer boiling duration reduced the %I. A 
boiling time of more than 5 min abolished the inhibitory ability of the cord plasma. 
Another experiment was similarly set up to study the effect of sample volume upon 
boiling of the cord plasma sample for 5 min. The different sample volumes used were: 
5, 10，15 and 20 ml. Results are shown in Table 2-4b. The lm-ger sample volumes 
preserved the inhibitory ability better, probably due to the uneven effect of heating for 
a short period of time. 
Results of the above experiments indicated that the uses of these pretreatment 
methods before Sep Pak extraction of ESTI in adult plasma or cord plasma samples 
did not improve the recovery. On the contrary, some of the pretreatment methods 
lowered the recovery dramatically. Since the nature of the ESTI was not known, the 
method that gave the highest inhibition would be considered desirable. None of the 
above pretreatment was considered further. 
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Table 2-3: The effect of different sample pretreatment methods on the 
recovery of ESTI on solid phase extraction using Sep Pak 
cartridges. 
Methods Normalized Mean %I 
Cord plasma Healthy adult plasma 
A 100 100 
B1 91 78 
B2 78 106 
B3 76 115 
CI 84 92 
G2 86 74 
C3 81 70 
D 44 79 
E 0 0 
F 18 0 
Methods: 
A. No treatment 
Bl. Dilution with same volume ofdeionized distilled water 
B2. Dilution with 2 volumes of deionized distilled water 
B3. Dilution with 4 volumes of deionized distilled water 
CI. Same asBl, adjust pH to 5.5 with 1 M HC1 
C2. Same as B2, adjust pH to 5.5 with 1 M HC1 
C3. Same as B3, adjust pH to 5.5 with 1 M HC1 
D. Dilution with 9 volumes of methanol/acetone (l:l,v/v) 
E. Dilution with same volume of 30% Trifluoroacetic acid (TFA) 
F. Dilution with 9 volumes of 3% of Trichloroacetic acid (TCA) 
Pooled cord plasma and lithium heparin plasma samples were pretreated with the above methods. The samples were then extracted 
for ESTI using Sep Pak. The % inhibition measured for method A was converted to 100% and the %Inhibition of other methods 
were then normalized to method A. 
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Table 2-4a: Effects of boiling for different times on the recovery of cord 
plasma ESTI by Sep Pak extraction. 








The %I for the unboiled sample was taken as 100% and the results of other 
boiling times were normalized to the unboiled sample. 
Table 2-4b: Effects of sample volume upon boiling for 5 min on the recovery 
of ESTI by Sep Pak extraction. 






Modification of the Sep Pak extraction method 
Lipids are beUeved to be non-ouabain-like inhibitors of the sodium pump and interfere 
with the measurement of the ouabain-like ESTI. Non-polar organic solvents were 
used to wash the Sep Pak C18 resin before the elution of ESTI with methanol. This 
modification was intended to remove lipids which coelute with ESTI, to improve the 
specificity of the method. 
Lithium heparin plasma sample was collected from a healthy volunteer and 1 ml of the 
plasma sample was loaded onto the Sep Pak cartridge as described in the previous 
sections. Washing of the cartridge with deionized distilled water and elution of ESTI 
with methanol were as described in the METHOD section. Incubation of the 
extracted ESTI with Na,K-ATPase for 30 sec was performed on the Gobas Bio. The 
measurement of residual Na,K-ATPase activity was as described in the METHOD 
section. Samples were analysed in triplicate. 
The above procedure was then repeated with the following additional washing step 
before the methanol elution: 
A. 5 ml ether 
B. 5 ml ether + 5 ml acetone 
C. 5 ml ether + 5 ml acetonitrile 
D. 5 ml ether + 5 ml chloroform 
E. 5 ml ether + 5 ml chloroform + 5 ml acetone 
F. 5 ml ether + 5 ml chloroform + 5 ml acetonitrile 
The eluted organic solvents were each collected into individual glass test tubes. The 
solvents were evaporated to dryness in a vacuum oven at 40 °C The residues were 
reconstituted with 500 卩 1 of Buffer A. ESTI was measured in these fractions. 
There was no measurable ESTI in any of the ether, acetone or acetonitrile fractions. 
In the chloroform fractions, %I ranged from 1.0 to 7.7% with very poor precision for 
the triplicates It was later learned from the manufacturer of the Sep Pak cartridges 
that chloroform has some intrinsic properties that damage the CI8 resin and it should 
not be used for elution with the C18 cartridges. Thus, results of modifications D, E 
and F were discarded. Plasma ESTI was detected in all methanol fractions for 
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modifications A to C. %I of these 3 methanol fractions was about 50% lower than 
the methanol fraction without any modification. However, the precision of the 
triplicates was very poor. The effects of combining the different organic solvents on 
the functioning of the C18 resin with the ESTI were not known. The observed poor 
precision could be a result of the complicated interactions among the multiple 
components involved. Thus, modification of the Sep Pak procedure using these 
organic solvents was not continued further. 
Evaluation of the efficiency of the Sep Pak cartridges 
The Sep Pak cartridges were recommended to be used only once by the manufacturer. 
However, the C18 resins could be regenerated by washing with methanol and water. 
The regeneration process can reduce the running cost of measuring ESTI. The cord 
plasma pool used to study the effect of sample pretreatment was used in this 
experiment to evaluate the number of times that a Sep Pak cartridge can be used for 
effective extraction of EST! Cord plasma was chosen instead of adult plasma 
because of the higher ESTI present in the cord plasma sample. 
Eight Sep Pak cartridges were prepared for the extraction of cord plasma ESTI as 
previously described. After the methanol elution step, the Sep Pak cartridges were 
regenerated with 5 ml of methanol wash, followed by 10 ml of deionized distilled 
water. Each Sep Pak cartridge was used 12 times. Extracts were incubated with 
Na，K-ATPase for 30 sec on the Cobas Bio before the measurement of enzyme activity 
as described previously. Statistical analyses of the %I were performed by the 
WinSTAR™ Statistic program (Anderson Bell, CO, USA). Analysis of variance was 
used to look for significant differences between the number of times of extraction. 
The results are shown on Table 2-5. The %I of the first 6 batches of extraction were 
not statistically different from one another. The mean %I values decreased steadUy 
from the 7也 round onwards and were all statistically different from the first set of 
results. The precision performance also deteriorated after 6 rounds of extraction. 
The Sep Pak cartridges were all used for not more than 5 extractions for the rest of 
the study. 
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Table 2-5: Efficiency of Sep Pak cartridges for the extraction of cord plasma 
ESTI. Eight Sep Pak cartridges were used for 12 successive 
extractions. 
No. of extraction Mean %I ( n ^ ) ~ Coefficient of variation (%) 
1 62.4 7.1 
2 64.4 6.7 
3 67.5 3.7 
4 64.7 3.4 
5 61.4 4.6 
6 62.0 5.2 
7 49.9 10.8 
8 39.3 24.7 
9 47.8 11.5 
10 43.7 10.1 
11 41.9 3.6 
12 32.5 24.2 
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Effect of equilibration time between plasma ESTI and the C18 resin on the 
recovery and precision of the extraction step 
This experiment was designed to improve the precision of the extraction of plasma 
ESTI. A plasma sample was collected from a healthy male volunteer on the 7仇 day 
of a high salt diet. 250 of the plasma sample was allowed to be in contact with the 
C18 resin inside the Sep Pak cartridge for 10 seconds before the subsequent washing 
and extraction steps. Methanol extracts were evaporated and analysed as described in 
the METHOD section. The %I of each extraction was calculated. These processes 
were repeated with 2 other new Sep Pak cartridges. 
The above procedure was then repeated except that the sample was allowed to stay 
inside the Sep Pak cartridges for 1，2, 3, 5，10 and 15 min. 
Results of this experiment are shown in Figure 2-2. The short equilibration time of 
the plasma with the C18 resin resulted in poor precision and lower recovery of ESTI. 
An equilibration time of 5 min was chosen as further increase in time did not improve 
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Figure 2-2: Effect of equilibration time between plasma and C18 resin on 
recovery and precision performance. 
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Effect of Na，K-ATPase activity on the sensitivity of ESTI measurement 
In an attempt to improve the sensitivity of the present method, the effect of varying 
the Na,K-ATPase activity in the reagent mixture was studied using ouabain as the 
ESTI. A series of 28 aqueous ouabain standard solutions was prepared by 
appropriate dilution of a 1 mmol/1 stock ouabain solution in volumetric flasks. The 
standard concentrations ranged from 20 nM to 0.1 mmol/1. The incubation of ouabain 
standard solutions with the Na,K-ATPase was performed on the Cobas Bio 
automatically for 30 sec before the measurement of the residual Na,K-ATPase activity 
as previously described. The reagent mixture was prepared to contain 150 U/l of 
Na,K-ATPase activity. This experiment was conducted with each ouabain standard in 
duplicate. The mean %I was plotted against each standard concentration. The 
ouabain concentration required to cause 50% inhibition of the enzyme activity (IC50) 
was estimated from the standard curve. The above experiment was then repeated 
withNa,K-ATPase activity of 100，50, 25 and 12.5 U/l. 
IC50 was used to indicate the sensitivity of the ESTI measurement. There was no 
significant difference over the range of Na,K-ATPase activities studied in this 
experiment. IC50 values ranged from 2.6 to 5.2 ^M. This implied that this 
experimental design can only be used to measure ESTI in the range of \iM ouabain 
equivalent concentration, which is not sensitive enough compared to many established 
methods. 
Effect of incubation time with Na,K-ATPase on the sensitivity of ESTI 
measurement 
To improve the sensitivity of the present method, the effect of incubating the extract 
for different time periods with Na,K-ATPase was studied using ouabain and plasma 
extract. A series of 20 aqueous ouabain standard solutions was prepared by 
appropriate dilution of a 1 mmol/1 stock ouabain solution in volumetric flasks. The 
standard concentrations ranged from 1 nM to 7 卩M. The incubation of ouabain 
standard solutions with the Na,K-ATPase was performed as previously described 
except the procedure was automated on the Cobas Bio. The incubation mixture was 
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inside the cuvette rotor for the programmed time of 6 min. At the end of the 
incubation time, the Cobas Bio was programmed to continue with the measurement 
of residual Na,K-ATPase activity immediately without any delay. The %I was 
calculated and plotted against the ouabain concentration for each standard on a semi-
logarithmic graph. The IC50 value was read from the curve. The above procedure 
was then repeated for incubation times of 0.25, 0.5, 1, 2, 3 and 4 h. 
The effect of incubation time is shown on Figure 2-3. The %I of Na,K-ATPase 
activity increased with ouabain concentration in a dose dependent manner as 
expected. The IG50 value decreased with increasing incubation time for the first hour 
and then gradually plateaued after 2 h. There was no significant improvement when 
incubated for 3 and 4 h. The introduction of a 2 h incubation time before the 
measurement of residual Na, K-ATPase activity increased the sensitivity of the 
method 7 fold. The present method was able to measure ESTI in the nM range of 
ouabain equivalents that is comparable with established methods. 
For the study of plasma extracts, a pooled plasma sample collected from healthy 
volunteers was processed as previously described. To increase the inhibitory activity 
of the plasma extract, the extract was concentrated 2 fold by reconstituting the 
residues with half of the required Buffer A. The extraction and concentration of 
plasma sample was performed in duplicates. The incubation of the concentrated 
plasma extracts with Na,K-ATPase was performed as described above. Incubation 
time periods tested were: 5，15, 30 and 45 min; 1.0, 1.25, 1.5, 1.75, 2.0，2.5, 3.0, 3.5 
and 4.0 h. The %I of the Na,K-ATPase activity was calculated for each incubation 
time. The results were plotted against the incubation times on a graph as shown on 
Figure 2-4 
The effect of incubation time on the inhibition of Na,K-ATPase activity in a plasma 
ESTI extract was similar to that for ouabain standards. The introduction of a 2-h 
incubation time also improved the sensitivity of the method, but only 1.7 fold in 
magnitude. Prolonged incubation did not significantly improve it further. 
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Figure 2-3: The effect of incubating aqueous ouabain standards (top) with 
Na,K-ATPase for different time periods and the ICsq values at 
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Figure 2-4: The effect of incubation time on the % inhibition of plasma 
extract and purified Na,K-ATPase. 
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Dose response characteristic of plasma ESTI 
Plasma samples collected from two male healthy volunteers on the last day of a 7-day 
salt loading experiment were used. The extraction of ESTI, incubation with Na,K-
ATPase and measurement of residual enzyme activity were performed as described in 
the METHODS section. A sample volume of 100, 150, 200 or 250 jul was loaded 
onto the Sep Pak cartridge in duplicate and extracted. The %I on the Na,K-ATPase 
activity was calculated and the mean result of the duplicates was plotted against the 
sample volume. 
The dose response curves for the 2 plasma samples are shown on Figure 2-5. The %I 
of the Na,K-ATPase activity was linear and directly proportion to the amount of 
plasma sample loaded onto the Sep Pak cartridge. The linear regression equations for 
both dose curves were very similar indicating that the characteristics of the ESTI 
extracted from the 2 samples were also similar. 
Analytical performance of the optimized method 
Between batch precision performance 
Five ouabain standard solutions with concentrations of 5, 10’ 20, 30 and 50 nM were 
incorporated into each batch of measurements. Over a period of 9 months, there were 
a total of 84 batches. The precision performance of these standards was calculated 
and is shown in Table 2-6. At a concentration of 5 nM, the between-batch precision 
was 15%. 
Sixty lithium heparin plasma samples were collected for a salt-loading experiment. 
Every sample was measured for plasma ESTI in duplicate as described in the 
METHODS section over a period of 2 weeks and the analytical coefficient of 
variation (CV) calculated for the 60 duplicates. The mean ESTI value was 11.9 nmol 
OE/1, and the CV was 11.8%. The precision performance was similar to the between-
batch precision of the aqueous ouabain standards of similar concentration. 
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Figure 2-5: Dose response curves for 2 plasma samples. 
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Recovery studies 
Recovery studies were performed using both aqueous ouabain standard solutions and 
lithium heparin plasma spiked with ouabain standards. The ouabain standard solutions 
described above were used. Each ouabain standard solution was extracted 10 times 
using 2 separate Sep Pak cartridges and analysed as described in the METHODS 
section. The results are shown in Table 2-7. The recovery ranged from 83% for the 5 
nM standard to 110% for the 10 nM standard. The average recovery for the 5 
standards was 98.6%. 
To a pool of lithium heparin plasma collected from healthy adult volunteers, aqueous 
ouabain solution was added to produce plasma samples containing 0, 5,10, 20,30 and 
50 nM of ouabain. Each plasma sample was extracted 5 times as described above. 
The results are also tabulated on Table 2-7. The recovery ranged from 132% for the 
5 nM sample to 98% for the 50 nM sample. The positive bias was observed 
significantly for the samples with low ouabain, probably due to non-specific ESTI 
present in the sample pool. The average recovery was 117 %. 
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Table 2-6: Between batch precision performance of aqueous ouabain 
standards over a period of 9 months (n=84). 
Ouabain concentration Mean Coefficient ofVairation 
(nlVH %Inhibition (%> 
5 14.3 15.3 
10 27.0 13.8 
20 49.3 4.5 
30 63.6 3.2 
50 75.4 2.3 
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Table 2-7: Recovery study for the established method using aqueous ouabain 
standard solutions and plasma samples spiked with ouabain 
% Recovery , 
Ouabain conc. (nlVh Aqueous standards Spiked plasma 
( n = 1 0 ) (n = 5) 
5 83 132 
10 110 128 
20 101 118 
30 99 109 
50 100 98 
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Improving the sensitivity of the RIANEN method for the measurement of DLI 
Attempts were made to reduce the lowest detection limit of the RIA assay so that the 
method could be used to measure lower concentration of DLI. The method of 
measurement was similar to that described in the METHODS section with several 
modifications. The sample volume was increased to 100 卩 1. Both the tracer and 
antibody volumes were varied between 50 to 200 |nl. The incubation time was also 
varied between 30 and 60 min. A set of standard solutions with low concentration of 
digoxin was prepared by appropriate dilution of the 8.0 |ng/l kit calibrator with the 
zero calibrator to give the following concentrations: 0.025, 0.050, 0.10，0.20, 0.30, 
0.50, 1.0，and 2.0 |ng/l. By running 10 replicates of the zero standard, the lowest 
detection limit was determined as the mean + 2 standard deviation of the measured 
values. Pooled samples of healthy adult plasma and cord plasma were extracted by 
the Sep Pak cartridges as described in the METHOD section. One digoxin quality 
control sample with an assayed value of 1.0 (ig/1 was included in each set of modified 
conditions. 
The results are tabulated in Table 2-8. The different protocols were able to lower the 
detection limits from 0.10 jig/1 to as low as 0.03 |ig/l. The prolonged incubation time 
and increased sample volume were most effective. The mean value of all the digoxin 
quality control samples was 0.96 土 0.032 jug/1 (n=9), ranging from 0.93 to 1.00 for all 
the protocols. However, the modified protocols detected lower DLI concentrations 
compared with the manufacturer's protocol. These results suggested that when the 
assay was made more sensitive for digoxin, conditions were less favourable for the 
cross-reacting ESTI. To optimise the measurable DLI, it was decided that the 
manufacturer's recommended protocol would be used for the rest of the study . 
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Table 2-8: Effect of modification of assay protocol on the detection limit for 
DLI in adult and cord-blood plasma pools 
Volume used f a " DLI measured fug/h 
Detection 
Sanifile Tracer Antibody Limitfug/n Adult Cord 
Incubation time = SO min 
40** 200** 200** 0.10 0.61 0.86 
100 200 200 0.03 0.32 0.41 
100 100 200 0.05 0.24 0.28 
100 50 200 0.06 0.16 0.23 
100 200 100 0.09 0.24 0.30 
100 200 50 0.08 0.29 0.33 
Incubation time = 60 min 
100 200 200 0.03 0.19 0.30 
100 100 200 0.03 0.17 0.19 
100 50 200 0.05 <0.05 0.10 
* *Manufacturer's recommended protocol with proportionately reduced volumes. 
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Analytical performance of the modified GEDIA method 
Precision performance 
The within-batch precision study was performed by running 8 replicates of the 3 
calibrators provided with the kit using the method described in the METHODS 
section. Between-batch precision was assessed by running 3 levels of digoxin quality 
control samples over a period of one month. To evaluate the difference in 
performance between the manufacturer's recommended protocol with the reduced 
reagent volume protocol, the between-batch precision was similarly studied using the 
recommended protocol for 2 weeks. Student's paired-t test was used to evaluate the 
difference among the 2 sets of data at the 95% confidence limit. 
The precision performance of the method was summarised on Table 2-9. The CV for 
between-batch precision ranged from 4.3 to 8.8% and was similar to the 
manufacturer's specification. There was no significant difference between the results 
obtained from the recommended protocol using full reagent volume and the modified 
protocol using reduced reagent volume. 
Accuracy performance 
The lowest detection limit of the method was evaluated by analysis of 10 replicates of 
the zero calibrator and was defined as mean + 2 standard deviation of the measured 
values. A correlation study for the measurement of DLI was performed using 25 cord 
heparinized plasma samples collected randomly, irrespective of sex, from newborns 
whose mothers were not on digoxin. DLI was measured as described in the 
METHODS section. 
The lowest detection limit was found to be 0.08 jig/1, which was better than the 
manufacturer's claim of 0.2 jxg/1. DLI was detected in 23 out of the 25 cord plasma 
samples and the concentration ranged from 0.08 to 0.76 |ag/l. 
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Table 2-9: Precision performance of the CEDIA digoxin method: within-
batch study used 3 calibrators (A，B，C); and the 2 between-batch 
studies used quality control samples (D，E，F) 
Samples Mean CV% 
Within-batch (n=8) A 1.07 5.7 
B 2.03 2.4 
C 3.99 1.0 
Between-batch 
fiill reagent (n=12) D 1.26 7.3 
E 1.86 6.1 
F 3.70 3.7 
reduced reagent (n=8) D 1.31 8 8 
^ E 1.94 5.9 
F 3.74 4.3 
1-48 
The use of acidified urine samples for the measurement of urine ESTI 
The aim of the project was to study the roles of urinary dopamine (DA) and ESTI in 
natriuresis. Urinary DA is stable in acidified urine samples. It would be more 
convenient if both parameters could be measured on the same urine sample. Thus, the 
effect of acid on the measurement of urine ESTI was studied. 
Fresh urine samples collected from two healthy male adult volunteers were used. The 
sample was separated into three 4-ml aliquots. The pH of two aliquots was adjusted 
to between 1.0 and 2.0 using 1 M HC1 solution. One acidified urine and the untreated 
urine were lyophilised 2 h after adjusting the pH. The second acidified aliquot was 
lyophilised 24 h after adjusting the pH. The lyophilised urines were reconstituted with 
1 ml of deionized distilled water. Urines were extracted and analysed as described in 
the METHODS section from one subject. 
The results are shown on Table 2-10. Acidification of the 2 urine samples increased 
the ability to inhibit Na,K-ATPase activity by over 200%. There was no significant 
difference between the acid treatment for 2 h and 24 h. However, the DLI was 
relatively unaffected. 
The effect of DA in the measurement of urine ESTI 
The effect of DA on Na,K-ATPase was studied systematically. A series of aqueous 
standards of DA were prepared by appropriate dilution of a 10 mmol/1 stock DA 
solution in 0.1 M HC1 using Buffer A. The concentration of the 18 working DA 
standard solutions ranged from 25 nM to 5 mmoM. DA solutions were inclubated 
and the Na,K-ATPase Na,K-ATPase activity performed as described in the 
METHODS section 
To examine the concentration of DA in urine extracts, a urine sample was extracted 
20 times after measuring the DA concentration. The methanol fractions were pooled 
and evaporated to dryness. The residues were reconstituted with 0.1 M HCl and the 
DA concentration in the Sep Pak eluants was measured. 
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Table 2-10: Effect of acid preservative on the measurement of urine ESTI. 
Treatment % Inhibition . % Increase . DLI (jig/H 
Sample 1 Sample 2 Sample 1 Sample 2 Sample 1 
Untreated 14.8 31.2 2.11 
Acid 2 h 39.0 67.7 264 217 2.08 
Acid 24 h 40.5 62.8 274 201 2.22 
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The comparison of the characteristic inhibition patterns of ouabain and DA is shown 
on Figure 2-6. The concentration of DA required to demonstrate inhibitory activity 
was 100 i^M. The IC50 value for DA was about 300 i^M. DA concentration in the 
Sep Pak eluants was only 1.6% of the original DA concentration. Thus it was 
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Figure 2-6: The inhibition characteristics of dopamine and ouabain. 
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DISCUSSION 
Two methods were developed for the measurement ofESTI in this project. Since the 
nature ofESTI has not been established, it is recommended to use a combination of at 
least two methods for its measurement (Goto et al 1992). It is desirable for one of 
the methods to be based on inhibition of cellular sodium transport. In this study, the 
first method developed was based on the inhibition of purified dog kidney Na,K-
ATPase and the second method on DLI using 2 different commercial available digoxin 
kits. To reduce the amount of other interfering substances, a preliminary purification 
procedure was developed using solid phase extraction. 
Inhibition of purified Na，K-ATPase measured by enzyme-coupled reactions 
In this method, Na,K-ATPase activity is measured spectrophotometrically by coupling 
to two other enzymes, PK and LD. This coupled enzyme reaction maintains an 
optimal ATP concentration for Na,K-ATPase activity as the ATP is regenerated by 
the subsequent reaction. As similar method has been used to demonstrate increased 
ESTI in subjects with essential hypertension (Hamlyn et al 1982). The present 
method has improved features compared to others reported in the literature. After the 
initial binding and inhibition of the ESTI on the enzyme, measurement of the residual 
Na,K-ATPase activities has been automated on a centrifugal analyser. The same 
method can also be easily automated on other discrete routine clinical chemistry 
systems Unlike some methods based on inhibition of purified Na,K-ATPase, this 
method does not use radioactively labelled substrate or sophisticated instrumentation 
such as a luminometer. It is efficient, and 28 samples can be measured in 15 minutes. 
No concentration of the plasma sample is required and only 200 卩 1 of plasma sample 
is necessary for duplicate analyses This method can handle a large number of 
samples in a short period of time. 
Different sources of Na,K-ATPase have been used, for example dog kidney (Hamlyn 
et al 1982), hog cerebral cortex (Gonick et al 1987) or pig kidney (Moreth et al 
1987) Purified dog kidney Na,K-ATPase was chosen for this study because the 
sodium pump on the renal tubule is the target site of action for ESTI. This enzyme is 
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conveniently available commercially. It has been reported that the action of ESTI 
may be specific (Hamlyn et al 1988). Dog kidney purified Na,K-ATPase may not be 
a good substitute for human enzyme. It would be ideal to obtain human purified 
kidney enzymes, but it is not practical to obtain fresh sample for purification. 
Methods based on this principle have been criticized. Na,K-ATPase is a complex and 
membrane-bound protein. It requires many ligands and substrates for cycling to 
occur，and for the binding of cardiac glycosides (Woolfson et a/ 1994) Purified 
enzyme is not embedded in the membrane and it becomes susceptible to inhibition of 
substances that do not have an effect in vivo. The situation can be exaggerated when 
these inhibitors are concentrated many fold after purification processes. The use of an 
optimal ATP concentration to measure the effect of Na,K-ATPase activity also does 
not reflect the physiological condition. The method described here does not require 
concentration of the sample, and the solid phase extraction purification procedure 
reduces interfering substances. Furthermore, the view that ESTI must be a cardiac 
glycoside has not been established. Therefore, the present method can be used to 
demonstrate the presence of ESTI in biological samples and to show changes of 
inhibitory activities after experimental maneuvers. Practically, very few methods 
reported in the literature can ensure that the measured ESTI reflects in vivo activity. 
In establishing the reaction conditions for measuring Na,K-ATPase activity, 
concentrations of sodium, potassium, magnesium, ATP, and EGTA were optimized 
(Figure 2-1). The optimal concentrations established were similar to those reported in 
the literature using a similar source of enzyme. 
ESTI are reported to be protein-bound (Valdes & Graves 1985). Different methods 
of pretreatment were used to disrupt the protein matrix of the samples so that the 
bound ESTI could be released to be measured more efficiently. These methods 
included a combination of dilution of the sample with water, acidification to 
deproteinize the sample, boiling, and extraction with organic solvents (Hamlyn et al 
1982, Lau & Valdes 1988, Giunta et al 1990). In this study, these methods of 
pretreatment were examined systematically. However, the results showed that these 
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pretreatment methods before the Sep Pak extraction could not improve the recoveiy 
ofESTI from both cord plasma and normal adult heparinized plasma (Tables 2-3, 2-
4a and 2-4b). On the contrary, some of the methods lowered the recoveiy 
dramatically . For example, boiling of the sample appeared to have denatured ESTI in 
the sample. Boiling of a larger volume within a short period of time preserved ESTI, 
probably due to uneven heating of the sample. With prolonged heating, inhibitory 
activities of the smnples were not observed. Denaturing ofESTI by boiling had been 
reported (Balzan et al 1984，Moreth et al 1987). On the other hand, ESTI had been 
reported to be heat-stable (Devynck et al 1983). The present results indicated that 
solid phase extraction is sufficient to overcome this protein-bound interaction. 
Therefore, none of these pretreatment methods was considered further in the method 
development. 
Attempts were also made to remove lipids adsorbed on the C18 resins before the 
methanol elution. Lipids were reported as non-ouabain-like inhibitors (Goto et al 
1992). Thus, removal of lipids could improve the specificity of the eluted ESTI. 
However, these attempts resulted in poor precision of the amount of ESTI eluted. 
This phenomenon could probably be due to the interaction between the organic 
solvents and the CI 8 resins. This interaction could damage structural integrity of the 
resin affecting the reproducibility of ESTI adsorption onto the resins. Furthermore, 
selective removal of lipids from the samples assumes that ESTI must be a cardiac 
glycoside and again this had not been absolutely established. 
In the course of evaluating the solid phase extraction of plasma samples, it was 
observed that precision performance was unsatisfactory. Automation of measuring 
Na,K，ATPase activity on Cobas Bio has good precision. Between-batch precision 
CV for measuring a 100 U/l enzyme solution (n=20) was better than 5%. However, 
within-batch precision CV for measuring ESTI extracted from a plasma pool was 
higher than 20% (n=10). Preliminary investigation indicated that the Sep Pak 
extraction step caused the precision problem. By allowing an equilibration time of 5 
minutes between the plasma sample and the C18 resins, both the recovery and 
precision performance improved dramatically (Figure 2-2). Prior to this finding, the 
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sample was introduced to the Sep Pak cartridge under vacuum. The rate at which the 
sample passed through through the Sep Pak cartridge was difficult to control. This 
rate depended on many factors, for example, condition of the cartridge, viscosity of 
the sample, strength of the vacuum etc. Thus, the amount of ESTI adsorbed onto the 
resins could vary depending on these conditions resulting in poor precision. With the 
new procedure, a measured volume of sample was introduced slowly with a syringe. 
The sample was allowed to stay inside the resin compartment of the cartridge for 5 
minutes before deionized distilled water was used to wash away the proteins and 
electrolytes. During this equilibration period, it is possible that interaction between 
the resins and the protein-bound ESTI reaches an equilibrium state. As a result, the 
amount of ESTI adsorbed onto the resin is proportional to the concentration of ESTI 
present in the sample. Thus, both the recovery and precision performance improved. 
This phenomenon had not been reported in the literature. Although the use of Sep 
Pak cartridges to extract ESTI has been popular, the analytical performance was 
rarely reported. 
Many methods developed to measure ESTI were able to detect ouabain in nanomolar 
concentration (Moreth et al 1987, Kelly et al 1988). These methods require the use 
of radioactive isotopes or sensitive techniques like bioluminescence. Initially, the 
enzyme-coupled method, as developed in this project, was only able to measure 
ouabain at micromolar level. Decreasing the amount of Na,K-ATPase in the reagent 
system did not have a significant effect. It was noticed that sensitive methods usually 
incorporated an incubation step in which ESTI and the Na,K-ATPase were incubated 
in a potassium-free medium for several hours (Kelly et a/ 1985). Thus, a systematic 
study of the effect of such an incubation step on the sensitivity of the present enzyme-
coupled method was done. As a result of the introduction of a 2-hour incubation step 
the sensitivity improved 7 fold (Figure 2-3). With this incubation step, the method is 
comparable with radioreceptor assays in terms of sensitivity and was able to measure 
ouabain in nanomolar concentration. However, the effect on measuring plasma ESTI 
was less dramatic. There was an almost 2 fold increase in sensitivity (Figure 2-4). 
Such a discrepency in response compared with ouabain standards indicated that the 
plasma ESTI may not be an ouabain-like entity or the extract contained a mixture of 
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different inhibitors, possibly including ouabain. Ouabain has been reported to be 
present in normal human samples (Ludens et al 1991). 
Analytical performance of the method was satisfactory. The between-batch CV over 
a P e r i o d o f 9 months ranged from 2% to 15% for ouabain standard solutions of 5 to 
50 nM (Table 2-6). The CV was higher with lower concentrations of ouabain. For 
plasma samples, the analytical CV for duplicate analyses was found to be less than 
12% for a mean ESTI concentration of 11 nM ouabain equivalent. When ouabain 
standards were spiked into a plasma pool, a recovery study showed that there was a 
high bias of 132% for low ouabain concentration (Table 2-7). The recovery was close 
to 100% when the spiked ouabain standards were more than 30 nM. The high bias 
with low ouabain standard may be due to the presence of non-ouabain-like ESTI 
present in the plasma samples. A dose response study showed that the inhibition of 
Na,K-ATPase activity was linear and proportional to the amount of plasma sample 
loaded on the Sep Pak cartridge. 
DLI 
The use of DLI as one of the methods to measure ESTI is popular. Most 
commercially available digoxin kit use antibodies that are directed against a specific 
portion of the steroid moiety of the digoxin molecule (Soldin 1986). Subjects who 
had not been on digoxin therapy were reported to have measurable DLI, for instance: 
neonates, pregnant women, patients suffering from hypertension, renal failure, 
congestive heart failure etc. It was suggested that DLI could be different in various 
conditions. 
There are conflicting reports on the validity of using this approach to study ESTI A 
significant relationship between the biological activities of ESTI and DLI has been 
reported by some research groups; while others found dissociation between the 
biological activity and DLI (Woolfson et al 1994). It has been claimed that non-
specific binding of digoxin antibodies to endogenous compounds which do not 
possess cardiac glycoside-like characteristics has probably contributed more to the 
confusion in this field than any other single factor (Wechter & Benskas 1990) In this 
1-57 
study，the measurement of DLI in samples was preceded by the extraction step using 
Sep Pak cartridges. Since the Sep Pak extraction was optimized for maximum 
inhibitory activity, the presence of cross-reacting but non-inhibiting species was 
reduced. The Sep Pak eluants were not concentrated, thus supra-physiological 
concentrations of analytes were not expected. The present method improved the 
measurement of ESTI by DLI. 
Two different commercial digoxin kits were used in this study. The unexpected 
discontinuation of the RIA kits forced the change to the other HEIA method. 
However,the change has been beneficial, as the new method can be automated on 
routine clinical chemistry analyzers. Precision performance was better compared with 
the manual RIA method. A correlation study between the two reagent kits was not 
possible as RIA kits were not available. The concentration of DLI by the Cedia HEIA 
in cord plasma was similar to that of the RIA method. 
An attempt was made to improve on the lowest detection limit of the RIA method. 
This was achieved by varying the ratio between sample，tracer and antibody volumes, 
as well as the incubation time. The detection limit for digoxin was lowered from 0.10 
\ig/\ to 0.03 |ig/l (Table 2-8). However, the concentration of DLI in adult and cord 
plasma samples detected was also reduced by these modifications. Sensitivity of the 
digoxin assay was improved by providing a more favorable reaction condition to 
digoxin. Such a condition, logically, reduces the opportunity of other cross-reacting 
species to bind onto the digoxin antibody. Thus, the manufacturer's recommended 
protocol was maintained in order to facilitate the measurement of DLI and no attempt 
to improve the detection limit for the HEIA kit was made. Instead, efforts were made 
to reduce the manufacturer's recommended reagent volume for economical reasons 
and it was possible to do this without affecting analytical performance (Table 2-9). 
Urine ESTI 
Measurement of urine ESTI can be used to assess the production of ESTI over a 
period of time. This has an advantage over measurement of plasma ESTI, which only 
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reflects the ESTI concentration at one point in time. The 2 methods developed in this 
study can be adapted to measure urine ESTI. 
The objective of this thesis is to study the roles of both DA and ESTI in natriuresis. It 
would be more convenient if both urine DA and ESTI could be measured in the same 
urine collection. Since acid preservative has to be used for collection of urine DA, it 
is necessary to study the effect of acid preservative on urine ESTI. It was interesting 
to observe that acid preservative increased the inhibitory activity of urine without DLI 
(Table 2-10). These results suggest that acid activated some inhibitors which have 
different immunoreactivity with the digoxin antibodies. There have been reports 
showing the presence of ESTI of different molecular weights in urine (Gonick et al 
1987). It is possible that the large molecular weight ESTI are hydrolyzed into smaller 
molecules in an acidic solution, increasing the inhibitory activities. 
Urine DA has also been reported to have an inhibitory effect on Na,K-ATPase 
activity. It is important to study whether the measured urine inhibitory activity is due 
to DA. The concentration required to inhibit Na,K-ATPase activity was supra-
physiological and was not seen in any of the studies conducted in this project (Figure 
2-6). Furthermore Sep Pak extraction removed more than 98% of DA from urine. 
Therefore, it can be safely concluded that the ESTI measured in urine extracts is not 
DA. 
Concluding remarks 
Two methods were developed for the measurement of ESTI for this project. The 
method based on the inhibition of purified dog kidney Na,K-ATPase is sensitive with 
satisfactory analytical performance. It can measure ouabain in nM concentration 
without using radioactive isotopes or complicated instrumentation. The method 
based on the measurement of DLI is convenient and has been automated for improved 
precision performance. The use of solid extraction to purify ESTI before 




URINARY FREE DOPAMINE 
I. LITERATURE REVIEW 
PROPERTIES OF DOPAMINE 
FOR MEASUREMENT METHODS 
The measurement of dopamine (DA) has been based on the biological, physical and 
chemical properties of DA (Nyyssonen & Parviainen 1989). It shares a common 
molecular formula with noradrenaline (NA) and adrenaline (A) as shown on Figure 3-
1. Hormonal actions of catecholamines (CATS) provided the basis for the early 
bioassays. The presence of both amino and phenolic groups provides the CATS with 
the amphoteric properties and high solubility in water. Such an ionic nature enabled 
the extraction, purification and separation of CATS by ion-exchange resin. The 
characteristic catechol ring structure (1,2-dihydroxybenzene) makes the CATS 
sensitive to oxidative agents which convert it to quinone forms. This property is 
commonly used for the detection of DA. However, this unique feature also requires 
the addition of reducing substances as preservatives to protect biological samples 
before and during the analytical processes. The ring structure also gives native 
fluorescence. The primary amino group of DA reacts with other chemicals to 
produce fluorescent derivatives. Fluorescence has been used for sensitive quantitative 
measurement. Furthermore, the 3,4-dihydroxyphenyl structure of CATS allows 
formation of complexes with other compounds, for example alumina and boric acid 
and this provides specific extraction procedure even at nanomolar concentration in 
different biological samples. Methods developed to measure plasma samples can be 
applied for the measurement of CATS in urine samples. However, the reverse is not 
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Figure 3-1: Molecular structures of catecholamines 
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PRESERVATIVES USED IN THE URINE COLLECTION 
FOR MEASURING FREE DA 
DA is unstable under neutral and alkaline conditions like other CATS. CATS are 
easily oxidized by the presence of free radicals. The formation of free radicals can be 
stimulated by ultraviolet radiation, elevated temperature and the presence of 
transition-metal cations. Thus, during the process of urine collection, the samples are 
kept in the cold, in the dark, in the presence of chelators and reducing substances 
(Hugh et al 1987). GATS are stable at pH values between 2 and 5. 
It has been a common practice to use acid preservatives for urine samples. A large 
variety of acids have been used, for example difference concentrations of hydrochloric 
acid (HC1), sulphuric acid (HjSO^ and acetic acid. Examples of common acid 
preservatives used are listed on Table 3-1. Urine samples have also been collected 
into plain bottles (de Jong et al 1987), bottles containing glutathione / EGTA 
(Demassieux et al 1981) or sodium metabisulphite (Anton & Sayre 1962, Westerink 
& ten Kate 1986). Research groups using lower concentrations of acids with/without 
other preservatives tended to adjust the final pH to approximately 2 to 4 by stronger 
acids like concentrated HC1 (Fotl et al 1987), 85% phosphoric acid (de Jong et al 
1987) or concentrated formic acid (Westerink & ten Kate 1986) before storage. 
Anderson et al collected 24 h urine in 6 M HC1 and before storing the samples at low 
temperature, solutions of sodium metabisulphite, EDTA and an internal standard were 
added to a fixed volume of urine (Anderson et al 1988). This not only preserved the 
sample, but also allowed the changes during storage to be evaluated by measuring the 
amount of internal standard remaining in the sample. 
There is no consensus in the literature on the appropriate type or optimal 
concentration of acid that should be used to preserve urine samples except that the pH 
should be low. The choice of acid and its concentration has rarely been explained in 
the literature. Thirty years ago, the use of 0.4 M perchloric acid was observed to 
increase urinary CATS significantly at room temperature and 5 °C (Anton & Sayre 
1962). However, this phenomenon has not been studied systematically. High 
concentrations of inorganic acids might hydrolyse conjugates of GATS giving falsely 
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high free CATS concentrations (Euler & Von Lishajko 1961，Henry & Pratt 1990). 
Most of the urinary DA is in conjugated forms, 5 times higher than that of the free 
DA (Westerink & ten Kate 1986). The optimal conditions to preserve and store free 
DA in urine should be established in order to avoid possible artifacts due to hydrolysis 
of conjugated DA. Lastly, a report questioning the need for any special collection 
conditions for urinary CATS has added to the confusion (Konstantinides et al 1988). 
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Table 3-1: Examples of acid preservatives used of collection of urine for free 
catecholamine measurement 
Preservatives: References: 
Concentrated HC1 Davidson & Fitzpatrick 1985, Wu & Gomet 1985 
6MHC1 Parker以a/1986，Fotletal 1987, 
Peaston et al 1988, Lee et al 1989 
5 M HC1 Nair & Munk 1987，Critchley et al 1989 
3MHC1 Oates^a/1980, GullnerHG^a/1982 
2 M HC1 Lundberg et al 1988 
25 mM HC1 Smedes et al 1982 
1 M H2S04 Moerman & de Schaepdryver 1984 
0.5 M 耶 0 4 Weinkove 1991 
33% glacial acetic acid Moyer et al 1979 
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SAMPLE PRETREATMENT PROCEDURES BEFORE 
THE MEASUREMENT OF URINARY CATS 
Since the concentration of CATS in urine is low and sensitive methods are required to 
perform quantitative measurement, sample pretreatment is required to remove 
interferences from the final reaction matrices. Organic solvent has been used to 
extract urinary CATS which are then back-extracted into acid aqueous solution. 
Most of the methods are based on complex formation between the hydroxyl groups of 
CATS with different resins at alkaline pH. The amphoteric properties of CATS also 
allow the extraction using ion-exchange resins. 
Alumina has been popular for a long time (Aston & Sayre 1962, Davidson & 
Fitzpatrick 1985, Fotl et al 1987, Anderson et al 1987, Weinkove 1991). Urinary 
CATS were adsorbed onto the alumina in an alkaline buffer at an optimal pH of 8 .6. 
However, the alkaline pH enhances oxidation of CATS leading to low recovery. 
Thioglycolic acid, EDTA, EGTA, sodium metabisulphite, ascorbic acid or a 
combination of the above have been used to protect the CATS during the process 
(Anton & Sayre 1962, Hugh et al 1987, Davidson & Fitzpatrick 1985). It was 
reported that the combination of 2.8 mM of ascorbic acid and sodium metabisulphite 
can protect the CATS for 5 h at the pH of 8.6 (Davidson & Fitzpatrick 1985). The 
buffer was then washed away with water or dilute buffer and CATS were eluted with 
an acid solution, for example acetic acid (Anderson et al 1988, Weinkove 1991), 
hydrochloric acid (Davidson & Fitzpatrick 1985) and perchloric acid (Aston & Sayre 
1962). Ethyl acetate washing has also been used to remove electro-active species 
after the alumina extraction (Davidson & Fitzpatrick 1985) to improve the specificity. 
The recovery by the alumina extraction ranged from 76% to almost 100% (Aston & 
Sayre 1962, Davidson & Fitzpatrick 1985, Nyyssonen & Parviainen 1989). It was 
claimed that alumina purification alone was sufficient for the subsequent 
chromatographic measurement (Foti et al 1987). 
Boric acid gels and boric acid affinity columns also form a stable complex with CATS 
at alkaline pH and have been used for the extraction of urinary CATS (Moyer et al 
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1979’ Oka et al 1982，Peaston 1988). Commercial columns of immobilized boric acid 
or phenylboric acid are available and the linkage of boric acid to the support matrix 
may influence its adsorptive / selective properties for CATS (Rosano et al 1991). 
Cation exchange resins such as Bio-Rex 70 were often used (Weicker et al 1984, 
Pillai 1987). Borate could be used to selectively elute CATS from ion-exchanger 
rather than the less-specific elution by pH adjustment (Odink et al 1986). 
Furthermore, some of these resins were used with alumina to improve the specificity. 
A combination of phenylboronic acid followed by alumina was reported to be the best 
among 4 extraction methods studied (Wu & Gornet 1985). An efficient solvent 
extraction method using ion-pair formation with diphenylborate under alkaline 
condition has also been reported (Smedes et al 1982). 
Automation of the extraction process was also attempted using more sophisticated 
instrumentation based on column chromatographic techniques. On-line pre-column 
extraction methods using either alumina or dihydroxyborylsilica column was 
successful (de Jong et al 1987). An alkaline low buffer concentration mobile phase 
was used to adsorb the CATS onto the pre-column. The system then switched to an 
acidic high buffer concentration mobile phase to elute the CATS. It finally switched 
to another column and a third mobile phase for the separation of individual CATS. 
Another automated commercial system was also reported using "automated sequential 
trace enrichment of dialysate" technique (Green et al 1989). The urine sample was 
not dialysed but enriched in a stainless steel cartridge using proprietary resin. The 
interference was washed away. The CATS was eluted and injected into another 
column for separation. These automated systems provided good recovery and 
precision performance, but were complicated and expensive. 
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METHODS OF MEASUREMENT 
Bioassays for the measurement of CATS 
Historically, CATS were discovered as a result of their pharmacological properties on 
biological systems. Bioactivity of CATS on tissues, isolated organs and even animals 
were used for quantitative measurement (Gaddum 1959). For example, the 
contraction of rat stomach strip preparation was sensitive to 1 to 10 ng of E 
(Armitage & Vane 1964); and the perfusion pressure of an isolated central artery of a 
rabbit ear increased in dose response with NE and E concentrations (de la Lande & 
Harvey 1965). Bioassays were sensitive but not specific (Vane 1966), An isolated 
guinea pig heart preparation was developed to measure less than 1 ng of NE and E 
(Booker et al 1962). But the same preparation was also reported to measure 
angiotensin (Watson & Booker 1965). The presence of contaminants that could have 
CATS-like activity, or potentiate the effects of CATS, or have antagonist properties 
make the bioassay methods unreliable. Thus, the extraction procedure was essential 
for accurate measurement. 
To improve the specificity of bioassays, superfusion techniques were developed. 
Tissues with different sensitivities to individual CATS were joined in series. For 
example, rat stomach strip was superfUsed with a chick rectum (Armitage & Vane 
1964). The chick rectum was about 100 times more sensitive to E than to NE. The 
degrees of contractions in the 2 tissues from test solutions were compared with that of 
E and NE standards. Proportions of E and NE in the test solutions were calculated by 
solving simultaneous equations. This technique combined sensitivity and specificity 
by careful selection of the tissue preparations. However, the problem of 
contamination was not resolved. 
Although bioassays were claimed to be cheap and did not require sophisticated 
instrumentation, they have been replaced by chemical and biochemical methods for the 
measurement of CATS. Working with isolated tissues and organs demanded more 
technical skill and suffered from the large variations inherent with biological systems. 
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Furthermore, the problem of contamination and non-specificity could only be resolved 
by chemical and biochemical techniques. 
Colorimetric method for the measurement of CATS 
Colorimetric methods for the measurement of CATS are based on the formation of 
adrenochromes from the oxidation of CATS in the presence of oxidizing agents, for 
example iodine, alkaline substances and sunlight. There are also reaction products 
with ninhydrin and diazobenzenesulphonic acid. However, colorimetric methods are 
neither specific nor sensitive for the determination of CATS (Kagedal & Goldstein 
1988). 
Fluorometric methods for the measurement of CATS 
The catechol ring structure makes CATS naturally fluorescent at an excitation 
maximum of 200 to 220 nm or 280 to 300 nm and an emission maximum of 310 to 
330 nm (Nyyssonen & Parviainen 1989). Although the characteristic fluorescence of 
CATS had been used for a fluorometric assay (Lowry 1948), the presence of other 
natural fluorescent compounds with similar fluorescence spectra in biological fluids 
rendered this method to be non-specific. Therefore, chemical methods to obtain 
different fluorescent derivatives for sensitive measurement were developed. 
Early assays were based on the oxidation of CATS under alkaline conditions to form 
fluorescent trihydroxyindole products called adrenolutins. Initially, only NE and E 
could be measured in urine samples (Jacobs et al 1961, Anton & Sayre 1962, Kahane 
& Vetergaard 1965). Examples of oxidizing agents were potassium ferricyanide 
(Anton & Sayre 1962, Moyer et al 1979) and manganese dioxide (Uuspaa 1963). 
Later modification of the method to include iodine as the oxidizing agent allowed for 
the additional measurement of DA (Carlsson & Waldeck 1958, Oka et al 1982). 
Stabilizers were required in the assay as the fluorescent products were unstable. 
Ascorbic acid was commonly used (Anton & Sayre 1962, Moyer et al 1979). 
However, the fluorescence blank was found unstable and other stabilizers were 
included to improve the situation, for example, ethylene diamine or propylene diamine 
plus ascorbic acid (Euler & Von Lishajko 1961) and dimercaptopropanol or cysteine 
hydrochloride (Haggendal 1963). Measurement of the individual CATS was achieved 
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by paper chromatography, by oxidation at different pH or by the differences in the 
activation and fluorescence spectra (Haggendal 1966). The detection limit of these 
methods was in the nanogram range. 
Ethylenediamine condensation was another group of fluorometric methods based on 
the condensation reaction between oxidized CATS with organic primary amines to 
produce polycyclic fluorescent compounds (Natelson et al 1949, Weil-Malherbe & 
Bone 1952). The product was more stable than the trihydroxyindole assays. These 
methods were more sensitive and had detection limits in the picogram range (Kagedal 
& Goldstein 1988). However, they were not commonly used as compared to the 
trihydroxyindole methods probably because of the lack of specificity (Haggendal 
1966). 
The measurement of urinary CATS with fluorometric assays was gradually replaced 
with new chromatographic methods (Rosano et al 1991). On the other hand, the 
principle of these methods is still used with the chromatographic technique for 
detection of the separated individual CATS. 
Radioimmunoassays for the measurement of CATS 
Although radioimmunoassay for the measurement of CATS was reported (Raum & 
Swerdloff 1981), the application for urinary DA has not been found. This technique 
suffers from the non-immunogenic nature of CATS and they must be conjugated with 
a carrier protein for the production of antiserum. Since the catechol ring is 
susceptible to oxidation during the conjugation process, the usefulness of this method 
has been limited (Knoll & Wisser 1984). 
Radioenzymatic methods for the measurement of CATS 
Radioenzymatic methods have been developed for the sensitive detection of plasma 
CATS whose concentrations are lower than that of the urine samples. They require 
very small sample volume and no pretreatment. The principle has been used for the 
measurement of DA in urine samples (Casson et al 1983, Harvey et al 1984) and 
tissues (Da Prada & Ziircher 1976). The enzyme catechol-o-methyltransferase, 
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purified from liver homogenates, is used to transfer radioactive methyl groups from S-
adenosyl-methionine to endogenous catecholamine acceptor molecules to form 
radioactive o-methyl catecholamines. The radioactive o-methyl derivatives are 
extracted from the reaction mixture and the products separated by thin-layer 
chromatography. Accuracy of the method can be improved by radioactively labeled 
internal standard (Johnson et al 1980). CATS have to be extracted from the urine 
samples before the measurement as the enzyme system is sensitive to inhibitors 
(Casson et al 1983’ Harvey et al 1984). The detection limit of DA was claimed to be 
32 finoles (Da Prada & Ziircher 1976). Despite its sensitivity, the method is tedious, 
time-consuming, involving the use of radioactive isotopes and expensive (Foti et al 
1987). Thus, this method is not extensively used for the measurement of urinary 
CATS. 
Chromatographic methods for the measurement of CATS 
Chromatographic methods are the most commonly used methods for the measurement 
of urinary CATS. Individual CATS can be separated by the partition of analytes 
between a stationary and a mobile phase. The specificity of the method is better than 
any of the above methods as the individual analytes can be identified by the specific 
retention times. 
Gas liquid chromatography is based on the partition of the analytes between a gaseous 
mobile phase and a liquid stationary phase. This technique has been used for the 
sensitive and specific measurement of plasma CATS, especially when coupled with 
mass spectrometer for detection (Nyyssonen & Parviainen 1989). Recently, 
application of this technique for urine samples was also reported (Graham et al 1993). 
However, the use of gas liquid chromatography to measure urinary CATS has not 
been popular, probably because of the need for derivatization of the analytes to 
volatile compounds and the more complicated /expensive instrumentation required. 
High performance liquid chromatography (HPLG) is a technique to separate analytes 
between a liquid mobile phase and a stationary phase. An HPLC system requires a 
liquid delivery pump to move the mobile phase through a column packed with the 
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stationary phase under high pressure for fast separation. The column eluant is 
connected to the detector for quantitation. Sample pretreatment is required for HPLC 
measurement of CATS as described in the previous section "sample pretreatment 
procedures before the measurement of urinary CATS" Dihydroxybenzylamine 
(DHBA) has been the most popular internal standard in this group of methods 
(Nyyssonen & Parviainen 1989). 
For the measurement of urinary DA, the popular stationary phase material is 
octadecylsilane (CI8) particles. Reversed phase CI8 chromatographic systems with 
ion-pair reagent are commonly reported in the literature (Rosano et al 1991). 
Examples of some of these chromatographic systems are listed in Table 3-2. The 
mobile phase is usually more polar than the stationary phase. Different buffer 
systems, such as phosphate, acetate/citric acid or formate, are used to maintain the pH 
of the mobile phase from 2.3 to 4.8. The pH and ionic strength of the mobile phase 
determine the ionization of the solutes in the system, thus affecting the partition of the 
solutes between the stationary and mobile phases (Moyer & Jiang 1978，Kontur et al 
1984). An increase in pH increases ionization of the solutes and reduces the retention 
time with the non-polar stationary phase; while a decrease in pH suppresses ionization 
and enhances the interaction with the stationary phase prolonging the retention time. 
A common problem with reversed phase HPLC is that the fast eluting NA cannot be 
separated from the solvent front and uric acid. Ion-pair agents are included in the 
mobile phase to solve this problem. These ion-pair agents possess both hydrophilic 
and hydrophobic functional ends. The hydrophobic ends adsorb onto the non-
polarstationary phase while the hydrophilic ends interact with the protonated CATS 
due to electrostatic interaction (Krsulovic et al 1981). Retention times are made 
longer with increasing concentration enabling the separation of NA from the solvent 
front. Common examples of ion-pair agents are octanesulfonate and heptanesulfonate 
and the effective concentration ranges from 0.35 to 4 mM. Organic modifiers, such as 
methanol and acetonitrile ranging from 2 to 30%, are added to fine-tune the retention 
time. These organic solvents attenuate the interaction between the solutes and the 
stationary phase resulting in shorter retention time with increasing concentration of 
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the modifiers (Moyer & Jiang 1978). Furthermore, the use of a different buffer 
system with ion-pair agents can affect the stability of the stationary phase. It was 
claimed that the use of formate buffer was preferable over phosphate, acetate or 
citrate buffers because the formate buffer produced long-term stability for the HPLC 
packing material (Peaston et al 1988). 
EDTA is often added to the mobile phase to chelate electroactive metal ions present 
in the mobile phase and this reduces noise in the electrochemical detector (Nyyssonen 
& Parviainen 1989). Amines are also used to saturate "active sites" of the stationary 
phase so that variation of inter-column performance can be reduced. Triethylamine 
has been commonly used. However, development of new technology to end-cap 
surfaces of the packing material makes the use of amines in the mobile phase 
unnecessary. 
The use of ion-exchange chromatography to separate urinary CATS is less popular. 
Compositions of the mobile phases are simply acidic buffers with added EDTA for 
those applications using electrochemical detector. A few examples are listed in Table 
3-2. Early applications were hampered by deficiencies in column reproducibility 
resulting in loss of the separation properties (Rosano et a/ 1991). There has been 
interesting reports that semi-irreversible loading of C18 columns with detergents 
altered the reversed phase column to behave like an ion-exchange mechanism 
(MefFord 1987’ Mefford et al 1987). Although this enhancement managed to impart 
a 3-fold relative increase in the analytical signal for E versus NA, there was no 
advantage for the measurement of DA. 
HPLC systems coupled with fluorometric measurement are based on the methods 
described in the section "Fluorometric methods for the measurement of CATS". 
Few methods managed to make use of the native fluorescence (Anderson et al 1981). 
Majority of the methods were based on pre-column or post-column derivatization of 
the CATS. For example, post-column adaptations included ethylenediamine 
condensation and trihydroxyindole method; pre-column methods included 1,2-















































































































































































































































































































































































































































































































































































































































































































o-phthalaldehyde (Rosano et al 1991). These methods are sensitive and specific, 
however, they have not been used extensively. 
Electrochemical detection is the most popular detection method. The principle of 
detection is based on the reduction or oxidation of CATS in an electrical cell. After 
the separation, analytes in the column eluant pass over an electrode and are oxidized 
or reduced by the potential of the electrode. When the potential of the working 
electrode versus the reference electrode is positive and greater than the potential 
required to electrolyze the analyte molecules, the molecules are oxidized; with 
negative potential the molecules are reduced. The electrons released from or captured 
by the analytes can be measured as electrical current that is proportional to the 
amount of analytes. The working electrode can be gold, silver, platinum, carbon paste 
and glassy carbon. Principle and design of electrochemical detectors has been 
reviewed in detail (Nyyssonen & Parviainen 1989). 
Depending on the design of the analytical cell, there are 2 main types of detectors: 
amperometric and coulometric. Amperometric cells are usually of thin-layer structure 
and due to the cell geometry only 10% of the analyte molecules undergo electrolysis. 
On the other hand, the coulometric detectors consist of fully porous graphite working 
electrode to provide large surface area for efficient electrochemical reaction. Nearly 
all analyte molecules complete the reaction. Thus, the coulometric type is many folds 
more sensitive than the amperometric type. Nevertheless, the amperometric detector 
is cheaper and sensitive enough for measurement of urinary CATS. For ion-pair 
reversed phase HPLC system, it is common to find a positive potential of around 0.70 
mV using amperometric detectors (Oka et al 1982, Wu & Gornet 1985, Fosti et al 
1987，Anderson et al 1988). Negative potentials were used with more complicated 
coulometric types (Hugh et al 1987, Weinkove 1991). 
1-15 
CONCLUDING REMARKS 
The ion-pair reversed phase HPLC method is the most popular and robust method for 
routine measurement of urinary GATS. It provides sufficient sensitivity and 
specificity and is robust to be adaptable onto different HPLC instrumentation. 
However, the preanalytical factors such as preservatives for urine and the 
pretreatment method before HPLC measurement need systematic study. 
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II. METHOD OF MEASUREMENT 
IN THIS STUDY 
PRINCIPLE OF THE METHOD 
An ion-pair reversed phase HPLC method was developed. A published mobile phase 
using acetate-citric acid buffer and octanesulfonate as the ion-pair reagent was 
modified (Weicker et al 1984). The percentage of methanol used in the mobile phase 
was increased to improve the separation time because of the use of a different 
stationary phase. Electrochemical detector (ECD) was used for the quantitation of 
separated CATS. 
An acid preservative, 0.5 mM HC1, is used in this project and this was selected after a 
systematic study on the effect of acid concentrations and storage temperatures. A 
published alumina extraction method for urinary CATS was adapted (Davidson & 
Fitzpatrick 1985). This method used a 3 M TRIS buffer to maintain an optimal pH 
condition during the adsorption process to overcome apparent interference from high 
urinary creatinine. Furthermore, the eluted CATS from the alumina was further 
washed with ethyl acetate to remove electro-active species from the eluant. This 
enabled low noise-to-signal chromatograms suitable for accurate quantitation. 
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MATERIAL AND METHODS 
Material 
Adrenaline-barbiturate (A), noradrenaline-L-tartrate.H20 (NA), 3,4-
dihydroxybenzylamine hydrobromide (DHBA), 3-hydroxytyramine (dopamine, DA), 
alumina (grade I), ascorbic acid, Trizma, ethylenediamine-tetraacetic acid disodium 
salt (EDTA), anhydrous sodium acetate, anhydrous citric acid, and 1-octanesulfonic 
acid sodium salt were obtained from Sigma Chemical Company (St. Louise, MO, 
USA). Methanol and ethyl acetate (HPLC grade) and triethylamine (AR grade) were 
purchased from Merck (Darmstadt, Germany). Sodium metabisulphite was obtained 
from British Drug House Chemical Ltd. (England). Deionized water was prepared by 
the Milli-Q water system from Waters Company (Millipore, Milford, MA, USA). 
Equipment 
Solvent delivery pump system model 600E, Nova Pak octadecylsilane column (4 nm 
particle size) with radial compression module (RCM) module and guard column, 
autosampler WISP model 712, electrochemical detector (ECD) model 460’ and the 
PowerLine software on NEC Powermate PC for system control and data integration 
were from Waters Company (Millipore, Milford, MA, USA). 
Reagent preparation 
Stock standard solutions 
Stock NA, A, DA, and DHBA standard solutions of 500 卩mol/1 were prepared by 
weighing the appropriate amount of the chemicals, dissolved in 0.1 M HC1, and made 
up to volume with 0.1 M HC1 in volumetric flasks. The stock solutions were stable at 
4 °C for 6 months and at -20 °C for over 2 years. 
Working standard solutions 
Three working standard solutions were prepared by adding appropriate volumes of 
the stock standard solutions to 100-ml volumetric flasks and made up to volume with 
0.1 M HC1 solution. The final concentrations of CATS were: 200 nMNA, 50 nM 
A and 500 nM DA in standard 1; 400 nM NA, 100 nM A, and 1000 nM DA in 
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standard 2; and 800 nM NA, 150 nM A and 2000 nM DA in standard 3. These 
standard solutions were aliquoted and kept at 4°C for 1 month or stored at -20°C for 
longer period. 
Internal standard solution 
The internal standard solution was prepared by adding 400 |iil of the DHBA stock 
standard solution into a 100-ml volumetric flask and made up to volume with 0.1 M 
HC1. The resulting concentration was 2 jliM. This solution were stable at 4 °C for at 
least 1 month. 
3M Tris buffer 
This buffer was prepared by weighing 363 g of Trizma and 50 g EDTA in a 1-liter 
flask and deionized water was added to make up to about 800 ml. The solution was 
mixed constantly on a magnetic stirrer kept at 40 °C until the solution was clear. The 
pH was adjusted to 8.75 with concentrated HC1 and the solution was made up to 1 
liter in a volumetric flask with deionized water. This buffer was kept at 4 °C. 
0.1M Tris buffer 
This buffer was prepared by diluting the 3M Tris buffer 30 times with deionized water 
and kept at 4°C. 
Reducing solution 
This solution was prepared fresh prior to use by dissolving 0.19 g sodium 
metabisulphite and 0.175 g ascorbic acid in 10 ml deionized water. This solution was 
stable for 24 hours. 
Alumina 
The alumina was pretreated according to the published method (Aston & Sayre 
1962). Alumina was washed sequentially with different concentrations of Hcl at 
different temperatures. The acid was washed away with deionized water and the 
alumina was finally dried thoroughly in an oven. 
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Stock mobile phase 
The stock mobile phase contained 1 M sodium acetate, 0.4 M citric acid and 2 mM of 
EDTA. This was prepared by dissolving 82.03 g anhydrous sodium acetate, 76.84 g 
anhydrous citric acid, and 0.7445 g of EDTA disodium salt.2H 20 in deionized water 
and made up to 1 litre in a volumetric flask. 
Working mobile phase 
The working mobile phase contained 1/20 dilution of the stock mobile phase, 2 mM 
ofoctanesulphonate, 1 mM of triethylamine, and 14% methanol. This was prepared 
by adding 50 ml of the stock mobile phase, 0.4326 g of sodium-1-octane sulfonate, 
139 |nl of triethylamine and 140 ml ofHPLG grade methanol to a 1-litre volumetric 
flask and made up to volume with deionized water. The working mobile phase was 
allowed to stand overnight before filtering with 0.45 micron aqueous filter, otherwise, 
the filter would get blocked easily. 
Preservation of urine samples 
For the collection of 24-h urine from human subjects, 100 ml of 0.5 M HC1 solution 
was added to each 2-litre plastic container. The urine samples were kept at 4 °C if the 
analyses could not be done within 3 days. Otherwise, the samples were frozen at -20 
°C and the analyses were completed within one month. 
For the collection of 24-h urine from rats, 10 ml of 0.5 M HC1 solution was added to 
each plastic urine container of the metabolic cage. Storage conditions for the sample 
were similar to that for human samples. 
Alumina extraction of urinary free CATS 
The extraction procedure was modified from a published method (Davidson & 
Fitzpatrick 1985). Two steps of the method were modified. Firstly, after the 
adsorption of free CATS onto the alumina in 3 M Tris buffer, the alumina was washed 
with 0.1 M Tris buffer instead of 0.1 M barbitone buffer. Secondly, the adsorbed free 
CATS were eluted with 0.1 M HC1 instead of 0.5 M HC1. 
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A. The following solutions were added to a screw capped glass tube: 
5 ml urine/standards/QC + 
250 jul reducing solution + 
1 ml internal standard solution + 
5ml3M Tris buffer + 
100 mg treated alumina. 
B. The glass tube was tumble-mixed on a roller mixer for 20 min. 
C. The tube was centrifuged for 3 min at 800 g. 
D. The supernatant was carefully discarded without removing the alumina. 
E. 10 ml of 0.1M Tris buffer was added and the tube was tumble-mixed for 
5min. 
F. The tube was centrifoged for 3 min at 800 g. 
G. The supernatant was carefully discarded without removing alumina. 
H. 1 ml of 0.1M HC1 was added and the mixture was vortexed for 30 sec. 
I. The tube was centrifuged for 3 min at 800 g. 
J. The supernatant was transferred to an Eppendorf centrifuge tube. 
K. The Eppendorf centrifuge tube was centrifuged for 5 min at 16000 g. 
M. 900 卩 1 of the supernatant was pipetted to 8 ml ethyl acetate in a glass 
centrifuge tube and vortexed for 1 min. 
N. The glass tube was centrifuged for 3 min at 800 g. 
O. The upper organic layer was discarded and the lower aqueous layer was 
transferred into a sample vial for HPLC analysis. 
Separation and quantitation of free CATS by HPLC 
A. The working mobile phase was delivered at a flow rate of 2 ml/min by the 
E600 pump. Helium was sparged at 30 ml/min continuously for degassing. 
The used mobile phase was recycled after filtering with 0.45 卩m filter until the 
background current exceeded 10 nA, 
B. The NOVAPAK C18 (4pim particle) was used with RCM and guard column. 
C. Applied potential on the ECD was set at +0.60 V. 
D. Analysis time per sample was programmed for 16 min. 
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E. 15 of sample was injected by the autosampler WISP. 
F. Powerline programming for signal collection and integration was as follows: 
1. signal collection interval 1 second 
2. time range 4 -16 min 
3. peak integration: width 0.1 min 
height 0.005 nA 
slope 0.001 nA/min 
minimum area 0.0001 nA.min 
smoothing 5 points 
G. Identification of the CATS was achieved by the retention times. 
H. Standardization was based on the standard analyte to internal standard peak 
area ratios. 
I. Two quality control samples, prepared by spiking of 2 sets of pure standards 
into acidified human urine pool, were included into each batch of analysis. 
J. Quantitation of unknown samples was performed by comparing the analyte to 
internal standard peak area ratios on the Powerline workstation. 
Statistical analyses 
Statistical analyses were performed using the WinSTAR™ program (Anderson-Bell, 
Arvada, CO, USA) on personal computer. Linear regression method was used to 
assess the linearity of standard curves. Analysis of variance (ANOVA) was used for 
multiple comparisons of sample means. The pairs with significant difference were 
identified with SchefFe test and also by Student's paired-t test. Significance level was 
set to p<0.05 for all these methods. 
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RESULTS 
Optimization of the method 
Optimization of mobile phase for the separation of CATS by HPLC 
According to the method published by Weickers et al (1985), the mobile phase 
contained 5% methanol. It was able to separate the 3 free CATS and the internal 
standard within 15 min at a flow rate of 1.0 ml/min. However, due to the use of a 
different type of column in the present system, it took more than an hour to complete 
the separation using the same mobile phase and the same flow rate. Optimization of 
the system was attempted by modifying the composition of the mobile phase and the 
flow rate. The aim was to obtain base line separation of the 3 free CATS and the 
internal standard in 15 min similar to the original method. 
An aqueous standard solution, containing 2.5 |xM of NA, A, DHB A and DA, was 
prepared by appropriate dilution of the individual CATS stock standard solutions with 
0.1 M HC1 solution in a volumetric flask. Three working mobile phase solutions were 
prepared as described in Reagent preparation. Each solution contained different 
amounts of methanol: 7%, 10% and 14%. The mobile phase containing 7% methanol 
was used to separate the different analytes in the aqueous standard solution as 
described in Separation and quantitation of free CATS by HPLC except that the 
flow rate was programmed at 1.0 ml/min. The time required to achieve base line 
separation of all the analytes was recorded. The procedure was then repeated using 
the mobile phase containing 10% methanol at a flow rate of 1.5 ml/min. Finally, the 
14% methanol mobile phase was repeated similarly at flow rates of 1.5 and 2.0 
ml/min. 
The variation of retention times under different conditions is summarized in Table 3-3. 
By increasing the flow rate and methanol concentration in the mobile phase, baseline 
separation of the 4 analytes in the aqueous standard was achieved within 15 min. 
Methanol and flow rate affected each analyte differently under various conditions. 
With the 14% methanol mobile phase and a flow rate of 2.0 ml/min, the retention 
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times for each analyte over a period of 72 h were recorded (n=14). A typical 
chromatogram is shown in Figure 3-2. The coefficients of variation for the retention 
times of all analytes were less than 1%. Thus, the optimized conditions for the HPLC 
was consistent and reliable for the subsequent studies. 
Optimization of the applied potential on the ECD 
The aqueous standard solution prepared for optimization of the mobile phase was 
used. Chromatographic separation of the analytes was performed in duplicate as 
previously described. Applied potential on the ECD was set to +0.30 V. The 
working potential was slightly different from the set value and was recorded. 
Retention times, peak heights and peak areas of each analytes were recorded. 
The experiment was then repeated with applied potentials of+0.35 V，+0.40 V，+0.50 
V, +0.60 V, +0.70 V，and +0.80 V. A minimum of 4 h was allowed for a new 
applied potential to become stable on the ECD before the aqueous standard solution 
was injected. The peak areas and peak heights of each analyte were plotted against 
the working potential to construct the hydrodynamic voltammograms for each 
analyte. 
Changes of peak heights and peak areas of the different analytes with different applied 
potentials are shown on Figures 3-3. The peak heights and areas increased sharply 
from +0.30 V to +0.45 V, but became stabilized after +0.55 V. The pattern of these 
hydrodynamic voltammograms was similar for all the 4 analytes. The potential of 
+0.60 V was chosen for all subsequent studies. Higher potential was not desirable as 
more electroactive species in the samples and the mobile phase would be oxidized. 
This could increase the background current significantly especially when the mobile 
phase is recycled. 
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Table 3-3: The effect of methanol concentration and flow rate on elution time of CATS 
% Methanol Flow rate Total elution time (min^ 
(ml/minV 
7 1.0 60 
10 1.5 30 
14 1.5 25 
14 2.0 15 
Results of the elution time are given as the mean of triplicate analyses 
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Figure 3-2: A typical chromatogram for the separation CATS by the 
developed HPLC method. 
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Figure 3-3: Hydrodynamic voltammograms for NA, A, DA and DHBA. 
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Linearity range and detection for the ECD 
A series of 28 working standard solutions containing NA, A and DA were prepared 
by appropriate dilution of the stock standard solutions in volumetric flasks and made 
up to the volume with 0.1 M HC1. Concentration of the 3 analytes in each working 
standard solution was the same, ranging from 5 nM to 5000 nM. Standards were 
subjected to HPLC analysis in duplicate as previously described. Peak areas of each 
analyte were recorded. The mean peak areas were plotted against the expected 
concentration to determine the linearity range of the ECD. The lowest detection limit 
for the detector was determined by the concentration of analyte that could not be 
integrated by the system. 
The linearity curve for DA is shown on Figures 3-4. ECD response was linear for the 
standard solution containing 30 nM to 5000 nM. There was no peaks that could be 
integrated for standard solutions less than 30 nM. The injection volume for each 
standard solution was 15 \xl Thus, the lowest detection limit for DA was 0.45 pmole 
and the linearity was at least up to 75 pmoles. Linearity curves for NA and A 
standards were similar to those of DA standards. 
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Figure 3-4: Linear range of DA on the ECD 
For concentration ranging from 30 - 5000 nM, the regression equation: 
y = 5.53 x 10-4 + 0.00166 r = 0.9999 
For concentration ranging from 30 - 500 nM, the regression equation: 
y = 5.27 x 10-4 + 0.00632 r = 0.9992 
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E f f e c t ° f t h e amount of alumina used on quantitation 
The extraction of urinary CATS with alumina was adapted from a published method 
(Davidson & Fitzpatrick 1985). The original article stated that 50 mg to 350 mg per 
10 ml of urine sample produced no significant change in the recovery. When the 
method was adapted, it was found that ascorbic acid was eluted at 1 min after 
injection. However, the total elution time for the ascorbic acid peak was inconsistent. 
There were situations where the NA, A and DHBA peaks were eluted with the 
ascorbic acid peak causing problem for automatic peak integration which in turn 
affected the quantitation. Preliminary experiments indicated that the amount of 
alumina could affect the amount of ascorbic acid present in the final solution injected 
into the HPLC. The higher ascorbic acid concentration in the sample would take a 
longer time for elution. To minimize the interference of ascorbic acid on peak 
integration, the amount of alumina used was optimized. 
The aqueous working standard solution prepared for the optimization of the mobile 
phase was extracted with 100 mg of alumina as previously described. Ethyl acetate 
washing was not done. Chromatographic separation of the analytes was performed as 
previously described. The total elution time for the ascorbic acid peak was recorded. 
The experiment was then repeated using 200 mg and 300 mg of alumina. 
Total elution time of the ascorbic acid peak for 100 mg of alumina was 4.5 min and 
did not interfere with the NA peak on the chromatogram. Elution times of ascorbic 
acid peak for the 200 mg and 300 mg alumina were 7 min and 10 min, respectively. 
These elution times interfered with the integration of NA and A. It was therefore 
decided to use 100 mg of alumina to the extraction mixture. A tailor-made plastic 
cup was made to weigh the alumina for 100 mg 土 5%. 
Effect of acid solutions on the elution of CATS from alumina 
The effect of different acid solutions on the elution of adsorbed CATS from the 
alumina was examined using the aqueous standard solution described above. 
Extraction of free CATS from the standard solution was performed as previously 
described. Elution of the adsorbed CATS was performed using 5 ml of 0.5 M acetic 
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acid in duplicates. Ethyl acetate washing was excluded from the procedure. 
Chromatographic separation and quantitation of free CATS were as previously 
described. The experiment was then repeated using 0.5 M HC1 and 0.1 M HC1. An 
aqueous standard solution was also subjected to the chromatographic procedure to 
obtain the expected peak area before alumina extraction. The % recovery for each 
analyte after the different acid elutions from the alumina was calculated by comparing 
the peak areas with that without the alumina extraction. 
The results are summarized on Table 3-4. 0.1 M HC1 gave the highest % recovery 
and was chosen to be the acid for elution in the subsequent studies. Furthermore, the 
use of a dilute acid for sample preparation would be desirable to provide a better 
condition for long-term stability of the HPLC column, 
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Table 3-4: Effect of acid solutions on elution of CATS from alumina 
% Recovery 
Acid solutions NA A DHBA DA 
0.5 M acetic acid 96.4 96.1 97.7 99.2 
0.5 M HC1 95.5 98.6 98.3 97 0 
0.1MHC1 101.1 103.9 103.6 103.1 
Results are given as the mean of triplicate analyses. 
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Analytical performance of the method developed 
Linearity of the method 
A series of 10 aqueous CATS standard solutions was prepared by appropriate 
dilutions of the stock standard solutions in volumetric flasks and made up to volume 
with 0.1 M HC1. The concentration of the NA, A and DA in each standard was the 
same. The range of concentrations was from 50 nM to 10 pM. The standard 
solutions were extracted with alumina and HPLC separation of the CATS was as 
described before. However, the injection volume had to be adjusted to keep the peak 
heights in the range of the detector's scale. The smallest volume used was 2 |til for the 
highest standard solution. Ratios of peak areas between the analytes and the internal 
standard were calculated and plotted against the expected concentrations. 
The linearity curve for DA standards are shown on Figure 3-5. The developed HPLC 
method could measure DA up to 10 juM in concentration. Linearity curves for NA 
and A were similar to that of DA. However, the injection volume had to be lower for 
concentrations higher than 2.5 |iM. This was more convenient compared to the 
alternative of diluting the sample and then repeating the entire procedure. 
Furthermore, urinary CATS concentration higher than 2.5 |liM is not common. 
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Figure 3-5: Linear range of DA of the HPLC-ECD method 
Peak area ratio = Peak area of DA + Peak area ofDHBA 
For concentration ranging from 50-10000 nM, the regression equation: 
y = 2.80 x 10-3 + 0.0538 r = 0.9999 
For concentration ranging from 50 - 800 nM, the regression equation: 
y = 2.86 x 10-3 + 0.00479 r = 0.9998 
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Intra-batch precision performance and recovery study using spiked human urine 
samples 
An acidified 24-h urine was obtained from the routine laboratory of this Department 
at the Prince of Wales Hospital. Three working standard solutions contmning 
different amounts ofNA, A and DA were prepared by appropriate dilutions of the 
stock standard solutions with 0.1 M HC1 in volumetric flasks. Final concentrations of 
the 3 standard solutions were 2 j l i M NA, 1 DA for solution l;4^iM NA, 
2 i^M A, 10 mM DA for solution 2; and 6 mM NA, 3 |iM A, 20 |liM DA for solution 
3. 
One milliliter of 0.1 M HC1 was added to a 10-ml volumetric flask and made up to the 
volume with the acidified urine. The procedure was then repeated replacing the 0.1 
M HC1 with the 3 standard solutions. These 4 urine samples were subjected to 
alumina extraction and HPLC analysis in triplicates as previously described. The % 
recovery was calculated for the urine samples containing the spiked standards. Intra-
batch precision performance was determined by calculating the CV values among the 
triplicates. 
The results of recovery and intra-batch study are shown on Table 3-5. For NA, the 
average % recovery was 100.8% (range 99.5-102.8%). The intra-batch precision 
(CV) ranged from 1.4 to 3.2%, depending on the concentration. For A, the average 
% recovery was 93%, (range 89-96%). The intra-batch precision ranged from 3.2 to 
17.4%. The precision performance was poor at the low end of the concentration 
range. Finally for DA, the average % recovery was 98.5%, (94-101.5%). The intra-
batch precision CV% ranged from 1.0 to 3.1%. 
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Table 3-5: Results of recoveiy and intra-batch precision study 
Concentration Measured 
of Concentration Intra-batch 
Standard (nM^ (nM) % Recovery % CV 
NA 
0 304 / 3.2 
200 503 99.5 3.0 
400 715 102.8 2.2 
600 905 100,2 1.4 
A 
0 58 / 17.4 
100 147 8 9 0 3 6 
200 246 94.0 8.4 
300 346 96.0 3.2 
DA 
0 1002 / 1.0 
500 1472 94.0 1 0 
1000 2003 100.1 3.1 
2000 3031 101.5 1.1 
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Inter-batch precision performance 
Two acidified 24-h urine samples were obtained from the routine laboratory. They 
were aUquoted into 5-ml portions and stored at -20 °C and served as quality control 
samples. For every batch of analysis, two quality control samples were thawed and 
analyzed. Results of the inter-batch precision performance are shown on Table 3-6. 
Due to the low concentration of A in both samples, the CV was higher. The 
performance was expected to be similar to those of NA and DA which were present in 
higher concentrations. For both NA and DA, the CV were less than 10%. 
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Tabic 3-6: Inter-batch precision performance using 2 quality control urine samples 
Quality control Mean 
Sample CATS Concentration (nM) C V% 
A (n = 97) NA 279 2.0 
A 69 11.6 
DA 1011 4.8 
B ( n = 47) NA 91 9.9 
A 27 29.6 
DA 612 6.2 
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Stability studies of urinary CATS under different storage conditions 
E f f e c t s of acid concentration on aqueous CATS standards 
The use of different acid concentrations to preserve urine samples could affect the 
efficiency of alumina extraction. The optimal pH of 8.6 required for the extraction is 
usually maintained by buffer solutions. Excess acid could affect the buffering capacity 
resulting in a lower pH environment. Furthermore, an increase in inorganic acid 
concentration could enhance the oxidative destruction of CATS in the absence of 
reducing solutions. 
A series of 5 CATS standard solutions, concentrations ranging from 100 to 1000 nM, 
was prepared by appropriate dilution of stock standard solutions in volumetric flasks 
and made up to volume with 0.1 M HC1 Standard solutions were allowed to stand at 
room temperature (23 °C) for 2 h. Then, alumina extraction and HPLC analysis were 
performed as previously described. The peak area ratios of each analyte with the 
internal standard were calculated. Another 4 experiments were similarly performed 
using 4 different series of standard solutions that were made with 0.25 M, 0.50 M, 1.0 
M and 2.0 M HC1. The effect of acid concentration on the peak area ratios for each 
analyte was assessed by 1-way ANOVA with replications. 
The 2M acid solution overcame the buffering capacity of the 3 M Tris buffer used in 
the extraction mixture. The pH value of the extraction mixture was around 6.0 
measured by pH paper. Results for this series of standard solutions were not included 
in the statistical analysis. For the others, pH values of the extraction mixtures were 
close to 8.5 and the variation in results could not be due to suboptimal pH for alumina 
extraction. The acid concentration appeared to have significant effect for NA and DA 
(p=0.0125 and 0.0130, respectively) and for A the effect was not significant 
(p=0.0510). The peak area ratios of the analytes decreased with increasing acid 
concentration. The concentration of CATS in 1.0 M HC1 solutions were significantly 
different from those of 0.1 M HC1 solutions. The relative changes between the results 
of these 2 acid solutions were - 1.0% for NA, -2.1% for A and -3 .7% for DA. These 
data suggest that the use of strong acid solutions denatured the free GATS. It also 
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indicated that DA is more susceptible to this oxidative destruction than the other 2 
CATS. 
E f f e c t s of acid concentration and storage temperature on human urine free DA 
The effect of different acid concentrations to preserve urinary free CATS has not been 
well documented. It has been commented that the use of high acid concentration 
could lead to the hydrolysis of conjugated CATS giving falsely high free CATS 
concentrations in the urine samples (Euler & Von Lishajko 1961’ Henry & Pratt 
1990). Furthermore, the process of hydrolysis is affected by temperature. An 
increase in temperature can enhance the rate of hydrolysis. Thus, this experiment was 
designed to investigate the effect of acid concentration at different storage 
temperatures on urinary free DA. 
Fresh urine samples were collected from healthy individuals and pooled. Twenty-five 
milliliters of deionized water were added to a 250-ml volumetric flask and made up to 
volume with the urine pool. This represented the urine sample without any acid 
preservative. The preparation of acidified urine samples was similarly performed 
using 25 ml of 1 M, 2.5 M, 5 M, 7 5 M and 10 M HC1 solutions. Thus, a series of 
acidified urine samples containing 0.1 M, 0.25 M, 0.50 M, 0.75 M and 1 M HC1 was 
produced. Each urine sample was aliquoted into 10-ml plastic tubes and stored at 
different temperatures. Three sets were kept in a 37 °C water bath; 3 sets were kept 
in the dark at room temperature (23 °C); and another 7 sets were kept at 4 °C in the 
cold room. 
Six hours after the preparation of the acidified urines, one set of urine samples was 
removed from the storage locations and extracted and analysed as described before. 
This was then repeated at 24 h and 48 h for the 3 storage temperatures. For the 
samples stored at 4 °C, the remaining 4 sets were measured at 1, 2, 3 and 4 weeks 
time. 
Results are shown on Figure 3-6. The results show that urinary free DA increased 
with increasing acid concentrations and at higher temperature, probably due to the 
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hydrolysis of conjugated DA in the sample. The urinary free DA increased 200 % 
when kept in 1 M HC1 at 37 °C after 24 h and 300 % after 48 h. The previous 
experiment also indicated that DA was susceptible to oxidative destruction at high 
acid concentration. Thus, the actual rate of hydrolysis could be higher. On the other 
hand, the absence of acid preservative caused a 4% decrease in free DA at 4 °C after 
48 h. Since the between-batch precision performance exceeded 4 %, this magnitude 
of change would not be considered significant. A final acid concentration of 0.1 and 
0.25 M at 4 °C was sufficient to protect urinary free DA for about 1 month. A 
detailed study was then designed to investigate the effects of storage conditions for all 
other urinary free CATS. 
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Figure 3-6: Effects of acid concentration and storage temperature on human 
urinary free DA 
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E £ e c t s of st�rage temperature and duration of alumina extracts of human urinary 
HPLC analysis is a sequential process. Extracted free CATS are stored in 1-ml glass 
sample vials and can be inside the autosampler up to 25 h at room temperature. 
Therefore, an experiment was designed to study the effect of storing extracts of free 
CATS inside the autosampler (the WISP) over a period of 36 h. 
One fresh human spot urine sample was collected from a healthy volunteer, The 
sample was separated into 12 aliquots. The alumina extraction and HPLC analysis 
were as described previously. After completion of the initial HPLC analysis, the 
sample vials were kept inside the WISP and measurements were repeated at 12 h, 24 
h and 36 h. Results were analyzed by 1-way ANOVA to study the effect of storage 
duration inside the WISP. 
The results are summarized in Table 3-7. Significantly higher NA results were 
observed after 24 h and 36 h (p<0.001). The mean NA for both 24-h and 36-h 
measurement was 3.7 % higher than the 0-h measurement. Although this was 
statistically significant, the magnitude of change was still within the analytical 
imprecision performance. There were no significant effect for A and DA (p=0.484 
and 0.140, respectively). Thus, keeping the extracts inside the WISP for 36 h would 
not affect the results of DA. 
Unexpected breakdown of the HPLC system might take over a week's time for repair 
and extracted samples may have to be stored until the problem is resolved. A batch of 
12 acidified human urine samples was extracted. After the first measurement, the 
sample vials were kept in the dark inside the cold room at 4 °C for 1 week and 2 
weeks. They were taken out and the measurement was repeated at the end of the 
storage period. Statistical analyses were the same as described above. 
The results are summarized on Table 3-8. Duration of storage had a significant effect 
on both NA and A (p<0.001 and p=0.003, respectively). After 1 week and 2 weeks, 
the NA concentration increased by 7.2% and 6.8 %，respectively. For free A, there 
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was a significant decrease of 23.4% after storage for 2 weeks. There was no 
significant change for free DA (p=0.363) stored at 4 °C over 2 weeks. It was also 
noticed that the ascorbic acid peak at the solvent front decreased in size with storage. 
Thus，extracted samples should be analyzed within 1 week to avoid significant 
changes of NA and A, but the DA remained unaffected. 
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Table 3-7: EfTects of storage over 36 h at room temperature on extracts of urinary free CATS. 
Time (h) Concentration ( n M � Relative % Change 
Mean 土 S.D. 敬 
NA Aa DA NA A DA 
0 273土15.5 53±11.2 1052土 86.4 / / / 
12 277116.7 60土11.2 1064土 81.7 +1.5 +13.2 +1.1 
24 283土 15.6* 58 土13.3 1069+69.8 +3.7 + 11.3 + 1.6 
36 283±15.2* 59+13.5 1083+72.2 +3.7 + 11.3 +2.9 
The changes of mean concentrations were compared with the 0-h measurement using 
Scheffe test ( * for p<0.002). 
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Table 3-8: EfTects of storage over 2 week at 4 °C in the dark on extracts of 
urinary free CATS. 
Time Concentration ( rM ) Relative % Change 
(wk) Mean 土 S.D. 
NA A DA NA A DA 
0 221±43.0 64126.7 1275±282.9 / / / 
1 237士38.5** 59±22.1 1280+279.6 +7.2 -7.8 +0.4 
2 236+37.5** 49土 12,5* 1280±289.0 +6.8 - 23.4 +0.4 
The changes of mean concentrations were compared with the 0-wk measurement 
using Scheffe test ( * for p<0.005; ** for p<0.0001). 
3-46 
E f f e c t s of storage duration on acidified human urinary free CATS 
To simulate the collection and handling of human urine samples, the effects of storage 
duration on acidified human urinary free CATS were studied. A final acid 
concentration of 0.025 M HC1 was chosen based on the previous experiment. The 
summer ambient temperature in Hong Kong is often over 30 °C. To simulate the 
collection of24-h urine samples by outpatients, acidified samples were stored at 30 ° 
C for 24 h and 48 h. For cross-sectional studies, urine samples are usually stored 
frozen and the analysis performed in big batches to improve the precision 
performance. To study the effects of storage, acidified urine samples were stored at -
20 °C for over 3 months. 
A batch of 10 fresh random spot urine samples was collected from healthy laboratory 
staff Each sample was separated into seven 5-ml aliquots and stored in plastic tubes. 
To each tube, 500 of 0.25 M HC1 was added. One tube was immediately extracted 
and analyzed and two tubes were stored in a 30 °C water bath and the urine samples 
were similarly processed and analysed 24 and 48 h later. The other 4 tubes were 
stored frozen at -20 °C. These samples were thawed, processed and analyzed at 2 
weeks, 1 month, 2 month and 3 months later. The effects of storage duration on the 3 
CATS were analyzed by 1-way ANOVA with replications as previously described. 
The results are summarized in Table 3-9. For samples stored at 30 °C, there were no 
significant changes for NA and A among the 0, 24-h and 48-h periods (p=0.743 and 
p=0.0929, respectively) but DA was affected by storage duration (p=0.0180). DA 
increased by 3.9% after 24 h, but showed no significant difference after 48 h. This 
could be caused by a systematic drift of the assay for the 24-h samples. Thus, 
acidified urine samples could be stored for 48 h even at 30 °C. For frozen samples at 
-20 °C, the ANOVA test showed that both NA and A were affected (p=0.0004 and 
p=0.0118，respectively). Follow-up with the Scheffe test, it showed that NA could be 
stored for up to 1 month and A for 2 months. No significant difference was found 
for DA results (p=0.115). The concentration decreased by 5.5% after one month, but 
then increased by 4%. This magnitude of changes was acceptable as the between-
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Table 3-9: Effects of storing human urine samples at 30 °C and -20 °C on free CATS. 
Storage Concentration ( n M � Relative % Change 
Conditions Mean ± S.D. w.r.t. 0-h sample 
NA A DA NA A DA 
Fresh 147 土77.1 97±53.0 1286土543.8 / / / 
Samples 
24 hat 146士81.8 96±51.1 1337土593.0 -0.7 - 1.0 +3.9 
30 °C 
48 hat 148士81.1 91 士51.6 1298 ±587.7 +0.7 -6.2 +0.9 
30 °C 
2 weeks 149 土78.0 95土54.9 1235±537.0 + 1.4 -2.1 -4.0 
at -20 °C 
1 month 159 土90.6 94土 51.1 1215±404.8 +8.2 -3.1 -5.5 
at -20 °C 
2 months 167土90.8* 101 土52.3 1341 士566.7 + 13.6 +4.1 +4.3 
at -20 °C 
3 months 161 土90.4 83土48.0 1343士607.6 +9.5 - 14.4 +4.4 
at -20 °C 
The changes of mean concentrations were compared with the fresh samples using 
Scheffe test ( * for p<0.005). 
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batch precision CV was about 6 - 7%. Thus, samples could be stored frozen at -20°C 
for up to one month after the collection. 
E f f e c t s of acid concentration and storage duration on rat urinary free CATS 
Composition of rat urine samples is different from that of human urine. For example, 
rat urine samples contained a higher bicarbonate concentration than that of human. 
The amount of acid required to preserve human urine sample might not be enough for 
rat urine sample because the bicarbonate can neutralize the acid, thus affecting the 
stability of urinary free CATS. An experiment was set up to study the effects of acid 
concentration and storage duration on rat urinary free CATS at room temperature 
over a period of 24 h and 48 h. 
Twelve rats were isolated in metabolic cages for the collection of 24-h urine samples. 
Ten milliliters of 0.1 M HC1 was placed in the urine collection container to provide 
the initial preservative. After the urine volumes were recorded, samples with a 
volume greater than 20 ml were regarded as a complete sample. Those samples with 
less volume were pooled to make up a volume of more than 20 ml and then used as a 
complete sample. 
Each complete sample was separated into nine 2-ml aliquots. The first aliquot ("0-
h" sample) was immediately extracted. The remaining 8 aliquots were acidified in 
duplicates using 0.2 ml of 1，2.5，5.0 and 10 M HC1, giving final concentrations of 
about 0.1，0.25, 0.50, and 1.0 M HC1. The final pH of the urine samples was found 
ranging from 3.5 to 6.0. The samples were kept in the dark and stored at room 
temperature for 24 h and 48 h. The samples were extracted as described previously 
except that 2 ml samples were used instead of 5 ml. During analysis, it was found that 
these samples contained an interfering peak which co-eluted with the internal standard 
DHBA peak leading to inaccurate quantitation of the free CATS. Therefore another 
internal standard, epinine, was used for these 2 experiments on rat urine stability. The 
use of epinine has been shown to have similar analytical performance as the DHBA 
(Wong 1992). HPLC analysis was as previously described except that the sample 
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cycle time was adjusted to 18 min instead of 16 min because epinine eluted 1 min after 
the DA peak. 
The results are summarised in Table 3-10. Two-way ANOVA showed that NA was 
significantly affected by acid factor (p<0.001), but not by duration of storage 
(p=0.774) and there was no interaction of the above 2 factors (p=0.057). Further 
analysis showed that samples stored in 0.50 M and 1.0 M HC1 were significantly 
different from the "0-h" samples. In 1 M HC1 sample, urinary free NA increased by 
6.8 % at 24 hand by 11.4% at 48 h. This shows that rat urinary free NA increased 
with increasing acid concentration, probably due to the hydrolysis of conjugated NA. 
Free A was also significantly affected by acid concentration (p<0.0001), but not by 
storage (p=0.819) and there was significant interaction between these 2 factors 
(p=0.003). However, the pattern was quite different from that of NA. The urine A 
concentrations was significantly lower at 24 h when compared with the "0-h" 
samples. These results indicated that the lower acid concentration might not protect 
A from oxidative destruction. On the other hand, urinary free A concentrations were 
higher after 48-h. The hydrolysis of conjugated A could explain this. Thus, samples 
containing 1 M HC1 were not significantly different from the 0-h samples after 48 h of 
storage. Results that were significantly different from the 0-h samples were identified 
by the SchefFe test and are summarized on Table 3-10. 
ANOVA analyses showed that DA was affected by the acid factor (p<0.001), but not 
by duration of storage (p=0.983) and there was no significant interaction between 
these 2 factors (p=0.743). All samples stored in acid had significantly lower DA 
concentration compared to the "0-h" samples. DA concentration decreased with 
increasing acid concentration. The presence of acid enhanced destruction of DA 
instead of protecting it. Furthermore, the rate of hydrolysis in high acid concentration 
was slower than the rate of destruction. The interplay of the 2 processes managed to 
limit the magnitude of decrease to less than 10%. 
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Table 3-10: EfTects of storing rat urine samples at room temperature over 48 h 
in different acid concentrations on free CATS. 
S t o r a g e Concentration ( nM ) Relative % Change 
Conditions Mean 土 S.D. w.r.t. 0-h sample 
NA A DA NA A DA 
"°-h" 340±51.5 130±22.5 1069±259.5 / / / Samples 
0.10 MHCl 345±49.6 120±20.7** 1042±243.1 + 1.5 - 8 . 2 - 2 . 6 for 24 h 
0.10 MHCl 348±46.8 117±22.2@ 10381248.4 + 2 . 2 - 9 . 9 - 2 . 9 for 48 h 
0.25 MHCl 345土45.7 119±20.4** 1034+247.8** + 1.4 - 8 . 4 -3 .3 for 24 h 
0.25 MHCl 350±45.8 119±22.5@ 1035±246.4* + 3 . 0 - 9 . 0 - 3 . 2 for 48 h 
0.50 MHCl 352土48.6 119±23.9@ 10231240.9@ + 3 . 6 -8 .5 -4 .3 for 24 h 
0.50 MHCl 353±51.5* 124±22.5* 1025±247.1** + 4 . 0 -5 .1 - 4 . 2 
for 48 h 
1.0 MHCl 363±53.6@ 122±23.0** 979±227.2@ +6 .8 -6 .5 - 8 . 4 
for 24 h 
1.0 MHCl 379土 51.3@ 130±22.2 989+222.3® +11 .4 -0 .5 -7 .5 
for 48 h 
The changes of mean concentrations were compared with the "0-h" samples using 
Scheffe tests ( * for p<0.05; ** for p<0.005; @ for p<0.0001 ). 
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E f f e c t s Of storage duration on acidified rat urinary free CATS at -20 °C 
Twelve rat urine samples were collected as described in the above section, except that 
10 ml of 0.5 M HC1 were added to each urine container. Each sample was separated 
into five 2-ml aliquots. The first aliquot was processed immediately as described 
above. Other aliquots were frozen and stored at -20 °C for 1，2，3 and 4 weeks. At 
the end of the storage duration, an aliquot was thawed and analysed. 
Storage had no significant effect on rat urinary free NA (p=0.326), but it was 
significant for A (p<0.0001) and DA (p=0.0016). The results are summarized in 
Table 3-11. Urinary free A concentrations in all frozen samples were significantly 
lower. The magnitude of decrease ranged from 20% to 35%. These results showed 
that the amount of acid preservative used was not sufficient to protect from oxidative 
destruction. After storage for one week, DA decreased significantly compared to the 
"0-h" samples (p<0.05). On the other hand, storage for 4 weeks had no significant 
effect compared to "0-h" samples. The rat urinary free DA again decreased in the 
presence of acid, but gradually increased with longer duration period. The use of 0. 5 
M HC1 and storage at -20 °C was acceptable for preserving rat urinary free NA and 
DA since the variation of concentration was only about 5%. However, this method is 
not suitable for measuring urinary free A. 
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Table 3-11: Effects of storing acidified rat urine in the dark at -20 °C 
on free CATS 
Time Concentration (nM) Relative% Change 
fei) Mean 土 S.D. w.r.t. 0-h sample 
NA A DA NA A DA 
"0-h" 230土37.1 80+19.9 13451237.3 / / / 
1 221 土43.0 64±26.7* 1275±282.9* -3.9 -20.0 -5.2 
2 222土40.7 62±39.9* 1294士 315.5 -3.5 -22.5 -3.8 
3 223±39.4 52+21.1@ 1289土319.3 - 3.0 -35.0 -4.2 
4 224士36.8 56士 19.0** 1351±322.9 -2.6 -30.0 +0.4 
The changes of mean concentrations were compared with the "0-h" samples using 
Scheffe tests ( * for p<0.05; ** for p<0.005; @ for p<0.0001 ). 
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DISCUSSION 
A reversed phase ion-pair HPLC method using ECD as detector was developed. The 
acetate-citric buffer mobile phase was modified from a published method (Weicker et 
a l 1 9 8 4 ) . 0 n e r e a s o n to adapt this published method was that the mobile phase is 
marketed commercially by a chromatography company. Similar to most published 
HPLC methods, modification is required when different columns or particle size of the 
same packing material is used. 
The mobile phase was modified mainly by increasing the % methanol and flow rate 
(Table 3-3). The objective was to maintain a total elution time of 15 min for all the 
CATS with baseline separation. Another modification was to replace the 1 mM di-n-
butylamine with 2 mM triethylamine because the butylamine was not available in the 
laboratory. The purpose of amine additive was to saturate the "active sites" of 
reversed phase column and to improve the between-column precision performance. 
However, the development of "end-cap" technology has removed the active sites and 
rendered the use of amines unnecessary. Other experiments (not reported here) using 
the present system showed that there was no difference in the separation of all 4 
analytes with or without the addition of amines in the mobile phase. 
For the preparation of the mobile phase, it was necessary to keep the freshly prepared 
solution overnight before filtering with 0.45 \xm aqueous filters. Freshly prepared 
mobile phase was found to block up the filters very rapidly suggesting that 
precipitates were present. The ion-pair reagent, octanesulfonate, might take more 
time to dissolve. After the mobile phase had been used, it could be recycled after 
filtering. Recycling of the mobile phase provided a more economical system. The 
number of useful cycles depended on the number of samples analyzed. Since the ECD 
used in the present system was an amperometric type, only 10% of the electroactive 
species was involved in the electrochemical reaction (Nyyssonen & Parviainen 1989). 
The remaining electroactive species were left in the mobile phase causing an increase 
in the background current for the subsequent cycle. A new mobile phase solution was 
used when the background current was above 10 nA. Use of a guard column reduced 
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the damage to the column due to the presence of precipitates in the sample. When the 
system was idle, the flow of mobile phase was maintained at 0.1 ml/min. Regular 
washing of the column with different amounts of methanol was done once every 3 
months. The same column was used for over 2 years with more than 9000 injections. 
Baseline separation of the CATS and the internal standard was satisfactory. Precision 
of the retention times with freshly prepared mobile phase over 72 h showed a CV of 
less than 1%. After the mobile phase had been recycled over a period of more than 2 
weeks, the retention times began to increase, probably due to the evaporation of 
methanol from the mobile phase. Since standard solutions and quality control samples 
were incorporated into every batch of HPLC analyses, small deviation of the retention 
times was acceptable for identification of the peaks. 
The applied potential for amperometric ECD was reported to be around +0.70 V 
(Oka et al 1982, Wu & Gornet 1985, Fosti et al 1987, Anderson ^ al 1988). 
Hydrodynamic votammograms of CATS and the internal standard showed that a 
lower potential of +0.60 V could be used for quantitation (Figure 3-3). The use of 
lower potential is beneficial because fewer electroactive species are involved in the 
electrochemical reaction giving a lower noise baseline. This is especially important 
when the mobile phase is recycled. Background current for a freshly prepared mobile 
phase was 0.3 - 0.5 nA. This was lower than that of another HPLC-ECD system of 
1.2 - 5.0 nA using an applied potential of +0.65 V (Foti et al 1987). 
Both the linearity and detection limit of the ECD in the present system was sufficient 
for the measurement of urinary CATS. With an injection volume of 15 (al, the 
linearity range of the ECD was from 30 nM to 5000 nM for all the CATS (Figures 3-
4). Thus, the lowest detection limit of CATS was 0.45 pmole. By increasing or 
decreasing the injection volume, the range of measurable concentrations can be 
expanded. Sensitivity of the detector was not assessed by direct injection of the 
standard solutions into electrochemical cell because the presence of other components 
in the mobile phase could affect the electrochemical reactions. For example, the 
presence of EDTA would enhance the signal to noise ratio as some interfering cations 
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can be chelated (Nyyssonen & Parviainen 1989). It would be more important to 
determine the linearity range and detection limit of the complete measurement system 
after urine samples had undergone preliminary purification procedures. 
For the extraction of urinary CATS, a published method using one step alumina was 
adapted (Davidson & Fitzpatrick 1985). Tedious procedure for the activation of 
alumina was followed to ensure good precision in recovery of CATS for the 
extraction step. The recovery performance of alumina varied from lot to lot and 
between suppliers (Anton & Sayre 1962). The activation procedure reduced the 
problem. 
Urinary CATS were adsorbed by alumina at an optimal pH of 8.6. It was reported 
that plasma CATS had maximum binding with alumina between pH 8.2 and 8.9 
(Bouloux et al 1985). In the present method, the optimal pH was maintained by a 3 
M Tris buffer solution that was higher than the commonly used 1 M Tris buffer (Foti 
et al 1987). This high buffer concentration was to overcome the interference of high 
creatinine concentration in some urine samples (Davidson & Fitzpatrick 1985). 
Furthermore, a freshly prepared reducing solution, containing 2.8 mM of ascorbic 
acid and sodium metabisulphite, was incorporated into the extraction mixture to 
protect the CATS from oxidative destruction at alkaline pH. It was reported that A 
was not affected at pH 8.6 for 5 h (Davidson & Fitzpatrick 1985). 
After the CATS adsorbed onto the alumina in the 3M Tris buffer, alumina was 
washed with 0.1 M Tris buffer，also at pH 8.6, instead of the published 0.1 M 
barbitone buffer. Preliminary experiment showed that there was no difference in 
recovery between the use of the 2 buffers. With the use of a diluted buffer for 
washing, the optimal pH was maintained until the elution step. This was reflected by 
a higher recovery of over 95% compared to about 70% for those using two to three 
washes with water (Foti et al 1987，Anderson et al 1988). 
Elution of the CATS from alumina was achieved using 0.1 M HC1 solution. Two 
other acid solutions were also tested (Table 3-4). With all the 3 solutions the 
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recovery was over 95%. The stronger 0.5 M HC1 was not preferred as the high acid 
concentration could affect the stability of the stationary phase. Furthermore, strong 
acid concentration could enhance oxidative denaturion of the eluted CATS. The 0.1 
M HC1 solution had higher recovery than the 0.5 M acetic acid and also it was 
reported that eluted CATS were unstable in acetic acid solution with sodium 
metabisulphite as antioxidant (Hugh et al 1987). 
Although the presence of ascorbic acid protected the CATS during alumina 
extraction, it also presented a problem in the subsequent chromatographic-ECD 
analysis. It was found that 42.3% of ascorbic acid in the extraction mixture also 
adsorbed onto the alumina and 3.3% of it was eluted with the CATS (Hugh et al 
1987). Adsorption of ascorbic acid may be related to the two adjacent hydroxyl 
groups on the ring structure of the acid. It is a free radical scavenger and may convert 
CATS quinone back to the parent compounds by inhibiting the irreversible cyclization 
to an aminochrome. However, ascorbic acid in the eluant was also oxidized in the 
ECD and eluted before the CATS during the HPLC separation. Total elution time of 
the ascorbic acid peak was concentration dependent. When the concentration was 
high, the elution time overlapped with that of NA and A. These 2 peaks were eluting 
on a changing slope, making integration of peak areas unreliable. This problem was 
overcome by adding an accurate amount of alumina, not more than 100 mg to the 
extraction mixture Similar interference has been reported in the literature (Hugh et al 
1987). 
The choice of extraction methods for urinary CATS is controversial. Based on an 
evaluation of analytical specificity, sensitivity, recovery and turnaround time, Wu & 
Gornet (1985) recommended the use of weak cation-exchange resins followed by 
alumina extraction. In their report, the lack of specificity was a main problem for the 
alumina extraction because of many other interfering peaks that appeared on the 
chromatogram. On the other hand, there have been reports claiming that the use of 
one step alumina extraction was sufficient for both urine and plasma samples (Foti et 
a/ 1987，Anderson et al 1988). In the present method, ethyl acetate was used to wash 
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the acid eluant and this improved the specificity of the alumina method by removing 
interfering electroactive species. 
Precision performance of the present method was comparable with other reported 
methods in the literature. For NA and DA, the intra-batch CV was better than 5% 
and the inter-batch CV was better than 10% (Tables 3-5 and 3-6). For A, both intra 
and inter-batch precision performance had CV values about 20%. The characteristic 
poor precision performance for A was a common observation due to the low 
concentration of the analyte in the sample. Most reports had intra-batch precision 
performance of 5 - 6% and inter-batch precision of 10-20% (Moyer et al 1979, 
Moerman & de Schaepdryver 1984, Wu et al 1985, Davidson & Fitzpatrick 1985, 
Parker et al 1986，Foti et al 1987，Anderson et al 1988). Peaston (1988) reported a 
day-to-day CV of better than 6% using a similar system. However, the 3 levels of 
urine samples studied had free A concentration ranging from 80 to 480 nM. 
Recovery performance of the method was mainly affected by the extraction procedure 
before the HPLG separation. The recovery for a one step alumina extraction has been 
reported to be 55-65% (Anderson et al 1988), 62-65% (Foti et al 1987)，at least 75% 
(Anton & Sayre 1962), 80% (Wu & Gornet 1985) and better than 95% (Davidson & 
Fitzpatrick 1985). Those extraction methods using water to wash away the buffer 
before the elution step had lower recovery. The washing of alumina with diluted 
buffer at optimal pH tended to have higher recovery. The present method had 
recovery of 98-100% for all three CATS (Table 3-5). 
The present HPLC-ECD method could measure urinary free CATS up to 10 |iM 
(Figure 3-5), This linearity range was comparable with published methods, for 
example 10 |iiM for NA/ A and 25 |oM for DA (Peaston 1988)，11.8 |iiM for NA and 
ll|nM for A (Parker et al 1986). However, the injection volume had to be adjusted. 
Preanalytical factors are also important for the reliability of any measurement of 
urinary free CATS. Due to the characteristic catechol ring structure of the CATS, 
they are sensitive to oxidative agents and are converted to their quinone forms. 
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Presence of divalent cations catalyzes the oxidative reaction, especially under alkaline 
pH condition. CATS are not stable in urine samples because of the presence of 
different cations and urine samples tended to become alkaline over time. CATS are 
stable at pH between 2 and 5. Therefore, a large variety of acid preservatives have 
been reported in the literature (Table 3-1). However, the use of acid preservative had 
not been studied in detail. The matrices of acidified urine samples could be very 
complicated as 2 different processes might be going on simultaneously in the samples, 
namely: the oxidative conversion of CATS and the hydrolysis of conjugated CATS to 
the free forms. 
During the study on effects of acid concentration on aqueous CATS standards, it was 
found that CATS decreased by 1 - 4 % two hours after the standards were prepared 
in 1 M HC1 solution, probably due to oxidative conversion. Free DA was more 
susceptible than NA and A. The results explained why some research groups 
incorporated antioxidants even in their standard solutions, for example: sodium 
metabisulphite (Moyer & Jiang 1978) and EDTA (Kontur et al 1984). It was also 
suggested that standard solutions should be prepared in dilute acids (Nyyssonen & 
Parviainen 1989). The present finding suggested that the validity of using 
concentrated acids as urine preservatives should be questioned. Although the final 
acid concentration in a 24-h urine collection is lower during the first few hours of 
collection, the acid concentration is high and may cause denaturation of CATS. 
To study the process of hydrolysis, a human urine pool was acidified with different 
amounts of acids and stored at different temperatures. The results showed that at 
higher acid concentration and higher temperature there was an increase in measurable 
free DA and NA probably due to the hydrolysis of conjugated CATS (Figure 3-6). 
There was no consistent pattern of change for A, probably due to the poor precision 
of method at low A concentrations. 
Before the detailed studies of stability of urinary CATS in different acid and storage 
conditions, effects of storage conditions for CATS in urine were studied first (Table 
3-7). Since HPLC analysis is a sequential process, extracts in the eluants have to wait 
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for the injection into the analytical column. If the extracts are not stable in the 
autosampler, the subsequent studies will be invalid. The use of 0.1 M HC1 for the 
elution of adsorbed CATS would not enhance oxidative conversion. Furthermore, 
ascorbic acid added to the extraction mixture was reported to elute with the CATS in 
an alumina extraction procedure (Hugh et al 1987). The CATS extracts were 
expected to be stable during the period inside the autosampler. However, 
concentration of NA increased significantly by 3.7%. This phenomenon cannot be 
explained by the presence of hydrolyzed conjugated NA since there should not be any 
in the eluants. Evaporation of the sample causing the increase was unlikely. All 
samples were capped inside the autosampler. The use of peak area ratios with the 
internal standard for quantitation provided an effective means of showing evaporation 
effects. Furthermore, if evaporation was the cause of higher NA results, the other 2 
CATS should have also been affected. The most likely explanation is a systematic 
drift during the assay. 
During the project, the HPLC system required system shutdown for maintenance and 
troubleshooting. Extracts had to be stored properly during this period. Thus, the free 
GATS in the extracts were also studied for their stability when kept in 4 °C over 2 
weeks (Table 3-8). The free DA was unaffected during the studied period. However, 
concentration of A significantly decreased by over 20% after 1 week. In the present 
chromatographic system, the presence of ascorbic acid could be conveniently 
observed as a fast eluting peak near the solvent front. The amount of ascorbic acid in 
the eluants was also observed to decrease. This demonstrated that the antioxidant 
protection was important for the stability of A in the eluants. Therefore, it is 
important to complete the HPLC analysis within one week, if measurement of free A 
is also required. If the extract needs to be stored for more than one week, an ascorbic 
acid solution should be added. However, the validity of such a practice needs to be 
proven by an experiment 
To study the effects of duration of storage of acidified human urine, a final acid 
concentration of 0.025 M HC1 was used. This concentration was selected based on 
the collection of 24-h urine samples into 2-liter containers with 100 ml of 0.5 M HC1. 
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This preservative was used throughout this project for human urine collection. In 
previous experiments, 0.5 M HC1 solution had been shown not to increase free CATS 
for a short period. As more urine sample is added during collection, the acid solution 
would be diluted. The lower acid concentration would not be sufficient to cause 
hydrolysis of the conjugated CATS. 
Urine samples acidified with 0.025 M HC1 were kept at 30 °C to simulate collection 
conditions by outpatients in tropical regions. There were no significant changes in the 
urinary free CATS over 48 h (Table 3-9). The same samples were also stored frozen 
at -20 °C to simulate practical situations of storing batches of samples before analysis. 
Although significant changes of free DA were detected by statistical analyses, the 
range of changes was within ±5% of the fresh samples. This magnitude of variation 
was within the inter-batch precision limits Both NA and A changed significantly by 
about 10% after 1 month of storage. Therefore, it would be best to store samples 
frozen at -20 °C for not more than 1 month. Effects of storage at lower temperature, 
for example, -70 °C, need to be studied. 
Separate studies to identify the optimum preservative conditions for rat urine samples 
are necessary. Composition of rat urine is different from human urine. For example, 
the bicarbonate concentration was higher in the rat urine sample. Higher acid 
concentration may therefore be required. However, the majority of rat urinary total 
CATS are in the conjugated forms (Wang etal 1983) and the problem of hydrolysis in 
the presence of high acid concentration is also of concern. 
To study the effects of acid concentration on rat urinary free CATS, urine samples 
were first collected in the presence of 10 ml 0.1 M HC1. This was necessary as the rat 
urine samples tended to be alkaline. The "0-h" samples had pH ranging from 3 to 6. 
The pattern of changes in rat urinary free NA was similar to that of human urine. 
Increased acid concentration and increased duration of storage at room temperature 
increased the concentration of NA, suggesting that the rate for hydrolysis of 
conjugated CATS exceeded the rate of oxidative conversion. However, increased 
acid concentration did not preserve urinary free A. Samples stored for 24 h had 
significantly lower concentrations. With prolonged storage, the concentration 
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increased gradually. Rat urinary free DA was sensitive to increased acid 
concentration. The duration of storage did not improve the situation. Study on the 
effect of acid on CATS standards showed that DA was more susceptible to the 
conversion than the other 2 CATS. The results may mean that the percentage of 
conjugated DA in the rat urine is lower. Another possible explanation is that the 
nature of conjugated DA is different in rat urine compared to that of the human type. 
It has been reported that glucuronide conjugates are predominant in rat and sulphate 
conjugates predominant in man (Wang et al 1983). 
When the rat urine samples were preserved with 10 ml of 0.5 M HC1 and stored 
frozen at -20 °C, both urinary free NA and DA decreased by less than 5% even after 4 
weeks. However, the urinary free A decreased significantly by more than 20%. This 
preservative was not suitable for the measurement of urinary A unless the samples 
were all measured within the first 48 h. 
Although acid preservatives are still popular, the results showed that the use of acid 
solutions to preserve urine samples did not provide satisfactory results. The interplay 
of the oxidative conversion and hydrolysis of conjugates is complicated. It is difficult 
to design an optimal condition for different types of urine. Inter-individual variations 
in the proportion of conjugated CATS could affect the stability results. Alternative 
preservatives should be studied in detail. The use of an acidic buffer solution might 
provide the optimal pH condition. The use of antioxidants is likely to delay the 
oxidative conversion process upon storage. Furthermore, a lower storage 
temperature could probably extend the storage duration. 
The HPLC method developed for the measurement of urinary free DA was up to the 
"state of the art" performance. Modifications made to the published sample 
pretreatment methods improved the efficiency of the method and eliminated the 
chromatographic interference caused by ascorbic acid present in the alumina extracts. 
The studies on the effects of acids and storage conditions of urine samples provided a 
better understanding of the limitation by acid preservatives. Thus, the urine samples 
collected for the subsequent studies were reliable. 
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CHAPTER 4 
CROSS SECTIONAL STUDIES 
IN THE HUMAN 
I. INTRODUCTION 
To understand the roles of DA and ESTI in natriuresis under physiological conditions, 
cross sectional studies were conducted. The local Chinese population was selected 
for these studies. They were allowed to continue their usual diet so that the status of 
the natriuretic factors and sodium homeostasis were all at equilibrium. 
The first two studies were conducted among young healthy university students. In the 
first study, the interrelationships between the Na,K-ATPase inhibitors, DLI, and 
sodium excretion in 51 medical students were examined. In the second study, the 
excretion of electrolytes, DLI and DA in 41 female students was studied. These two 
studies served to confirm previous findings on the interrelationships among the 
natriuretic factors in the Chinese population. 
For the third study, the DA-sodium relationship was investigated among 3 groups of 
Chinese subjects: normotensives without a family history of hypertension, 
normotensives with a family history of hypertension, and hypertensives. At the time 
of the study, there were no published reports on this relationship in the Chinese 
population. 
In the last study, 164 patients with non-insulin-dependent diabetes mellitus (NIDDM) 
were recruited. It was previously reported that there was decreased urinary DA in 
microalbuminuric IDDM and NIDDM patients (Murabayashi et al 1989, Patrick et al 
1990). Thus this population showed a reduced ability to mobilize DA under 
physiological conditions. It was argued that study of such a population is better than 
pharmacological manipulation of DA production or DA action. 
1-1 
II. RELATIONSHIP OF URINARY SODIUM 
EXCRETION AND PLASMA ESTI 
IN MEDICAL STUDENTS 
MATERIALS AND METHODS 
Fifty-one healthy medical students collected 24-hour urine samples in plain plastic 
containers. Urine volumes were recorded. A 5-ml aliquot of each sample was stored 
at 4 °C before being sent for the measurement of urinary sodium, potassium and 
creatinine. From each student, 5 ml venous blood was also collected into a lithium 
heparin tube. Plasma samples were stored in screw-capped tubes at -70 °C until 
analysis for plasma ESTI. 
Urinary measurements were performed on the Astra-8 Clinical Chemistry Analyser 
(Beckman Instruments, Irvin, CA, USA). Urinary sodium and potassium were 
measured by an indirect ion-selective electrode potentiometry method. The linearity 
ranges for sodium and potassium were 10-300 mmol/1 and 2-300 mmol/1, respectively. 
The between-batch precision CV for sodium was 1.2% at 100 mmol/1 and 2.0% at 35 
mmol/1 for potassium. Measurement of urinary creatinine was by the kinetic Jaffe 
reaction. The linearity range was up to 35 mmol/1 and the between-batch precision 
CV was 2.0% at 8.7 mmol/1. Plasma ESTI was measured as the ability to inhibit 
purified Na,K-ATPase and DLI by radioimmunoassay as described in Chapter 2. 
Correlation studies were performed using the WinSTAR program as previously 
described, and the significance level was set to 0.05. 
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RESULTS 
Among the 51 medical students, there were 42 males and 9 females. Their ages 
ranged from 20 to 25 years. Urinary excretion of creatinine was used to evaluate 
complete collection of 24-hour urine samples. A creatinine excretion of < 7 mmol 
was considered an incomplete collection and all 51 samples were included in the 
study. 
Table 4-1 shows a summary of the results for this study. Since there were 
overwhelmingly more male students than females, the data were not separated 
according to sex. There was a large variation of sodium excretion, ranging from 3 5 to 
361 mmol/d. All samples showed measurable inhibition on the purified Na,K-ATPase 
activity. Four samples had DLI results less than 0.10 nmol/1, the lowest detection 
limit for the method. There were no significant correlations between the plasma ESTI 
and excretion of sodium and potassium. Excretion of sodium was significantly 
correlated with the urine volume (r=0.4615, p<0.001). The 2 assays for measuring 
plasma ESTI correlated significantly with each other (r=0.5152, p<0.001). The 
results showed that in healthy Chinese medical students, there was no correlation 
between the excretion of sodium and plasma ESTI. 
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Table 4-1: Urinary excretion of electrolytes and plasma ESTI in 51 healthy medical students 
Mean S.D. Range 
Urine voiume (ij i . l 1 0.30 a J d - lT90 
Sodium excretion (mmol/d) 161 60.4 35 -361 
Potassium excretion (mmol/d) 28 10.4 11 - 56 
Na,K-ATPase inhibitor 39.5 11.21 21.1 -73.0 
(% Inhibition) 
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Figure 4-1: Correlation between plasma Na,K-ATPase inhibition and DLI in 
51 Chinese healthy medical students. 
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DISCUSSION 
The 24-hour urinary sodium excretion in this group of medical students is lower than 
those reported for Chinese in mainland China (Elliott 1989). The 24-hour urinary 
excretion of potassium in this group of Hong Kong Chinese is lower than that in many 
parts of the world, but is similar to that reported from China (Elliott 1989) and Hong 
Kong (Arumanayagam et al 1987), 
There is no correlation between the urinary sodium excretion and the concentration of 
plasma ESTI A similar finding has been reported (Devynck et a/ 1987). In healthy 
normal individuals, the kidney can eliminate excess sodium. Thus, the sodium intake 
does not stimulate the production of ESTI. This finding agrees with the de 
Wardener's hypothesis (de Wardener & MacGregor 1983). Furthermore, the two 
methods for measuring ESTI were correlated indicating that the inhibition of purified 
Na,K-ATPase enzyme and the DLI in healthy subjects are likely to measure the same 
entity in plasma. However, the correlation between DLI and other methods of 
measuring ESTI has been reported to be significant in normotensive and hypertensive 
subjects by some workers (Devynck et a/ 1987, Saitoh et al 1988, Graves ^ al 1989) 
but not by others in hypertensive patients (Hamlyn 对 al 1985). Furthermore, DLI 
was not correlated with ESTI measured by a quantitative radio-receptor assay in 
plasma of hypertensive patients (Moreth et al 1987). On the other hand, DLI was 
found to be significantly correlated with inhibition of [3H]-ouabain binding in plasma 
samples of normal adults, pregnant women, and even neonates (Balzan et al 1986). It 
can be concluded that the correlation between DLI and other methods of measuring 
ESTI depends on the methodology as well as the origin of the samples. 
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HI. EXCRETION OF URINARY 
ELECTROLYTES AND NATRIURETIC 
FACTORS IN YOUNG CHINESE FEMALES 
MATERIALS AND METHODS 
Forty-one young healthy female Chinese subjects who were taking part in a larger 
study of determinants of bone mass were asked to collect 24-hour urine samples while 
they were on their usual intake of nutrients. Urine samples were collected into bottles 
containing 3 M HC1. The volume of urine samples was measured and aliquots were 
stored at -20 °C for assay of sodium, potassium, creatinine, calcium, DA and DLL 
Measurements of sodium, potassium and creatinine were as described in section I. 
Urinary excretion of creatinine was used to evaluate complete collection of 24-hour 
urine samples as previously described. Calcium was measured by a cresolphthalein 
method on the Parallel Analytical System (American Monitor, Indianappolis, IN, 
USA). The linearity range was 0.35 , 4.5 mmol/1 and between-batch precision CV 
1.5% at 2.50 mmol/1. Urinary DA was measured as described in Chapter 3. Urinary 
DLI was measured as described in Chapter 2，using HEIA. 
Correlation studies were performed on the different measured variables, Stepwise 
multiple regression analysis was also used to further examine the variables with 
significant correlations. This method searches through all the variables and adds in, at 
each step, the variable that increases the coefficient of multiple correlation to the 
greatest extent. The process continues until either the increase in the coefficient is 
non-significant or all the variables are included. 
• . . . 
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RESULTS 
The age range of the group was 18 _ 23 years. Table 4-2 summarizes the mean, 
standard deviation, and range for the variables measured in this study. Sodium and 
potassium excretion in this group of students were similar to the medical students in 
the previous study. All urine samples demonstrated measurable DLL Table 4-3 
shows the correlation between the variables. Sodium excretion was significantly 
related to the excretion of potassium, calcium, free DA and DLL Potassium excretion 
was not related to that of calcium, free DA or DLI DLI was significantly correlated 
with calcium excretion. Stepwise multiple regression analysis with free DA as the 
dependent variable and sodium, potassium, calcium and DLI as independent variables 
showed that sodium excretion contributed significantly to free DA excretion. Of the 
variation in free DA excretion, 29.7% was accounted for by variation in sodium 
excretion. When a similar analysis was done with DLI as the dependent variable, only 
calcium excretion was significantly related (r = 0.338, p<0.05) and 11.4% of the 
variation in DLI was accounted for by calcium excretion. 
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Table 4-2: Urinary excretion of electrolytes and natriuretic factors in 41 
healthy Chinese females. 
- -ir-in-innni1iiiyi.iuuLjuL„ 
Mean S.D. Range 
Sodium excretion (mmol/d) 132 52.8 54- 302 
Potassium excretion (mmol/d) 39 12.2 18-75 
Calcium excretion (mmol/d) 2 83 1.21 0.8 -6.2 
Free DA excretion (nmol/d) 1463 304 920 - 2134 
DLI excretion (nmol/d) 1.14 0.408 0.42 - 1.98 
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Table 4-3: Correlation between excretion of sodium，potassium, calcium, free DA and DLI. 
…. Sodium Potassium Calcium Free DA 
Potassium r = 0.5i4 (p<6"6bi) 厂 丁……—•，——•「—— 
Calcium r - 0.348 (p<0.03) NS / / 
Free DA r = 0.545 (p<0.0005) NS NS / 
DLI r-0.359 (p<0.02) NS 0.345 (p<0.03) NS 
NS for p > 0.05 
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DISCUSSION 
The 24-hour urinary sodium and potassium excretion in this group of young Chinese 
females is similar to that of the medical students studied earlier (Table 4-1). Mean 
excretion of calcium in this group was 2.83 mmol/d and lower than reported from 
Western Countries (Elliott 1989). The 24-hour excretion of calcium in the steady 
state reflects intestinal absorption of calcium (Nordin 1988) and the amount of 
calcium absorbed is directly related to the intake of calcium (Nordin et al 1988). The 
low calcium excretion among the Chinese reflects the low dietary intake of calcium 
(Ho et al 1988，MacDonald et a/ 1992). 
Excretion of DA and sodium are correlated in normotensive Caucasians (Critchley et 
a/1989) and Japanese (Saito ^ a/ 1986). The present results confirm the observation 
for the Hong Kong Chinese. Furthermore, the results show that the major 
determinant of urinary free DA among the electrolytes is sodium (Table 4-3). Further 
studies are necessary to explain the relationship between DA and sodium excretion. 
Increased dietary salt stimulates the release of ESTI (Doris 1988，Haddy 1990). 
Using the HEIA, DLI were detected in all urine samples and the excretion of DLI was 
directly related to the excretion of sodium (r = 0.359, p<0.02) and to calcium (r = 
0.345, p<0.03). However, stepwise multiple regression analysis showed that only 
calcium excretion was positively correlated with excretion of DLI. If in normal 
subjects there is no abnormality in mobilization of DA, sodium intake is unlikely to 
stimulate the production of ESTI (de Wardener & MacGregor 1983). On the other 
hand, calcium intake in some manner may stimulate the release of the inhibitor. In the 
rat, increased calcium intake reduced the plasma concentration of DLI (Doris 1988), 
However, the relationship between DLI and the calcium excretion in this experiment 
was a positive one. If low calcium intake is a factor in the pathogenesis of 
hypertension (Lufl & McGarron 1991) then one would expect a negative relationship. 
Further detailed studies are required to understand this complex interrelationship. 
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Thus it can be concluded that in young healthy Chinese female subjects, urinary free 
DA excretion is determined at least partly by sodium intake and the excretion of DLI 
is independent of sodium intake. 
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IV. URINARY SODIUM/DOPAMINE 
RELATIONSHIP IN CHINESE 
NORMOTENSIVES AND HYPERTENSIVES 
MATERIALS AND METHODS 
Forty-two healthy Chinese subjects, aged 21-62 years, were recruited randomly from 
hospital staff’ medical students and the community by the Department of Clinical 
Pharmacology of the Chinese University of Hong Kong. Their family history of 
hypertension and other individual personal data were recorded, including age, sex, and 
past medical history. Blood pressure was measured after 5 min sitting by a random 
zero sphygmomanometer and phase V (disappearance of sound) was taken as the 
diastolic blood pressure (DBP). The subjects were divided into 2 groups: those 
without a family history of hypertension (Group A) and those with one or more first-
degree relatives suffering from hypertension (Group B). Fourteen hypertensive 
subjects with normal renal funetion were also recruited from the Hypertension 
outpatient clinic at the Prince of Wales Hospital during the same period (Group C). 
Their medications were stopped for at least 2 weeks before the study. 
While the subjects were on their usual diet, each of them was asked to collect one 24-
hour urine sample in a plastic bottle containing 25 ml of 5 M HC1 solution. During 
the collection, they were asked to abstain from alcoholic consumption and any 
medication. The urine volumes were measured and the samples were aliquoted and 
stored at -20 °G until analysis. Urinary sodium and creatinine were measured as 
described in section I. Excretion of creatinine was used to evaluate completeness of 
collection of 24-hour urine samples as previously described. Urinary free DA and NA 
were measured as described in Chapter 3. Statistical analyses were performed by the 
WinSTAR program. Correlation studies were done for the relationship between the 
excretion of sodium and free DA. The inter-group comparison was analyzed by 
ANOVA, followed by Scheffe’ s test to test for significant difference between each 
group. Signficance was set to p<0.05. 
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RESULTS 
The 42 normotensive subjects had systolic blood pressures (SBP) below 140 mm Hg 
and diastolic blood pressures (DBP) below 90 mm Hg. They were further divided 
into Groups A and B. Group A had 27 subjects with 9 males and 18 females. Group 
B had 15 subjects with 4 males and 11 females. Among the hypertensive Group C, 
there were 14 subjects with 4 males and 10 females. Their SBP was above 160 mm 
Hg and DBP was above 95 mm Hg. Mean arterial pressure (MAP) was calculated 
according to the formula: MAP = (SBP - DBP)/3 + DBP. 
The clinical data and urinary excretion were summarized on Table 4-4. The ANOV A 
showed that the hypertensives had significantly higher MAP .(p<O .001 ). There was no 
significant difference in the excretion of creatinine, sodium, DA and NA among the 3 
groups. Although not statistically significant, the mean sodium, NA and DA excretion 
were higher in Group C. Furthermore, the MAP of group B is also higher than the 
Group A. However, the Scheffe test indicated that the difference was not statistically 
significant. 
There was no significant correlation between MAP and the excretion of sodium and 
DA in any of the groups. A significant positive correlation between the excretion of 
sodium and DA was observed for Group A (r = 0.502, p<O.Ol), while there were no 
significant correlations for Group B (r = 0.251) or Group C (r = 0.343) or even a 
combination of the Groups Band C. Results are also shown on Figure 4-2. A 
positive significant correlation between excretion ofNA and DA was also observed ( 
r = 0.444, p<O.OOI). 
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Table 4-4: Clinical and urinary excretion data for the study of the 
relationship between sodium and free DA in Chinese 
normotensive and hypertensive subjects. 
Group A Group B Group C 
N (males, females) 27 (9, 18) 15 (4, 11) 14 (4, 10) 
Age (years) 38.1±13.1 41.9 土 11.2 46.6 土 9.6 
SBP(mmHg) 104 土 10.8 110 土 15 162 土 16.2* 
DBP(mmHg) 68 土 7,7 71 土 7.2 101 土 8.2* 
MAP(mmHg) 80 土 8.3 85 土 9.0 118±10.1_ 
24-hour urine volume 1.67 土 0.51 1.49 土 0.57 1.73 ±0.60 
(litre) 
Creatinine excretion 9.1 土 2.60 8.8 土 2.52 9.7 土 2.47 
(mmol/d) 
Sodium excretion 131 土 43.6 137 土 29.3 168 土 77.5 
(mmol/d) 
DA excretion 1495 土 526.8 1616 士 433.5 1629 土 410.3 
(nmol/d) 
NA excretion 183 土 80.2 184 ±44.4 192 土 54.3 
(nmol/d) 
Results as mean 土 SD 
Group A : normotensive subjects without family history of hypertension 
Group B : normotensive subjects with family history of hypertension 
Group C : hypertensive subjects 
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Figure 4-2: Relationship between the excretion of sodium and DA in groups 
of Chinese subjects. 
Group A: 27 normotensives without family history of hypertension 
Group B: 15 normotensives with family history of hypertension 
Group C: 14 hypertensives 
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DISCUSSION 
Impaired urinary excretion of sodium may be related to the deficiency in mobilization 
of renal DA in patients suffering from essential hypertension (Lee 1986). In Japan, a 
strong correlation between urinary DA and sodium was observed in normotensive 
subjects without a family history of hypertension (Saito et al 1986). Family history of 
hypertension was defined as at least one first-degree relative, for example parents or 
siblings, having been diagnosed as hypertensive. However, this correlation was not 
observed in subjects with a family history of hypertension. In another study where the 
family history of hypertension was not considered, a strong correlation between the 
excretion of DA and sodium was observed in Caucasians, Zimbabweans and the Thais 
(Critchley et al 1989). However, the same report also showed a lack of correlation in 
the excretion of free DA and sodium in two other ethnic groups, most of them 
residing in the United Kingdom. Based on this finding, it was argued that there is a 
difference among the ethnic groups in conserving salt. The present study was the first 
study in an ethnic Chinese population. The results showed a strong correlation 
between urinary DA and sodium in normotensive subjects without a family history of 
hypertension (Group A). The coefficient of correlation was similar to that reported 
for Caucasians (Critchley et al 1989). There was no correlation between sodium and 
DA in normotensives with a family history of hypertension (Group B) or 
hypertensives (Group C), similar to the Japanese (Saito et al 1986). 
The loss of the association between sodium and DA excretion in the hypertensive 
group provides evidence that DA may be an important factor facilitating sodium 
excretion. The loss of this association may lead to volume expansion and 
subsequently to development of hypertension. However, the failure to mobilize DA in 
the kidney may be a consequence of the hypertension process rather than the cause of 
hypertension. The loss of correlation between sodium and DA excretion in 
normotensives with a family history of hypertension, suggests that the abnomality of 
renal DA production in the hypertensive patient is inherited, not acquired (Lee 1993). 
Furthermore, other studies have also suggested that renal DA receptors are up-
regulated in hypertensives showing that the production of renal DA is defective and 
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insufficient (Lee 1993). On the other hand, studies in the spontaneously hypertensive 
rat model showed that there is a defect in the receptor G protein coupling to 
adenylate cyclase in the proximal convoluted tubule of the kidney (Kinoshita et al 
1989). 
No statistically significant differences in the excretion of DA were found among the 3 
groups of subjects but there was a trend for DA excretion to increase from Group A 
to C (Table 4-4). This trend is in contrast to reports showing DA excretion to be 
lower in hypertensives than in normotensives (Lee 1993). Furthermore, the urinary 
DA excretion was significantly lower in young normotensives with a family history of 
hypertension compared to age-matched normotensives without a family history. On 
the other hand, there are also reports showing that free DA is higher in borderline 
essential hypertensives (Kuchel 1989) and in young patients with essential 
hypertension (Saito et al 1994). To further complicate the issue, it has also been 
reported that there is no difference on DA excretion between hypertensive patients 
and age- and sex-matched healthy volunteers (Romero et al 1992). 
Discrepancies between the results of these studies could be due to the differences in 
the study populations. A study of 1000 subjects using a specific HPLC method 
showed that there were age- and sex-related differences in the excretion of DA in 
adults aged 17-88 years (Gerlo et al 1991). Urinary 24-hour DA excretion was 
significantly higher in the males than the females for all the age groups studied. 
Furthermore, an inverse relationship between age and DA excretion was also 
observed for both sexes. The decrease in DA excretion was about 6.5% per decade. 
It was postulated that the age-dependent decrease may be related to a decrease in the 
amount of L-dopa or a diminished activity of dopa decarboxylase in the kidney. 
Although the cause is unknown, it may play a pathophysiological role in the reduced 
ability of the elderly to handle a sodium load. However, when the results were 
expressed in relation to the excretion of creatinine, the excretion of DA was unrelated 
to age in men but still significant in women. This is probably due to the parallel 
decrease in creatinine excretion with age (Morgan et al 1978). On the other hand, 
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urinary creatinine excretion is affected by diet and exercise, thus excretion of CATS 
should not be expressed in relation to creatinine (Jenner et al 1987). 
It would be very interesting to study the DA and sodium relationship in different age 
groups. Reported sodium and DA relationships were observed mostly in the younger 
population. Since blood pressure increases with age, the age-dependent decrease in 
DA could be one contributing factor. In this study, there was no significant difference 
in age among the 3 groups, thus, the age-dependent effect of DA excretion is not a 
factor. However, distributions of men and women in the 3 study groups were uneven. 
To understand the sodium and DA relationships, more subjects would need to be 
recruited in the different groups. 
There was a positive correlation between the excretion of DA and NA. This 
correlation has also been reported in a group of young hypertensives (Saito et al 
1994). Urine NA excretion reflects sympathetic nervous activity. This correlation 
suggests that renal DA production is in part under the influence of sympathetic 
nervous activity. It is also possible that renal DA stimulates sympathetic nervous 
discharge via dopaminergic receptors, or renal NA is a link between sodium intake 
and tubular DA production. However, such a correlation is not compatible with the 
theory that DA inhibits NA release from sympathetic nerves via DA2 receptors 
(Goldberg 1984). Another possible explanation is a pre-analytical factor Acid 
hydrolysis of conjugated NA and DA in the 24-hour urine collection might give falsely 
high NA and DA as described in Chapter 3. More studies are required to understand 
this relationship. 
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v. URINARY DA EXCRETION 
AND PLASMA ESTI 
IN NORMOTENSIVE AND HYPERTENSIVE 
NON-INSULIN DEPENDENT DIABETES 
MELLITUS (NIDDM) PATIENTS 
MATERIALS AND METHODS 
This study was a collaboration between the Departments of Chemical Pathology, 
Clinical Pharmacology and Medicine at the Prince of Wales Hospital, The Chinese 
University of Hong Kong. Measurement of plasma atrial natriuretic peptide (ANP) 
was performed by the Department of Medicine. Measurement of other plasma and 
urinary analytes was performed by the Department of Chemical Pathology. 
A total of 164 Chinese patients with NIDDM, 67 males and 97 females, aged from 25 
to 75 years, were recruited from the Diabetes Clinic at the Hospital and were studied 
on 2 occasions over a 6-week period. All patients received their usual dietary and 
oral hypoglycaemic therapy and none was receiving insulin. Anti-hypertensive 
treatment was taken by 102 patients, but was withdrawn for at least 2 weeks before 
the study. 
On each of the two study visits, supine (after 5 min of rest) and erect (after 2 min of 
standing) BP was measured by a single research nurse using a random zero 
sphygmomanometer. Phase V (disappearance of sound) was taken as the DBP. MAP 
was calculated as described in section III. The mean of the supine and erect MAP is 
shown for each subject unless otherwise stated. After the BP measurement, venous 
blood was taken for the measurement of plasma electrolytes, urea, creatinine, 
hemoglobin Ai (HbAi)，ANP, renin, aldosterone and ESTI. Twenty-four hour urines 
were also collected for the measurement of electrolytes, creatinine, albumin (UAE), 
and CATS. Urinary tract infection was excluded by examination of a midstream 
specimen of urine. 
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Plasma ANP measurement was performed as described (Yandle et al 1986). Briefly, 
blood sample was collected in an EDTA bottle containing Trasylol. Plasma ANP was 
extracted by G18 Sep Pak cartridges (Millipore, Milford, PA, USA) pre-washed with 
methanol and 4% acetic acid. After the plasma was loaded onto the cartridge, the 
resin was washed with 4% acetic acid, and then ANP was eluted with an aqueous 
solution containing 80% ethanol and 4% acetic acid. The eluant was dried under an 
air stream and the residue was reconstituted in buffer solution for radioimmunoassay. 
The plasma extract was incubated with a rabbit antiserum against the c-terminal 
region of ahuman-ANP for 21 h at 4 °C. Then, [125I] ANP was added to incubate 
with the reaction mixture for another 24-hour at 4 °C The bound and free ANP were 
separated by addition of goat anti-rabbit antiserum. The precipitated bound fraction 
was counted in a gamma counter. Intra- and inter-assay coefficients of variation were 
both between 11 and 14% at varying concentrations of ANP in human plasma. The 
detection limit was 10 pg/mL 
The following analytes were measured by the routine laboratory of the Department of 
Chemical Pathology at the Prince of Wales Hospital. HbAr was measured by agarose 
gel electrophoresis using a commercial kit (Ciba Corning Diagnostics Corp., Alto, 
CA, USA), The inter-assay CV was better than 8%. Plasma renin concentration was 
measured by a radioimmunoassay kit (ERIA Diagnostics Pasteur, France). The inter-
assay CV was 11% and the detection limit was 7.5 ng/1. Plasma aldosterone 
concentration was measured by a coated tube radioimmunoassay kit (Diagnostic 
Products Corp., CA, USA). The inter-assay CV was 12% and the detection limit was 
68 pmol/l. UAE was determined by immunoturbidimetry on the centrifugal analyser 
Cobas Bio (Cheung & Swaminathan 1989). The inter-assay CV was better than 7%. 
The detection limit was 2.5 mg/1. 
Plasma ESTI was measured by the inhibition of purified Na,K-ATPase activity and 
DLI by the CEDIA HEIA as described in Chapter 2. Urinary DA and NA 
concentrations were measured as described in Chapter 3. Plasma and urinary 
electrolytes and creatinine were measured as described in the previous sections of this 
Chapter. 
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Statistical analyses were performed with the WinSTAR statistical package on a 
personal computer. The mean values of all variables obtained on both visits were 
used for statistical analyses. Since the distributions of UAE, sodium, DA and NA 
outputs and plasma ANP, renin, aldosterone and ESTI concentrations were skewed, 
these data were log transformed for some statistical analyses. Their results were 
expressed as medians and their ranges. Other results were expressed as mean 土 SD. 
Correlation coefficients were calculated by Pearson's method. Stepwise multiple 
regression analysis was used to study the interrelationships between these variables. 
Comparisons between groups of the subjects were performed using ANOVA. A p 
value of less than 0.05 (two-tailed) was considered to be statistically significant. 
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RESULTS 
Grouping of patients according to urine albumin excretion 
Patients were divided into 3 groups according to UAE results. Based on the mean 
value of two measurement of UAE, 86 patients had normoalbuminuria (UAE <30 
mg/d)’ 48 patients had microalbuminuria (UAE between 30 - 300 mg/d) and 30 
patients had macroalbuminuria (UAE > 300 mg/d). Table 4-5 summarizes the clinical 
data and the ANOVA results of these 3 groups. There were no significant difference 
in age and glycaemic control between these 3 groups of patients. The MAP was 
higher in patients with abnormal albuminuria. Urinary sodium output was similar in 
all 3 groups of patients. Plasma ANP concentration increased with increasing 
proteinuria, whereas urinary DA output was lower in proteinuric patients. 
Creatinine clearance and urine NA output showed a similar pattern to that of urine 
DA output. Plasma ESTI concentrations were not different among the 3 groups of 
patients. Finally, plasma renin concentration increased whereas plasma aldosterone 
decreased with increasing albuminuria. 
UAE correlated positively with plasma ANP concentration (r=0.312, p<0.0001) and 
negatively with urine DA output (r= -0.179，p<0.05). Supine systolic blood pressure 
(SSBP) also showed a similar correlation with ANP (r=04579, p<0.0001) and DA 
output (r= -0.221, p<0.01). These inter-relationships are shown on Figures 4-3 and 
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Figure 4-3: Relationships between UAE, urinary DA and plasma ANP in 164 
NIDDM patients. 
All values of UAE, urinary DA and plasma ANP were plotted on 
logarithmic scales. 
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Figure 4-4: Relationships between SSBP, urinary DA and plasma ANP in 164 
NIDDM patients. 
Values of SSBP was plotted on a linear scale; while both urinary DA 
and plasma ANP were plotted on logarithmic scales. 
4-26 
Inter-relationships between the measured variables 
Since some the variables were inter-correlated, stepwise multiple regression analysis 
was used to identify the most significant relationship. Tables 4-6 summarizes the 
standardized regression coefficients (p) and their significant level. 
MAP is dependent on a number of factors and it correlates with ANP, Na,K-ATPase 
inhibitor，sodium excretion and age. Urine excretion of sodium was significantly 
correlated with the creatinine clearance and DA excretion and weakly correlated with 
albumin excretion. DA excretion significantly correlated with NA and sodium 
excretion and weakly with creatinine clearance. 
Simple correlation analysis showed that there was a weak inverse relationship 
between plasma ANP and urine DA output (r=-0.1626, p;0.0492). The correlation 
coefficients between plasma ANP and urine DA output were negative in both 
microalbuminuric (r=-0.192，p=0‘2057) and macroalbuminuric (r=-0.280, p=0.1336) 
patients. When these 2 groups were combined and analyzed, the relationship became 
more significant (r=-0.236, p=0.0417). With stepwise multiple regression, however, 
plasma ANP concentration was not significantly correlated with urinary DA output 
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Table 4-6: Inter-relationship between age, mean blood pressure, sodium 
output, dopamine output, noradrenaline output, albumin output, 
creatinine clearance，ANP, Na,K-ATPase inhibitor, DLI, renin， 
aldosterone, using stepwise multiple regression anlysis. 
Dependent Variables Mean Arterial Sodium Dopamine 
Pressure Output Output 
ANOVA for the regression: 
F ratio 19.94 25.76 49.14 
上响？ .. • <0.0001 . • . H 9 9 9 1 <0.0001 
Independent Variables: 
Age p = 0.177* NS NS 
MAP / NS NS 
Creatinine Clearance NS P = 0 3 7 7 _ p = 0.186* 
Sodium Output P = 0 209料 / p = 0.265@ 
DA Output NS p = 0.315@ / 
NA Output NS NS P = 0.459@@ 
UAE NS P = 0.211, NS 
ANP 3 = 0.392@@ NS NS 
Na,K-ATPase inhibitor p = 0.299@@ NS NS 
DLI NS NS NS 
Renin NS NS NS 
Aldosterone NS NS NS 
(3 for standardized regression coefficient 
NS for p>0.05; * for p<0.05; ** for p<0.01; @ for p<0.001; @@ for p<0 0001 
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Grouping of patients according to blood pressure 
Blood pressure is another factor affecting natriuresis. These 164 patients were 
divided into 2 groups according to their SSBP. The normotensive group was those 
with SSBP less than 160 mmHg; while the others with SSBP greater than 160 mmHg 
were considered hypertensives. Table 4-7 summarizes the ANOVA results for the 
measured plasma and urine parameters. There were 90 normotensives and 74 
hypertensives. The hypertensive group was significantly older than the normotensive 
group. There was no difference in their glycaemic control, plasma DLI, renin and 
aldosterone concentration, or urine sodium excretion. The plasma ANP, sodium, 
Na,K-ATPase inhibitor concentrations and urine albumin outputs were significantly 
higher in the hypertensives. Figure 4-5 shows the relationship between Na,K-ATPase 
inhibitor and the SSBP. On the other hand, the creatinine clearance, DA and NA 
excretion were lower in the hypertensives. 
The sodium and DA excretion correlated significantly for both the normotensive and 
hypertensive groups (r=0.487，p<0.0001 for nomotensive and r=0.483, p<0.0001 for 
hypertensive) Figure 4-6 shows the correlations of the 2 parameters slopes of the 
regression lines were similar. 
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Table 4-7: Clinical data and laboratory data for the NIDDM subjects 
grouped according to supine systolic blood pressure. 
Supine SBP Supine SBP ANOVA 
< 160 mmHg > 160 mmHg F values 
Clinical data 
Males : Females 44 : 46 23 : 51 / 
Age (years) 49.2 土 10.4 60.5 土 8.7 56.40@@ 
Plasma concentration 
HBAi (%) 10.5 土 1.8 10.1 土 1.9 NS 
ANP(pg/ml) 28.5(9.0-13.7) 47.2(19.1-141 0) 42.46@@ 
Sodium (mmol/1) 139.5 土 2.0 1412± 1.9 31.58@@ 
Na,K-ATPase 4.9 (4.9-10.6) 7.0(4.9-16.9) 42.95@@ 
Inhibitor (nmol/1) 
DLI(|ig/l) 0.10 (0.07-0.27) 0.09 (0.07-0.22) NS 
Renin (ng/1) 26.1 (7.4-254) 35.4 (7.4-271) NS 
Aldosterone (pmol/1) 378 (69-1336) 299 (68-982) NS 
Daily Urine Output 
Creatinine clearance 84.5 士 31.6 68.6 土 25.1 12.33@ 
(ml/min) 
Sodium (mmol) 157 (33-329) 134 (36-264) NS 
Dopamine (nmol) 1350 (508-3475) 1188 (150-3282) 9.650** 
Noradrenaline (nmol) 183 (60-1077) 134 (24-453) 17.94@@ 
Albumin 16.1 (2.3-5193) 71.4(1.3-7547) 20.75@@ 
l r i f m n n n n n n n n n 门门门 j^ j-tflnnnnnnf^ nflnnnnfin 酬.nnnnfriAAnnnnnnnahnnnnnrinnnnnnnnmnrinnnnnnnnnnn。rr 
Results are shown in mean 土 SD or median (range). 
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Figure 4-5: Relationship between plasma Na,K-ATPase inhibitor and SSBP 
in 164 NIDDM patients. 
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Figure 4-6: Correlation between urinary excretion of sodium and DA in 
normotensive and hypertensive NIDDM patients. 
Urinary DA and sodium values were both plotted on logarithmic scales 
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DISCUSSION 
There is evidence that patients with IDDM and NIDDM have an increase in 
exchangeable body sodium that correlates with their level of blood pressure 
(Weidmann & Ferrari 1991). The pathophysiology of this phenomenon is not fuUy 
understood. To study the contribution of DA to sodium excretion, inhibitors of the 
L-dopa decarboxylase or antagonists ofDA receptors are often used. However, these 
inhibitors or antagonists are not present naturally and these pharmacological agents 
may have other effects and the results obtained with these agents may not be readily 
applicable to physiological or pathophysiological states. Decreased urinary DA 
excretion has been reported in microalbuminuric patients with IDDM and NIDDM 
(Murabayashi et al 1989, Patrick et al 1990). Thus, diabetic patients can be used as a 
model where there is reduced DA production. Furthermore, hypertension is another 
common complication in NIDDM patients. Increased plasma ESTI concentration has 
been reported in hypertensive patients (Poston et al 1981，Hamlyn et al 1982). 
Another natriuretic factor, ANP, has also been reported to increase in hypertensive 
patients (Sagnella et al 1986) and in patients with IDDM and NIDDM (Bell et al 
1989, Shinoda et al 1990, Lieberman et al 1991). Intravenous infu$ion of ANP 
induces proteinuria in patients with essential hypertension (Suenaga ^ al 1989) and 
primary glomerular diseases (Zietse & Schalekamp 1988, Ishi et al 1989, Hirata et al 
1991). The population of NIDDM patients appears to be a good model to study the 
interplay of the various types of natriuretic factors, sodium excretion, proteinuria and 
effects on blood pressure. 
In the present study, 164 NIDDM patients were recruited from the Diabetic Clinic. 
Among them, 102 were on anti-hypertensive treatment. Effects of anti-hypertensive 
medication were minimized with a 2-week wash-out period. Each subject had 2 study 
visits over a period of 6 weeks. They were allowed to continue with their usual diets 
and hypoglycaemic medication. All measurements and samplings represented an 
average of the 2 visits. This would provide more representative data for the 
population. 
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D e c r e a s e d D A excretion has been reported in N I D D M patw^^ ^^  
(Murabayashi^ a/ 1989). It has been suggested that early microangiopathic changes 
within the renal tubules may initiate and exacerbate diabetic nephropathy (Pinter & 
Atkins 1990). Structural damage to the tubule may reduce the amount of L-dopa 
decarboxylase present and reduce production of intrarenal DA When the NIDDM 
patients were divided into 3 groups according to UAE, it was observed that DA 
excretion decreased significantly with increasing UAE (Table 4-5). Renal function 
assessed by creatinine clearance also decreased as UAE increased (Table 4-5). These 
results support the concept that patients with microalbuminuria (Group B) and 
macroalbuminuria (Group C) suffer from reduced renal function. The observed 
decrease in DA production is probably due to structural damage to the renal tubules. 
The differences in DA excretion between the 3 groups cannot be explained by age as 
there were no significant differences in age among the 3 groups of subjects (Table 4-
Despite differences in DA excretion between the three groups, there was no 
signficant difference in urine sodium excretion (Table 4-5). This suggests that sodium 
balance is maintained by other natriuretic factors. Increased circulating ANP in 
NIDDM patients has also been reported (Shinoda et al 1990). It is possible that 
increase in ANP is a compensatory phenomenon and helps to promote sodium 
excretion. Such a complementary role between plasma ANP and urine DA is further 
supported by their inverse relationship with UAE (Figure 4-3). 
There was a significant increase in MAP with increasing UAE (Table 4-5). Stepwise 
multiple regression shows that MAP correlated significantly not only with age, sodium 
excretion and ANP, but also with the Na,K-ATPase inhibitor (Table 4-6). The 
correlation between Na,K-ATPase inhibitor with MAP has been reported for 
essential hypertensive patients (Poston et al 1981, Hamlyn et al 1982). When the 
NIDDM patients were grouped according to their SSBP, the hypertensive group was 
older than the normotensive group (Table 4-7). There was no difference in HBAi 
concentration between the 2 groups indicating that there was no difference in 
glycaemic control. Hypertensive NIDDM patients were associated with higher 
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proteinuria, plasma sodium, ANP and Na,K-ATPase inhibitor concentrations. Figure 
4-5 shows the correlation between plasma Na,K-ATPase inhibitor and SSBP. 
Hypertensive NIDDM patients had significantly lower urinary DA outputs (Table 4-
7)，probably due to damage to the renal tubule as discussed above. This was 
supported by the presence of increased UAE and decreased creatinine clearance. 
When the urinary DA and sodium excretion were analyzed in both the normotensive 
and hypertensive groups, there was significant correlation between them (Figure 4-6). 
This was in contrast to the results observed in section IV of this Chapter, where the 
correlation between urinary sodium and DA relationship was lost in the hypertensive 
as well as normotensive subjects with a family history of hypertension. Subjects in the 
previous study had normal renal function. The dissociation of the DA-sodium 
relationship in that group of hypertensives might be due to a genetic defect in the 
production of intra-renal DA (Lee 1993). The hypertensive NIDDM patients in this 
study maintained the correlation between sodium and DA excretion. It is unlikely that 
they have the same genetic defects as described for patients studied in section IV. 
Other natriuretic factors were also measured in this study. Urine NA excretion was 
significantly decreased with increasing UAE (Table 4-5) and increasing blood pressure 
(Table 4-7). This indicates that there was reduced renal sympathetic nervous activity 
in patients with increasing UAE and MAP. There was a strong positive correlation (r 
>0.45, p<0.0001) between urine NA and DA excretion (Table 4-6a). A similar 
correlation was observed previously in section IV. 
The renin-angiotensin system is another system that affects natriuresis. Decreasd 
plasma renin and aldosterone concentrations facilitate sodium excretion Plasma 
aldosterone decreased significantly with increasing UAE (Table 4-5) as expected. 
Plasma aldosterone was lower in the hypertensive group, but this was not statistically 
significant (Table 4-7). It was surprising to find that plasma renin concentration 
increased, as opposed to plasma aldosterone concentration, with increasing UAE 
(Table 4-5). Furthermore, in the hypertensive NIDDM patients, the plasma renin 
concentration also was higher although not statistically significant. It has been 
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suggested that plasma renin behaves paradoxically in patients with renal failure, due to 
reduced metabolic clearance rate of the enzyme (Rosenberg et al 1994). NIDDM 
patients with increasing UAE and blood pressure had reduced creatinine clearance. 
Thus the paradoxical increase in renin could be explained by the diminished renal 
function. Furthermore, plasma renin concentration, not bioactivity, was measured in 
this study. It is possible that some renin molecules measured is not bioactive. Higher 
plasma renin may lead to higher concentrations of angiotensin II in the circulation. It 
has been demonstrated that infusion of angiotensin II in subpressor doses in man can 
reduce DA excretion (Eadington et al 1991). 
Based on the results of the present study, it can be postulated that, in patients with 
NIDDM, early renal tubular damage may result in impaired sodium excretion, in part 
through defective DA mobilization. A compensatory rise in plasma ANP 
concentration in response to plasma volume expansion and to hypertension may limit 
the renal sodium retention, but this could also contribute to worsening of albuminuria 
and possibly renal damage. This may lead to a further reduction in the urinary DA 
response to salt intake and initiate a vicious cycle involving sodium retention, 
hypertension and albuminuria. Diminished renal function also leads to the paradoxical 
increase in renin which may contribute to fiirther reduction in DA production. The 
increase in plasma Na,K-ATPase inhibitor observed in these patients may contribute 
to the development of hypertension. 
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CHAPTER 5 
VOLUME EXPANSION STUDIES 
IN THE HUMAN 
I. INTRODUCTION 
Sodium excretion is the major mechanism for the maintenance of ECF volume. There 
are a large variety of mechanisms to increase sodium excretion in order to maintain 
homeostasis. To study the role of various factors influencing sodium excretion, the 
ECF volume is altered experimentally and the effects studied. To expand ECF 
volume three common methods are used: headout water immersion, acute saline 
infiision and oral salt loading. This Chapter reports the effect of expanding the ECF 
volume by these three different methods on DA and ESTI in order to examine their 
role in sodium excretion. 
Section H describes the effect of headout water immersion in 7 Caucasian females. 
This is the only experiment studied in non-Chinese subjects in the thesis. Headout 
water immersion is a method to induce prompt redistribution of circulating blood 
volume by the pressure gradient effects on the cardiopulmonary receptors. When a 
subject is allowed to sit in a water tank with the body immersed in water up to the 
neck at thermal neutrality, the central blood volume, intracardiac volume, central 
venous pressure and cardiac output are all increased. The increase in central blood 
volume produces natriuresis and diuresis, without changes in plasma osmolality and 
serum electrolyte concentrations. The detailed mechanism and renal effects of 
headout water immersion has been recently reviewed (Epstein 1992). An advantage 
of this method is that endogenous plasma constituents are only affected by the process 
itself, as there is no alteration in dietary intake or infusion into the blood stream. 
There have been conflicting reports on the role of DA in sodium excretion induced by 
this method. Furthermore, very few studies have examined the role ofESTI. 
Section III describes the experiment to study the effect of volume expansion by 
intravenous saline infusion. ECF volume can be expanded acutely by this method to 
elicit prompt natriuresis. However, it is invasive and involves venous catherization of 
the subjects. There is no standardized protocol for the volume and duration of the 
saline infusion. Plasma concentrations of the different components are diluted by the 
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infiised saline. Biological actions of some analytes can be affected, especially those 
depending on the plasma protein concentration. Like in headout water immersion, 
there have been conflicting reports on the role of DA, and very few reports on the 
role of ESTI in the sodium excretion induced by saline infusion. 
The last 2 sections in this Chapter describes the effect of dietary salt loading in healthy 
Chinese subjects. This method simulates what happens in our daily life. According to 
the hypothesis of the pathogenesis of essential hypertension, failure to excrete sodium 
promptly in response to increased dietary salt intake initiates the pathological process 
(de Wardener & Clarkson 1985). This method can be used with a large number of 
subjects without using expensive equipment. However, to maintain the subjects on a 
constant dietary sodium intake can be difficult as most processed foods contain high 
amounts of sodium. The mechanism of inducing natriuresis is different from that of 
intravenous infusion as it has been shown that the liver plays a significant role in 
maintaining sodium homeostasis during oral salt loading (Morita et al 1993). In these 
studies, the roles of DA and ESTI in sodium excretion were examined with subjects 
on their usual diets and on a controlled diet. 
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II. VOLUME EXPANSION BY 
HEADOUT WATER IMMERSION 
MATERIALS AND METHODS 
Serum and urine samples were collected from a study which was designed to 
investigate the effect of the menstrual cycle on sodium handling (Bisson et al 1992). 
T e n healthy Caucasian female volunteers aged 18 - 30 years (median 24.5) with 
regular menstrual cycles participated in a headout immersion study. The women were 
not taking any medication and none of them complained of symptoms suggesting 
premenstrual syndrome. All subjects gave informed consent and the study was 
approved by the district ethics committee in the United Kingdom. 
Subjects were studied on their normal diets. Each was asked to keep a record of her 
dietary intake on the three days preceding the first study and followed a similar diet 
before the second study to reduce within-subject variability in sodium excretion. This 
was then assessed by a 24-h urine collection immediately preceding each study. 
Each subject was immersed twice: once between day 7 -10 of the follicular phase and 
once between day 18 - 24 of the luteal phase of the same cycle. After an overnight 
fast, the subjects took a 400-ml water load an hour before the start of the study. They 
continued to take 200 ml of water hourly during the study to maintain hydration. For 
the first hour, they sat outside the tank (preimmersion control hour), followed by 3 h 
of immersion and then a final postimmersion hour outside the tank to allow all the 
changes to return to normal. The subjects emptied their bladder at the end of each 
hour by leaving the tank briefly during the immersion hours. Blood samples were 
taken through an indwelling cannula. They were given lunch during the final hour. 
At each period, 25 ml of venous blood was taken and divided into chilled tubes, kept 
on ice, centrifiiged at 4 °C for 10 min, and serum separated and frozen within 30 min. 
The serum samples were stored at -20 °C. Portions of the urine samples were 
acidified for the measurement of urinary free CATS and frozen at -20 °C. Aliquots of 
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the frozen serum and urine samples were sent to Hong Kong for the measurement of 
urinary free CATS and plasma ESTI. 
Urine sodium, potassium, calcium and creatinine; serum sodium, potassium, 
creatinine, calcium, and progesterone; plasma renin activity, aldosterone and ANP 
were measured in the United Kingdom as described (Bisson et al 1992). Results of 
the urine samples and plasma electrolytes were sent with the samples to Hong Kong. 
Plasma ESTI was measured by the inhibition of purified Na,K-ATPase activity and 
DLI using the homogeneous enzyme immunoassay as described in Chapter 2. Urinary 
free DA and NA were measured as described in Chapter 3. 
Results of urine and plasma samples were expressed in mean 土 standard error of the 
mean (SEM). The pre-immersion control data were compared between the two 
cycles using a paired t-test for normally distributed data or a Wilcoxon signed rank 
test when the data were not normally distributed. If there was no difference in control 
values, the responses to immersion were compared using ANOVA for repeated 
measurement. Data were log transformed when necessary to normalize the 
distribution. When there was a difference in control values, the data were converted 
to relative changes to allow comparisons of the response to immersion to make 
between the two phases of the cycle using the ANOVA test. 
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RESULTS 
Seven of the 10 women ovulated as assessed by a 6-fold increase in the mid-luteal 
phase serum progesterone level (Table 5-1). Only samples from these 7 subjects were 
analyzed. There was no renal sodium and water retention during the luteal phase of 
the menstrual cycle (Bisson et al 1992). There were no differences in body weight, 
creatinine clearance, basal sodium excretion and plasma ANP between the 2 phases 
of the cycle. There was a significant rise in basal progesterone, aldosterone and renin 
activity in the luteal phase. Renal and hormonal responses to headout immersion 
including sodium and calcium excretion, elevation of ANP, suppressions of 
aldosterone and renin activity are identical in the 2 phases of the cycle. Some relevant 
data are tabulated on Table 5-1. 
Only 3 of the ? subjects had measurable DLI in most of their samples. Similarly, most 
urine samples had urinary free A lower than the lowest detection limit. Thus, these 2 
parameters were not analyzed. 
Using the Wilcoxon signed rank test, there was no significant difference between the 
two phases of menstrual cycle in the pre-immersion control values for plasma ESTI, 
urinary free NA and DA. Examining the distribution of data, plasma ESTI and 
urinary free NA were log transformed for the ANOVA test. There were no 
significant differences for the pre-immersion control results between the 2 phases. To 
reduce the intra-individual variation, results of the 2 phases were averaged for further 
analyses. Table 5-2 shows the changes for NA, DA excretion and plasma ESTI. 
Figure 5-1 shows the relative % changes of these parameters and sodium excretion. 
There was no significant change in DA excretion during the 5 h. There was a 
significant change in NA excretion during the 5 h (F=48.68, p<0.0001). Free NA 
excretion was suppressed throughout the 3 h of immersion by more than 50%, and it 
increased by 180% during the post-immersion recovery period. The ANOVA test 
also showed significant changes in plasma ESTI (F=7.534，p=0.0007). The plasma 
concentration increased by about 10% and peaked at the last hour of immersion. 
During the recovery period, the plasma ESTI concentration decreased by 50% 
compared to the control period. 
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Table 5-1: Relevant control data of the follicular and luteal phases during a 
menstrual cycle of 7 ovulating women (Bisson et al 1992). 
Follicular Phase Luteal Phase Significanc 
Weight (Kg) 51.9 ±1.5 51.8 土 1.5 NS 
24 h urine volume (1) 1.0 士 0.08 1.2±0.15 NS 
24 h urine sodium (|nmol/min) 69 士 4 73 ± 7 NS 
24 h creatinine clearance 129 ± 19 118 士 8 NS 
(ml/min) 
24 h urine potassium 40 土 3 43 士 4 NS 
(|iimol/min) 
ANP (pg/ml) 25 士 5 21 土 2 NS 
Serum progesterone (nM) 1.3 土 0.4 34 4 ±2.4 p = 0.002 
Plasma aldosterone (pM) 310 土 24 1077 土 202 p = 0.01 
Plasma renin activity (ng/ml/h) 1.01 ±0.1 1.97 土 0.4 p = 0.02 
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Table 5-2: Excretion of NA and DA and plasma ESTI concentration in 7 
ovulating women during and after the headout immersion study. 
The results are shown as mean 土 SEM and obtained from the average 
of results between the follicular and luteal phases. 
Time NA excretion DA excretion Plasma ESTI 
( pmol/min ) (pmol/minV (nM OE ^ 
Pre-immersion 94 + 9 1125 ±54 6 61 土 1.31 
Immersion 1 h 44 土 4 1186 土 105 8.57 土 1.31 
2h 39 土 5 1093 士 51 9.01 ±1.51 
3 h 54 土 6 1079 士 62 7.53 土 1.17 
Post-immersion 171 土 17 936 ±100 4.69 土 0.92 
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Figure 5-1: Relative changes in the excretion of sodium, NA, DA and plasma 
ESTI for 7 women during headout immersion. 
Results are shown as mean 土 SEM. They were obtained from the 
average of results between the follicular and luteal phases. Results of 
pre-immersion period were taken as 100 %. 
5-8 
Opposite effects of DA and NA on the renal handling of sodium suggest that relative 
concentrations of DA versus NA may be an important factor mediating the natriuretic 
response to certain physiological events (Krishna et al 1983). Thus, the ratio of DA 
to NA (DA/NA) was calculated and analysis of variance showed that there were 
significant changes in the ratio during the study period (F=29.854, p< 0.0001). Figure 
5-2 shows the relative percentage changes of sodium excretion, DA/NA and plasma 
ESTI. The ratio doubled during the first hour of immersion, peaked at the second 
hour, and decreased to 175% at the third hour. It decreased further to 50% of the 
control value during the recovery period. 
The correlations between the different variables were calculated for the results during 
the 3 hours of immersion period. Excretion of sodium did not correlate with urinary 
DA excretion or with plasma ESTI concentration. It correlated significantly with NA 
excretion and the ratio of DA/NA. Stepwise multiple regression showed that sodium 
excretion correlated significantly only to the DA/NA ratio (P=-0.6360, p<0.02). 
Plasma ESTI concentration correlated significantly with both DA excretion and 
DA/NA ratio. Stepwise multiple regression showed that plasma ESTI correlated with 
DA excretion (p=0.5574，p<0.05), but other variables did not account significantly for 
any further variation in ESTI. 
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Figure 5-2: Changes in DA/NA ratio, plasma ESTI and sodium excretion for 7 
women during headout immersion. 
Results are shown as mean 士 SEM. They were obtained from the 
average of results between the follicular and luteal phases. Results of 
pre-immersion period were taken as 100%. 
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DISCUSSION 
A highly significant increase in fractional excretion of sodium during immersion 
indicates that the natriuresis is attributable primarily to decreased tubular reabsorption 
of sodium rather than to alterations in filtered sodium load (Epstein 1992). In a 
recent review, 8 different possible mechanisms have been listed for the decrease of 
sodium reabsorption (Epstein 1992). These mechanisms have been studied with 
variations in the experimental conditions. In the study designed to examine renal 
sodium handling during the follicular and luteal phases of the menstrual cycle in the 
present group of 7 women, it was shown that ANP increased 2-fold, and plasma renin 
activity and aldosterone concentration decreased by over 60% during the immersion 
period (Bisson et al 1992). Both ANP and the renin-aldosterone system are 2 of the 
mechanisms suggested to be responsible for natriuresis during immersion (Epstein 
1992). The results presented here examine 3 other mechanisms on the list: the role of 
renal sympathetic nervous activity assessed by the excretion of free NA, the roles of 
free DA and the humoral natriuretic factor. This represents the largest number of 
mechanisms studied in a single group of subjects in one immersion study. The sodium 
status and the pattern of natriuresis during the 2 phases of the present group of 
subjects were not different (Bisson et al 1992). Pre-immersion urinary free NA, DA 
and plasma ESTI were also not significantly different. Results of the 2 phases were 
therefore averaged to reduce intra-individual variation. 
In this study, the excretion of NA was suppressed by 50% throughout the course of 
immersion but during the post-immersion hour, NA excretion recovered by more than 
180% compared to the pre-immersion level (Table 5-2 and Figure 5-1). The data 
clearly showed that the sympathetic nervous activity was depressed during water 
immersion. Recently, a similiar experimental design reported that suppression of 
urinary NA excretion was 30% in 10 healthy males throughout the course of the 
immersion (Grossman et al 1992). However, during the recovery post-immersion 
period，NA excretion was back to the baseline level. The difference in the magnitude 
of suppression during immersion may not be significant between the 2 studies. 
However, the increase in NA excretion during the post-immersion was much higher in 
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the present study. The significance of this phenomenon is not clear. It was 
speculated that it might be because the 2 populations studied were of different sexes. 
Sex-dependent variations in the excretion of urinary CATS during immersion have not 
been studied. 
Urinary free NA reflected the circulating plasma NA concentration. However, 
previous immersion studies using plasma NA have shown conflicting results. There 
were studies showing no significant changes in plasma NA (Weihl et al 1981, Epstein 
e t a l 1983’ Knight & Horvath 1987) and studies showing significant decrease 
(Krishna et al 1983, O'Hare et al 1986). No report showed an increase in plasma or 
urine NA levels during immersion. In one recent study, the measurement of 
cardiovascular variables such as central venous pressure, cardiac output, and stroke 
volumes were included in an immersion study, and plasma NA concentration was 
suppressed (Norsk et a/ 1990). The changes in measured cardiovascular variables 
suggest that the decrease in NA reflected a decrease in sympathetic nervous activity 
initiated by stimulation of low and high-pressure baroreceptors. 
Suppression of plasma or urine NA concentrations during water immersion can only 
be used as an indirect measure of the renal sympathetic nervous activity. More direct 
indices, such as the measurement of renal venous NA levels, are required to delineate 
the effects of immersion on the kidney (Epstein 1992). The use of direct 
microneurographic recordings in renal nerves demonstrated reduced renal sympathetic 
nervous activity in dogs with natriuresis and diuresis during immersion (Miki et al 
1989). In another animal study, NA was infused into cats to preinfusion levels and 
this abolished the renal responses to intravascular volume expansion (Rasmussen et al 
1988). These results led to the conclusion that the reduction in renal sympathetic 
nervous activity plays an important role in the natriuresis in animals. Although the 
animal results may not be applicable to the human, a recent review on the subject 
summarized evidence to suggest suppression of renal sympathetic nervous activity is 
an important contribution to the natriuresis of immersion (Epstein 1992). 
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In this study, the excretion of free DA decreased over the period of infusion (Table 5-
2 3X16 药糾比 ^ 1 ) , b u t 促础 to reach statistical significance. Similar results were 
observed in a 4-h immersion study (Predel et al 1988). However, this finding did not 
agree with the result of a recent immersion study in which DA excretion exhibited a 
triphasic pattern (Grossman et al 1992). DA excretion was shown to decrease at the 
beginning of immersion, increased after the first hour，and significantly decreased 
during the recovery period. The experimental design of the 2 studies was similar. 
This discrepancy could be due to the difference in the magnitude of renal sympathetic 
nervous activity suppression, since the present group of women showed a 
comparatively higher suppression of NA excretion during the immersion period, 
which could facilitate natriuresis without an increase in DA. Furthermore, there was 
no correlation between sodium and DA excretion during immersion in this study. 
DA has been considered a potentially important mediator of the natriuretic response 
to volume expansion (Epstein 1992). Dopaminergic blockage by domperidone and 
metoclopramide caused blunted natriuresis during immersion (Krishna et al 1985， 
Goruzzi et al 1989). The immersion-induced suppression of plasma aldosterone was 
prevented during metoclopramide administration but was unaffected by domperidone. 
It has been proposed that the DA system is important in natriuresis and aldosterone 
secretion during immersion (Crouzzi et al 1989). With dopaminergic blockage, there 
was a 6-8 fold increase in plasma prolactin level (Coruzzi et al 1989). Prolactin could 
attenuate natriuresis as it has been shown that prior administration of bovine prolactin 
results in a blunted natriuretic response to saline infusion (Lucci et a/ 1975). 
Plasma DA concentration was reported to increase significantly during immersion 
(Krishna et al 1983). The physiological role of increased circulating DA was not 
clear. Furthermore, the excretion of urinary DA mainly reflected the renal synthesis, 
rather than the circulating plasma level (Lee 1993). However, this observation was 
not reproduced in another study (Grossman et al 1992). 
It has been suggested that the DA/NA ratio may be an important factor mediating the 
natriuretic response to water immersion due to the opposite effects of NA and DA on 
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the renal handling of sodium. Plasma DA^A ratio correlated significantly with 
natriuresis during water immersion and saline infusion (Krishna et a/ 1983). Urinary 
DA/NA ratio was reported to be significantly increased at the third hour of water 
immersion，but significantly decreased during the recovery period (Grossman ^ al 
1992). In this study, the urinary DA/NA ratio was also calculated. The relative 
change of the ratio was plotted against the relative change of excretion of sodium and 
the plasma ESTI concentration (Figure 5-2). The ratio increased over 200% at the 
first hour of immersion, peaked in the second hour to over 250%, and remained at 
about 200% during the last hour of immersion. The ratio decreased significantly 
during the recovery phase, to 50% of the pre-immersion level. Sodium excretion 
correlated significantly with the DA/NA ratio in this study. Stepwise multiple 
regression analysis showed that there was an inverse relationship between this ratio 
and sodium excretion as the standardized coefficient of regression (p=-0.6360) was 
negative. This suggested that decrease in NA, i.e. reduced sympathetic nervous 
activity, was the driving force for sodium excretion during water immersion. The 
pattern of change was quite different from that reported by Grossman et al except 
during the recovery period (Grossman et al 1992). Difference in the pattern was 
expected as the changes of NA and DA excretion were different between the 2 
studies. 
The presence of a circulating natriuretic factor in volume expanded states has been 
documented (de Wardener & Clarkson 1985), Studies during the recovery hour 
following immersion revealed a continuing natriuresis despite the progressive volume 
contraction induced by the earlier period of immersion (Epstein 1992). It was shown 
that the continuous natriuresis during the recovery phase was not attributable to 
persistent aldosterone suppression (Epstein et al 1973). In this study, plasma ESTI 
concentration increased during the immersion hours but failed to reach statistical 
significance (Table 5-2, Figure 5-2). The increase was about 13% at the third hour. 
It would be of interest to see the changes if the immersion period was extended. 
However, the ESTI concentration decreased significantly to 66% of the pre-
immersion level during the recovery period. The results suggest that plasma ESTI 
concentration was affected by physiological alterations in central blood volume in the 
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studied subjects. However, such a small increase indicates that ESTI does not play an 
important role in the natriuresis of immersion. If ESTI had to play a significant role, 
the natriuretic effect must be very potent. The presence of a urinary natriuretic factor 
and plasma sodium transport inhibitor in normal subjects undergoing immersion has 
been reported (Epstein 1976). A preliminary study also showed that plasma 
immunoreactive ouabain-like factor was increased during immersion and decreased 
promptly following cessation of immersion (Epstein 1992). The description of that 
preliminary result was similar to the findings of the present study. 
It was also of interest to note that there was a significant correlation between the 
excretion of free DA and the plasma ESTI concentration during the course of 
immersion. This reflected similar responses of the 2 variables as shown on Figure 5-2‘ 
The physiological significance of this correlation is not clear. 
This study showed that the relative change of NA and DA excretion was important in 
the natriuresis of immersion. Plasma ESTI concentration probably did not play an 
important role. 
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III. VOLUME EXPANSION BY 
SALINE INFUSION 
MATERIALS AND METHODS 
Four healthy Chinese male volunteers, aged 25 to 36 years, were recruited for the 
saline infusion study. They were on their usual diet and were not on any medication 
before the study. 
After an overnight fast, the subjects arrived at the Clinical Pharmacology Study Unit 
at the Prince of Wales Hospital around 08:30 in the morning. Intravenous cannulae 
were inserted into both arms. One was for saline infusion and the other was for blood 
sampling Heparin solution was used to keep the line open. The subjects emptied the 
bladder and the urine was discarded. They drank 200 ml of water and laid down on a 
bed at about 09:00. Subjects remained in the supine position for 30 min and a blood 
sample was taken. They remained supine throughout the study except to empty their 
bladder. Blood pressure was measured at 09:50. A urine sample was collected at 
10:00 as the first hour urine sample. The same procedure was repeated at the next 
hour when a blood sample was collected at 10:30 and a second hour urine sample 
was collected at 11.00. 
At 11:00，after the second set of samples, the intravenous saline infusion began. A 
0.9% sodium chloride solution (153 mmol/1) was infused at 500 ml/h for 2 h. The 
blood and urine collections, and the blood pressure recordings were continued 
similarly to the first 2 hours. The saline infusion was stopped at 13:00, but the blood 
and urine collections, and monitoring of blood pressure, were continued for another 2 
h. The study was completed at 15:00, 
Urine samples were acidified for the measurement of urinary CATS as described in 
Chapter 3. Urinary electrolytes and creatinine were also measured as described in 
Chapter 4. Lithium heparin plasma was used to measure plasma ESTI concentration 
as described in Chapter 2. Plasma samples were also used to evaluate the renal 
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function tests and the total protein, albumin, and calcium on the Parallel Analytical 
System as described in Chapter 4. EDTA plasma was kept frozen at - 7 0 � C for the 
measurement of renin activity. Serum samples were also kept frozen at -70 °C for the 
measurement of aldosterone. 
Plasma renin activity was measured using a commercial kit, (Biodata Renin MAIA kit, 
Serono-Baker Diagnostics, Allentown, PA, USA). The kit was used according to the 
manufacturer's instructions. Plasma renin activity was measured as the angiotensin I 
liberated by renin. Briefly, plasma samples were incubated to generate angiotensin I 
at pH 7.4 at 37 °C for 3 h. An enzymatic inhibitor, phenylmethylsulphonyl fluomre, 
was added to prevent further enzymatic degradation of angiotensin I during the 
generation step. Afterwards, angiotensin I was measured by radioimmunoassay. 
Angiotensin I in samples or standards competed with iodinated angiotensin I for the 
binding sites on rabbit anti-angiotensin I antibody. Reaction mixtures were incubated 
at 4 °G overnight. After the incubation, the bound and free fractions were separated 
by adding sheep anti-rabbit y-globulins coupled with magnetic particles. The 
application of a magnetic field allowed the sedimentation of the immunocomplexes. 
The supernatant was decanted and the radioactivity in the bound fraction was counted 
in a y-counter. Cross reactivity of the anti-angiotensin I antibody is 0.06 % to 
angiotensin II and 0.02 % to angiotensin III. Sensitivity of the method is 0.1 ng/ml. 
The inter-assay precision CV was better than 10%. 
Serum aldosterone was measured by a commercial solid-phase radioimmunoassay kit 
(Coat-A-Count® Aldosterone, Diagnostic Product Corporation, Los Angeles, CA, 
USA). The kit was designed to quantitate aldosterone levels in unextracted serum 
samples and it was used as described by the manufacturer. Briefly, serum samples and 
iodinated aldosterone tracer were added to polypropylene tubes coated with anti-
aldosterone antibody and incubated overnight at 4 °C. The reaction mixture was 
aspirated and the tubes were counted in a y-counter. Cross reactivity of the antibody 
is 0.06% to spironolactone, 0,033 % to 18-OH-corticosterone, 0.007 % to 
progesterone, 0.006 % tol 1-deoxycortisol, 0.002 % to corticosterone, less than 0.001 
o/0 t 0 androsterone, cortisone, 11-dexamethasone, DHEA, prednisolone, and not 
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detected to androstendione, Cortisol, estradiol, estriol, estrone, fludrocortisone, 
prednisone, pregnenolone, 17a-hydroxyprogesterone and testosterone. Detection 
limit of the method is 44 pM. The inter-assay precision CV was better than 10%. 
Statistical analyses were as described in the previous section. 
4-18 
RESULTS 
The results of plasma sodium, albumin-adjusted calcium and total protein 
concentrations are shown on Table 5-3. Significant changes were observed in plasma 
concentrations of sodium, calcium, total protein and albumin. Plasma sodium 
concentration increased by 2 mmol/1 from the start of infusion and remained elevated. 
The albumin-adjusted calcium concentration did not show any significant change 
during infusion and recovery periods. Total protein concentration decreased during 
the infusion period and remained lower than the baseline level at the end of the 
recovery period. Mean relative changes of total protein concentration showed that 
there was a 10% decrease in concentration at the second hour ofinfusion period and a 
6% decrease in concentration at the second hour of recovery period. These changes 
were used to show that an average of 10% expansion of the extracellular fluid volume 
was achieved by the saline infusion procedure. 
Table 5-4 summarises the results for urine flow rate, sodium excretion and GFR. 
One-way ANOVA showed that there were significant changes in the urine flowrate 
and the excretion of sodium. Urine flowrate increased during the second hour of the 
baseline period, probably due to the initial drinking of 200 ml of water leading to a 
diuresis. However, the urine flowrate decreased during the course of saline infusion 
and the subsequent recovery period. Excretion of sodium increased during saline 
infusion and the subsequent recovery period. Using the average values of 2 initial 
baseline results as the background sodium excretion, the mean cumulative sodium 
excreted during saline infusion and the subsequent recovery period was 19%(range 
14-24%) of the infused sodium load. There was a tendency for the GFR to decrease 
during the 2 hours of saline infusion, hut it did not reach statistical significance. 
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Table 5-3: Plasma sodium, albumin-adjusted calcium, and total protein 
concentration data for the 4 subjects undergoing saline-infusion. 
Results are expressed as mean 土 SEM 
Time ( h ) Sodium Albumin-adjusted Total Protein 
(mmol/1 ^  Calcium (mmol/1) ( g/H 
Baseline - 1 136 土 2 2.10 土 0.04 74 士 1 
Baseline - 2 136 ±1 2.15 ± 0.04 76 士 1 
Infusion - 1 138 ± 1 2.14 ± 0.05 76 土 2 
Infusion-2 138 土 1 2.15 土0.01 69土 1 
Post-infusion - 1 138 土 1 2.06 士 0.02 70 士 1 
Post-infusion -2 138 土 1 2.13 土 0.04 71 土 1 
ANOVA 
F-Ratio 6.0000 1.9659 10.474 
p 0.0030 0.1426 0.0002 
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Table 5-4: Urine flow, sodium excretion, and GFR data for the 4 subjects undergoing saline infusion. 
Results are expressed as mean 土 SEM 
Time 丫 h � Urine Flowrate Sodium excretion G F R 
(nil/ min) (|umol/min ) (ml/min ) 
Baseline - 1 3.93 士 0.98 187 土 52 130 ±13 
Baseline-2 5.60 + 1.06 176 土 48 130 土 9 
Infusion-1 2.26土0.50 2 2 4 ± 4 6 118 士4 
Infusion _ 2 2.46 士 0.41 322 土 44 128 士 7 
Post-infusion - 1 2.07 土 0.26 350 ±33 131 + 10 
Post-infusion-2 1.56 土 0.27 318 ± 38 133 士 8 
ANOVA 
F-Ratio 9.2497 31.029 1.0768 
p 0.0004 < 0.0001 0.4119 
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As the baseline value for sodium excretion varied between the 4 subjects the relative 
changes of sodium excretion were calculated. The pattern of relative changes is 
shown on Figure 5-3. There was a significant difference between the baseline, 
infbsion and recovery periods (F=6.9104, p=0.0040). Maximum excretion was 
observed during the first hour of recovery, reaching 227% of the baseline value. 
Table 5-5 shows the results for excretion of GATS ANOVA showed that there were 
no statisticallly significant differences between the 6 hours of study for the 3 urinary 
CATS. Since there were large variations in the excretion of urinary free CATS 
between the subjects, relative changes of each CATS were calculated. The patterns 
of relative changes of urinary free CATS and the DA/NA ratio are shown on Figure 
5-3. The ANOVA tests on the relative changes of CATS excretion did not show any 
significant changes. NA excretion decreased by 16% during second hour of infusion 
and the first hour of recovery, but increased to 90% of the baseline level during the 
second hour of recovery. Excretion of A remained elevated during the infusion and 
recovery periods, reaching 32% higher than the baseline level during the recovery 
period Excretion of DA decreased by 8% during the first hour of infusion, but 
returned to baseline levels during the remaining time of the study. The DA/NA ratio 
and relative changes of the ratio were also calculated. The ratio increased during the 
infusion and remained elevated at the end of the recovery period. However, the 
changes were not statistically significant by 1-way ANOVA. 
Changes in plasma ESTI，plasma renin activity and serum aldosterone concentrations 
are summarized on Table 5-6 and the patterns of relative change are shown in Figure 
5-4. Renin and aldosterone were suppressed till the second hour of the recovery 
period. Suppression of aldosterone was more severe than that of renin at the last hour 
of observation. Aldosterone was only 38.5% of the baseline level and renin was 
50. 5% of the baseline level. Plasma ESTI increased during the first hour of infusion 
and then decreased by 10% during the remaining observation period, but these 
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Figure 5-3: Relative changes of urinary free CATS, DA/NA ratios and sodium 
excretion during saline infusion. 
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Table 5-5: Urinary excretion of CATS in the 4 subjects undergoing saline infusion. 
Results are expressed as mean ± SEM 
Noradrenaline (NA), Adrenaline (A), Dopamine (DA) 
Time ( h ) NA excretion A excretion DA excretion 
(pmol/min� ( pmol/min� ( pmol/min� 
Baseline - 1 155 土 35 68 土 36 1382 土 97 
Baseline - 2 137 土 64 66士31 1326 土 67 
Infusion - 1 116 士 25 56 土 19 1250 ±49 
Infusion - 2 100 土 24 49±11 1351 土 41 
Post-infusion - 1 96土21 57 土 10 1318 土 38 
Post-infusion-2 99 土 15 57 土 9 1305 土 45 
ANOVA 
F-Ratio 1.2644 0.3465 0.6565 
p 0.3294 0.8732 0.6615 
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Table 5-6: Plasma ESTI, renin activity and serum aldosterone concentration 
data for the 4 subjects undergoing saline infusion. 
Results are expressed as mean 土 SEM 
Time (h ) Plasma ESTI Plasma Renin Serum 
(nMQE) (ng/ml/h) Aldosterone 
(pM^ 
Baseline - 1 9.9 土3.53 0.58 土 0.15 483 土 143 
Baseline - 2 15.6土 3.58 0.60 土 0.10 294 土 81 
Infusion- 1 15.9± 1.98 0.55 土0.05 279士94 
Infusion-2 13.3 ±1.11 0.37±0.05 184土55 
Post-infUsion - 1 13.3 土 2.27 0.27 ± 0.01 141 土 39 
Post-infusion -2 13.6 ± 1.23 0.28 士 0.02 138 ± 25 
ANOVA 
F-Ratio 1.0351 4.1665 3.4951 
p 0.4327 0.0142 0.0271 
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Figure 5-4: Relative changes of plasma renin, ESTI, and serum aldosterone 
levels and sodium excretion during saline infusion. 
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To understand the contributing factors for natriuresis during saline infusion, the data 
of the infusion and recovery periods were used for a correlation study. The recovery 
period was also included as 80% of the infused sodium load was retained in the body 
at the end of the recovery period. Sodium excretion was significantly correlated with 
urine flowrate (r=0.527, p=0.0361), GFR (r=-0.572, p=0.020), DA excretion 
(r=0.874, pcO.OOOl)，renin activity (r=-0.716, p=0.0018) and aldosterone 
concentration (r=-0.687, p=0.0033). Stepwise multiple regression analysis showed 
sodium excretion was only correlated positively with DA excretion (p=0.763, 
p<0.0001) and inversely with plasma renin activity (|3=-0.434，p=0.0002). The 
correlation of sodium excretion with DA excretion is shown on Figure 5-5. 
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Figure 5-5: Correlation of sodium excretion and DA excretion. 
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DISCUSSION 
Acute intravenous infusion of isotonic saline in man has been widely used to study the 
intra- and extra-renal factors that can modulate natriuresis. Results are often 
conflicting as the procedures for infusion are not standardized. The volume of 
isotonic saline infused ranged from 1 liter (Herlitz 祐 a/ 1990) to over 4 liters (Jeffrey 
e t a l 1 9 8 9 ) and the duration of infusion ranged from 10 min (Widgren 权 al 1991) to 4 
h (Tulassay et al 1988). These maneuvers affect the degree of volume expansion and 
may trigger different physiological mechanisms. For example, most saline infusion 
studies reported significant increases in plasma ANP, however an infusion of 22 ml/kg 
of saline over 20 min failed to show an increase in ANP (Drummer et al 1992). This 
makes comparison of data between studies difficult； In the present study 1 liter of 
isotonic saline was infused over a period of 2 h. Significant volume expansion was 
achieved as indicated by the 10% decrease in the plasma total protein concentration 
during the second hour of infusion (Table 5-3) and it was 6% lower than the baseline 
level at the end of the recovery period. A similar combination of conditions to study 
the contributions of urinary free DA and plasma ESTI in natriuresis has not been 
reported in the literature. 
In the present study, the subjects drank 200 ml of water at the beginning of the 2 h 
baseline period. An increase in urine flowrate was observed, probably as a result of 
this initial water intake. However, the urine flowrate decreased significantly after 
starting the saline infusion (Table 5-4). The average total urine output for the last 4 h 
of the experiment for the 4 subjects was about 50% of the infused volume of saline. 
In many studies reported in the literature water intake was allowed during saline 
infusion to ensure adequate urine flow (Singer et a/ 1987, Jeffrey et al 1989, 
Stenvinkel et al 1992) and the urine flow rate did not significantly change during 
infusion and recovery periods. In studies that did not provide additional water intake 
during infusion, urine flow rate decreased significantly (Alexander ^ a/ 1974， 
Tulassay et at 1988). Saline infusion increased the plasma osmolality as shown by a 
significant increase in plasma sodium concentration (Table 5-3). Osmolality is an 
important modulator of antidiuretic hormone secretion. An increase in osmolality 
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would cause an increase in the antidiuretic hormone concentrations and a decrease in 
the urine output. When isoosmotic glucose is infused there is a significant increase in 
the urine flow without affecting the excretion of DA (Stenvinkel et al 1992). 
However, it has not been shown whether a decrease in urine flow rate can affect 
excretion of DA 
In the present study, significant natriuresis was observed in all the subjects. Sodium 
excretion was over 200% of baseline at the second hour of infusion and peaked at the 
first hour of the recovery period to 230% of the baseline period (Figure, 5-3) The 
relative increase in sodium excretion appears to be related to the amount of sodium 
infused. Infusion of more than 300 mmol sodium led to a 3 to 4-fold increase in 
sodium excretion (Alexander et al 1974, Singer et al 1987, Tulassay et al 1988). A 
higher sodium load of more than 600 mmol was reported to cause a 5-fold increase in 
sodium excretion (JefFery et al 1989). Since only 154 mmol of sodium was infused in 
the present study, a 2-fold increase in sodium excretion was appropriate. Most of the 
studies also observed that peak excretion of sodium occurred within an hour after the 
infusion and the plasma ANP response followed that of sodium (Singer et al 1987, 
Tulassay et al 1988, JefFery et a/ 1989). This observation led to investigation of the 
contribution of other factors, such as DA and plasma ESTI, to the natriuresis in saline 
infusion. 
It is generally believed that the GFR is stable or will increase following ECF volume 
expansion with saline (Burg 1981). In this experiment, GFR was estimated by the 
creatinine clearance. It was observed that GFR decreased by 9% during the first hour 
of infusion and returned gradually to 2% above the baseline value at the end of the 
observation periods. However, the changes did not reach statistical significance. 
Despite a 4-fold higher sodium load during the infusion, a similar pattern was 
observed in another study using creatinine clearance for the estimate of GFR (Jeflfery 
e t al 1989). The changes also did not reach statistical significance. Using the inulin 
clearance to measure GFR, a significant decrease of GFR was observed with saline 
infusion, but not during water diuresis or infusion of isoosmotic glucose solution 
(Stenvinkel et al 1992). Another study using 51Cr-EDTA clearance also reported a 
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significant fall in GFR in healthy controls and unilaterally nephrectomized humans 
following saline infusion (Serensen et al 1987). The accuracy of the measurement of 
GFR by creatinine clearance is inferior to that of the inulin or 51Cr-EDTA clearance 
methods and this may explain the lack of the significant decrease of GFR in the 
present study. 
Both plasma renin activity and serum aldosterone concentration decreased during 
infUsion and remained suppressed at the recovery period (Table 5-6 and Figure 5-4). 
This pattern is consistent with other reports in the literature (Krishna 过 al 1983, 
Singer et al 1987，Stenvinkel et al 1992). The renin-angiotensin system is important 
in the physiologic regulation of fluid and electrolyte balance (Rabkin & Dahl 1993) 
In this study, both renin and aldosterone were among factors significantly correlated 
with the excretion of sodium during and after the saline incision. However, only DA 
excretion and plasma renin activity showed significant correlation with sodium 
excretion in stepwise multiple regression analysis. 
The role of urinary free DA excretion in the natriuresis of saline infusion has been 
conflicting. In the present study, there was an initial fall of 8% in DA excretion at the 
first hour of the infusion period and then it rose back to the baseline level throughout 
the study periods (Table 5-5 and Figure 5-3). These changes were not significant. 
There was large variation in baseline DA excretion and the response to saline infusion 
also varied widely. With the small number of subjects involved in the study, large 
relative changes are required to reach statistical significance. The excretion of DA 
and sodium were significantly correlated during the study period (Figure 5-5). 
Isotonic saline infusion by 600 mmol of sodium over a period of 4 h did not show a 
significant rise in urinary free DA excretion in 9 healthy male subjects (Jeffery et al 
1989). However, during the recovery period, urinary DA increased significantly by 
26% compared to the pre-infUsion level. A 5-fold increase in sodium excretion was 
reported and the increase in DA excretion was comparatively small. When the same 
subjects were given carbidopa to inhibit intrarenal production of DA before a second 
saline infusion, sodium excretion was not affected. The results showed no evidence of 
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a facilitating role for DA in the natriuretic response to saline infusion. The authors 
also noted that less than 30% of the sodium was excreted during the observation 
periods. They suggested that DA may assume greater significance during the later 
stages of the response. 
On the other hand, there are other studies which show a significant increase in DA 
excretion during saline infusion. Alexander et a/(1974) reported a 3.5-fold increase 
in sodium excretion and a significant 28% increase in DA excretion after 3 h saline 
infbsion in 7 women. The subjects were kept on a 59 mmol/1 sodium diet for 3 days 
before the infusion. Castellano et al (1986) reported an 18% increase in 24-h DA 
excretion in a group of 8 healthy subjects after a 2-h saline infusion. They were kept 
on a diet containing 120 mmol/d sodium and 80 mmol/d potassium for 5 d before the 
infusion. Two other studies from the same research group reported less than 20% but 
significant increase in DA excretion during the second hour of the incision and the 
recovery periods (Stenvinkel et al 1992, Stenvinkel et al 1992a). Both studies 
showed that the subjects had more than 2 fold increase in sodium excretion. The DA 
response to the large increase in sodium excretion in human studies was 
comparatively small. 
DA excretion in saline infusion was more exaggerated in animal models. There was a 
40% increase in rats (Hansell et al 1988) and 300% increase in dogs (Sowers et al 
1984). A significant increase in DA excretion in these 2 animal studies was not 
observed during the first hour of saline infusion. In rats, the relative contribution of 
DA excretion to the natriuretic response of saline infusion was related to the degree of 
volume expansion (Chen & Lokhandwala 1991). DA appears to play a greater role in 
the overall natriuresis response during modest degrees of volume expansion (2.5-
5 0% increase in body weight). Another study also concluded that endogenous DA 
contributes to the natriuresis of saline infusion by small, but not large, increases in 
extracellular fluid volume in anaesthetized rats (Bass & Murphy 1991). Validation of 
this observation in human studies has not been reported. 
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The use of DA receptor blockade suggests that renal DA may play a significant role in 
the natriuresis of saline infusion. Administration of metoclopramide, blocking mainly 
D A 2 receptors, in 2 different human studies decreased the magnitude of the saline 
infosion induced natriuresis, but did not completely abolish it (Krishna ^ al 1985, 
Tulassay et al 1988). The results suggested that in acute volume expansion, 
natriuresis is mediated only in part by DA (Tulassay et al 1988). Furthermore, 
metoclopramide prevented the suppression of plasma aldosterone and thus, may play 
a critical role in mediating the aldosterone response in volume expansion (Krishna et 
a l 1985). On the other hand, administration of carbidopa, an inhibitor of dopa 
decarboxylase, in 9 males failed to suppress sodium excretion significantly indicating 
that renal DA does not play an important role in natriuresis of saline infusion (Jeffery 
^t al 1989). These few reports in human studies do not support a major role of DA in 
saline infusion to facilitate natriuresis. 
In the rat, the natriuresis associated with modest (1.7 to 3.4% body weight), moderate 
(6.3% body weight) and large (13% body weight) increments in extracellular fluid 
volume with either saline or Ringer's lactate solution was attenuated by selective and 
nonselective DA receptor antagonists (Bass & Murphy 1990). The effect of DA 
receptor blockade was also reported to be dependent on the degree of hypervolemia 
(Hansell & Fasching 1991). The DA system appears to be relatively more important 
in promoting natriuresis at the lower physiological range of hypervolemia, and other 
factors have a greater impact at the high range. Carbidopa was also reported to 
attenuate natriuresis produced by saline infusion in conscious dogs (Sowers et al 
1984). On the other hand, Cuche et al (1983) showed that infusion of hypoosmotic 
saline into anesthetized dogs caused a large natriuresis without a change in DA 
excretion. DA excretion did increase during infusion with isoosmotic and 
hyperosmotic saline. The authors concluded that the dissociation between sodium 
and DA excretion does not support a physiological role in renal handling of sodium 
during volume expansion. It has also been reported that neither DA! receptor 
blockade with SCH 23390 nor D ^ receptor blockade with domperidone can 
demonstrate any effect on the natriuresis accompanying extracellular volume 
expansion with isoosmotic saline (Bass & Murphy 1990). A recent report where 
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saline was infused at a very slow flowrate directly into the renal artery concluded that 
renal DA is not directly responsible for the observed natriuresis (Bullivant & Mufioz 
1993). Thus, renal DA may not play a significant role in saline infusion natriuresis 
even in animal studies. More studies to understand the conflicting results are 
necessary. 
Urinary NA excretion in this study decreased by 16% at the second hour ofinfusion 
and remained suppressed during the first hour of recovery period. It rose back to 
90% of the baseline level at the last hour of the recovery period. However, these 
changes were not statistically significant by ANOVA (Table 5-5 and Figure 5-3). 
Although the urinary DA/NA ratio increased by 30% after the first hour of the 
infusion, the increase did not reach statistical significance. The results indicated that 
there was no significant decrease in the renal sympathetic nervous activity as observed 
during water immersion as described in the previous section. Excretion of NA was 
reported to decrease or remain unchanged during saline infusion in both human and 
animal studies (Alexander etal 1974, Cuche etal 1983, Sowers ^ a / 1984, Castellano 
et al 1986, Hansell et al 1988, Stenvinkel et al 1992). Most studies have reported a 
decrease in plasma NA during the infusion and the recovery period (Cuche et al 1983， 
Krishna et al 1983, Tulassay et al 1988，Widgren et al 1991, Stenvinkel et al 1992). 
The decrease in plasma NA concentration could be caused by the dilution of the 
plasma instead of a decrease of the renal sympathetic nervous activity. It has also 
been reported that renal nervous activity may not be a major factor for controlling 
renal excretory function during either hypovolemia or hypervolemia in an animal study 
(Peterson et al 1984). Krishna et al (1983) reported the plasma DA/NA ratio was 
significantly correlated with the sodium excretion. However, there was no correlation 
of this ratio with sodium excretion in the present study. 
Plasma ESTI concentration did not decrease significantly during the infusion and 
recovery periods in this study (Table 5-6 and Figure 5-4). The decrease in ESTI 
could reflect a dilution of plasma volume as the magnitude of decrease was similar to 
that of the total protein and as plasma ESTI is tightly bound to proteins. The results 
were consistent with de Wardener's hypothesis that a normal intact kidney should 
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have the ability to excrete additional sodium load. Other mechanisms were operating 
to excrete the sodium challenge, for example, the renin-angiotensin system. Recently, 
it was reported that plasma Na,K-ATPase inhibitory activity remained unchanged in a 
group of salt-resistant borderline hypertensives undergoing saline infusion (Borghi et 
a/ 1992). On the other hand, plasma Na,K-ATPase inhibitory activity in a group of 
salt-sensitive borderline hypertensives increased during the second hour of saline 
infosion. The salt-sensitive group also showed a delayed ANP response to saline 
infosioa It was suggested that the increase of plasma ESTI in the salt-sensitive group 
was due to the lack of ANP response. ANP has been reported to inhibit the release of 
sodium pump inhibitor in vivo in man (Grabos ^/ a/ 1988，Borghi et al 1991). 
Increase in plasma ESTI after saline infusion has been reported in some studies in man 
and animals (Goniek e/a/ 1977，Pamnani ^ a/ 1978, Poston 对 a/ 1982，Tamura ^ a/ 
1987, Hamlyn ^ al 1988) A 4 fold increase in serum inhibitory action after saline-
infiision was reported in rats (Gonick et al 1977) Pamnani et al (1978) using a 
vascular transport bioassay showed that circulating inhibitors were modestly increased 
in response to saline infusion. Poston et al (1982) showed that urine extracts from 
saline infused subjects caused a significant fall in the total sodium efflux rate constant 
in a leucocyte preparation. However, the inhibition may not be specific to the Na,K-
ATPase activity as both the ouabain-sensitive and ouabain-insensitive components of 
the rate constant were affected. Lysophosphatidylcholines were identified as one of 
the plasma ESTI in saline infused pigs (Tamura et al 1987). Hamlyn et al (1988) 
showed an average of 14% reduction in sodium pump activity after saline infusion in 
rats, pigs, sheep and man. 
In summary, the present saline infusion study showed a significant increase in sodium 
excretion and significant depressions in renin and aldosterone. Both excretion of 
urinary free DA and the plasma ESTI appeared not to be major facilitators for the 
natriuresis induced by saline infusion. Measurement of these 2 factors should be 
continued for several hours as 80% of the sodium load had not been excreted at the 
end of the study. 
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IV. ORAL SALT LOADING 
ON A FREE DIET 
: MATERIAL AND METHODS 
F i v e normotensive, ambulatory, healthy Chinese subjects (4 males and 1 female, aged 
23 to 35 years) without a family history of hypertension were studied. All participants 
gave informed consent. During the nine day study period, alcohol and medications 
were avoided. From day 1-3，all subjects were on a diet of 70 mmol sodium per day 
(low salt diet) provided by the hospital kitchen. From day 4-6, they were on their 
normal diet plus 200 mmol of sodium supplement. They took 10 "Slow Sodium" 
tablets (Ciba Laboratories, West Sussex, UK) at 9:00 am and another 10 tablets at 1 
pm (high salt diet). From day 7-9’ they were on their normal diet with unrestricted 
sodium intake (free diet) 
At the end of the low salt diet (morning of day 4)，subjects were weighed and their 
blood pressure measured at 8 am before breakfast and after sitting for 5 min, using a 
Hawksley random-zero sphygmomanometer. Mean arterial pressure (MAP) was 
calculated as described in Chapter 4. Venous blood samples were collected for the 
measurement of plasma ESTI, sodium, potassium, creatinine, total protein and 
albumin. At the end of the high salt diet (morning of day 7)，body weight, blood 
pressure and venous blood samples were similarly taken. 
Throughout the study period, subjects collected their daily urine samples into 2 plastic 
bottles containing 25 ml of 5 M HC1. The first bottle was used to collect urine from 8 
am to 10 pm (the day collection), and the second bottle was for the collection 
between 10 pm to 8 am (the night collection). Aliquots of the urine samples were 
frozen at -20 °C until assayed for urinary free CATS, sodium, potassium and 
creatinine. 24-hour urinary excretion of these measured analytes were calculated as 
the sum of the excretion from the day and night collections. 
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Plasma ESTI was measured as described in Chapter 2. Other plasma variables were 
measured on the Parallel Analytical System as previously described in this Chapter. 
Urinary sodium, potassium and creatinine were measured on the Astra 8 analyser as 
previously described in Chapter 4. Urinary free CATS were measured as described in 
Chapter 3. 
All data were expressed as mean 土 SEM. For plasma results, the Wilcoxon signed 
rank test was used to determine the significance of the difference between the low salt 
and high salt diets. The urine collections on the last day of the low salt diet were 
chosen as the baseline for comparison. Changes in urinary measurements were 
analysed with respect to time using ANOVA for repeated measurement. There were 
large inter-individual variations in the urinary excretion of the measured analytes. 
Thus, relative % changes of sodium, DA, NA and DA/NA ratio were calculated. 
Excretion at the end of the low salt diet were taken as 100%. Correlation coefficients 
between the different measurements were determined by simple regression analyses. 




Table 5-7 shows the effect of oral salt loading on blood pressure, body weight, plasma 
concentrations of the different measured parameters. The 5 subjects showed changes 
in their MAP from -17.2 to 1.6% but the overall mean was not significantly different 
from the baseline. There was a significant decrease in diastolic BP during the high salt 
diet. There was a significant increase in body weight (mean 1.0%, p<0.05, range 0.3-
2.8%) after high salt intake for 3 days. Both plasma total protein and albumin 
showed a significant decrease in concentration. However, there was no significant 
change in plasma ESTI concentration. 
Urine sodium excretion 
Figure 5-6 shows the sodium excretion for the day, night and 24-hour collections. 
ANOVA showed that there were significant differences in sodium excretion for all the 
3 collections (F=17.24, p<0.0001 for the 24-hour collection; F=11.87, p<0.0001 for 
the day collection; F=7.34, p < 0.0001 for the night collection). During the first 3 
days of low salt diet, sodium excretion decreased to 40 mmol/d. On day 4, the 
subjects were on their own free diets plus 200 mmol of sodium supplementation. The 
sodium excretion increased and peaked on day 6 to 390 mmol/d. On day 7, the 
supplementation was stopped and the subjects were on their own free diets. Sodium 
excretion decreased gradually and reached 190 mmol/d on day 9. Using the Scheffe 
test, sodium excretion on days 5 - 7 were statistically higher than that on day 3. For 
the day urine collection, sodium excretion peaked on day 5 and decreased slightly on 
day 6. On the other hand, sodium excretion continued to increase to day 6 during the 
night collection. About 70% of the sodium load was excreted during the day 
collection period. However, on day 4，the day immediately after the low salt diet, 
only 50% of the sodium load was excreted during the day collection. 
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Table 5-7: Effect of oral sodium intake on blood pressure, body weight, 
plasma ESTI, and other plasma variables. 
Low salt diet High salt diet 
Blood pressure (mmHg) 
Systolic 98 士 2 100 土 3 
Diastolic 67 士 4 59 ±3* 
Mean arterial 78 土 2 73 ± 3 
Body weight (kg) 56.1 ± 2.7 56.7 土 2 .7� 
Sodium (mmol/1) 137 ±0.7 137 土 0.4 
Potassium (mmol/1) 3.7 土 0.1 3.5 土 0.1 
Creatinine (|imol/l) 90 士 4 85 士 3 
Total protein (g/1) 82 土 2 75 ±2* 
Albumin (g/1) 49 土 1 45 土 1 * 
Na,K-ATPase 
inhibitor (nmol OE/1) 14.1 土 2.1 14.1 土 1.7 
D L I (|Lig/l) 1.24 土 0 .04 1.21 土 0 .17 
* denotes p<0.05 by Wilcoxon signed-rank test when compared with low salt diet. 
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Figure 5-6: Excretion of sodium during the low salt, high salt and free diet 
periods. 
Low salt: low salt diet provided by the hospital kitchen for days 1-3. 
High salt: free diet supplemented with 200 mmol sodium (20 Slow 
Sodium tablets taken twice daily) for days 4-6. 
Free diet: free diet for days 7-9. 
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Urine DA excretion 
Figure 5-7 shows the DA excretion for the day, night, and 24-hour collections for the 
9-day study period. There were no significant changes in DA excretion in any of the 
collections. Comparing the excretion between the day and night for each day, only on 
day 4 was there a significant difference. On day 4, DA excretion was highest during 
the day collection, but lowest during the night collection when compared to all the 
other collections during the study. On this day, DA excretion increased as the sodium 
increased during the day; however, DA excretion showed a paradoxical drop when 
the sodium excretion continued to rise during the night period. 
Figures 5-8, 5-9, and 5-10 show the relative % changes of DA excretion for the day, 
night and 24-hour collections, respectively. There were no significant changes of DA 
excretion. On day 4，the relative %change of DA excretion for the day collection was 
still the highest (Figure 5-8) and that for the night collection was also the lowest 
(Figure 5-9). 
Urine NA excretion 
Figure 5-11 shows the NA excretion for the day, night and 24-hour collections. For 
the 24-hour collection, NA excretion showed an inverse relationship with the sodium 
excretion. It increased from day 1 to day 4 during the low salt period, decreased 
sharply during the sodium supplementation, and then gradually increased during the 
free diet period. However, these changes did not reach statistical significance. For 
the day collection, NA excretion peaked on day 4 and was lowest on day 6. For the 
night collection, NA excretion showed relatively smaller changes. It increased slightly 
during the low salt period, decreased on day 4, and continued to increase from day 5 
to day 9. When the relative % changes in NA excretion were calculated, there were 
still no significant changes by ANOVA. 
5-41 
… LOW SALT I HIGH SALTl FREE DIET cOOO L — _ _ _ I L j I I 
Z 1500 _ 丁 T " T T T / ^ 1 2 4 - H R 
I 
1 ^ y 
2 5 0 0 - ^ ^ I ^ ^ ^ N y ^ T ^ ^ T ^ 
: 0 -
1 1 I 1 1 I I ~ 1 
1 2 3 4 5 6 7 8 9 
D A Y 
Figure 5-7: Excretion of DA during the low salt’ high salt and free diet 
periods. 
Low salt: low salt diet provided by the hospital kitchen for days 1-3. 
High salt: free diet supplemented with 200 mmol sodium (20 Slow 
Sodium tablets taken twice daily) for days 4-6. 
Free diet: free diet for days 7-9. 
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Figure 5-8: Relative % changes w.r.t. end of low salt period for the excretion 
of sodium, DA, NA and DA/NA ratio during the day collection 
period (8 am to 10 pm). 
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Figure 5-9: Relative % changes w.r.t. end of low salt period for the excretion 
of sodium, DA, NA and DA/NA ratio during the night collection 
period (10 pm to 8 am) 
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Figure 5-10: Relative % changes w.r.t. end of low salt period for the excretion 
& of sodium, DA, NA and DA/NA ratio for 24 hour collection. 
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Figure 5-11: Excretion of NA during the low salt, high salt and free diet 
periods. 
Low salt: low salt diet provided by the hospital kitchen for days 1-3. 
High salt: free diet supplemented with 200 mmol sodium (20 Slow 
Sodium tablets taken twice daily) for days 4-6. 
Free diet: free diet for days 7-9. 
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DA/NA Ratio 
Figure 5-12 shows the DA/NA ratios for the day, night and 24-hour collections. For 
the 24-hour collection, the DA:NA ratios were relatively stable for days 1-5. It rose 
sharply on day 6 and then return to the previous level. ANOVA indicated that there 
were significant changes of the DA:NA ratios (F=2.6468, p=0.0238). However, the 
SchefFe test did not show significant difference of the ratio among the different days. 
A similar situation was also observed for the day collection (F=l 1.867, p<0.0001). 
On the other hand, DA:NA ratios for the night urine collections showed a different 
pattern and were higher than that of the day and 24-hour collections. The ratios were 
fluctuating throughout the study period and did not have a consistent pattern. 
Relative % changes of DA/NA ratios were similar to that show on Figure 5-12 except 
that the wide variation during the night collections was reduced (Figures 5-8, 5-9, 5-
10). 
Correlation between the different measured urine parameters 
For the 9 day study period, the 24 hour sodium excretion was not correlated with the 
excretion of NA and DA, but correlated significantly with the DA:NA ratio (r=0.300, 
p=0.0453). However, this correlation disappeared when the data for day collections 
and night collections were studied separately. Furthermore, when the data were 
grouped into low salt, high salt and free diet periods, there was no correlation 
between sodium excretion and the excretion of GATS. There was a strong and 
positive significant correlation between the excretion of NA and DA throughout the 
study periods (r=0.800, p<0.0001). Such a relationship continued to hold true when 
the data were studied for the day and night collections, or separately for the 3 salt-
loading periods. 
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Figure 5-12: Urinary DA/NA ratio during the low salt, high salt and free diet 
periods. 
Low salt: low salt diet provided by the hospital kitchen for days 1-3. 
High salt: free diet supplemented with 200 mmol sodium (20 Slow 
Sodium tablets taken twice daily) for days 4-6. 
Free diet: free diet for days 7-9. 
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DISCUSSION 
Natriuresis follo^dng sodium loading is partly mediated by increased production of 
DA in the kidney which is reflected by an increase in urinary DA excretion. This has 
been demonstrated in man (Oates et al 1979) and animals (Ball et al 1978). It has 
been suggested that an impaired DA response to salt loading may lead to 
hypervolemia and hypertension in some individuals (Lee 1981). Urine DA failed to 
increase with salt loading in hypertensive patients (Harvey et al 1984) and this 
appeared to occur in salt-sensitive rather than salt-resistant hypertensives (Gill et al 
1988). Subsequent cross-sectional studies in different ethnic groups have 
demonstrated that Caucasians and Thais show a strong positive correlation between 
24-hour sodium and DA outputs whereas other groups such as Iranians and black 
West Africans do not (Critchley et al 1989), This could indicate that the ethnic 
groups lacking the sodium-DA relationship may not show a renal DA response to salt 
loading and thus be more prone to salt-sensitive hypertension or else have another 
predominant mechanism for dealing with increased salt intake. Cross-sectional studies 
in normotensive Chinese subjects without a family history of hypertension, reported in 
Chapter 4，have also shown a positive correlation between urinary sodium and DA. It 
was anticipated that normal Chinese subjects would respond to oral sodium with 
increase in urinary DA similar to Caucasians. 
Another mechanism which appears to contribute to the natriuresis following sodium 
loading is a reduction in sympathetic activity which can be demonstrated by reduction 
in urinary NA excretion (Alexander et a/ 1974, Weinberger et al 1982, Castellano et 
a/ 1986，Gill et al 1988). Furthermore，plasma ESTI concentration has been reported 
to increase after oral salt loading in man (de Wardener et a/ 1981, Quintanilla et al 
1988, Goto et al 1990) and in animals (Devynck et a/ 1987, Wauquier & Devynck 
1989). The present study was set up to study the role of these 3 mechanisms in 
dealing with oral salt loading in healthy Chinese subjects. 
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In this study, the 5 subjects were first on a low salt diet of 40 mmol/d, then on a high 
salt diet of 390 mmol/d, and finally on their own free diets of 190 mmol/d (Figure 5-
6) ‘ There was a 10-fold increase in sodium loading between the low salt and high salt 
periods. Significant ECF volume expansion was achieved as supported by a 
significant increase in body weight and decrease in plasma protein concentrations 
(Table 5-7). Since there was no increase in the MAP upon salt loading, these subjects 
can be considered as salt-resistant (Gill et al 1988). 
The data show that 3 days of salt loading in this group of healthy Chinese subjects 
was not accompanied by any change in DA excretion (Figure 5-7). To minimize the 
effect of inter-individual variation, relative % changes of DA with respectto the end of 
the low salt diet were also calculated and analyzed. Again, there was no significant 
increase in DA excretion (Figures 5-8, 5-9, 5-10). Circadian variation of DA 
excretion has been reported (Kawano et al 1990). DA excretion is high during the 
day and low during the night. Thus, urine samples were collected for the day and 
night periods, DA excretion were higher for the day collection than that of the night 
collections throughout the 9 days (Figure 5-7). However, there was no significant 
increase of DA excretion in either the day or the night collections during high salt 
diet. These results are different from studies reporting an increase of 50-100% DA 
excretion in Caucasian subjects (Alexander et al 1974, Lee 1986, Gill et al 1988, 
Goldstein 过 al 1989), The lack of DA response was further supported by the absence 
of a significant correlation between sodium and DA excretion during the different salt 
loading periods. This is in contrast with results reported in Chapter 4 where 
normotensives without a family history of hypertension showed a significant 
correlation between urinary sodium and DA excretion. On the other hand, there have 
been animal s tudies sho\^ng that urine DA excretion does not increase during dietary 
salt loading. Urine DA excretion failed to increase in both Dahl salt-sensitive and salt-
resistant rats (DeFeo et al 1987); spontaneous hypertensive rats and normotensive 
Wis ta r -Kyo to rats (Stier et al 1993) when given a 8% salt diet. 
Plasma ESTI concentra t ion was not increased after the salt loading in this group of 
Chinese subjects (Table 5-7). This result was different from that reported in the 
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literature (de Wardener et al 1981, Quintanilla et al 1988，Goto et al 1990). The 
discrepancy could be due to the use of different methods for measuring ESTI (Moreth 
e t a l 1987). Furthermore, the length of salt loading could be important for significant 
increase of ESTI. Chronic salt loading in rats showed that plasma ESTI continued to 
rise with the time of salt loading (Wauquier & Devynck 1989). In these studies, low 
salt and high salt periods were at least 5 days. A study on the kinetics of renal sodium 
excretion during changes in dietary sodium intake in man shows that it takes at least 4 
days for the subjects to reach a new steady state for a low salt diet and 3 days for a 
high salt diet (Sagnella et al 1990). 
Although there was no statistically significant reduction in NA excretion, there was a 
30% lower NA excretion on the day of peak sodium excretion (Figure 5-11). Since 
this study was conducted with a small group of subjects, a larger number of subjects 
may be required to show statistical difference. It is possible that reduction in 
sympathetic nervous activity is the predominant mechanism for sodium excretion in 
Chinese subjects after dietary salt loading. 
It has been suggested that the DA/NA ratio may be an important factor mediating 
sodium excretion due to the opposing effects of NA and DA on the renal handling of 
sodium. The previous experiment on water immersion in this Chapter showed that 
this ratio is important for sodium excretion. In this study, the DA/NA ratio was 
signifieantly different during the 9-day study period. This ratio was relatively stable 
for the day and 24-hour collections during both the low salt and free diet periods 
(Figure 5-12). It peaked on the last day of high salt diet (day 6) when sodium 
excretion was highest. However, the ratio did not show a consistent pattern for the 
night collections. Sodium excretion correlated weakly with this ratio for the 24-hour 
collection (r=0.30, p<0.05); but the correlation did not hold true when the analysis 
was performed for the day and night collections separately. However, the strong 
positive correlation between NA and DA observed is puzzling. If indeed, there were 
an opposite effects of NA and DA in renal handling of sodium in the Chinese, there 
should be an inverse relationship between them. The correlation was similar to the 
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findings in Chapter 4 and also a report for a group of young hypertensive Japanese 
(Saito etal 1994). 
Dietary protein may be another factor influencing the results of this salt loading 
experiment. It has been reported that dietary protein has a significant effect on the 
excretion of DA (Williams et al 1986). Ingestion of 60 g of dietary protein induced a 
prompt increase of DA excretion by 50%, Subjects in this salt loading study were on 
their free diet after the low salt period. Variations in their protein intake can 
introduce variations in DA excretion. This may have increased the background 'noise' 
and the effect of salt loading was not clearly seen. 
In this study of dietary salt loading with 5 Chinese subjects on free diet, a 10-fold 
increase in sodium intake did not show a significant increase in DA excretion nor 
plasma ESTI concentration. Although there was a reduction of NA excretion, it was 
not statistically significant. Extension of both the low salt and high salt periods could 
be necessmy to elicit signals which are required to increase both DA and ESTI 
production. Furthermore, the subjects should be kept on a constant diet to reduce the 
influence of protein on the production of DA. 
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V. ORAL SALT LOADING 
UNDER CONTROLLED DIET 
MATERIALS AND METHODS 
The experimental design of this study was altered to improve on the previous study of 
oral salt loading while on a free diet (Section IV) To minimize the effects of other 
dietary factors on the excretion of DA, the diet in this study was controlled. A group 
of young male Chinese medical students was recruited for the study so that variations 
due to age could be reduced. Furthermore, both the low salt and high salt diet 
periods were extended to 5 days to ensure that the new steady state was attained. 
Seven normotensive healthy male Chinese medical students (aged 19 to 22 years) 
were studied. These subjects were kept on a controlled hospital diet for 10-day study 
period (days -4 to 0 and days 1 to 5). The diet contained 1800 calories, 60 g protein, 
20 mmol sodium and 60 mmol potassium. In addition, from days 1-5, subjects were 
given 20 "Slow Sodium" tablets (200 mmol), taken after breakfast. Subjects were 
asked to abstain from alcohol, medication, and strenuous exercise. 
Blood pressure and body weight were measured on day 0 and day 6 as described in 
the previous section. Daily urine samples for the measurement of sodium and CATS 
were collected into 2 plastic bottles containing 100 ml of 0.5 M HC1. The day and 
night collections were similar to those described in the previous section. Before 
breakfast, venous fasting blood was collected daily from day -1 to day 6 for the 
measurement of sodium, protein, ESTI, ANP, renin and aldosterone. The methods 




Urine sodium excretion 
Figure 5-13 shows the sodium excretion for the day, night and 24-hour collections. 
ANOVA showed that there were significant increases in sodium excretion upon salt 
loading in all 3 collections (F=56.20, p<0.0001 for 24-hour collection; F=40.24, 
p<0.0001 for day collection; and F=13.33, p<0.0001 for night collection). From day 
-4 to day 0，sodium excretion decreased from 130 mmol/d to 32 mmol/d. Upon the 
supplementation with "Slow Sodium", sodium excretion increased 9 fold to 287 
mmol/d. For the low salt period (days -4 to 0)，excretion of sodium was higher 
during the day. With the high salt supplement, sodium excretion continued to 
increase for the first 3 days and then remained relatively constant for days 4 and 5 
during the day. In contrast to the low salt period, sodium excretion during the night 
were higher than that during the day for the first 2 days. For days 3-5, sodium 
excretion decreased slightly and were lower than the day time. 
Plasma results 
Table 5-8 summarizes the effect of oral salt loading under controlled diet on body 
weight, MAP, plasma sodium, potassium, total protein and albumin. There were no 
significant changes in body weight and MAP. The mean plasma sodium increased 
significantly by 3 mmol/1 after 5 days of oral salt loading. On the other hand, plasma 
potassium, total protein and albumin decreased upon salt loading significantly. 
5-54 
3 5 0 � 
* * 
3 0 0 _ * T T 
两 HR 
1 > - y ^ 
I f 2 0 ° - / t ^ D A V 
i 旦 1 5 0 " i Y L 
I 100 - \ / / / > ^ T ' ' 1 n i g h t 
^ O y h ' A * I * 
0 L 
‘ ‘ • I • • I _ - L - _ I 1 
- 4 - 3 - 2 - 1 0 1 2 3 4 5 D A Y S 
Figure 5-13: Excretion of sodium during the 10-day study period. 
Days -4 to 0，on controlled low salt diet 
Days 1 to 5，on controlled low salt diet + 200 mmol sodium supplementation. 
* denotes significant different (p<0.05) on the day when compared to that on day 0 
by Scheffe's test after ANOVA. 
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Table 5-8 Effect of oral salt loading on blood pressure, body weight and 
other plasma variables. 
Low salt diet High salt diet 
(on dav OV (on day 6 � 
Body weight (Kg) 63.5 ±5.87 63.7 土 5.83 
MAP (mmHg) 82.5 土 5.51 80.6 士 4.56 
Plasma sodium (mmol/1) 137 土 2.2 140 士 1.4孝* 
Plasma potassium (mmol/1) 4.2 士 0.31 3.8 ±0.23林 
Plasma total protein (g/1) 86 土 5.1 82 士 3 . 6 � 
Plasma albumin (g/1) 50 + 1.5 48 土 2.5* 
Results are given as mean 士 SD 
* denotes p<0.05 and ** denotes p<0.02 by Wilcoxon signed-rank test when 
compared with the low salt diet. 
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Figure 5-14 shows daily changes in some of the plasma natriuretic factors measured in 
this study. ANOVA showed significant changes of all 5 factors after 5 days of salt 
loading. Plasma renin and aldosterone increased during the low salt period and then 
decreased significantly upon salt loading (F=5.788, p=0.0007 for renin; F=15.27, 
p<0.0001 for aldosterone). Plasma ANP increased gradually after salt loading, 
peaked on day 4 and then returned to a concentration similar to days 2-3 (F=3.131, 
p=0.022). Na, K-ATPase inhibitor decreased on the low sodium diet. On 
supplementation with 200 mmol of sodium, it increased significantly on day 3，peaked 
on day 5 and remained high on day 6 (F=23.90, p<0.0001). Plasma DLI increased 
significantly on day 2 and then remained relatively stable for the remaining 4 days (F = 
10.81，pcO.OOOl). 
Urine DA excretion 
Figure 5-15 shows the DA excretion for the day, night and 24-hour collections. 
There were no significant differences in DA excretion on any of the collections. 24-
hour DA excretion decreased slightly during the low salt diet and increased during the 
last 3 days of salt loading. After 3 days of low salt diet, DA excretion decreased 
during the day, but remmned relatively stable during the night. Upon the first day of 
salt loading, DA excretion increased promptly during the day. However, during the 
night, DA excretion decreased paradoxically despite of the high sodium excretion. 
DA excretion continued to increase during the day after day 2, but it remained lower 
during the night. 
Figure 5-15 also shows the relative % change of DA excretion in relation to that on 
day 0 during oral salt loading. DA excretion increased during the day but did not 
reach statistical significance. During the night, DA excretion was lower than that of 
the day. Furthermore, night time DA excretion were all lower than that of the low 
salt period. 
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Figure 5-14: Effects of oral salt loading on different plasma natriuretic factors-
Na, K-ATPase inhibitors，DLI, ANP, renin activity and 
aldosterone concentration. 
** denotes that the plasma concentration/activity on the day was significantly 
different (p<0.05) from that on day 0 by Scheffe's test after ANOVA. 
5-58 
2500 r 
1 2000 HR 
i . 丄 O 
X = UJ o 供 E 1500 -2 I 
§ T T 工-五 T T . J I DAY 
§• 1000 - - T ' l NIC3HT 
500 -
I I I I I I i I I I 
- 4 - 3 - 2 - 1 0 1 2 3 4 5 
, � D A Y S 
1 5 0 � 
© T I : | 二一一丄-」day 
10 霣 JL T ^ ^ 
r 坊 / ^ 、 T Z 
° 爹 • 24 HR 
袄 o 100 m . _ ^ ^ ^ ^ 5 它 � 、 、 分 - J - - — — NIGHT 
•口 w T 1 
IP TJ 
cc ® o 
50 - • • 
I I I 1 1 
0 1 2 3 4 5 
D A Y S 
Figure 5-15: Excretion of DA during the 10-day study period. 
(Top) DA excretion for the day, night & 24_hour collections 
(Bottom) Percentage changes relative to day 0 
Days -4 to 0，on controlled low salt diet 
Days 1 to 5，on controlled low salt diet + 200 mmol sodium supplementation. 
5-59 
Urine NA excretion 
Figure 5-16 shows NA excretion for the day, night and 24-hour collections. For the 
24-hour collection, ANOVA showed that there were significant differences during the 
10-day study period (F=2.944, p=0.0065). However, Scheffe's test failed to identify 
any pair of days that were significantly different. There were no significant 
differences between the day and night collections. NA excretion were higher during 
the day throughout the entire study period. With the 24-hour collection, NA 
excretion maintained an inverse relationship with sodium excretion. It increased 
during the low salt period and decreased for the first 3 days of the high salt period. 
On day 4，NA excretion increased and it decreased again on day 5. The increase on 
day 4 was mainly due to the increase of NA excretion during the night. NA excretion 
were relatively stable during the day during the last 2 days of study. 
Figure 5-16 also shows the relative percentage changes in NA in relation to day 0. It 
shows that NA excretion decreased during the first 3 days of high salt period. 
However, NA excretion increased sharply during the night on day 4 and then returned 
to a lower level. 
DA/NA ratio 
Figure 5-17 shows the DA/NA ratios for the day, night and 24-hour collections. 
There were significant changes in the ratio for all 3 collections (F=8.970, p<0.0001 
for the day collection; F=3.552, p=0.0016 for the night collection; F=5.505, p<0.0001 
for 24-hour collection). DA/NA ratio paralleled the sodium excretion during the day. 
It decreased during the low salt period and increased significantly during the last 3 
days of salt loading. DA/NA ratio was higher during the night throughout the study 
period. The ratio also showed larger variations during the night. It fluctuated 
between day -4 to day 0 and then showed a large increase from day 1 to 3. On day 4， 
the ratio decreased abruptly at night and increased again the next night. The relative 
percentage changes in relation to day 0 show that the ratios were all higher than day 0 
after salt supplementation. 
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Figure 5-17: Changes of DA/NA ratio during the 10-day study period. 
te (Top) DA/NA ratios for the day, night & 24-hour collections 
(Bottom) Percentage changes relative to day 0 
Days -4 to 0，on controlled low salt diet 
Days 1 to 5，on controlled low salt diet + 200 mmol sodium supplementation. 
* denotes significant different (p<0.05) on the day when compared to that on day 0 
by Scheffe，s test after ANOVA. 
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Figure 5-16: Excretion of NA during the 10-day study period. 
(Top) NA excretion for the day, night & 24_hour collections 
(Bottom) Percentage changes relative to day 0 
Days -4 to 0，on controlled low salt diet 
Days 1 to 5，on controlled low salt diet + 200 mmol sodium supplementation. 
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Correlation between the different measured variables 
There were significant correlations between the different natriuretic factors during 
oral salt loading except for ANP. Plasma ANP showed no correlation with any of the 
other 4 factors measured in this study. Multiple linear regression showed that plasma 
sodium was significantly correlated with Na, K-ATPase inhibitor (p=0.7059, 
p<0.0001). When Na, K-ATPase inhibitor was used as a dependent variable, it 
correlated significantly with plasma sodium (p =0.6068, p<0.0001) and inversely with 
serum aldosterone (p=-0.276，p= 0.021). When DLI was used as a dependent 
variable, it only correlated inversely with aldosterone (|3=-0,495, p=0.001). 
Sodium excretion correlated significantly with the DA/NA ratio during day time (P 
=0.602，p=0.0001), but not during night time. Furthermore, the excretion of DA 
correlated significantly with NA excretion only for day collections (r=0.551, 
p=0.0006), not for the night collections. 
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DISCUSSION 
The oral salt loading study described in the previous section failed to show any 
significant changes in urine DA excretion and plasma ESTI concentration. The 
present study was designed to improve on some of the possible experimental design 
faults that might have contributed to the lack of DA and ESTI response. For 
example, the duration of the low salt and high salt diets was extended to 5 days to 
ensure that a new steady state was reached (Sagnella et a/ 1990). The subjects were 
under the same controlled diets throughout the study period so that variations of DA 
and other natriuretic factors due to variation in other constituents in the diet, e.g. 
protein intake, can be minimized. 
In this study, the 7 medical students were taking a low salt diet for the 10-day study 
period (day -4 to day 5). On day 1，they were given 200 mmol of sodium supplement 
as "Slow Sodium". There was a 9-fold increase in sodium excretion between the low 
salt and high salt periods (Figure 5-14). Suppression of plasma renin and aldosterone 
(Figure 5-13) shows that significant volume expansion was achieved. These students 
did not show a significant change in MAP during the high salt periods and therefore 
are salt-resistant. 
Plasma samples were collected daily from day -1 to day 6 for the measurement of 
natriuretic factors Fasting blood samples were taken early in the morning and before 
taking "Slow Sodium" tablets on days 1-5. The responses observed are the results of 
the previous days intake. 
There was a significant increase in plasma ESTI concentration during the salt loading 
period (Figure 5-13). The Na, K-ATPase inhibitor increased significantly on day 3 
whereas the increase of DLI was seen on day 2. The increase of plasma ESTI during 
oral salt loading is consistent with other studies (de Wardener et al 1981, QuintaniUa 
e t ai 1988，Goto et al 1990). The amount of salt loading was comparable between 
the present study and the previous one described in section IV where there was no 
difference in plasma ESTI concentration between the low and high salt periods. This 
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suggests that the duration of low salt and high salt period could be critical to induce a 
significant response of plasma ESTI. Furthermore, there was a dissociation between 
plasma Na, K-ATPase inhibitor and DLL 
A significant increase in plasma ANP was observed on day 4 (Figure 5-13). It 
increased from 18.9 pg/ml on day 0 to 33.7 pg/ml on day 4. Increase in ANP during 
oral salt loading has been reported (Sagnella ^ al 1987, Solomon et al 1987, Sagnella 
^t al 1989, Doorenbos et al 1990). The magnitude of increase was closely associated 
with cumulative sodium balance (Sagnella et al 1989). In this present study, the 
increase in ANP was nearly 2-fold with a 9-fold increase in sodium excretion. This 
increase was similar to that reported in the literature. However, plasma ANP 
decreased abruptly on day 5. Again, reference to such a phenomenon could not be 
found. The decrease in plasma ANP could be a contributing factor for the surge in 
plasma Na, K-ATPase inhibitor. However, the reason for this decrease in ANP 
cannot be easily explained on the present data. Daily changes in plasma ANP are not 
usually reported in the literature. Sodium excretion reached a new steady state on day 
3 (Figure 5-14, Sagnella etal 1990). 
Despite increasing the duration of salt loading to 5 days and controlling the diet 
throughout the study, there was still no significant change in urinary DA excretion 
during the day or night (Figure 5-15 top). In previous studies of DA response to oral 
salt loading, 24-hour urinary excretion has been examined. Under the present 
experimental design, separate collections of day and night urine samples revealed that 
DA excretion correlated with sodium excretion better during the day than the night 
The circadian variation of DA excretion reported (Kawano et al 1990) was not 
observed during the low salt period. Upon salt loading, there was a 23% increase in 
day time DA excretion from day 0 to day 5. However, this increase did not reach 
statistical significance. During the same period of time, there was a 10% decrease in 
night time DA excretion. When the relative percentage change in DA excretion 
(Figure 5-15 bottom) was examined it confirmed that night time DA excretion was 
lower than day 0 during salt loading. Such a phenomenon has not been reported 
previously. From day 1 onwards, there was an interesting pattern in DA excretion. 
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When there was a higher increase in DA excretion during the day, there was a 
corresponding lower DA excretion during the night. 
There was no statistical significant change in NA excretion during the 10-day study 
period for any of the 3 collections (Figure 5-16 top). NA excretion correlated 
inversely with the sodium excretion. During the low salt period, NA excretion 
increased gradually. On day 1 of oral salt loading, NA excretion decreased for 3 days. 
Then there was a sharp rise in NA excretion during the night. Increase in NA 
excretion could be due to the activation of the sympathetic nervous system or the 
removal of inhibitory actions on the nervous system. This sudden increase could be in 
response to the lowering of plasma ANP It has been reported that ANP can inhibit 
the sympathetic nervous system (Goetz 1990). Thus, the inhibitory effects of ANP on 
the sympathetic system may be a signal for the increase in production of ESTI. 
DA/NA ratio correlated positively with the sodium excretion. The ratio decreased 
during the low salt period and increased during the sodium supplementation. There 
were significant changes of DA/NA ratio for the day and 24-hour urine collections 
(Figure 5-17), but not for the night collection. With multiple regression analysis, 
sodium excretion correlated significantly with this ratio during the high salt period 
during the day, but not during the night. Furthermore, there was a significant 
correlation between DA and NA again during the day, but not during the night. The 
results were similar to the findings in Chapter 4，and also salt loading study on a free 
diet (Section IV). 
In this study of oral salt loading under controlled diet in Chinese subjects, a 9-fold 
increase in sodium intake did not have significant increase in DA excretion. The urine 




STUDIES ON THE EFFECTS 
OF SALT LOADING 
IN THE RAT 
I. INTRODUCTION 
Effects of salt loading on the urinary excretion of DA and ESTI have been commonly 
studied using the rat model. It has been shown that urinary excretion of DA increases 
during salt loading in the rat (Ball et al 1978). Furthermore, increased circulating 
ESTI has been shown in the rat while on a high salt diet (Wauquier & Devyneck 
1989). However, their temporal relationship in natriuresis has not been studied. In 
the first study of this Chapter, the relative contributions and temporal relationship of 
urinary DA and ESTI in natriuresis were studied. 
It has been suggested that in hypertensives, renal DA mobilization is impaired and 
ESTI increases to maintain salt balance (Lee 1987). In the second study of this 
Chapter, production of renal DA was inhibited by the use of carbidopa. Carbidopa 
inhibits dopa decarboxylase activity which is responsible for the conversion of L-dopa 
to DA in the renal tubules. Excretion of ESTI would be increased if Lee's hypothesis 
is correct. 
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II. TEMPORAL RELATIONSHIP BETWEEN 
EXCRETIONS OF DA AND ESTI 
DURING SALT LOADING IN THE RAT 
MATERIALS AND METHODS 
Six female Sprague-Dawley rats weighing 250 g were studied. They were fed ad 
libitum throughout the study with normal rat chow containing 0.2% sodium chloride 
(Nad). The animals were placed in individual metabolic cages and given tap water to 
drink for 4 days. 24 hr urine samples were collected for two days (days -2 and -1). 
For days 1-7, the tap water was changed to 18 g/1 NaCl solution and urine collection 
was continued. Urine samples were collected in 6.0 M HC1 and after recording the 
volume, they were stored at -70 °C. 
Urinary sodium and creatinine concentrations were measured as described in Chapter 
4. Urinary DA was measured as described in Chapter 3 and urinary ESTI was 
measured as described in Chapter 2. Excretion of sodium, DA and ESTI were related 
to creatinine in order to compensate for any loss of urine during collection and for any 
differences in lean body mass during the study. 
For statistical analysis, the mean values of day -1 and -2 were used to represent the 
excretion before salt loading. The data were subjected to ANOVA and when the null 
hypothesis was rejected, Scheffe's comparisons were performed on the means. 
p<0.05 was considered significant. 
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RESULTS 
Table 6-1 summaries the results. Urine sodium excretion on day 1 was significantly 
higher than pre-salt loading . Sodium excretion reached a peak on day 2 and thereafter 
remained relatively stable. Urine DA excretion on day 1 was 9% higher than basal 
value but the difference was not significant. On day 2, the urinary DA excretion was 
21% higher than the mean before the salt loading (p<0.01). Urine DA excretion 
reached a peak on day4 and remained high thereafter. On the other hand, urine 
excretion of ESTI on day 1 was 4.2 fold higher than the basal values. Figure 6-1 
shows the relative changes of the measured parameters with time. The excretion of 
ESTI paralleled the rise in sodium whereas DA excretion lagged behind. 
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Table 6-1: Effect of salt loading on the excretion of sodium, DA and ESTI in 
rats. 
Day Urine volume Sodium/ Gr DA/ Cr ESTI / Cr 
(ml/d) (mmol/mmol Cr) (nmol/ mmol Cr) (nmol OE/mmol Cr) 
-2 10.0 ± 1.9 37 土 3.3 240 土 22.0 0.46 土 0.15 
-1 9.8 土 3.0 39 土 5.5 211 ± 21 3 0.40 ±0.15 
1 27.5 土 8.3* 174士48.CT 246 土34.6 1.80±0.3(T 
2 29.2 土 11.2* 210±46.4" 273 土 31.9' 2.67土 0.45" 
± * * * * 
3 24.7 土 10.6 203 土 33.5 329 土 45.7 2.61 士 0.44 
4 23.3 土 7.0V 192士 29,0" 336 土 56.广 2.83 土 1.10" 
* * * * * * * 
5 17.1 土 5.9 190 土 13.8 308±53.2 3.74 士 1.07 
6 27.6 土 8.3* 186 士 17.6" 305 土 39.(T 2.92 土 0.96" 
j|c ** ** 
7 19.2 ±5,8 206 土 18.2 371 士 46.7 2.76 士 0.64 
..^..-.-JuujLaAAAA^-JuuuuumarumjuumJtiiumvn ^ ^ ^ ^ ^ ^ w ^ ^ w w ^ w ^ w i h ^ i ^ ^ ^ ^ v i ^ ^ w w v w i M n r w w w v w w v w v v v w w v v v v v w v v y w w v w v w w w w w w v w w w w w w w v w w w w w v w w w ^ w w v w w w v ^ 
Results are mean 土 SD, n=6 
* f o r p<o.01, ** for p<0.001 significantly different from the mean of days -1 and -2 
Sodium / Cr denotes for sodium / creatinine ratio 
OE for ouabain equivalent 
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Figure 6-1: Relative changes of excretions of sodium, DA and ESTI during 
salt loading in rats. 
6-5 
DISCUSSION 
High salt intake has been shown to cause an increase in excretion of DA (Ball et al 
1978，Oates et al 1979) and ESTI (Wauquier & Devyneck 1989). The evidence for 
the release of ESTI during salt loading comes from direct measurement of the 
inhibitory activity (Poston et al 1982, Wauquier & Devyneck 1989) or from indirect 
measurement of Na,K-ATPase activity of circulating cells (Quintanilla et al 1988). 
This experiment has been set up to investigate the relative importance of DA and 
ESTI to the natriuresis of salt loading in the rat 'by examining the temporal 
relationships. The results confirm previous observations that high salt intake causes 
an increase in DA excretion (Ball et al 1978). The magnitude of increase 
(approximately 50% on day 4) is similar to that reported by others (Alexander et al 
1974, Ball et al 1978，Oates 过 al 1979). 
The results also confirm that high salt diet causes an increase in ESTI (Gonick et al 
1977, Poston et al 1982, Wauquier & Devyneck 1989). So far there has been no 
reports on the temporal relationship between DA and ESTI during salt loading. 
Results of this study show that ESTI closely followed the excretion of sodium (Table 
6-1) where as the excretion of DA lagged behind by a day. Furthermore, unless the 
natriuretic effect of DA is several fold higher than other natriuretic factors, the 
observed increase in DA excretion may not be quantitatively adequate to explain the 
natriuresis (Figure 6-1), However, it is possible that the local concentration of DA at 
the tubule may be high enough to account for this degree of natriuresis. 
These observations on DA could be interpreted in two ways. Firstly, DA is not 
important in the natriuresis of salt loading and the increased excretion of DA is 
secondary to the excretion of sodium. Observations such as lack of increase in DA 
excretion during headout water immerison as described in Chapter 5 and the lack of 
effect of carbidopa on the natriuresis induced by saline infusion (Jeffrey et al 1989) 
support this theory. However, there are other observations which support a 
natriuretic role for DA. For instance, administration of carbidopa to healthy subjects 
reduced sodium excretion suggesting that DA has a tonic role in the excretion of 
sodium (Ball et al 1971，Lee 1987). Dopaminergic blockade by the use of the DA 
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receptor antagonist metoclopramide abolished the natriuretic response to saline 
inflision (Krishna et al 1985). Secondly, DA may be important in maintaining the 
natriuresis initiated by other factors such as ESTI or ANP. 
There was a surge in the excretion of Na，K-ATPase inhibitor on day 5 of salt loading 
(Figure 6-1). However, the surge only lasted for one day and the excretion decreased 
again to the level similar to that of day 4. The phenomenon cannot yet be explained. 
It may be due to the reduced activities of some natriuretic factors after 4 days of salt 
loading, for example ANP. If so, the excretion of ESTI would have to increase to 
maintain sodium excretion. This surge could signal the activation of some other 
natriuretic factors. As suggested by de Wardener' s hypothesis, the action of the Na, 
K-ATPase inhibitor is non-specific, and a very high concentration could be 
unfavourable to the system leading to increase in blood pressure. 
The present results strongly suggest a role for ESTI in the natriuresis of salt loading 
and that the increase in ESTI precedes that of DA ‘ 
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III. ROLES OF DA AND ESTI IN 
NATRIURESIS IN RATS TREATED 
WITH CARBIDOPA 
MATERIALS AND METHOD 
Twenty-four male Sprague-Dawley rats of 1 month old were studied. They were fed 
ad libitum throughout the study with normal rat chow containing 0.2% sodium 
chloride. The animals were placed in individual metabolic cages and given tap water 
to drink for 3 days. They were then randomly divided into 4 groups: Group A _ low 
salt group with tap water to drink; Group B - high salt group with 18 g/1 of NaCl 
solution to drink; Group C - low salt + carbidopa; and Group D _ high salt + 
carbidopa. Carbidopa (kindly supplied by Merck, Sharp & Dohme，PA, USA) was 
dissolved in water and fed orally to Groups C and D twice daily at a dose of 120 
mg/Kg body weight/day. Groups A and B were also fed orally with water twice daily 
at the time of feeding the 2 experimental groups. 
24 hour urine samples were collected into 0.5 M HC1 solutions for 7 days. Groups A 
and C had a smaller urine volume and the containers were filled with 4 ml of acid 
solution; while Groups B and D had larger urine volumes and the containers were 
filled with 10 ml of acid. Measurement of DA was performed on the day after the 
completion of urine collection to avoid any artifacts introduced due to the instability 
of CATS in the urine samples. Aliquots of the urine were stored at -70 °C for the 
measurement of urinary ESTI. Methods of measuring sodium, creatinine, DA and 
ESTI were as described in section II of this Chapter. 
Excretions of sodium, DA and ESTI were also related to creatinine in order to 
compensate for any loss of urine during collection and for any differences in lean body 
mass during the study. For statistical analysis, one-way ANOVA was used to 
compare results between the 4 Groups and also for changes of the excretion within 
the Group. Significance was to set to p<0.05. 
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RESULTS 
Figure 6-2 shows the excretions of sodium in the 4 groups of rats over the study 
period. Within each group of rats, there was no significant difference of sodium 
excretion over the 7 days. Sodium excretions were almost 10-fold higher in the high 
salt groups than the low salt groups. Sodium excretion was higher in the earbidopa 
treated high salt rats (Group D) compared to the high salt one (Group C), but the 
difference did not reach statistical significance. Thus, inhibition of DA production by 
earbidopa treatment had no effect on sodium excretion as there was no significant 
difference between the control and the treatment groups for both low salt and high 
salt rats. 
Figure 6-3 shows the excretion of DA in the 4 groups of rats over the study period. 
DA excretion in Group A (low salt) decreased over the 7 days ^=2.34, p=0.053). 
DA excretion in the Group B (high salt), though not statistically significant, rose from 
day 1, peaked on day 5, and then decreased on the last 2 days. On the other hand, 
DA excretion in Group D (high salt rats treated with earbidopa) increased 
significantly over the 7 days (F=2.6l8, p-0.035). There was also a slight by not 
significant increase of DA excretion in Group C (low salt rats treated with earbidopa). 
Both high salt groups (Groups B&D) had higher DA excretions than the 
corresponding control groups (Groups A&C) Group B (without earbidopa 
treatment) showed a significantly higher DA excretion than the corresponding low salt 
group (Group A) after the second day of salt loading. However, the earbidopa 
treated high salt rats (Group D) did not have significantly higher DA excretion than 
Group C. After 4 days of earbidopa treatment, the high salt rats began to show an 
increase in DA production on day 5 and onwards. 
Figure 6-4 shows the excretions of Na, K-ATPase inhibitor in the 4 groups of rats 
o v e r the study period. There were significant changes in the excretion of inhibitor 
within each group over the 7 days (p<0.001 for each group). In groups that did not 
receive earbidopa treatment (Groups A&B), excretion of the inhibitor peaked on day 
5 ^ ^ then returned to a level even lower than day 1. The high salt rats (Group B) 
had •significantly higher inhibitor excretion than that of the low salt rats (Group A) 
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(F=7.99, p<0.0001). For rats treated with carbidopa (Groups C&D), excretion of 
inhibitor was significantly higher than that of Group A, but not different from Group 
B. The pattern of excretion was also similar to that of Group B except that the peak 
was on day 4. Group D (high salt) tended to have higher excretion of inhibitor than 
that of the corresponding low salt group (Group C) but the difference did not reach 
statistical significance. 
There were no significant difference in the body weights between the 4 groups of rats 
(F=0.715, p=0.544). Groups A, B and C all had significant increase in body weights 
during the study period, ranging from 34.7% to 47.9%. However, in Group D, the 
increase in body weight (24.3%) did not reach statistical signifiance. 
Correlation studies were performed in the 4 groups of rats. There was a strong 
positive correlation between the excretion of sodium and DA in the high salt rats 
(r=0.757, p<0.0001 for Group B; r=0.685, p<0.0001 for Group D) There was a 
weak and inverse correlation between sodium and DA excretion in Group C ( r = 
-0.330，p=0.033). In Group D, there was also a significant inverse correlation 
between the excretion DA and inhibitor (r= -0.376，p=0.019). Since there were inter-
relationships between the 3 measured parameters in Group D, multiple regression 
analysis was performed. When sodium excretion was used as the dependent variable, 
it correlated significantly with DA excretion (P =0 781，p<0.0001) and inhibitor 
excretion (P =0.254, p=0.048). Furthermore, 47% of sodium excretion can be 
attributed to DA excretion and only 6% to inhibitor. When DA excretion was used as 
the dependent variable, it correlated significantly with sodium excretion (P • 0.672， 
p<0.0001) and inversely with inhibitor excretion (p 〒一 0.349, p=0.0023). Similarly, 
47% of DA excretion can be attributed to sodium excretion, and 13% to inhibitor. 
6-10 
5 0 0 「 
I 4 o o T j 
<D T � ^ ^ ^ B 
1 1 3 0 0 
3 O 2 0 0 h 
i 
- B 1 0 0 k 
CO A , C 
m— ~ « , _ _ t 
o L 
» ‘ I I I • i 
1 2 3 4 5 6 7 
D a y s 
Figure 6-2: Changes of sodium/creatinine ratio in the 4 groups of rats. 
Group A: low salt 
Group B: high salt 
Group C: low salt + carbidopa 
Group D: high salt + carbidopa 
Results as mean 士 SEM 
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DISCUSSION 
When renal DA is inhibited by inhibitors of dopa decarboxylase or specific DA 
receptor anatogonists, sodium excretion has been reported to decrease in man (Ball & 
Lee 1977, Williams et al 1986) and in the rat (Yoshimura et al 1987，Shigetomi et al 
1989). This observation supports the role of renal DA as an important natriuretic 
factor. However, there are other, conflicting, reports showing that neither dopa 
decarboxylase inhibitor nor DA receptor anatgonists affect sodium excretion in animal 
studies (Bass & Murphy 1990). Though DA could be an important natriuretic factor 
in the kidney when DA is blocked, other natriuretic mechanisms will help to maintain 
the sodium homeostasis so that effective ECF volume remains unaffected. Reduced 
natriuresis should only be a temporary phenomenon. Therefore, the inter-
relationships between the different natriuretic mechanisms should be studied in detail 
to understand these conflicting results. It has been postulated that impaired DA 
mobilization could lead to an increase in ESTI which in turn may initiate the genesis 
of hypertension (Lee 1987). Elevation ofESTI has been reported in rats treated with 
metoclopramide (Shigetomi et al 1989). The present experiment was designed to 
study the inter-relationship between DA and ESTI in carbidopa treated fats on high 
salt diet . 
Carbidopa has been used commonly to study the effect of DA on sodium excretion 
both in man and animals. When the dosage of 40 mg/Kg/day was used in one study of 
spontaneous hypertensive rats, both sodium and DA excretions were reduced 
(Yoshimura ^ al 1987). However, there has not been any explanation as to how the 
dosage of carbidopa was selected. In a preliminary experiment using 40 mg/Kg/day 
of carbidopa, DA excretion was observed to increase 3 days after the treatment, 
suggesting that the dosage was not high enough to suppress DA production 
throughout the study period. Thus, it was decided to use a dose of 120 mg/Kg/day 
hoping that the 3-fold higher dosage would be enough to inhibit DA production 
throughout the 7 days. In man, 50 mg carbidopa was reported to inhibit DA 
excretion for only 1-2 hours (Williams et al 1986). 
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In the present study, carbidopa treatment did not induce significant decrease in 
sodium excretion (Figure 6-2). Although in the high salt group carbidopa treatment 
(Group D) gave a slightly lower sodium excretion than in Group B, the difference did 
not reach statistical significance. Furthermore, sodium excretion in Group D 
appeared to increase on the last day of the experiment. This result does not agree 
with the previous observation on carbidopa treatment (Yoshimura et al 1987)，but is 
consistent with the report on treatments of rats on normal salt diet on benserazide 
(Bass & Murphy 1990). The discrepancies in results could be due to biological 
variation in the animals studied, for example, different animal strains and age of the 
animals. It could also be due to the type of inhibitor and, for example, dosage, and 
the duration of treatment. In a study with spontaneous hypertensive rats on high salt 
diet, the animals were treated with 40 mg/Kg/day of carbidopa for 4 weeks 
(Yoshimura et al 1987). There was no difference in sodium excretion between the 
experimental group and the control group for the first week of carbidopa treatment. 
Sodium excretion was lower in the carbidopa treated group only after 1 week 
Another study using benserazide for 10 days showed no difference in sodium 
excretion (Bass & Murphy 1990). In a 7-day study using metoclopramide treatment, 
sodium excretion was lower in the treated group, but did not reach statistical 
significance (Shigetomi et al 1989). It is possible that several weeks of dopa 
decarboxylase treatment is necessary before significant decrease in sodium excretion 
can be demonstrated. 
DA excretion in the high salt group (Group B) was significantly higher than in the low 
salt group (Group A) on day 2 and onwards (Figure 6-3). This result is consistent 
with the results obtained in section II of this Chapter. A significant correlation 
between sodium and DA was also observed (r=0.715, p<0.0001), 
DA excretion decreased significantly over the study period in the low salt group 
(Group A). A similar decrease was also observed in the high salt group after day 5 
(Group B) However, the decrease did not reach statistical significance. DA 
excretion was expressed as DA/creatinine ratio in this study to correct for incomplete 
collection of urine and any difference in lean body mass between the groups. The rats 
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used in this experiment were only 1 month old. They were growing and likely to be 
coupled with an increase in lean body mass, leading to an increase in urinary creatinine 
excretion. When the rats were kept on a constant salt diet, DA excretion should 
remain relatively constant. However, the increase in creatinine excretion may explain 
the apparent decrease in the DA/creatinine ratio. On the other hand, high salt rats had 
an initial increase in DA excretion for several days before reaching a new steady state. 
Then, the decrease in DA/creatinine ratio might be delayed by a few days. It is also 
possible that high salt rats had a reduced rate of increase in body weight due to the 
increase in salt intake or poor apeptite. This is supported by the smaller increase in 
body weight. The increase in creatinine excretion will be slower and thus the decrease 
in DA/creatinine ratio. 
There was approximately 70% inhibition of DA on the dosage of carbidopa used in 
this study. In a study using 40 mg/Kg/day carbidopa treatment in spontaneous 
hypertensive rats, there was about 60% inhibition of DA excretion after one week of 
treatment (Yoshimura et al It appears that a higher dose of carbidopa is 
required to inhibit DA excretion from day 1 of treatment ‘ However, whether such a 
dosage leads to other systemic effects has not been reported. The carbidopa treated 
high salt group (Group D) had the least increase in body weight in this study. 
Despite an increase in body weight, and probably an increase in creatinine excretion, 
there was a trend for DA/creatinine ratio to increase in both carbidopa treated groups. 
This was more obvious in the high salt group (Group D). Dopa decarboxylase 
activity is regulated by its substrate L-dopa (Christenson 钉 a/1970) and high salt diet 
has been reported to increase the L-dopa production both in rat (Grossman ^ al 
1990) and man (Wolfovitz et al 1993). Increase in the substrate will up-regulate the 
synthesis of dopa decarboxylase. Thus the same dosage of carbidopa will not be 
sufficient to maintain the inhibition on DA production. The gradual recovery of DA 
excretion under carbidopa inhibition has been reported both in rat (Yoshimura et al 
1987，Yoshimura et al 1987a) and in man (Ball & Lee 1977，Williams et al 1986). 
Furthermore, when 50 mg of carbidopa was given to healthy males, the inhibition of 
D A excretion only lasted for 1-2 hours (Williams et al 1986). Carbidopa treatment 
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twice daily may not provide a constant inhibitory effect on renal dopa decarboxylase. 
Continuous infusion of carbidopa may provide a better model for consistent inhibition 
of DA production for future studies. 
Without carbidopa treatment, the high salt group (Group B) had significantly higher 
Na, K-ATPase inhibitor excretion than the low salt group (Group A) throughout the 
study period (Figure 6-4). The pattern of ESTI excretion was similar to that observed 
on the previous study described in section II of this Chapter. The surge on day 5 was 
again clearly reproducible. However, a relatively smaller surge was also observed for 
the low salt rats. The fact that this surge was observed in two different studies makes 
it unlikely that this is an artifact due to analytical errors. 
Carbidopa treatment of both low salt and high salt groups caused significantly higher 
inhibitor excretion than in the low salt rats without carbidopa (Group A). There was 
no significant difference between Groups B, C and D. The low salt group on 
carbidopa treatment (Group G) had similar ESTI excretion to the high salt group. 
This result suggests that DA may have an inhibitory effect on the production of ESTI. 
Furthermore, the surge of Na, K-ATPase inhibitor excretion was seen on day 4 for 
both groups on carbidopa treatment. Again, this result suggests that DA has an 
inhibitory effect on whatever the signal is that relates to the ESTI surge. The 
decrease in DA production stimulates this signal to be effective one day earlier. In a 
study using metoclopramide-treated high salt rats, both plasma and urinary Na, K-
ATPase inhibitory activities were significantly higher in the treated rats than the 
untreated rats (Shigetomi et al 1989). However, that study only measured the urinary 
excretion on days 0, 3 and 7. The surge of inhibitor excretion on days 4 and 5 could, 
therefore, not be observed. The inhibitor surge had not been reported before and 
deserves further understanding. 
Correlation studies confirmed that DA excretion is significantly correlated with 
sodium excretion in both groups of high salt rats (Groups B & D). This supports the 
role of DA being an important natriuretic factor during oral salt loading. With 
multiple regression analysis, it is shown that almost 50% of sodium excretion can be 
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attributed to DA. In the presence of carbidopa treatment, there was a significant 
inverse relationship between DA excretion and ESTI excretion. This may support the 
hypothesis that ESTI increases when DA production is inhibited (Lee 1987). 
The hypothesis tested in this study is that inhibition of DA production during salt 
loading will cause a much higher ESTI. ESTI increased in control groups given high 
salt (Group B and Section II). Carbidopa treatment of rats on low salt diet increased 
ESTI excretion suggesting that under normal circumstances DA is important for 
natriuresis and that when DA production is inhibited ESTI is secreted to maintain 
ECF volume (Fig 6-4). This supports the suggestions of Lee. When rats on high salt 
were treated with carbidopa, ESTI excretion, although higher, was no different from 
group B (high salt control group). This suggests that either other natriuretic factors 
come into play or that D A is not important in natriuresis. The observation could also 
be interpreted to show that ESTI may not be a natriuretic factor or that there is a 
maximum response above which ESTI cannot increase. ESTI has been suggested to 
stimulate ANP and vice versa (Crabos et al 1988). The observation in this study 
could be explained as follows: when rats on high salt diet are treated with carbidopa, 
sodium excretion transiently falls leading to a transient increase in EGF volume which 






Review of the literature shows there are several complex mechanisms to maintain the 
effective ECF volume. The kidney appears to be the major organ responsible for the 
regulation of effective ECF volume through the excretion of sodium. There are many 
sensors, hemodynamic forces and hormonal factors to ensure homeostasis and this 
presents difficulties in studying the functionial roles of individual factors. It is almost 
impossible to dissect out an individual factor and study its contribution to sodium 
excretion. In this thesis, the contributions of two controversial factors, renal DA and 
plasma ESTI, were studied in greater detail. There have been conflicting reports on 
the roles of these two factors in natriuresis. Furthermore, the plasma ESTI has been 
suggested to be a key factor in the pathogenesis of essential hypertension (de 
Wardener & Clarkson 1985). In this hypothesis, the inability to excrete excess dietary 
sodium due to an inherited defect in the kidney is the primary feature leading to the 
development of high blood pressure. Later, it was proposed that this inherited fault is 
a failure to produce appropriate amounts of renal DA in response to sodium challenge 
(Lee 1987). The study of these two natriuretic factors provided a unique opportunity 
not only to understand their contributions to natriuresis, but also to understand the 
pathogenesis of essential hypertension. 
MEASUREMENT OF ESTI 
Two methods were developed for the study ofESTI in this thesis. The first one was 
based on the inhibition of purified Na, K-ATPase and the second one was based on 
the measurement of DLI Both methods were applied for the measurement ofESTI in 
plasma and urine samples. 
The method developed for the measurement of Na，K-ATPase inhibitor was based on 
the automated measurement of Na，K-ATPase activity coupled to PK and LD on a 
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centrifugal clinical chemistry analyzer. Because of the use of an automated analyzer, 
the precision of the method was better than other, manual, methods. This method 
was also efficient as 28 samples can be handled in 15 minutes. By incorporating a 2-
hour incubation of the plasma extracts with the enzyme in a potassium-free buffer, the 
detection limit of the method was lowered to 5 nM, a value similar to that reported 
for radioreceptor assay (Kelly et al 1985). Methods based on the inhibition of 
purified Na, K-ATPase activity usually require either concentration of the sample, the 
use of radioactive isotopes or expensive instrumentation. Concentration of biological 
samples might increase the contribution of other non-specefic inhibitors which are not 
physiologically important in the regulation of the sodium transport in vivo (Woolfson 
et al 1994). With this sensitive method, there was no need for concentration of 
samples. 
The use of solid phase extraction to eliminate protein and electrolyte interference has 
been commonly used in the measurement of ESTI (page 2-2). However, the 
analytical performance has rarely been reported. In this thesis, a systematic study was 
conducted. The introduction of an equlibration time between the sample and the C18 
resin improved the precision and recovery. The use of other pretreatment methods, 
for example boiling and extraction with organic solvents, was studied and found not 
to be useful. Sep Pak extraction reported in this thesis has been applied for the 
extraction of ESTI in both plasma and urine samples sucessfully. 
Based on coupled enzyme assay Hamlyn et al (1982) showed a correlation between 
plasma ESTI concentration and MAP in essential hypertensive patients. Using the 
method reported in this thesis a correlation between plasma ESTI concentration and 
systolic blood pressure was observed in a group of hypertensive NIDDM patients 
(Figure 4-5, page 4-31). 
The method developed for the measurement of ESTI by DLI in this thesis was first 
based on a RIA method. It was later replaced by a HEIA method automated on a 
centrifugal clinical chemistry analyser. The automation improved the efficiency as 
well as the precision performance of the method. Improvement in the sensitivity of 
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the digoxin method has been commonly achieved by altering reaction conditions, such 
as the antigen and antibody reagent volume ratio (Wijdicks et al 1987). In the course 
of improving the sensitivity of the RIA DLI method, the detection limit was lowered 
from 0.1 i^g/1 to 0.03 ng/1 (Table 2-8, page 2-46). However, this reaction condition 
did not improve the detection limit for ESTI in plasma. This finding provides a 
different perspective on the use of DLI to measure ESTI. 
Measurement of DLI in samples was preceded by sample extraction with Sep Pak C 
18 resins. This provided a common and convenient preliminary purification method 
for measuring ESTI by two independent methods. Only 300 |j,l of plasma sample was 
required for both assays. Furthermore, as the Sep Pak extraction was optimized for 
inhibition of Na, K-ATPase activity, the presence of cross-reacting but non-inhibiting 
species was reduced. Since the Sep Pak eluants were not concentrated, any 
interference from supra-physiological concentrations of other interfering analytes was 
redeuced. 
There have been conflicting reports on the relationship between Na, K-ATPase 
inhibitory activity and DLI. In the present study a significant correlation between Na, 
K-ATPase inhibitory activity and DLI was found in a group of 51 Chinese medical 
students (Figure 4-1, page 4-5). However, the two methods did not show significant 
correlations in other studies. It can therefore be concluded that the correlation 
between Na, K-ATPase inhibitor and DLI depends on both the method of 
measurement and the origin of the sample. 
Since the exact nature of ESTI is not known, it is recommended that a combination of 
at least two methods be used for its measurement (Goto et al 1992). It is desirable 
for one of the methods to be based on inhibition of cellular sodium transport to 
simulate the biological actions in vivo. The two methods developed in this thesis do 
not fulfill this criteria. However, only a few studies reported in the literature fulfil this 
ideal condition. The use of oral rubidium loading to study sodium transport in vivo 
could be considered an ideal method (Boon et al 1984). 
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MEASUREMENT OF URINARY FREE DA 
The HPLC method developed for the measurement of urinary free DA was based on 
the use of ion-pairing reagent in the mobile phase, reverse phase stationary phase and 
a sensitive ECD. For preliminary purification of the CATS, urine free CATS were 
adsorbed onto alumina and eluted with 0.1 M HC1. During the process of extraction, 
the alumina was kept at optimal alkaline pH to ensure good recovery. To protect the 
CATS from auto-oxidation at alkaline pH, ascorbic acid and sodium metabisulfite 
were used. Furthermore, to reduce the presence of electrochemical active species in 
the ECD reaction, ethyl acetate washing was introduced (Davidson & Fitzpatrick 
1985). Chromatographic separation of all the three CATS and the internal standard 
DHBA was achieved in 15 minutes. The developed method is robust and has an 
analytical performance up to "state of the art". 
Due to the intrinic sensitivity of CATS to oxidative agents, preanalytical factors are 
also important for the reliability of any measurement of urinary free CATS. The use 
of acid preservatives for urine collection of CATS measurement is common (Table 3-
1, page 3-5). In this thesis, a systematic study on the effects of acid concentration, 
duration and temperature of storage was studied. It was found that HC1 was not an 
ideal preservative for urinary free CATS. 1 M HC1 decreased CATS standard 
solutions by 1-4% in 2 hours at room temperature, probably due to oxidative 
conversion. Furthermore, the presence of a high acid concentration in the urine 
samples hydrolyzed the conjugated CATS into free CATS giving falsely high results 
(Figure 3-6，page 3-42). The rate of hydrolysis is dependent on acid concentration, 
temperature and duration of storage. 100 ml of 0.5 M HC1 in a 2-liter container was 
found to be a satisfactory preservative based on this systematic study. With this 
preservative, urinary free DA was stable up to 3 months when stored a t，20�C. 
However, urinary free NA and A were stable for only up to 1 month (Table 3-9，page 
3-48). 
Although acid preservatives are still popular, alternative methods for the preservation 
of CATS in urine samples should be studied in the future. The use of an acidic buffer 
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solution should provide the optimal pH condition. Addition of antioxidants, like 
ascorbic acid and sodium metabisulfite, is likely to delay the oxidative conversion 
process upon storage. Storage of urine samples at lower temperature is also another 
approach to solve the stability problem. 
CROSS SECTIONAL STUDIES IN THE HUMAN 
The roles of DA and ESTI in natriuresis were studied in Chinese subjects under 
physiological conditions by cross-sectional studies. The subjects were allowed to 
continue their usual diet so that the status of natriuretic factors and sodium 
homeostasis were all at equilibrium. 
In a group of 51 medical students, there was no correlation between sodium excretion 
and plasma ESTI (page 4-3). In another group of 41 young females, the excretion of 
DLI did not correlate with sodium excretion (page 4-8). Furthermore, 30% of the 
variation in DA excretion was accounted for by the variation in sodium excretion. 
These findings agree with the hypothesis of de Wardener & MacGregor (1983). In 
healthy normal subjects, the kidney can eliminate excess sodium and there is no 
stimulus for the production of plasma ESTI. The positive correlation between sodium 
and DA excretion suggests that there is no abnormality of DA mobilization. 
The sodium and DA relationship was also studied in 2 groups of healthy normotensive 
subjects: a group without a family history of hypertension (Group A) and another 
group with a family history of hypertension (Group B). Sodium intake was not 
different between these 2 groups as supported by the insignificant difference in their 
sodium excretion (Table 4-4，page 4-15). There was a significant correlation between 
excretion of sodium and DA in Group A, but no correlation in Group B (Figure 4-2, 
page 4-16). Another group of hypertensive patients (Group C) also did not have a 
correlation between sodium and DA excretion. The loss of association between 
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sodium and DA excretion in Group C provides evidence that DA may be an important 
factor facilitating sodium excretion. Furthermore, the loss of the association in Group 
B suggests that the abnormality of renal DA production in the hypertensive patient is 
inherited, not acquired (Lee 1993). 
Excretion of DA has been reported to be dependent on age and sex (Gerlo et al 
1991). In order to understand the relationship between DA and sodium excretion, 
fUrther study with age- and sex-matched subjects is important. Instead of relying on 
the family history of hypertension, classification of subjects according to their blood 
pressure response to salt challenge can be used (Gill et al 1988). 
DA excretion has been reported to show circadian variation (Kawano et al 1990). 
The DA and sodium relationship could be different between the day and the night. 
This was shown in oral salt loading studies in this thesis (Figure 5-15, page 5-59). 
Collection of 24-hour urine samples should be replaced with day and night collections 
to understand this relationship better. 
The importance of renal DA in sodium excretion has been demonstrated by the use of 
DA receptor antagonists or dopa decarboxylase inhibitor to reduce sodium excretion 
(Bass & Murphy 1990). However, other effects of these pharmacological 
manipulation are not well-understood. It has been reported that there is decreased 
urinary DA in microalbuniinuric IDDM and NIDDM patients (Murabayashi et al 
1989, Patrick et al 1990). Thus, 164 NIDDM patients were recruited to study the 
effects of reduced DA production on sodium excretion under physiological 
conditions. Both urine collection and venous blood sampling were done twice over a 
period of 6 weeks in order to obtain a more representative sample from these patients. 
The 164 patients were divided into three groups according to UAE. Group A had no 
albuminuria (UAE <30 mg/d), Group B had microalbuminuria (UAE 30-300 mg/d) 
and Group C had macroalbuminuria (UAE >300 mg/d). Urine DA excretion 
decreased inversely with UAE (Table 4-5，page 4-24). However, there was no 
significant difference between sodium excretion among the 3 groups. This suggests 
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that sodium balance is maintained by other natriuretic fectors. Increased plasma ANP 
was observed. It may serve as a compensatory mechanism to facilitate sodium 
excretion. This was supported by their inverse relationships with UAE (Figure 4-3� 
page 4-25). Increased circulating ANP may increase proteinuria further (Zietse & 
Schalekamp 1988, Ishi et al 1989, Suenaga et al 1989，Hirata et al 1991). 
There was also a dissociation between plasma renin and serum aldosterone 
concentrations in the NIDDM patients. Serum aldosterone was lower in Group C but 
plasma renin was higher. The paradoxical increase in plasma renin concentration 
could be due to a reduced metabolic clearance because of reduced renal function 
(Rosenberg et al 1994). Higher renin concentration may lead to an increased 
concentration of angiotensin n, which can also reduce DA excretion (Eadington et al 
1991). 
There was a significant increase in MAP with increasing UAE (Table 4-5, page 4-24). 
MAP of these NIDDM patients correlated significantly with not only age, sodium 
excretion and ANP, but also with Na, K-ATPase inhibitor (Table 4-6, page 4-28). 
The patients were also grouped according to their SSBP (Table 4-7, page 4-30). 
Hypertensive NIDDM patients also had lower DA excretion than the normotensive 
ones. Again, there was no significant difference in sodium excretion between the two 
groups. On the other hand, there was significant correlation between the sodium and 
DA excretion in both hypertensive and normotensive groups. This finding was in 
contrast to the results observed previously for the hypertensive patients and 
normotensive subjects with a family of hypertension, in whom the association between 
sodium and DA excretion did not hold. This suggests that hyertensive NIDDM 
patients do not have the same genetic defect. 
Measurement of the different natriuretic factors in this group of patients provided an 
insight to the development of hypertension in NIDDM. It can be postulated that, in 
patients with NIDDM, early renal tubular damage may lead to reduced renal DA 
production, resulting in impaired sodium excretion. In response to volume expansion 
and increase in blood pressure, there is a compensatory rise in plasma ANP 
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concentration. This can facilitate sodium excretion and limit the sodium retention. 
However, this compensatory phenomenon could also contribute to worsening of 
albuminuria and possibly renal damage. This may lead to a further reduction in the 
urinary DA response to salt intake and initiate a vicious cycle involving sodium 
retention, hypertension and albuminuria. Diminished renal function also leads to the 
paradoxical rise in renin which may contribute to further reduction in DA production. 
The increase in plasma Na, K-ATPase inhibitor observed in these patients may 
contribute to the development of hypertension. 
A significant positive correlation between excretion of DA and NA had been observed 
in all the cross-sectional studies in which urinary CATS were measured. Urinary NA 
reflected the sympathetic nervous activity. The effect of NA on renal handling of 
sodium has been reported to be opposite to that of DA. Increased sympathetic 
nervous activity induces vasoconstriction and increased sodium reabsorption. 
However, their consistent correlation in these cross-sectional studies suggests that 
renal DA production is in part under the influence of sympathetic nervous activity. It 
is possible that renal DA stimulates sympathetic nervous discharge via dopaminergic 
receptors, or renal NA is a link between sodium intake and tubular DA production. 
Further studies are required to elucidate the relationship betwen the excretion of 
sodium, DA and NA. 
From this series of cross-sectional studies, there was evidence that DA has a direct 
association with sodium excretion under physiological conditions. However, in 
patients with essential hypertension or normotensive subjects with a family history of 
hypertension, there may an inherited defect in DA mobilization. Reduced production 
of DA did not result in decreased sodium excretion because of the presence of other 
natriuretic factors. Plasma ANP, rather than plasma ESTI, appears to be the 
immediate plasma hormone compensating to facilitate sodium excretion. Longitudinal 
studies to understand the temporal relationships between DA, ANP, ESTI and 
renin/aldosterone system in normotensive subjects with a family history of 
hypertension and in NIDDM patients, should provide further information in the 
development of hypertension. Furthermore, salt loading experiments on normotensive 
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subjects with and without a family history of hypertension, and NIDDM patients with 
different renal DA capacity should give more insights in the roles of DA and ESTI in 
sodium excretion and their contributions to the development of hypertension. 
VOLUME EXPANSION STUDIES IN THE HUMAN 
To study the role DA and ESTI in sodium excretion, ECF volume is altered 
experimentally by headout immersion, saline infusion and oral salt loading. Two oral 
salt loading studies were performed to simulate events in daily life. 
During headout water immersion, it has been shown that there is a highly significant 
increase in fractional excretion of sodium (Epstein 1992). This suggests that 
natriuresis by this method of expanding ECF volume is attributable primarily to 
decreased tubular reabsorption of sodium. A group of 7 Caucassian women 
undergoing headout water immersion for 3 hours was studied. There were significant 
increases in plasma ANP and decreases in both renin and aldosterone during the 
immersion period (Bisson et al 1992). No significant changes of both DA and ESTI 
were observed during the course of immersion (Figure 5-1，page 5-8). On the other 
hand, there was a 50% reduction in NA excretion indicating that the decrease in 
sympathetic nervous activity was another driving force for sodium excretion during 
headout water immersion. Furthermore, the DA/NA ratio increased 250% during the 
course of immersion (Figure 5-2, page 5-10). Multiple regression analysis showed 
that sodium excretion correlated inversely with the ratio (P =-0.636, p<0.0001). This 
result suggested that the decrease in NA, i.e. reduced sympathetic nervous activity, 
rather than DA, was an important contributor to sodium excretion. Plasma ESTI 
concentration did not play an important role in this method of ECF volume 
expansion. 
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When 4 healthy Chinese males were infused with 1 liter of saline over a period of 2 
hours, significant volume expansion was achieved (Table 5-3, page 5-20). Sodium 
excretion increased more than 2-fold (Figure 5-3, page 5-23). However, there was no 
significant increase in either DA excretion or plasma ESTI concentration during the 
course of saline infusion. Although there was a 16% decrease in NA excretion and a 
30% increase in the DA/NA ratio, these changes did not reach statistical significance 
(Figure 5-3, page 5-23). This suggests that the sympathetic nervous system was not 
involved in the sodium excretion induced by saline infusion. On the other hand, the 
renin-aldosterone system was suppressed during infusion and may be one of the 
important factors in facilitating sodium excretion (Figure 5-4, page 5-26). Under the 
present experimental design, the results suggested that neither DA excretion nor 
plasma ESTI concentration played significant roles in sodium excretion during saline 
infusion. 
Experimental design of the present saline infusion study could be improved. The 
number of subjects should be increased‘ In the present study, subjects were only 
given 200 ml of water at the start of the infusion. Urine volume decreased 
significantly during the course of infusion. This was probably due to the increase in 
plasma osmolality which in turn increases the circulating AVP concentration. A VP is 
another known factor which can affect sodium excretion. If water were given to 
maintain sufficient urine flow, the results might have been different. Furthermore, at 
the end of the infusion period, only 20% of the infused sodium load had been 
excreted. Urine and blood sampling should be continued for a longer period to 
monitor the changes of both urine DA excretion and plasma ESTI concentration. 
In the first oral salt loading experiment, five healthy Chinese subjects were studied 
over 9 days. They were on a low salt diet of 40 mmol/d for 3 days, a high salt diet of 
390 mmol/d for 3 days, and then on their normal diet of 190 mmol/d for 3 days 
(Figure 5-6，page 5-40). Sodium excretion was 10-fold higher during the high salt 
period when compared to the low salt period. Volume expansion was achieved as 
shown by a significant increase in body weight and decrease in plasma protein 
concentration (Table 5-7，page 5-39). In this study, the collection of day and night 
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urine samples was expected to provide more information on the relationship between 
excretion of DA and sodium as there is a circadian variation of DA excretion. 
However, there was no signficant increase in either DA excretion or plasma ESTI 
concentration during this salt loading study in the day or night collections. There was 
no significant correlation between the sodium and DA excretion. It was recognized 
that the 3-day period of low salt and high salt might not be sufficient to establish a 
new steady state for these subjects (Sagnella et al 1990). The study period should be 
extended to at least 5 days as used by other research groups. Furthermore, the 
subjects should be kept on the same diet to reduce the influence of protein on the 
production of DA (William et al 1986). 
The second oral salt loading study was designed to improve on possible experimental 
design faults that might have contributed to the lack of DA and ESTI response in the 
first study. Seven young Chinese medical students were recruited. They were kept 
on the same low-salt hospital diet for 10 days (day -4 to day 5). On day 1, they were 
given 20 'Slow Sodium" tablets after breakfast. There was a 9-fold increase in 
sodium excretion between the low and high salt periods (Figure 5-13, page 5-55). 
Significant ECF volume expansion was achieved as supported by significant 
suppression of the renin-aldosterone system (Figure 5-14, page 5-58). 
A significant increase in plasma ESTI was observed: Na, K-ATPase inhibitor on day 3 
and DLI on day 2 (Figure 5-14, page 5-58). This result suggests that the duration of 
low salt and high salt periods could be critical to induce a significant response of 
plasma ESTI. Furthermore, there was a dissociation between Na, K-ATPase inhibitor 
and DLI indicating that the 2 methods were measuring different entities in the plasma 
samples. 
Upon salt loading, sodium excretion reached its new equilibrium on day 3. Plasma 
ANP increased with salt loading (Figure 5-14, page 5-58). A significant increase of 
plasma ANP was observed on day 4, and then it decreased abruptly on day 5. Since 
plasma samples were collected daily before the salt loading, the measured plasma 
concentration represented the results of the previous day. Plasma ANP peaked when 
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the sodium excretion reached a new steady state and then it decreased abruptly on the 
next day. The cause of this decrease in plasma ANP cannot be explained by the 
results of this study. It is speculated that there could be a maximum limit for the rise 
of ANP concentration. Infusion studies have shown that ANP induces proteinuria in 
patients with essential hypertension (Suenaga et al 1989) and primary glomerular 
diseases (Zietse & Schalekamp 1988，Ishi et al 1989，Hirata et al 1991). 
Nevertheless, the decrease in ANP could be a contributing factor for the surge of Na, 
K-ATPase inhibitor on day 5. This phenomenon has not been reported before. 
During the low salt period, circadian variation in DA excretion was not observed 
(Figure 5-15, page 5-59). This suggests that circadian variation of DA excretion was 
due to sodium intake. Although there was a 23% increase in DA excretion during the 
day on the high salt diet, this increase did not reach statistical signficance. 
Furthermore, there was a 10% decrease in DA excretion during the night over the 
same period. It was interesting to observe that when there was a higher increase in 
DA excretion during the day, there was a corresponding decrease in DA excretion 
during the night. Such a phenomenon has not been reported before and deserve 
further study. 
There was no signficant decrease in NA excretion during the 10-day study period 
(Figure 5-16, page 5-61). However, there was a sharp rise of NA excretion during 
the night on day 4. This coincided with the decrease in plasma ANP concentration 
and the increase of plasma Na, K-ATPase inhibitor. It has been reproted that ANP 
can inhibit the sympathetic nervous system (Goetz 1990). Thus, the inhibitory effects 
of ANP on the sympathetic system may be a signal for the increase in the production 
of ESTI. Furthermore, sodium excretion correlated significantly with the DA/NA 
ratio during day time when the "Slow Sodium" tablets were being taken. 
The second oral salt loading experiment provided more insights on the interactions 
between the different natriuretic factors. One important aspect of the experimental 
design was to collect blood samples daily and urine samples for both day and night 
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periods. The frequent sample collection was time consuming and has not been 
reported in the literature. 
From this series of volume expansion studies, it can be concluded that plasma ESTI 
does not contribute signficantly to sodium excretion during acute volume expansion 
like headout immersion and saline infusion. On the other hand, it has been 
demonstrated that plasma ESTI had a significant role in sodium excretion during oral 
salt loading. With increased dietary sodium intake, expansion of ECF volume can 
induce increased production of plasma ESTI. When there is a defect in renal 
excretion of sodium, persistant expansion of ECF volume can lead to increased 
production of the Na, K-ATPase inhibitor. The result supports de Wardener's 
hypothesis (de Wardener & Clarkson 1985). On the other hand, DA excretion does 
not play a significant role in experimentally induced volume expansion. Together with 
the association between sodium and DA excretion observed in the cross-sectional 
studies, these results suggest that DA excretion contributes significantly when sodium 
excretion is at steady state under physiological conditions. 
In order to test the hypothesis that a renal fault in DA production leads to the 
production of ESTI which may be responsible for the pathogenesis of hypertension, 
sodium loading in a larger number of subjects should be studied. A direct relationship 
between DA and ESTI will support the hypothesis. Furthermore, inhibition of DA 
production or inhibition of DA action should show increased production ofESTI. 
However, the pharmacological effects of the inhibitor or antagonists are not well 
understood. Thus, NIDDM patients, with a different degree of renal DA capacity, 
should also show an exaggerated ESTI response. Another possibility is to study 
normotensive subjects with a family history of hypertension in whom it is likely there 
is an inherited defect for the DA and sodium relationship. Again, the response of 
ESTI should be increased. 
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STUDIES ON THE EFFECTS OF 
SALT LOADING IN THE RAT 
The effects of dietary salt loading in the rat have been studied to examine the temporal 
relationship between excretion of ESTI and DA. It was found that the excretion of 
ESTI closely followed the excretion of sodium whereas the excretion of DA lagged 
behind by a day (Figure 6-1，page 6-5). Furthermore, the observed increase in DA 
excretion may not be quantitatively adequate to explain the natriuresis. Similar to the 
observation in the salt loading studies in medical students, a surge in Na, K-ATPase 
inhibitor excretion was observed on day 5 in the rat. This surge was two days after 
the sodium excretion reached a new steady state, and also lasted only for 1 day. This 
phenomenon has not been reported before. Furthermore, this surge was reproducible 
in the subsequent salt loading study in the rats. Thus, it is unlikely that this is an 
artifact due to analytical errors. The changes in ANP could be the reason for this 
increase in ESTI production. 
When rats were treated with carbidopa 120 mg/kg/day, there was 70% inhibition of 
the excretion of DA However, during salt loading of carbidopa treated rats, there 
was no significant decrease in sodium excretion compared with the control group 
(Figure 6-2, page 6-11). This suggests that there are other natriuretic factors 
maintaining the sodium excretion. Carbidopa treatment of both low salt and high salt 
groups of rats caused significantly higher Na, K-ATPase inhibitor excretion (Figure 6-
4，page 6-13). In the carbidopa treated low salt group, inhibitor excretion was not 
significantly d i fferent from the carbidopa treated high salt group. The result suggests 
that DA may have an inhibitory effect on the production of ESTI. Furthermore, the 
surge of Na, K-ATPase inhibitor was seen 1 day earlier on both groups upon 
carbidopa treatment. This suggests that DA has an inhibitory effect on whatever the 
signal is that relates to the ESTI surge. The decrease in DA production stimulates 
this signal to be effective one day earlier. Results of this study support the hypothesis 
that ESTI increases when DA production is inhibited (Lee 1987). 
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When rats on a high salt intake were treated with earbidopa, ESTI excretion was not 
significantly higher than in the corresponding control rats. This suggests either that 
other natriuretic factors come into play, or DA is not important in natriuresis. The 
observation could also be interpreted to mean that ESTI may not be a natriuretic 
factor or that there is a maximum response above which ESTI cannot increase. 
In the present earbidopa study, urine NA was not measured due to the presence of 
other interfering peaks coeluting in some of the urine samples. Similar to the 
observation made with the salt loading experiments with the medical students, urine 
NA excretion may provide more insights into the interaction of the DA production 
and the sympathetic nervous system. Furthermore, changes in circulating ANP 
concentration may be responsible for the surge ofESTI production. Therefore, ANP 
concentration in blood should be measured in future studies. 
SUMMARY 
Both DA excretion and ESTI have been found to be contributing to the process of 
sodium excretion under different conditions. Under acute volume expansion of ECF 
volume, ESTI does not play a significant role. DA excretion correlated with sodium 
excretion under physiological conditions. Changes in different natriuretic factors by 
experimental manipulation did not affect sodium excretion, probably because of the 
large number of different mechanisms available to maintain sodium homeostasis. 
Furthermore, the idea of a maximum concentration for some natriuretic factors like 
ANP and ESTI, above which fiirther increase is limited, deserves further study. 
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negative predictive value with both adults tod from cord blood were used tein binding of endogenouH digoxin-immu-
testq, which is particularly relevant to a s s e f s the effidenqr of detecting OLIS noactive factors in human serum and its 
when these kits are used as screening by various protocols. The two samples variation with clinical conditions. J Clin 
tests. . were pretreated by two different meth- Endocrinol Metab 1985;60:1135-43. 
. r . ods to improve detection of D U S ( 2 ) , References namely, the SeJ> Pak extraction and _ _ s ; , H o 1. Capp. NE, Bottomley S, OUa™ P. P«. deprotdniration by boiling. The Sep n ^^ l , R Swaminathan 
dictive value of Albuacreen and Albuatix f ^ (Waters Cw Cartridge) extraction Dept of Chem. Pathol. 
results [Letter]. Clin Chem 1988:34:1368. 鉍 performed by passing 1 mL of sample Prince of Wales Hosp. 
2. Townsend JC, Solder WA, Shanks GM. Jh™吨h the Sep Pak Cartridge fol- Shatin, NT 
The effect of storage pH on the predpitation loWed by washing with 5 mL of water. Hong Kong 
of proteins in deep frozen urine samples. 
Ann Clin Biochem 1987^4:111-2. • • . 
3. Townaend JC. SpecimenpreparaUonfor Table 1 Effect of Modification of Assay Protocol on the Detection Limit for 
mieroalbuminuna assay fTech Bnefj. Clm A j..,- • < . Chem 1986,32:559. DUS In Adult and Cord-Blood Plasma 
• 4. Mogenaen CE. A complete screening of • 0 0 8 drteeted, fiqU. 
albumin conoentaitioii in an unae- . V o — ‘ _ • S«p PBk Bolting 
lected diabetic outpatient cliiuc population. “ Detection Diabetic Nepfaropathj 1983^ :11-3. Sample Tracw Antibody Ihntt, ^ ig/L Adult Cord Adult Cord i, •. • • - “.. . Incubaaon time - 30 min 
• •: E m m a ^ u a g n e l l i m 40- 200 ' 200' 0.10 0.61 0.86 0.41 0.56 i . t ManoMella 100 200 200 0.03 0.32 0.41 0.33 0.35 
Augusto Lovagnim-Scher 100 100 200 0.05 0.24 0.28 0.25 027 
LoborntorioAmdisi ?00 • 0.06 0.16 0.23 0 19 
1 0 0 200 100 0.09 0.24 0.30 0.18 0.23 Giovanni Segalini 1 0 0 2 0 0 50 0.08 0.29 0.33 0.13 (U1 c . . .. n.�;^丄”,•” incubation time - 1 h 
f T T l n 100 200 200 0.03 0.19 0.30 020 0.27 “ Ospcdaje Bassuu 100 100 200 0.03 0.17 0.19 0.18 0.19 50 via Gorki 100 -SO 200 0.05 0.04 0.10 0.03 0.10 溫 2 CuuseUo Balsamo (MI) *Man»fct»W-, recommwdad protocol with proportlonate.y decreased votum,. 
. 2604 CLINICAL CHEMISTRY, Vol. 34, No. 12, 1988 • , 
• 1 
Clinical Science (1992) 83, 247-253 (Printed in Great Britain) 2 4 7 
Atrial natriuretic peptide and urinary dopamine output 
in non-insulirvdependent diabetes mellitus 
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i 如 i. j • L . P < 0.001).- In patients with urinary albumin excre-
L ? T n ^ ° — water homoeostasis tfon > 30 mg/day, plasma atrial natriuretic peptide 
Z L 1 ！ ， A d 0 S \ concentration was negatively correlated with irinary 
I ^ i ^ y P e r t e n S 1° n ^ proteinu.na- .WeLtherefore dopamine output (r= -0.25,尸<0.02). 
7 d i e d thZ P a t t e ™ °.f _ .^tnuretic hormones, 3 . Rased on these observations, we hypothesize that, plasma atnal natriuretic peptide and urinary dopa- i n p a t i e n t s w i t h non-insuUn^ependent Lbetes meUil mine, in 165 Chinese patients with non-insulin- tus, defective dopamine mobilization in the renal ^pei^eiit diabetes mellitus controlled by diet or oral tubules may cause impaired natriuresis with increased hypoglycaemic agents on ^ o occasions over a 6-week blood pressure. A compensatory rise in the plasma peno^. Patients were divided into three groups based atrial natriuretic peptide concentration may then con-on the mean value of two 24 h urinary albumin tribute to the development of abnormal albuminuria. 
excretion measurements. In group 1, 88 patients 
had normoalbuminuria (urinary albumin ex-
cretion ^  30 mg/day), in group 2, 48 patients had microalbuminuria (urinary albumin ex- INTRODUCTION cretion between 30 and 300 mg/day), and in group 3, 29 patients had macroalbuminuria (urinary albumin There is evidence that patients with insulin-
excretion ^  300 mg/day). dependent (IDDM) and non-insulln-dependent 
•2* The supine systolic blood pressure (mean 士 SD) was (NIDDM) diabetes mellitus have an increase in 
higher in patients with abnormal albuminuria (group exchangeable body sodium that correlates with their 
1: 140.9 士 27.4 mmHg; group 2: 15&1 土 26.4 mmHg; level of blood pressure (BP) [1]. Plasma atrial 
group 3: 166.7 土 23.9 mmHg; /*= 13.1, P < 0.001, natriuretic peptide (ANP), a known diuretic hor-
analysis of variance). Urinary sodium output was mone [2], has also been reported to be elevated in 
similar in these three groups of patients. The geo- hypertensive patients [3] and in patients with 
metric means (anti-logarithm of 95% confidence IDDM and NIDDM [4-8]. Intravenous infusion of 
interval logarithm) of plasma atrial natriuretic pep- ANP, on the other hand, induces proteinuria in 
tide concentrations increased with increasing protein- patients with essential hypertension [9] and primary 
aria [group 1: 333 (29.9-37.1) pg/ml; group 2: 39.1 glomerular diseases [10-12]. Urinary free dopamine 
(34.2-44.6) pg/ml; group 3: 50 (38.6-54.7) pg/ml; (DA) mobilization in renal tubular cells may be 尸=4.24，P<0.01; analysis of variance], whereas those important in promoting natriuresis in response to a 
of urinary dopamine output were related inversely salt load [13] via inhibition of Na + ,K +-ATPase 
to proteinuria [group 1: 1291.7 (1167.2-1437.0) activity [14]. Decreased urinary DA excretion has 
nmol/day; group 2: 11423 (975.9-1337.2) nmol/day; been reported previously in microalbuminuric 
group 3: 982.7 (775.7-1245) nmol/day; F=3.10, patients with IDDM and NIDDM [15,16]. Based 尸 <0.05，analysis of variance]. Using stepwise mul- on these previously reported findings, we hypo-
tipie regression analysis, plasma atrial natriuretic thesize that defective urinary DA excretion second-
peptide concentration (#^=031, F=56.2, P < 0.001) ary to microangiopathic changes in renal tubular 
was associated with supine systolic blood pressure cells may contribute to the sodium and water 
(彡=0*56，P< 0.001), which was (^=038, 0.001) retention, and consequent hypertension in patients 
related to urinary albumin excretion (/J=0.23, with NIDDM. A compensatory rise in plasma ANP 
Key words: albuminuria, atrial natriuretic peptide, Chinese, hypmension, non-insuliiHlependent diabetes, urinary dopamine output. Abbreviations: ANP. atrial natriuretic peptide; BP. blood pressure; DA. dopamine; H b A „ glycated haemoglobin; IDDM, insulirndependent diab«tes mellitus; NIDDM, 
non-insuliiHlependent diabetes mellitus; UAE. urinary albumin excretion. , l , , Present address: SOepartment of Medicine, aratchurch School of Medidne, Christchurch Hospital, PO Box 4345, Christchurch, New Zealand. 
Present address: llDepartnient of Clinical Biochemistry. United Medical and Dental S<hooU. Guy's Hospial Medial School, London Bridge, London SEI 9RT. U.K. 
Correspondence: Dr juliana C. N. Chan, Department of Clinical Pharmacology, Prince of Wales Hospital, Chinee University of Hong Kong, Shatin. Hong Kong. 
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concentration to promote natriuresis may then con- Dorset, U.K.), 20 mmol/1 citric acid from Sigma 
tribute to the development of proteinuria in these (Poole, Dorset, U.K.), 4 mmol/1 1-octanesulphonic 
pati�nts. To examine the possibility of this hypo- acid from Sigma, 2 mmol/1 triethylamine from 
tresis，we have studied the relationships between Merck (Darmstadt, Germany) and 0.1 mmol/1 
th�se two natriuretic hormones, plasma ANP and EDTA from BDH were dissolved in 1 litre of Milli-
i ^ ia ry DA, and BP and albuminuria in a group of Q water/methanol (86:14, v/v). The mobile phase 
Chinese patients with NIDDM. was filtered by a 0.45 ^m filter and was degassed 
before application. The flow rate was 2 ml/rain. The 
METHODS intra-assay and inter-assay coefficients of variation “ —� were 1.27% and 8.7% respectively. The mean re-
Patients covery of urinary free DA was 91.1%, and the detection limit was 3 nmol/1. Urinary albumin con-The study was approved by the Ethical Com- centration was determined by immunoturbidimetry mittee of the Chinese University of Hong Kong. A [20] with intra-assay and inter-assay coefficients of total of 165 Chinese patients with NIDDM were variation of 3.3% and 6.7%, respectively. The detec-recruited from the diabetes clinic at the Prince of tion limit was 2.5mg/l. Urinary sodium con-Wales Hospital, Hong Kong, and were studied on centration was measured by indirect ion-selective two occasions over a 6-week period. All patients electrodes on the parallel multi-channel analyser received their usual dietary and oral hypoglycaemic (American Monitor). Plasma and urinary creatinine therapy and none was receiving insulin. Anti- concentrations were measured by the Jaffe method hypertensive treatment was taken by 102 patients, 0 n a Beckman Astra-8 Clinical Chemistry Analyser but was withdrawn for at least 2 weeks before the (Beckman Instruments, Fullerton, CA, U.S.A.). study. Glycated haemoglobin (HbAJ was measured by gel On each of the two study visits, supine (after electrophoresis (Ciba Corning Diagnostics Corp., 5 min of rest) and erect (after 2 min of standing) BP Alto, CA, U.S.A.) with a normal reference range was measured by a single research nurse using a between 6.5 and 8.5%. Plasma fructosamine con-random zero sphygmomanometer. Phase V (dis- centration was measured by published methodology appearance of sound) was taken as the diastolic BP. [21], and fasting plasma glucose concentration by a Venous blood was sampled for measurement of glucose oxidase method (Reagent Kit; Diagnostic plasma ANP concentration after erect BP was mea- Chemicals Ltd), sured. Twenty-four hour urinary excretions of albu-min (UAE), DA and sodium were also measured oil 
"the two visits. Urinary tract infection was excluded Statistical analysis 
by examination of a midstream specimen of urine. _ , r „ . , . , ^ . , u Normoalbuminuria was defined as a mean UAE . m e a n ^ o f a 1 1 t o n b o t h f <30mg/day, microalbuminuria as 30-300mg/day v l s l t s w e r ® u s e d for analysis. The distnbutions of 
a"nd macroalbuminuria as >300mg/day being deter- u " n a r y s o f d l ^ m a n d D A . t o u t P u t t ."： * J , ® , plasma ANP concentration were positively skewed mined on two separate 24 h samples during the P ^ 肌代 l o g t r a n s f o r m e d . ^ r e S ults were 6-weeK period. expressed as geometric means (anti-logarithms of 
95% confidence interval logarithms); other results 
Analyses were expressed as means 土 SD. Correlation co-efficients were calculated by least squares analysis. Twenty-four hour urine samples for measurement stepwise multiple regression analysis was used to of DA and sodium were collected into acid- s t u d y t h e interrelationships between these variables, containing bottles and were stored at - 2 0 C before Comparisons between the patient groups were per-analysis. Urine samples for measurement of albumin f o r m e d u s i n g a n a lys is of variance and Student's were collected into plain bottles and were stored at t _ t e s t > a s appropriate. A P value of less than 0.05 4°C before analysis within 1 week of collection. (two-tailed) was considered to be statistically signi-Plasma ANP concentration was measured by radio- ficant Bonferonni's Inequality Theorem was used to immunoassay after extraction using Sep-Pak car- adjust the P value for multiple group comparisons, tridges (Waters Chromatography Division, Milli-pore Corporation, Milford, PA, U.S.A.) as described previously [17]. Intra- and inter-assay coefficients of RESULTS variation were both between 11 and 14% at varying 广， . u concentrations of ANP in human plasma. The The clinical features of the patients are shown m ^ t c t ^ n limit was 10 pg/ml. Urinary free DA was Table 1. Based on the mean value of tw^ > measure-ex rac ted Z to alumina [18] and quantified by merits of UAE, 88 patients had normoalbummuna 
r ^ l c ^trelectHKhemical detection based on pre- (UAE ^  30 mg/day), 48 patients had micro-
i l f 二 二hodology [19] with a modi- albuminuria (UAE between 30 and 恐mg/d监二 fiS ^ f the composition of the mobile phase, i.e. 29 patients had macroalbuminuna (UAE ^  300 mg ^ m o l ^ sodium acetate from BDH (Poole, day). The supine systolic BP was higher in patients 
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y a b k I. Clinical features and laboratory data of the patients with NIDDM. Values are means 土 so. Swistical significance (analysis of variance): *P < 0.05, fP <0.001. Normoalbuminuria Microalbuminuria Macroalbuminuria (UAE ^ 30 mg/d>y) (UAE 30-300 mg/day) (UAE^300mg/day) 
A8« ( y ^ ) 士 10.0 57.0 士 11.9 54.4 土 112 
^ (
k
«) 60.7 土 10.4 618 士丨 19 60.4 士 11.3 Supine BP (mmHg) 141 土27/83 土 12 IW 士 27/87 土丨4 167土 2竹/87 土 10 Erect BP (mmHg) 142 土 29/88 士 丨 3 . IS9 士 27/92 士 13 160 士 2竹/85 士 13* Plasma creatinine concn. (/zmol/l) 76.3 土 16.3 80.3 土 19.6 98.3 ± 35.8| 一 H b A i(*) 10.2 土 1.7 10.7 土 1丨 10.7 士丨.6 Plasma fructosamine concn. (mmol/1) 134 士 0.30 139 士 0.27 122 土 (U5* Fasting plasma glucose concn. (mmol/1) 8.4 ± 1 4 8.9 土 13 9.1 
卷 
t . 
with abnormal albuminuria (normoalbuminuria: 2 0 0 「 I 户 <o.wi 1 
140.9 土 27.4 mmHg; microalbuminuria: 158.1 土 pP<o.ooi-, 26.4 mmHg, macroalbuminuria: 166.7 土 23.9 mmHg; & t d k 
F=13.1, P<0.001, analysis of variance). Urinary 1 5 0 " ^ ^ 
sodium output was similar in all three groups of \ \ ?8s 
patients. Whereas the plasma ANP concentration 旦 loo - / y ^ 
increased with increasing proteinuria ^ / y \ \ 毅 
[normoalbuminuria: 33.3(29.9-37.1) pg/ml; micro- ^ \ \ >8s 
albuminuria: 39.1 (34.2-44.6) pg/ml; macro- 50 1~rZ/l KVl 199一 albuminuria: 50 (38.6-54.7) pg/ml; F=4.24, P<0.01, 
analysis of variance], urinary DA output was re- 5 0 0 
lated inversely to proteinuria [normoalbuminuria: s 
1291.7(1167.2-1437.0) nmol/day; microalbuminuria: t t 
1142.3(975.9-1337.2) nmol/day; macroalbuminuria: + 0 f loo 卜図网 _ 982.7(775.5-1245)nmol/day; F=3.10, P<0.05, f l M K ^ S 3 analysis of variance]. The P values for between- | r/yj KNq gg^ 
group comparisons are shown in Fig. 1. = rXj kNN ^ ^ 
Supine systolic BP correlated significantly and | yy^ 
positively with plasma ANP concentration (r=0.57, 1 0 """ 
P < 0.001) and negatively with urinary DA output � j P<0.0i 1 (r= -0.25, P<0.01, Fig. .2). UAE was related in a � ] 
positive fashion to plasma ANP concentration I i b 
(r=0.31, P < 0.001) and negatively to urinary DA | 50 [ ^ T 丄 output (r= 一 0 . 1 8 , 尸 = 0 . 0 2 5 , Fig. 2). Urinary DA 出肉 88 output was significantly related to urinary sodium ：茬 V / \V Og 
output whether the patients were analysed as a I \ y / V\ >S< 
whole (r=0.51, P < 0.001) or divided into those with /V \ \ 3 3 UAE^30mg/day (r=0.50, P<0.001) or with .. L i Z Z ^ L ^ 一 UAE >30 mg/day (r=0.54, P <0.001, Fig. 3).消”计，〈卞—� 一 �s，屮1�―广 ~ � 
Table 2 shows the correlation matrix between age, , : . ^ . p — - p < 0 0 2 — | body weight, • glycaemic control, renal function, - 二 UAE, plasma ANP concentration, BP, urinary s L 肉 去 丄 sodium output and urinary DA output. Since some i - ^ 1 0 0 0 | ^ Kg of these variables were inter-correlated, we further < f <3> 
used stepwise multiple regression analysis to predict ^ I / Z 8 8 
the most significant relationship and the results are I I V W summarized in Table 3. ⑵ ⑶ 购 There was a weak inverse relationship between | M I__\/A NM ixxl—— p l a s m a A N P c o n c e n t r a t i o n a n d u r i n a r y D A o u t p u t R , < S u p i l i e B p, urinary sodium output, plasma A N P 
( r = - 0 . 1 5 , P = 0.056). T h e co r r e l a t i on coe f f i a en t s concentration and urinary DA output in patients with normo-
between plasma ANP concentration and urinai7 m i c r o s (S) a n d m a c r o " (H) albuminurii Valu« are means with 9SS 
D A o u t p u t w e r e nega t ive in b o t h m i c r o a l b u m i n u r i c confidence intervals shown as error ban. All values, except supine systolic / r = _ _ 0 2 5 n o t s i g n i f i c a n t ) a n d m a c r o a l b u m i n u r i c BP, are expressed on logarithmic scales. The adjusted P values for b«twe«n-
/ ~ ^ 0 2 5 ^ n o t s i ^ l i f i can t ) pa t ien t s , a l t h o u g h the group comparisons, considered to b« significant at 0.016, are also shown, r e l a t i o n s h i p b e c a m e s i g n i f i c a n t o n l y w h e n b o t h See the text for f values usins analysis of variance. 
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Fig. 1 Relationships between supine systolic BP, U A E , urinary DA output and plasma A N P concentration in 165 patients with NIDDM. All values, except supine systolic BP, are expressed on logarithmic scales. The regression line and 95% confidence, intervals are also shown. See the text for correlation coefficients. 
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Fig. 1 Relationships between urinary sodium and DA outputs in patients with normal (UAE^30mg/day, a) and abnormal (UAE>30mg/dayt b) albuminuria. All values are expressed on logarithmic scales. The regression line and 9SX confidence intervals are also shown. See the text for correlation c o e f f i c i e n t s . . 
groups (UAE>30mg/day) were analysed as a whole IDDM and NIDDM. Possible mechanisms for the 
(r= 一 0 . 2 5 , 0 . 0 2 7 , Fig. 4). volume expansion and hypertension in these ‘ patients include，among others, enhanced proximal 一 ， tubular sodium-glucose co-transport owing to hyper-DISCUSSION glycaemia and the anti-natriuretic effects of high 
The nature of the relationships between hyper- circulating levels of insulin [1, 23]. tension, diabetes mellitus and albuminuria remains Plasma ANP is primarily secreted from the atrial ill-understood although a recent report indicates tissues in response to atrial distension due to that oersistent microalbuminuria precedes the in- plasma volume expansion [2]. Increased plasma l . e a s e i n a r t erial BP in patients with IDDM.[22]. ANP levels have been previously reported in There is evidence suggesting that an increased ex- patients with essential T ^ x e ^ n s i o n [3], and changeable body sodium might contribute to the recently in patients with IDDM and NIDDM [ f -devel^ment of hypertension among patients with 8]. The actions of plasma ANP include diuresis, 
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T a b > e _ V C ° r r d a t i 0 n m a t r i x 如妨呷彻 correlation coeffidents between age, body weight, BP, (lycaemic control, renal function, plasma ANP concentration and urinary sodium and DA outputs in patients with NIDDM. Abbreviation: NS, not significant. Staciscicai sitnifiance: »P<0.05, tP<0.0l, 
tf <(K00l, §P=0.0S&. 
Age Body Supine Plasma Plasma HbAt Plasma Plasma Urinary DA Urinary UAE wt. systolic glucose fructosamine creatinine ANP output NA+ BP concn. concn. concn. concn. output Age I Body w l — I 
Supine systolic BP Oil J 一 0 . 1 8 * I Plasma glucose concn. —0.15* NS NS I 
Pbsma fnictosamine concn. NS NS NS 0i8J I 
HbA, NS NS NS 0.70t 0.68{ I 
Plasma creatinine concn. 0J{ NS 0J3f —0.17* NS —O^f I Plasma ANP concn. 0 J 2 J NS 0i7t NS NS NS. 0.16* 丨 Urinary DA output 0.33J - 0 J 5 f NS NS NS' - 0 J 7 t 一 O . I 5 § I Urinary Na + output - 0 1 4 | 0.35t NS NS NS NS NS NS O i l t I 
UAE NS NS 0.42J NS NS NS 0.28t 0.31J 一 0.18* NS I 
Table 3. Inter-relationships between age, body weight, BP, glycaemic control, renal function, plasma ANP concentration and uriniry sodium and DA outputs in patients with NIDDM using stepwise multiple regression analysis. Abbreviations: fi, standarized regression coefficient; NS, not signifiant. Statistiai signifiance: *P<0.05, "jf <0.01, f <0.001. Dependent variables... Plasma fynP Urinary DA UAE Supine systolic BP concn. output 
Analysis of variance for f»=0.3l =^0.38 r»=0.30 =^0.48 regression model... F=56.2J F = 2 0 J J F=I4.0J F=39.2J Independent variables 
* Age NS NS ~NS =^0.38{ Bodywt NS /?=0.I6* NS NS Supine systolic BP /?=0.56t 烀=0.15* /J=0.33J — Plasma glucose concn. NS NS p=0ASt NS 
Plasma fructosamine concn. NS NS P= ~0J8J NS Plasma creatinine concn. NS 弇=一0.30$ /?=0«23t NS Plasma ANP concn. - NS NS 及=0J9J Urinary DA output NS — NS NS Urinary Na^output NS NS NS U A E NS NS -
natriuresis and vasodilatation. In conjunction with is actively taken up and converted to DAby L-dopa the renin-angiotensin-aldosterone system, ANP decarboxylase in the renal tubular cells. This uptake modulates the vascular tone and renal excretory process is dependent on the sodium concentration functions in man [2]. In addition, intravenous in- in the proximal tubule [26]. The pro^ss o f i n-fusion of ANP has been reported to induce protein- uresis has been shown to be faali ated by the u T L patients ^ t h essential hypertension [9] and inhibition of Na + , f - A J P - e a c ^ t y by DA orimary glomerular diseases [10-12]. A rise in intra- synthesized intra-renally [14, 27 28]. E m l f r vascular resistance owing to post- It has been suggested that early microanpopath^c K 二 二constriction and increased renal changes witWn the renal tubuses may initiate and C f l o w 二 explain the increase in glomerular exacerbate diabeUc nephropathy [29]. ？e ^ M c ^ n rate and filtration fraction after ANP between these early structural changes and the ffltration rate ana development of proteinuria and hypertension is 
“ 1 ^ 1 ? ? L ' 2- ^ hi 0h urinarv free DA con- likely to be multifactorial and complex, but may A ^二二 d 5 the renal involve an interplay between defective renal mobili-n a t i o n which cannot 二 = 二 inresponse to sodium loading which 
leads to expansion of the extra^Uular fluid volume, 二 二 二 S K : suggeJAhat L-dopa increased arterial BP and ANP levels, wbch, 
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a n d p l a s m a A N P c o n c e n t r a t i o n i n p a t i e n t s w i t h 1- Weidmann. P. & Ferrari, P. Central role for sodium in hypertension in 
abnormal albuminuria (Fig.4) suggests the possibi- , G ^ a c C . ,88； , , 747-53. 
l i t y t h a t d e f e c t i v e D A m o b i l i z a t i o n i n p a t i e n t s w i t h 3 Sagnella. G.A., Markandu, N.D., Shore. A.C. & MacGregor, G人 Raised 
a b n o r m a l a l b u m i n u r i a m i g h t l e a d t o a c o m - circulating levels of atrial natriuretic peptides in essential hypertension, 
nensatorv rise in plasma ANP concentration in Lancet 1986； i, 179-81. pensatory nbe m yia^  4. Lieberman, J.S., Parn, L.f Newton. L, Scandling. ).D., Loon, N. & Myers, 
o r d e r t o p r o m o t e n a m u r e s i b . B D A t r j a j natriuretic peptide and response to changing plasma volume in 
B a s e d o n t h e s e c l i n i c a l o b s e r v a t i o n s , w e h y p o - diabetic nephropathy. Diabetes 1991;893-901. 
t h e s i z e t h a t , i n p a t i e n t s w i t h N I D D M , e a r l y r e n a l s. shinoda, T., Ishihara, M., Kurimoto, F. et al. Elevated plasma atrial natiuretic 
t u b u l a r d a m a g e m a y r e s u l t i n i m p a i r e d s o d i u m peptide level in the early phase of microalbuminuria in patients with • f U ^ ^ r t V . D A mnhili7a- noiHnsulin-dependent diabetes mellitus. Clin. Nephrol. 1990; 34, 202-7. excretion, in part through (^fcc^ve f � 6 K a h n > JK., G r p e k i n. RJ., S h e n k e r . Y. 4 V i n i k, A.i. Plasma levels of 
tion, a n d h e n c e c o n t r i b u t e t o t n e a e v e i o p m e n i OI immunoreactive atrial natriuretic hormone in patients with diabetes mellitus. 
hypertension. A compensatory rise m plasma ANP Regui. Pept. 1986； is, 323-31 
c o n c e n t r a t i o n i n r e s p o n s e t o p l a s m a v o l u m e e x p a n - 7. Trevisan, R., Fioretto, P., Semplicini, A. et al. Role of insulin and atrial 
s i o n a n d t o h y p e r t e n s i o n m a y l i m i t t h e r e n a l natriuretic peptide in sodium p a t i e n t s 
a i u " a L l . J. J frt during isotonic volume expansion. Diabetes 1990; 3?, 
s o d i u m r e t e n t i o n , b u t c o u l d a l s o c o n t r i b u t e t o t h e g B e | | | S G M , B e r n s t e i n > R.K|； La n g h , J.H. et al. Increased plasma atrial 
d e v e l o p m e n t o f a l b u m i n u r i a a n d p o s s i b l y r e n a l natriuretic factor and reduced plasma renin in patients with poorly controlled 
d a m a e e T h i s m a y l e a d t o a f u r t h e r r e d u c t i o n i n t h e diabetes mellitus. Clin. Sci. 1989； 77,177-82. nrinarv'DA response to salt intake and initiate a 9. Suenaga, K. Mizuno, K., Nimura, S. et al Atrial natriuretic ^or (ANF) 
u r i n a r y U / \ r e s p o n s e I r p t p n t : n n h v n e r . increases urinary protein excretion in patients w.th essential hypertension: a v i c i o u s c y c l e i n v o l v i n g s o d i u m r e t e n t i o n , n y p e r possible role of ANF for renal handling of protein. Biochem. Biophys. Res. tension and albuminuria. The individual elements [ 酬 m | M , 9 3 M 1 
c o n t r i b u t i n g t o t h i s h y p o t h e s i s h a v e s u p p o r t from IO. Ishi. M., Hirata, Y., Sugimoto, T. et al. Effect of alph^uman atrial natriuretic 
二 h e r c l i n i c a l a n d e x p e r i m e n t a l s t u d i e s . H o w e v e r , peptide on proteinuria in patients with primary glomerular disease. Clm. Sc. further dynamic tests examining the responses of M F u k u i, K. e t al.瞧re咖 effects of atrial natriuretic plasma ANP and urinary DA to salt loaaing ana p e p t j d e m i dopamine on urinary protein excretion in chronic r h e : r relationship with BP and proteinuria m glomerulonephritis. Clin. Sci. 1991,80,131-6. 
J - a r e r e a u i r e d i n o r d e r t o c l a r i f y a n d 12. Zietse. R. & Schalekamp, M.A. Effect of synthetic human atrial natriuretic 
r c l ^ X T ^ a t i 狐 一 e (.02-,06) in nephrotic -nc.賺 H 
Atrial natriuretic peptide and urinary dopamine in diabetes 253 
9 
l 3 . STa i^BiWS^；；. j L t 丨 丨 t ^ d 0 P O T l n e 2 L M a C D 0 M W , � C . P . ^ p . Sw^han, R. Fructasa,nine 14 Bertorello A A A M « a a w l . ^ , ! U l ? " i a “ 7 9 ' 5 6 ! 26丨“4. measurements in serum and plasma. Clin. Chem. Acta 1987; 168, 247-51 L T ^ I H a ^ r i d M = t l l Z ^ d 0 r m e ' d l h y d r 0 ^ e n ^ t i c 2 1 认，Ronn, B.. Jensen. T., Storm, B. 4 Deckert T. Relationship Z f ^ ^ ^ J T l Z m ^ P r 0 X i m d t U b U , e _ 棚 b l 0 0 d P 剛 ^ ^nary albumin excretion in development </ .r S ® ； w . ^ - o c r 丨 ; j 3 0 ' 5 7 1 ^ microalbuminuria. Diabetes 1990： 39, 245-9. 
^ t n ^ J f ^ L ' ^ , ？！Tkes' B F- 4 T L e e , M.R. R e , K i o n s h i P D e F r o n M , R S . & E. Insulin resistance: a multifketed syndrome ^ w ^ Z ^ T , 丨 广 M d ！ 1 ° r n e i n T y p e 1 d j a b e t i c responsible for NIDDM, obesity, hypertension, dyslipidaemia and ^ ^ T ^ T r ^ T r m 7 , atherosclerotic cardiovascular dlse»T Diabetes £ e l 9 9 l ; M, 173-95. m r t H T ” u T _ y ^ T & Jakebe, K. Urinary dopamine. 24. Martin^rez, M., Fleming, j.T. i Sttinh删n, M. Atrial nttriJretic peptide 
M ^ k V " _ ^ 磁舰 a u s « P^lomerular vasodilatation and post-glomerular vasoconstriaion in 
17 Y ^ T / " ? ^ ： ？WL2> rat 昍 哪 N 咖 e (^ ndon) 1986; 324, 47W 17. Tandle, T.G., Esp丨ner, E人，Nicholis. M.G. & Duff, H. Radioimmunoassay and 25. Ballermann, B.j. & Brenner, B.M. Atrial natriuretic peptide and the kidney diaractenntion of atrial natriuretic peptide in human plasma. J. Clin. Am. J. Kidney Res. 1987; I (Suppl. I), 7-11 , a ^ 7 n p e ? p , 9 8 6 ; ？ 1 ' , 饭 & M R . Dopamine and the k l e y . Clin. Sci. 1982; 62, 43M8. •8. Davidson, D.F. & Fitzpatnck. J. A simple, optimised and rapid assay for 27. de Wardener, H i . Kidney, salt intake, and N a + , K+-ATPa$e inhibitors in " " n a f y f r e « catecholamines by HPLC with electrochemical detection. Ann. hypertension. Hypertension 1991; 17, 830-6 •9 w l i f j r i i ^ J 9 8 5 ； 2 ?； ^ 3 0 , 3 ' u . M B PI C l a r k s o n . E . M . 4 和 Wardener, H i . Observations on a low molecular weight w e i c * e ^ H.,样““山，M - Ha«e,«» H . 4 Pl咖，R- Electrochemical detection of natriuretic and Na-K-ATPase inhibitory material in urine. Clin. Exp atecholammes in urine and plasma after separation with HPLC Clin. Chem. Hypertens. 1985; 7, 67W3. Acta 1984; 141, 17-25. 29. Pinter. G.G. & Atkin，, j .L What causes diabetic renal failure? Lancet 1990; i, tlwung, C.K. & Swaminathan, R. Automated immunoturbidimetric method 590-1. for the determination of retinol binding protein, prealbumin and transferrin 30. Casson, I.F., Lee, M.R., Brownjohn, A.M. et al. Failure of renal dopamine in urine. Clin. Biochem. 1989; 22, 425-7. response to salt loading in chronic renal failure. Br. Med. J. 1983; 286, 503-6. 
/ 
• • • 
f * 
R e n n T l ? f Vol. 2, No. 3, pp. 189-194 © 1992 Harwood Academic Publishers GmbH 
& 二 二 = ” m t h C P U b , i S h 6 r in the United K i n g d o , . 
EFFECTS OF ORAL SODIUM LOADING ON THE 
URINARY EXCRETION OF CATECHOLAMINES IN 
NORMOTENSIVE CHINESE 
, THOMAS Y. K. CHAN 1, JULIAN A. J. H. CRITCHLEY1, C. S. HO 2, 
”� WISTER K. K. WONG 1, BRIAN TOMLINSON1 and R. SWAMINATHAN2 
j Departments of1 Clinical Pharmacology and 2Chemical Pathology，The Chinese 
V University of Hong Kong, Prince of Wales Hospital, Shatin, NT，Hong Kong. 
The renal excretion of noradrenaline (NA) and dopamine (DA) and the interrelationships between 
urinary sodium and D A in response to oral sodium loading (unrestricted sodium intake + 200 mmol/day) 
for 3 days were studied in 5 healthy Chinese subjects without a family history of hypertension. There was 
a five- to eightfold increase in urinary sodium outputs during the high sodium intake period 0.001). 
There was no significant increase in urinary D A outputs in response to the salt load and thus no 
correlation between urinary sodium and D A excretion. This is in direct contrast to previous findings in 
Caucasian normotensive subjects. A bigger study is needed to confirm or refute if a reduction in 
sympathetic activity is the predominant mechanism for dealing with increased salt intake in Chinese. 
KEY WORDS: Dopamine, noradrenaline, sodium loading, urine. 
INTRODUCTION 
. Natriuresis following sodium loading is partly mediated by increased production of dopamine (DA) in the kidney which is reflected by an increase in urinary DA excretion. This has been demonstrated in man (Oates et al., 1979) and animals (Ball et a/.,rr1978). Lee (1981) suggested that an impaired DA response to salt loading may lead to hypervolaemia and hypertension in some individuals. Urine DA failed to increase with salt loading in hypertensive patients (Harvey et al., 1984) and this '-appeared to occur in salt-seiisitive rather than salt-resistant hypertensives (Gill '1988).rSubsequent cross-sectional studies in different ethnic groups have demonstrated that Caucasians and Thais show a strong positive correlation between 24-hour urinary sodium and DA outputs whereas other groups such as Iranians and black West Africans do not (Critchley et al.，1989). This could A indicate that the ethnic groups lacking the sodium-DA relationship may not show a '5 renal DA response - to salt loading and thus be more prone to salt-sensitive J hypertension or else have another predominant mechanism for dealing with ^ increased salt intake. Cross-sectional studies in normotensive Chinese subjects have also shown a positive correlation between urinary sodium and DA (Chan et 
ai，1991) so it was anticipated that normal Chinese subjects would respond to oral sodium with inicrease in urinary DA similar to Caucasians. � � - ；-
：‘•• rr j h-J-VOft? + C ;:•,】”？ -..’;5 i'A ’•.•':.��:• .••.。:、.，•:” 二 :::.:::?二.二.,-.: 
Address correspondence to: Dr Julian A. J . H . Critchley, Department of Clinical Pharmacology, 
Prince of Wales Hospital, Shatin, NT, Hong Kong. [Tel. (852) 6363130] [Fax. (852) 6373929] 
Present address: Professor R. Swaminathan, Department of Clinical Biochemistry, Guy's Hospital 
Medical School, London, UK. 
. “ 189 
190 THOMAS Y.K. CHAN, JULIAN A.J.H. CRITCHLEY ETAL. 
Another mechanism which appears to contribute to the natriuresis following sodium loading is a reduction in sympathetic activity which can be demonstrated by reduction in urinary noradrenaline (NA) excretion (Alexander et al., 1974; Weinberger et al.，1982; Castellano et al.，1986; Gill et al.，1988). The present study 
w f s a preliminary investigation into the role of these two mechanisms in dealing with oral salt loading in healthy Chinese subjects. 
MATERIALS AND METHODS . 
‘ . » 
Five normotensive, healthy, ambulatory Chinese subjects without a family history of hypertension (4 men and 1 woman, aged 23 to 35 years) were studied. All the ‘ 
participants gave informed consent. 
During the 9-day study period, alcohol and medications were avoided. All 5 subjects were on a low salt diet (70 mmol sodium) provided by the hospital kitchen from days 1 to 3, and on their normal diet with unrestricted sodium intake from days 4 to 9. In addition, they took 20 ‘Slow Sodium' tablets (10 tablets at 9 a.m. and 1 p.m.) on days 4-6 (high salt intake). 
Subjects were weighed and their blood pressure measured after sitting for 5 minutes using a Hawksley random-zero sphygmomanometer at 8 a.m. before breakfast on days 4 and 7. Mean arterial pressure (MAP) was calculated by adding one-third of the pulse pressure to the diastolic pressure (phase V). 
From days 1 to 9，all subjects collected their urine for 24 hours into plastic bottles containing 25ml 5M HC1. Aliquots were refrigerated at —20°C until assayed for DA, NA, creatinine, sodium and potassium. 
Urinary free DA and NA were determined by HPLC with electrochemical detec-- tion (Davidson and Fitzpatrick, 1985) after extraction onto alumina. The intra-
assay and inter-assay variabilities of this assay were 3 and 9% for DA and 1.5 and 10% for NA, respectively. Urinary sodium and potassium were measured by ion-selective electrodes and creatinine by the Jaffe reaction on a Beckman Astra-8 Analyzer (Beckman Instruments, USA). 
All the data were expressed as means 土 SEM. The urine collection on the last day of the low sodium diet (day 3) was chosen as the baseline. Changes in urinary volume, sodium, potassium, DA, and NA were analyzed with respect to time (from days 3 to 6) using multivariate analysis for repeated measures (MANOVA). Signifi-cance of differences for all variables when compared with the baseline were asses-sed by Wilcoxon signed-rank test. Correlation coefficients between urinary excretion of DA and that of sodium were determined by simple regression analysis. ( p values of less than 0.05 were considered statistically significant. 
V RESULTS 
The 5 subjects showed changes in their MAP from -17.2 to 1.6% but the overall average was not significantly different from baseline (Table 1); they were therefore regarded as salt-resistant (Gill et al.，1988). All the subjects showed increases of 0.3 to 2.8% (mean 1.0%，p<0.05) in body weight after high sodium intake for 3 days. 
The mean daily excretion of sodium, potassium, creatinine, DA and NA and the 
urine volume during the 9-day study period are shown in Table 2 and Figure 1. 
� • 
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TABLE 1 
Effect of sodium intake on blood pressure (systolic, diastolic and mean arterial) and body weight in 5 
healthy Chinese subjects 
Low sodium intake High salt intake 
(70 mmol/day (free diet + 200 mmol/day) 
Blood pressure (mmHg) 
Systolic 98±2 100 土 3 
Diastolic 67±4 59±3a 
Mean arterial 78±2 73±3 
Body weight (kg) 56.1±2.7 56.7±2.7a 
a p<0 .05 by Wilcoxon signed-rank test when compared with low sodium intake. 
r 
TABLE 2 
The 24-hour urine volume and urinary excretion of sodium, potassium, creatinine, dopamine and 
noradrenaline following oral salt loading (days 4-6) 
Days Volume Sodium Potassium Creatinine Dopamine Noradrenaline 
(1) (mmol) (mmol) (mmol) (nmol) (nmol) 
1 2 .1±0.3 109±12 46.6±3.4 12.1±1.4 1077±57 128±11 
2 1.6±0.3 66±8 42.8±4.0 13.4±1.9 1318±207 170±27 
3 1.2±0.2 40±3 38.9±2.8 12.2±1.3 1284±243 158±34 
4 1.5±0.2 216±37b 67.8±3.4b 13.6±1.7b 1408±57 179±11 
5 2.3±0.3b 382±43b 60.7±6.6b 13.3±2.1 1379±180 164±32 
6 2.2±0.5b 389±39b 40.0±3.7 11.8±1.5 1298±265 121 ±33 
7 , 2.8±0.5b 317±53b 39.5±2.8 12.4±1.2 1481 ±265 174±14 
8 ' 1.8±0.3 237±45b 49.9士9.8 14.9±3.1 1670±168 197±20 
9 1.9±0.2b 183±36b 40.0±1.4 12.6±1.5 1528±182 205±26 
- a Values are means±SEM. 
b p < 0 . 0 5 by Wilcoxon signed-rank test when compared with day 3 on low sa l t . . 
There was a five- to eightfold increase in urinary sodium output during the high 
sodium intake period (p< 0.001; MANOVA) and peak sodium excretion was seen 
on day 6. Mean.sodium excretion gradually fell to around 180 mmol/day by days 8-
9 after stopping sodium supplementation. Potassium excretion and urine volume 
also increased (p<0.05; MANOVA) with the sodium loading on days 5-7 and 4-5, 
respectively (see Table 2). 
There were no significant changes in urinary DA (p<0.5; MANOVA) or NA 
" (p<0.5; MANOVA) outputs during high sodium intake. At the time of peak 
sodium excretion (on day 6)，the changes in NA excretion varied from —77.2 to 
16.5% (mean —30%) when compared with baseline and the changes in DA excre-
“ tion were from -20.4 to 23.6% (mean 0.6%). However, both changes did not reach 
statistical significance. As a whole, urinary excretion of DA showed a similar 
pattern to that of NA throughout the study (Figure 1). 
There was no significant relationship between urinary sodium and DA (n=45, 
r=0.21, p � 0 . 1 ) . However, a positive correlation between urinary NA and DA 
outputs was seen (n — 45, r=0.83，p<0.001). 
r 
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FIGURE 1 Group means ± SEM of urinary sodium, dopamine and noradrenaline outputs in response 
to oral sodium loading in 5 healthy Chinese subjects. *p<0.05 when compared with baseline (day 3). 
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DISCUSSION 
Dietary sodium loading and the acute infusion of isotonic saline have been widely used to determine the factors controlling natriuresis in health and disease. An increase in renal DA output (Alexander et al.y 1974; Weinberger et a!” 1982; Castellano et al., 1986) and a reduction in the activity of the sympathetic nervous system (Alexander et al., 1974; Weinberger et al. ’ 1982; Castellano et al., 1986; Gill 
et al., 1988) and of the renin—angiotensin—aldosterone axis (Coghlan et al., 1980) 
: would all be expected to facilitate sodium excretion. In addition, there are sugges-
tions that atrial natriuretic peptide (Laragh, 1985; Sagnella et ai, 1985) and renal prostaglandins (Lifschitz et al, 1978; Epstein et al., 1979) play important roles in the physiological regulation of sodium excretion. In the present study, we investi-gated the role of two of these factors in modulating natriuresis in healthy Chinese subjects during periods of different sodium intake. 
Our data demonstrate that a high sodium intake (unrestricted sodium diet + 200 mmol/day) for 3 days was not associated with an increase in MAP in these normal Chinese subjects. Unlike the studies on healthy Caucasian subjects in whom 50-100% increases in urine DA was seen (Alexander et al., 1974; Lee, 1986; Gill et al” 1988; Goldstein et ai, 1989)，we did not find a significant increase in urine DA following salt loading. Although the present study might be too small to show a DA response of smaller magnitude, the lack of a DA response in this small group of Chinese subjects is also supported by the absence of a significant correla-tion between urinary sodium and DA outputs. This is in contrast to our findings from a cross-sectional population study of healthy Chinese subjects without a family history of hypertension in whom a significant urinary sodium/DA correlation was seen (Chan et al” 1991). 
- It is also worth noting that at the time of peak sodium excretion (day 6), a 30% 
reduction in urinary NA output was seen, although such a change did not reach statistical significance. As a reduction in sympathetic activity is known to facilitate sodium excretion (Alexander et al., 1974; Weinberger et al., 1982; Castellano et al.， 1986; Gill et a!.，1988), this might well be the predominant mechanism for dealing with increased salt intake in the Chinese. However, a bigger study is required to confirm this hypothesis. 
We have previously reported highly significant positive correlations between urinary NA and DA outputs in a cross-sectional study of normotensive and hypertensive subjects (Chan et aL，1991) and this was confirmed in the present study. The significance of this positive relationship between urinary free NA and � DA is not clear. 
In conclusion, high sodium intake for 3 days was not associated with an increase 
in MAP or urinary DA output in normotensive Chinese subjects. A bigger study is 
1 needed to confirm if a reduction in sympathetic activity is associated with increased 
salt intake in Chinese subjects. 
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Dietary electrolytes and urinary natriuretic factors 
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We examined the relationship between the excretion of electrolytes (sodium, potassium and calcium), 
dopamine and digoxin-like immunoreactive substance in 41 young healthy female subjects (age 18—23 
years) in order to study the interaction of electrolyte intake on dopamine and digoxin-like immunoreactive 
substance~factors which have been postulated to have a pathogenic role in hypertension. Sodium excre-
tion was significantly correlated with dopamine excretion (r = 0.545, P < 0.0005) and digoxin-like immu-
noreactive substance (r = 0.359, P < 0.02). There was also a significant correlation between calcium and 
digoxin-like immunoreactive substance (r = 0.345, P < 0.03). Stepwise multiple regression analysis further 
confirmed that sodium is the only contributor to dopamine excretion and calcium is the only contributor 
to digoxin-like immunoreactive substance (r 2 = 0.114). We conclude that in young healthy subjects 
dopamine excretion is determined partly by sodium intake and that the excretion of digoxin-like immuno-
reactive substance is independent of sodium intake. 
" K e y words: Natriuresis; Calcium intake; Sodium intake; Digoxin-like immunoreactive substance 
Introduction calcium homeostasis have been described in 
hypertensives [1� .The mechanism of action of 
Dietary intake of sodium, potassium and cal- these nutrients on raising blood pressure is not 
cium has been suggested to be involved in the clear. It has been proposed that in ’susceptible，in-
pathogenesis of hypertension [1�.Epidemiological dividuals the ability of the kidney to excrete salt is 
studies show that blood pressure is directly related impaired. As a result sodium retention occurs and 
to sodium intake and inversely related to potas- the ensuing volume expansion stimulates the re-
sium intake [2-7]. Potassium depletion increases lease of a natriuretic substance which causes in-
blood pressure in hypertensive [8�as well as nor- hibition of sodium pump [11]. In vascular smooth 
motensive subjects [9]. A low potassium intake has muscle, inhibition of sodium pump leads to hyper-
been suggested to be an important risk factor for tension via a change in intracellular calcium 
the development of hypertension [10]. Hyperten- [12,13]. Dietary potassium and calcium may act 
sive subjects have been reported to ingest less cal- through the same mechanism [8�.Calcium sup-
cium than normal subjects and abnormalities in plementation has been shown to cause a reduction 
in plasma concentration of sodium transport inhi-
, „ c * 州會 bitor [14�.It has been shown that dopamine is a 
L o n d o T s E l ^ T UK dopamine may be the renal ‘abnormality, seen in 
2 
salt sensitive hypertensives [15-18]. The Na + , K + coefficient of multiple correlation to the 今TPase inhibitor (sometimes called digoxin-like greatest extent. The process continues until 
immunoreactive substance) has been measured either the increase in the coefficient is non-
using its cross reactivity to digoxin antibodies. We significant or all the variables are included, 
postulated that if dopamine and digoxin-like im-
munoreactive substance were directly or indirectly Results 
regulated by dietary intake of sodium, potassium 
and calcium then there should be a relationship be- Table 1 gives the mean, S.D. and range for the 
tween the excretion of these electrolytes and the variables measured in the study. The age range of 
excretion of dopamine and digoxin-like im- the group was 18-23 years. The mean dopamine 
munoreactive substance. In this study we have excretion was 1463' /imol/day and the excretion of 
examined the relationship between these variables digoxin-like immunoreactive substance varied 
in a group of young healthy female subjects. from 0.42-1.98 nmol/day. Table 2 shows the cor-
relation between the variables. Sodium excretion 
Materials and Methods was significantly related to the excretion of 
potassium, calcium, free dopamine and digoxin-
Forty one young healthy female Chinese sub- like immunoreactive substance. Potassium excre-
jects who were taking part in a larger study of tion was not related to calcium, dopamine or 
determinants of bone mass were asked to collect digoxin-like immunoreactive substance. Digoxin-
24-h urine samples while they were on their usual like immunoreactive substance was also 
intake of nutrients. Urine samples were collected significantly correlated with calcium excretion, 
into bottles containing hydrochloric acid and the Stepwise multiple regression analysis with 
volume of the urine samples was measured and ali- dopamine as the dependent variable and sodium, 
quots were stored at :20 o C for assay of dopamine, potassium, calcium and digoxin-like immunoreac-
digoxin-like immunoreactive substance, sodium, tive substance as independent variables showed 
potassium and calcium. Sodium, potassium and that sodium contributed significantly to dopamine 
calcium concentrations in urine were measured by excretion. Of the variation in dopamine excretion 
standard methods in an automated analyser. 29.7% was accounted for by variation in sodium 
Urinary free dopamine was extracted onto intake. When a similar analysis was done with 
alumina using the method of Davidson et al. [19] digoxin-like immunoreactive substance as the 
and quantitated by high performance liquid dependent variable, only calcium excretion was 
chromatography using electrochemical detection significantly related (r = 0.338，P < 0.05) and 
as described previously [20]. The intra-assay and 11.4% of the variation in digoxin-like im-
inter-assay coefficient of variation were 1.3% and munoreactive substance was accounted for by 
8.7%, respectively. The mean recovery of urinary calcium excretion, 
free dopamine was 91.1% and the detection limit 
was 3 nmol/1. Urinary digoxin-like immunoreac- n i c , 
J « • TABLE 1 
tive substance was measured by immunoassay 
using a commercial kit ( C E D I A Digoxin, Age a nd urinary excretion of sodium, potassium, calcium, 
Microgenic, Concord, C A , U S A ) adapted to a dopamine and DLS in 41 healthy young females. 
centrifugal analyser (Cobas Fara, Hoffmann La ~ ~ M e a n S D ~ ^ 
Roche, Basle, Switzerland). The limit of detection 
was 0 08 nmol/1 and the inter-assay coefficient of Age (years) 19.1 l.i 18-23 
variation was better than 7.5%. Stepwise multiple Sodium excretion (mmol/day) 132 52.8 54-302 
rearession analvsis was used to examine the rela- Potassmm excretion (mmol/day) 39 12.2 18.4-75^ 2 regression anaiysib waa Calcium excretion (mmol/day) 2.83 1.21 0.8-6.2 
tionship between these variables and others. This D o p a m i n e excre t ion (Mmoi/day) 1463 304 920-2134 
method searches through all the variables and DLS (nmol/day) 1.14 0.408 0.42-1.98 




Correlation between variables. 
Sodium Potassium Calcium Dopamine 
Potassium 0.514 ( < 0.001) _ 
C a I c i u m 0.348 (<0.03) N.S. — 
Dopamine 0.545 ( < 0.0005) N.S. N.S. — 
D L S 0.359 ( < 0.02) N.S. 0.345 ( < 0.03) N.S. 
Figures in parentheses give the P-value. 
Discussion the excretion of digoxin-like immunoreactive sub-
stance was directly related to the excretion of sodi-
The 24-h urinary excretion of potassium in this um (r = 0.359, P < 0.02) and to calcium 
group of Hong Kong Chinese is lower than that in (r = 0.345, P < 0.03). However, stepwise multiple 
many parts of the world, but is similar to that regression analysis showed that only calcium ex-
reported from China [21] and Hong Kong [22]. cretion was positively correlated with excretion of 
The mean excretion of calcium in this group was digoxin-like immunoreactive substance. This lack 
2.83 mmol/day and it is also lower than that of significant association between sodium excre-
reported from Western Countries [21]. The 24-h tion and digoxin-like immunoreactive substance 
excretion of calcium in the steady state reflects in- agrees with the hypothesis of De Wardener and 
testinal absorption of calcium [23] and the amount MacGregor [11]. If in normal subjects there is no 
of calcium absorbed is directly related to the in- abnormality in mobilization of dopamine, sodium 
take of calcium [24]. The low calcium excretion intake is unlikely to stimulate the production of 
among the Chinese reflects the low dietary intake Na + , K+-ATPase inhibitor. On the other hand, 
- of calcium [25,26]. calcium intake in some manner may stimulate the 
Dopamine has been shown to be a natriuretic release of this inhibitor. In the rat, increased cal-
hormone [16] and the excretion of dopamine and cium intake reduced the plasma concentration of 
sodium are correlated in normotensive Caucasians digoxin-like immumoreactive substance [14]. 
[18] and Japanese [15]. We have previously found However, the relationship between digoxin-like 
a significant relationship between sodium excre- immunoreactive substance and calcium excretion 
tion and dopamine excretion in healthy Chinese in this study was a positive one. If low calcium in-
men and women (Chan, Ho, Critchley and take is a factor in the pathogenesis of hypertension 
Swaminathan, unpublished observations). Our fin- [1] then one would expect a negative relationship, 
dings confirm this and furthermore we show that Further detailed studies are required to unders-
the major determinant of dopamine among the tand this complex interrelationship, 
electrolytes is sodium (Table 2). Further studies We conclude that in young healthy subjects 
are necessary to elucidate the relationship between dopamine excretion is determined at least partly 
dopamine and sodium excretion. by sodium intake and the excretion of digoxin-like 
Increased dietary salt stimulates the release of a substance is independent of sodium intake. 
Na + , K+-ATPase inhibitor [13,14]. This inhibitor 
can be detected by inhibition of sodium pump ac- Acknowledgements 
tivity of intact cells, inhibition of enzyme activity ‘ 
or by immunoassay using antibodies raised against 
digoxin [14 27]. We would like to acknowledge financial support 
Using an'immunoassay we detected digoxin-like from the Croucher Foundation (HK) and the help 
immunoreactive substance in all urine samples and of Miss Caroline Trim for typing the manuscript. 
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THE EFFECT OF SALT LOADING ON THE URINARY EXCRETION 
OF DOPAMINE AND SODIUM TRANSPORT INHIBITOR IN THE RAT 
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ABSTRACT 
1. The temporal relationship between the excretion 
of dopamine and sodium transport inhibitor (STI) 
during salt loading was examined in the rat. 
2. ‘ Urine samples were collected before and during 
salt loading (given as 18 g/1 NaCl solution to 
replace drinking water) for the measurement of 
* sodium, creatinine, dopamine and STI in 6 female 
rats. Dopamine was measured by HPLC and STI was 
extracted and measured by its ability to inhibit 
purified Na+, K+-ATPase enzyme. 
3 . Urinary sodium and STI (expressed in relation to 
creatinine) on day 1 of salt loading were 4.6 and 
4.2 times respectively of the control values. 
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Urinary excretion of dopamine did not increase 
significantly until day 2 when it was 21% higher. 
4. The excretion of STI paralleled that of sodium 
excretion whereas the excretion of dopamine 
lagged behind. 
5. We conclude that salt loading increases STI and 
dopamine and that the increase in STI precedes 
that of dopamine. ' , 
INTRODUCTION 
The mechanism by which high salt intake or 
expansion of'ECF by saline infusion causes natriuresis 
has been extensively studied and several ,natriuretic 
factors have been identified. These include atrial 
natriuretic peptide, renal prostaglandins, 
kallikreins, renal dopamine and sodium transport 
inhibitor (STI, Ouabain-like factor). 
As it has been shown that urinary excretion of 
d o p a m i n e increases during salt loading [1-3] and 
dopamine infusion causes natriuresis [4] ‘ it has been 
suggested that renal dopamine participates in the 
'regulation of sodium balance [5] . It has also been 
demonstrated that the natriuresis induced by volume 
expansion is mediated at least in part by a 
circulating sodium transport inhibitor (STI) [6-12]• 
F u r t h e r m o r e dopamine and STI are implicated in the 
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pathogenesis of salt-sensitive hypertensive. It has 
been suggested that in hypertensives renal dopamine 
production is impaired [13] and STI increases to 
maintain salt balance. Increased STI levels may lead 
to contraction of.the vascular smooth muscle [14]. 
Although dopamine [2] and STI [11,15] have been shown 
to increase during salt-loading, the role of these 
substances in the natriuresis of salt loading is not 
clear. The purpose of this study was to examine the 
s 
temporal relationships between the changes . in the 
excretion of sodium, dopamine and STI during salt 
loading in the rat. 
\ 
- MATERIALS AND METHODS 
Six female Sprague-Dawley rats weighing 250 g 
were studied. They were fed ad libitum throughout the 
.study with normal rat chow containing 0.2% sodium 
chloride. The animals were placed in individual 
metabolic cages and given tap water to drink for 4 
days. 24 hr urine sample were collected for two days 
(days -2 and -1) • On day 1 the tap water was changed 
to 18 g/1 NaCl solution and urine collection was 
continued for another 7 days. Urine samples were 
collected in 6. 0M HC1 and after recording the volume, 
they were stored at -70°C. 
f 
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Urinary sodium and creatinine concent rat ions were 
measured by indirect ion-selective electrode and Jaffe 
reaction, respectively on a Beckman Astra-8 Clinical 
chemistry analyzer (Beckman Instrument, CA, USA) • . The 
interassay coefficients of variation for both assays 
were less than 3%. 
Urinary free dopamine was determined as described 
previously [16] . Briefly, dopamine was extracted onto 
alumina, eluted with 0.1 M HC1, washed with 
ethylacetate as described by Davidson and Fitzpatrick 
[17] and quantitated by high performance liquid 
chromatography with electrochemical detector based, on 
_ a method described by Weicker et al [18] . Intra-assay 
and inter-assay coefficient of variation were 1.3% and 
8.7% respectively. The mean recovery was 91% and the 
detection limit was 3 nM.: 
Urinary STI was extracted using Waters Sep-Pak 
C18 cartridges (Millipore, Milford, MA, USA) and 
！ 
q u a n t i t a t e d by its ability to inhibit purified dog 
kidney Na+, K* ATPase activity (Sigma, St Louis, MO, 
USA) • Briefly, Sep-Pak cartridges were first 
activated by washing with methanol and water. 300 ul 
of sample was applied and was allowed to equilibrate 
f 
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with the C18 resin in the cartridge for 2 min before 
washing twice with 10 ml of water to remove salts and 
other interfering substances. The equilibration step 
was found necessary to improve the precision of the 
extraction step. STI was eluted twice with 1 ml of 
methanol. The methanol eluate was evaporated to 
dryness and the residue was reconstituted in 100 ul 
Tris buffer, pH 7.4. These reconstituted eluates 
contained no measurable dopamine. The reconstituted 
extract was then incubated with a 250 U/l of purified 
dog kidney Na+, K+-ATPase solution in the presence of 
100 nM of sodium and 5 nM of ATP at 37°C for 2 hours. 
The reaction was terminated by immersing the reaction 
- mixture in ice. The residual ATPase activity was 
determined by an enzyme coupled reaction as described 
previously [19] • Ouabain in Tris buffer, ranging from 
5 nM to 50 nM, were used as standards and the results 
are expressed as nM ouabain equivalent. Interassay 
coefficient of variation ranged from 18% to 3% over 
the standard concentrations. 
I •‘ 
Excretion of sodium, dopamine and STI were 
related to creatinine in order to compensate for any 
loss of urine during collection and for any 
differences in lean body mass during the study. 
r 
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Table 1 Effect of salt loading on the excretion of 
sodium, dopamine and sodium transport inhibitor (STI) 
in rats. ‘ 
D a y U r i n e S o d i u m / C r D o p a m i n e / C r S T I / C r 
v o l u m e ( m m o l / m m o l ) ( n m o l / m m o l ) ( n m o l 
( m m o l / d ) o u a b a i n / m m o l ) 
-2 1 0 . 0 土 1 . 3 37 土 3 . 3 240 土 2 2 . 0 0 . 4 6 + 0 . 1 5 
-1 9 . 8 土 3 . 0 39 土 5 . 5 211 土 21.31- 0 . 4 0 + 0 . 1 5 
1 2 7 . 5 土 8 . 3 * 174 土 4 8 . 0 * * 246 土 3 4 . 6 1 . 8 0 土 0 . 3 0 * * 
2 2 9 . 2 土 1 1 . 2 * 210 + 4 6 . 4 * * 273 + 3 1 . 9 * 2 . 6 7 + 0 . 4 5 2 * * 
3 2 4 . 7 ± 1 0 . 6 * 203 土 3 3 . 5 * * 329 + 4 5 . 7 * * 2 . 6 1 ± 0 . 4 3 6 * * 
4 _ _ 2 3 . 3 土 7 . 0 * 192 土 2 9 . 0 * * 336 土 5 6 . 1 * * 2 . 8 3 土 1 . 1 0 * * 
5 1 7 . 1 土 5 . 9 * 190 土 1 3 . 8 * * 308 土 5 3 . 2 * * 3 . 7 4 土 1 . 0 7 * * 
6 2 7 . 6 土 8 . 3 * 186 土 1 7 . 6 * * 305 土 3 9 . 0 * * 2 . 9 2 土 0 : 3 5 7 * * 
7 1 9 . 2 土 5 . 8 * 206 + 1 8 . 2 * * 371 土 4 6 . 7 * * 2 . 7 6 土 0 . 6 4 2 * * 
Results are mean 土 SD, n=6 
*, ** Significantly different from days -1 and -2 
For statistical analysis the mean values of day -1 arid 
-2 were used to represent the excretion before salt-
loading . The data were subjected 'to analysis of 
variance and where the null hypothesis was rejected. 
Scheffe's comparisons were performed on the means； 
P<0.05 was considered significant. 
RESULTS 
Table 1 summaries the results• Urine sodium 
excretion on day 1 was significantly higher than pre-
salt loading and the sodium excretion reached a peak 
r 
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on day 2 and thereafter remained relatively stable. 
Urine dopamine excretion on day 1 was 9% higher than 
basal value but the difference was not significant. 
On day 2 the urinary excretion of dopamine was 21% 
higher than the mean before the salt loading (p<0.01) • 
i # 
Urine dopamine excretion reached a peak on day 4 and 
remained high there after. On the other hand, urine 
excretion of STI on day 1 was 4.2 fold higher than 
basal values. 
As can be seen from Table 1 the excretion of 
STI paralleled the. rise in sodium whereas dopamine 
excretion lagged behind. 
DISCUSSION 
High salt intake has been shown to cause an 
increase in excretion of dopamine [2,3] and STI [15]. 
The evidence for the release of STI during salt 
loading comes from direct measurement of the 
；Inhibitory activity [15,20] or from . indirect 
m e a s u r e m e n t of Na+, K+-ATPase activity of circulating 
cells [21] • We have attempted to investigate the 
relative importance of dopamine and STI to the 
natriuresis of salt-loading by examining the temporal 
relationships. Our results confirm previous 
observations that high salt intake causes an increase 
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in dopamine excretion [2] • The magnitude of increase 
(approximately 50% on day 4)' is similar to that 
reported by others [1-3]. 
Our results also confirm that high salt diet 
causes an increase in STI [7,11,15,20] . However as 
far as we are aware there has been no reports on the 
temporal relationship between dopamine and STI during 
salt loading. The results presented here show that 
STI closely followed the excretion of sodium (Table 1) 
where as the excretion of dopamine lagged behind by a 
day. Furthermore unless the natriuretic effect of 
dopamine is several fold higher than other natriuretic 
- factors, the observed increase in dopamine excretion 
may not be quantitatively adequate to explain the 
natriuresis. However, it is possible that local 
concentration of dopamine at the tubules may be high 
enough to. cause this degree of natriuresis. 
These observations on dopamine could be 
interpreted in two ways. (a) Dopamine is not 
important in the natriuresis of salt loading and that 
the increased excretion of dopamine is secondary to 
the excretion of sodium. Observations such as lack of 
increase in dopamine excretion during head out water 
f 
DOPAMINE AND SODIUM TRANSPORT INHIBITOR 143 
immersion (Ho, O'Hare, Bison & Swaminathan -
unpublished results) and the lack of effect of 
earbidopa, a DOPA decarboxylase inhibitor on the 
natriuresis induced by saline infusion [23] support 
this theory. However, there are other observations 
which support a natriuretic role for dopamine. For 
instance, administration of Carbidopa to healthy 
subjects reduced sodium excretion suggesting that 
dopamine has a tonic role in the excretion of sodium 
[13,24] . Dopaminergic blockade by the use of ‘dopamine 
receptor antagonist metoclopramide abolished the 
natriuretic response to saline infusion [25] • (b) 
Dopamine may be important in maintaining the 
‘ natriuresis initiated by other factors such as STI or 
ANP. 
The results reported here also strongly suggest 
a role for STI in the natriuresis and further work is 
needed to define the relative roles of STI, dopamine, 
ANP and other natriuretic factors. 
I 
We conclude that salt loading in the rat causes 
an increase in STI and dopamine and that the increase 
in STI precedes that of dopamine. 
r 
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